All our publications are maintained in a Zotero library. To request access, please click here.
Jump to year
2024
2775998
GXCKG69T
2024
1
padagogische-hochschule-bern-institut-vorschulstufe-und-primarstufe
50
date
desc
1194
https://www.iedea.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A50%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%224HQSQPK4%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Parcesepe%20et%20al.%22%2C%22parsedDate%22%3A%222024-10%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EParcesepe%2C%20Angela%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStockton%2C%20Melissa%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBernard%2C%20Charlotte%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKanguya%2C%20Tukiya%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKwobah%2C%20Edith%20Kamaru%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Prevalence%20and%20co-occurrence%20of%20symptoms%20of%20mental%20and%20substance%20use%20disorders%20among%20people%20with%20HIV%20age%2040%20and%20older%20in%20low-%20and%20middle-income%20countries%3A%20a%20cross-sectional%20study.%20%3Ci%3EJournal%20of%20the%20International%20AIDS%20Society%3C%5C%2Fi%3E%2C%20%3Ci%3E27%3C%5C%2Fi%3E%20%2810%29%2C%20S.%20e26359.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26359%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26359%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prevalence%20and%20co-occurrence%20of%20symptoms%20of%20mental%20and%20substance%20use%20disorders%20among%20people%20with%20HIV%20age%2040%20and%20older%20in%20low-%20and%20middle-income%20countries%3A%20a%20cross-sectional%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%20M.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melissa%22%2C%22lastName%22%3A%22Stockton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tukiya%22%2C%22lastName%22%3A%22Kanguya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edith%20Kamaru%22%2C%22lastName%22%3A%22Kwobah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mpho%22%2C%22lastName%22%3A%22Tlali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Goodrich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Perazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Musabyimana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Smita%22%2C%22lastName%22%3A%22Nimkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Lancaster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22IeDEA%22%2C%22lastName%22%3A%22Consortium%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Due%20to%20the%20increased%20effectiveness%20of%20and%20access%20to%20antiretroviral%20therapy%20%28ART%29%2C%20people%20with%20HIV%20%28PWH%29%20are%20living%20longer.%20As%20a%20result%2C%20the%20population%20of%20older%20PWH%20has%20increased.%20Mental%20and%20substance%20use%20disorders%20%28MSDs%29%20are%20common%20and%20frequently%20co-occurring%20among%20PWH%20and%20are%20associated%20with%20poor%20HIV%20care%20outcomes.%20Research%20into%20the%20prevalence%20and%20co-occurrence%20of%20MSDs%20among%20ageing%20PWH%20remains%20limited%2C%20particularly%20in%20low-%20and%20middle-income%20countries%20%28LMICs%29.%5CnMETHODS%3A%20We%20analysed%20data%20collected%20between%202020%20and%202022%20from%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Sentinel%20Research%20Network%20cohort%20of%20PWH%20aged%2040%20years%20or%20older%20on%20ART%20at%2011%20HIV%20clinics%20in%20Brazil%2C%20C%5Cu00f4te%20d%27Ivoire%2C%20India%2C%20Kenya%2C%20Mexico%2C%20Uganda%2C%20Rwanda%2C%20Togo%2C%20Vietnam%2C%20Zambia%20and%20Zimbabwe.%20We%20estimated%20the%20prevalence%20and%20co-occurrence%20of%20unhealthy%20alcohol%20use%20%28AUDIT-C%20%5Cu22653%20for%20women%2C%20%5Cu22654%20for%20men%29%2C%20unhealthy%20drug%20use%20%28ASSIST%20%3E3%20for%20cannabis%2C%20cocaine%2C%20amphetamines%2C%20inhalants%2C%20sedatives%2C%20hallucinogens%20and%5C%2For%20opioids%29%2C%20and%20moderate%20to%20severe%20symptoms%20of%20depression%20%28PHQ-9%20%5Cu226510%29%2C%20anxiety%20%28GAD-7%20%5Cu226510%29%20and%20post-traumatic%20stress%20disorder%20%28PTSD%29%20%28PCL-5%20%5Cu226533%29.%20Psychiatric%20multimorbidity%20was%20defined%20as%20having%20symptoms%20of%20two%20or%20more%20disorders%20assessed.%20Log%20binomial%20models%20assessed%20the%20association%20between%20socio-demographic%20and%20HIV%20care%20characteristics%20and%20symptoms%20of%20anxiety%2C%20depression%2C%20PTSD%20or%20unhealthy%20substance%20use.%5CnRESULTS%3A%20Of%202821%20participants%2C%20the%20prevalence%20of%20unhealthy%20alcohol%20and%20drug%20use%20was%2021%25%20and%205%25%2C%20respectively.%20The%20prevalence%20of%20moderate%20to%20severe%20symptoms%20of%20depression%2C%20anxiety%20and%20PTSD%20was%2014%25%2C%209%25%20and%206%25%2C%20respectively.%20Overall%2C%20the%20prevalence%20of%20psychiatric%20multimorbidity%20was%2011%25.%20Among%20those%20with%20symptoms%20of%20at%20least%20one%20mental%20health%20or%20substance%20use%20outcome%20assessed%20%28n%20%3D%201036%29%2C%20the%20prevalence%20of%20psychiatric%20multimorbidity%20was%2031%25.%20In%20binomial%20models%2C%20the%20prevalence%20of%20symptoms%20of%20depression%20and%20anxiety%20was%20higher%2C%20while%20the%20prevalence%20of%20unhealthy%20alcohol%20and%20drug%20use%20was%20lower%20among%20women%20than%20men.%5CnCONCLUSIONS%3A%20Unhealthy%20alcohol%20use%20and%20symptoms%20of%20depression%20were%20most%20commonly%20reported%2C%20among%20this%20cohort%20of%20PWH%20aged%2040%20or%20older%20across%2011%20LMICs.%20Integration%20of%20MSD%20screening%20and%20treatment%20into%20HIV%20care%20should%20be%20prioritized.%20The%20effectiveness%20and%20implementation%20of%20transdiagnostic%20or%20multi-focus%20mental%20health%20treatment%20approaches%20in%20HIV%20care%20settings%20should%20be%20examined.%22%2C%22date%22%3A%222024-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26359%22%2C%22ISSN%22%3A%221758-2652%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22369YB7BV%22%2C%22NMNPNZRP%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222024-10-09T09%3A11%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22X85V6KKC%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ssemasaazi%20et%20al.%22%2C%22parsedDate%22%3A%222024-09-27%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESsemasaazi%2C%20Amutuhaire%20Judith%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKalyesubula%2C%20Robert%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EManabe%2C%20Yukari%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMbabazi%2C%20Phoebe%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENaikooba%2C%20Susan%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Higher%20prevalence%20of%20kidney%20function%20impairment%20among%20older%20people%20living%20with%20HIV%20in%20Uganda.%20%3Ci%3EBMC%20Nephrology%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%281%29%2C%20S.%20321.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12882-024-03761-1%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12882-024-03761-1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Higher%20prevalence%20of%20kidney%20function%20impairment%20among%20older%20people%20living%20with%20HIV%20in%20Uganda%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amutuhaire%20Judith%22%2C%22lastName%22%3A%22Ssemasaazi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Kalyesubula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yukari%20C.%22%2C%22lastName%22%3A%22Manabe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Phoebe%22%2C%22lastName%22%3A%22Mbabazi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%22%2C%22lastName%22%3A%22Naikooba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faizo%22%2C%22lastName%22%3A%22Ssekindi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Esther%22%2C%22lastName%22%3A%22Nasuuna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Byakika-Kibwika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Castelnuovo%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20People%20living%20with%20HIV%20%28PLWH%29%20are%20at%20risk%20of%20kidney%20function%20impairment%20due%20to%20HIV-related%20inflammation%2C%20antiretroviral%20therapy%20%28ART%29%2C%20diabetes%20mellitus%2C%20and%20hypertension.%20Older%20persons%20may%20experience%20a%20higher%20burden%20of%20chronic%20kidney%20disease%20%28CKD%29%20as%20kidney%20function%20declines%20with%20increasing%20age.%20There%20is%20a%20paucity%20of%20data%20comparing%20the%20prevalence%20of%20kidney%20function%20impairment%20in%20older%20PLWH%20to%20that%20in%20people%20without%20HIV%20in%20sub-Saharan%20Africa.%5CnMETHODS%3A%20We%20conducted%20a%20cross-sectional%20study%20among%20people%20aged%5Cu2009%5Cu2265%5Cu200960%20years%20living%20with%20and%20without%20HIV%20in%20Kampala%2C%20Uganda%20who%20were%20matched%201%3A1%20by%20community%20location.%20We%20collected%20data%20on%20sociodemographics%2C%20comorbidities%2C%20and%20HIV-related%20clinical%20characteristics.%20We%20defined%20kidney%20function%20impairment%20as%20an%20estimated%20glomerular%20filtration%20rate%28eGFR%29%5Cu2009%3C%5Cu200960mls%5C%2Fmin%5C%2F1.73m2%20with%20or%20without%20proteinuria.%20We%20constructed%20multivariable%20logistic%20regression%20models%20to%20study%20associations%20between%20participant%20characteristics%20and%20kidney%20function%20impairment.%5CnRESULTS%3A%20We%20enrolled%20278%20people%20%28median%20age%2066%20years%29%3B%2050%25%20were%20PLWH%2C%20and%2051.8%25%20were%20female.%20Among%20PLWH%2C%2033.1%25%20%2895%25%20CI%3A%2025.7-41.4%25%29%20had%20kidney%20function%20impairment%20versus%2012.9%25%20%2895%25%20CI%3A%208.3-19.7%25%29%20among%20people%20without%20HIV%2C%20%28p-value%5Cu2009%3C%5Cu20090.01%29.%20The%20prevalence%20of%20proteinuria%20among%20PLWH%20versus%20people%20without%20HIV%20was%2043.9%25%20%2895%25%20CI%3A35.8-52.3%25%29%20versus%2019.4%25%20%2895%25%20CI%3A13.6-26.9%25%29%20p-value%5Cu2009%3C%5Cu20090.01.%20Living%20with%20HIV%20%28OR%5Cu2009%3D%5Cu20093.89%2895%25%20CI%3A%202.04-7.41%29%2C%20p-value%5Cu2009%3C%5Cu20090.01%29%2C%20older%20age%20%28OR%5Cu2009%3D%5Cu20091.13%2C%20%2895%25%20CI%3A1.07-1.20%29%2C%20p-value%5Cu2009%3C%5Cu20090.01%29%2C%20female%20sex%20%28OR%5Cu2009%3D%5Cu20091.95%2C%20%2895%25%20CI%3A1.06-3.62%29%2C%20p-value%5Cu2009%3D%5Cu20090.03%29%20and%20a%20prior%20diagnosis%20of%20hypertension%20%28OR%5Cu2009%3D%5Cu20092.19%2895%25%20CI%3A1.02-4.67%29%2C%20p-value%5Cu2009%3D%5Cu20090.04%29%20were%20significantly%20associated%20with%20kidney%20function%20impairment.%5CnCONCLUSIONS%3A%20HIV%20infection%20is%20strongly%20associated%20with%20kidney%20function%20impairment%20among%20older%20PLWH.%20Prioritizing%20routine%20measurements%20of%20kidney%20function%20and%20proteinuria%20in%20older%20PLWH%20will%20enable%20early%20detection%20and%20institution%20of%20measures%20to%20reduce%20the%20progression%20of%20kidney%20disease.%22%2C%22date%22%3A%222024-09-27%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12882-024-03761-1%22%2C%22ISSN%22%3A%221471-2369%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222024-10-09T09%3A33%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22S5ZQS6AG%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Technau%20et%20al.%22%2C%22parsedDate%22%3A%222024-09-20%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETechnau%2C%20Karl-G%26%23xFC%3Bnter%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMaskew%2C%20Mhairi%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENattey%2C%20Cornelius%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHwang%2C%20Candice%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3Evan%20Dongen%2C%20Nicola%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Cohort%20profile%3A%20Rahima%20Moosa%20Mother%20and%20Child%20Hospital%20maternal%20HIV%20cohort%2C%20Johannesburg%2C%20South%20Africa.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E14%3C%5C%2Fi%3E%20%289%29%2C%20S.%20e085082.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2024-085082%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2024-085082%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cohort%20profile%3A%20Rahima%20Moosa%20Mother%20and%20Child%20Hospital%20maternal%20HIV%20cohort%2C%20Johannesburg%2C%20South%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karl-G%5Cu00fcnter%22%2C%22lastName%22%3A%22Technau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mhairi%22%2C%22lastName%22%3A%22Maskew%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cornelius%22%2C%22lastName%22%3A%22Nattey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Hwang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22van%20Dongen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thalia%22%2C%22lastName%22%3A%22Ferreira%20Brizido%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%22%2C%22lastName%22%3A%22Wise%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20The%20Rahima%20Moosa%20Mother%20and%20Child%20Hospital%20%28RMMCH%29%20maternal%20HIV%20cohort%20originated%20from%20data%20systems%20that%20were%20developed%20to%20support%20HIV-related%20birth%20care%20and%20track%20outcomes%20of%20a%20complete%20birth%20cohort%20of%20HIV-exposed%20infants%20at%20Rahima%20Moosa%20Hospital%20and%20their%20mothers%20living%20with%20HIV.%5CnPARTICIPANTS%3A%20Supported%20by%20the%20Empilweni%20Services%20and%20Research%20Unit%2C%20maternal%20and%20infant%20data%20from%2013%5Cu2009654%20pregnant%20women%20living%20with%20HIV%20who%20delivered%20their%20infants%20%28and%20a%20subset%20also%20attended%20antenatal%20care%29%20were%20collected%20at%20RMMCH%20in%20Johannesburg%2C%20South%20Africa%20since%202013.%20Maternal%20data%20were%20collected%20using%20counsellor-administered%20interviews%20and%20the%202013-2018%20subset%20of%20this%20cohort%20was%20linked%20to%20the%20National%20Health%20Laboratory%20Services%20%28NHLS%29%20national%20HIV%20cohort-a%20longitudinal%20cohort%20of%20people%20living%20with%20HIV%20accessing%20care%20in%20the%20public%20sector%20antiretroviral%20therapy%20programme%20in%20South%20Africa%20that%20can%20observe%20national%20access%20to%20HIV%20care%20through%20laboratory%20testing%20data.%5CnFINDINGS%20TO%20DATE%3A%20Topics%20addressed%20by%20the%20cohort%20include%20antenatal%20care%20history%2C%20HIV%20treatment%20exposure%2C%20delivery%5C%2Fbirth%20management%2C%20prophylaxis%20and%20maternal%20blood%20results%20relevant%20to%20HIV%20captured%20at%20delivery.%20The%20cohort%20was%20also%20one%20of%20the%20first%20to%20describe%20implementation%20of%20early%20infant%20diagnosis%20procedures%20in%20South%20Africa%20including%20evaluations%20of%20novel%20point-of-care%20testing%20strategies%20demonstrating%20improvements%20in%20uptake%20of%20HIV%20care%20among%20infants%20accessing%20point-of-care%20services.%5CnFUTURE%20PLANS%3A%20Annual%20linkage%20of%20infant%20delivery%20and%20testing%20data%20to%20longitudinal%20laboratory%20test%20data%20in%20the%20NHLS%20national%20HIV%20cohort%20is%20planned%20to%20allow%20for%20analysis%20of%20both%20infant%20continuity%20of%20care%20outcomes%20and%20as%20well%20as%20evaluation%20of%20maternal-infant%20pair%20treatment%20and%20mobility%20outcomes%20in%20the%20post%20partum%20and%20later%20period.%22%2C%22date%22%3A%222024-09-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2024-085082%22%2C%22ISSN%22%3A%222044-6055%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22NMNPNZRP%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222024-10-09T09%3A36%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22CTS44ZKW%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kuniholm%20et%20al.%22%2C%22parsedDate%22%3A%222024-09-12%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKuniholm%2C%20Mark%20H.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMurenzi%2C%20Gad%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShumbusho%2C%20Fabienne%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrazier%2C%20Ellen%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPlaisy%2C%20Marie%20K.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Association%20of%20cardiovascular%20disease%20risk%20with%20liver%20steatosis%20and%20fibrosis%20in%20people%20living%20with%20hiv%20in%20low-%20and%20middle-income%20countries.%20%3Ci%3EAIDS%20%28London%2C%20England%29%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000004012%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000004012%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20cardiovascular%20disease%20risk%20with%20liver%20steatosis%20and%20fibrosis%20in%20people%20living%20with%20hiv%20in%20low-%20and%20middle-income%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20H.%22%2C%22lastName%22%3A%22Kuniholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Shumbusho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20K.%22%2C%22lastName%22%3A%22Plaisy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ephrem%22%2C%22lastName%22%3A%22Mensah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlotta%22%2C%22lastName%22%3A%22Riebensahm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Belinda%20V.%22%2C%22lastName%22%3A%22Chihota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Niharika%22%2C%22lastName%22%3A%22Samala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%20S.%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thida%22%2C%22lastName%22%3A%22Chanyachukul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rohidas%22%2C%22lastName%22%3A%22Borse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dung%20T.%20H.%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Perazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Lopez-Iniguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20understand%20the%20relationship%20between%20cardiovascular%20disease%20%28CVD%29%20risk%20and%20liver%20steatosis%20and%20fibrosis%20among%20people%20living%20with%20HIV%20%28PLWH%29%20%5Cu226540%5Cu200ayears%20on%20antiretroviral%20therapy%20%28ART%29%20in%20low-%20and%20middle-income%20countries%20%28LMIC%29.%5CnDESIGN%3A%20We%20used%20cross-sectional%20behavioral%20and%20clinical%20data%20collected%20during%20study%20enrollment%20visits%20in%202020-2022%20for%20the%20Sentinel%20Research%20Network%20of%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28SRN%20of%20IeDEA%29.%5CnMETHODS%3A%20Ten-year%20CVD%20risk%20was%20calculated%20using%202019%20World%20Health%20Organization%20non-laboratory%20and%20laboratory%20models.%20Transient%20elastography%20%28TE%29%20was%20used%20to%20assess%20liver%20disease.%20Presence%20of%20steatosis%20and%20significant%20fibrosis%20were%20defined%20by%20Controlled%20Attenuation%20Parameter%20%28CAP%29%20%5Cu2265248%5Cu200adB%5C%2Fm%20and%20liver%20stiffness%20measurement%20%28LSM%29%20%5Cu22657.1%5Cu200akPa%2C%20respectively.%20Participants%20with%20viral%20hepatitis%2C%20hazardous%20alcohol%20consumption%20and%20unsuppressed%20HIV%20viral%20load%20were%20excluded%20from%20the%20analysis.%20Logistic%20regression%20was%20used%20to%20estimate%20odds%20ratios%2C%20adjusting%20for%20study%20site%2C%20CD4%5Cu200aT%20cell%20count%2C%20stavudine%20and%20didanosine%20exposure%2C%20and%20in%20models%20stratified%20by%20sex%20and%20geographic%20region.%5CnRESULTS%3A%20There%20were%201%2C750%20participants%20from%20nine%20LMIC.%20Median%20CVD%20risk%20was%203%25%20for%20both%20non-laboratory%20and%20laboratory-based%20models.%20Adjusted%20odds%20ratios%20%28ORs%29%20for%20steatosis%20and%20significant%20fibrosis%20associated%20with%20laboratory%20CVD%20risk%20%28%5Cu226510%25%20vs.%20%3C5%25%29%20were%20OR%5Cu200a%3D%5Cu200a1.83%20%2895%25%20confidence%20interval%3A%28CI%29%5Cu200a%3D%5Cu200a1.21-2.76%3B%20P%5Cu200a%3D%5Cu200a0.004%29%20and%20OR%5Cu200a%3D%5Cu200a1.62%20%2895%25%20CI%5Cu200a%3D%5Cu200a0.85-3.07%3B%20P%5Cu200a%3D%5Cu200a0.14%29%2C%20respectively.%20Associations%20of%20CVD%20risk%20with%20steatosis%20were%20stronger%20in%20males%20and%20among%20participants%20at%20study%20sites%20outside%20Africa.%5CnCONCLUSIONS%3A%20Higher%20CVD%20risk%20was%20associated%20with%20steatosis%20but%20not%20with%20significant%20fibrosis%20in%20PLWH%20in%20our%20LMIC%20cohort.%22%2C%22date%22%3A%222024-09-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000004012%22%2C%22ISSN%22%3A%221473-5571%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22369YB7BV%22%2C%22NMNPNZRP%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222024-10-09T09%3A16%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22575JPXGV%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kimmel%20et%20al.%22%2C%22parsedDate%22%3A%222024-09-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKimmel%2C%20April%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPan%2C%20Zhongzhe%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrazier%2C%20Ellen%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMurenzi%2C%20Gad%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMuhoza%2C%20Benjamin%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Development%20and%20calibration%20of%20a%20mathematical%20model%20of%20HIV%20outcomes%20among%20Rwandan%20adults%3A%20informing%20equitable%20achievement%20of%20targets%20in%20Rwanda.%20%3Ci%3EMedRxiv%3A%20The%20Preprint%20Server%20for%20Health%20Sciences%3C%5C%2Fi%3E%2C%20S.%202024.09.06.24313223.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2024.09.06.24313223%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2024.09.06.24313223%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Development%20and%20calibration%20of%20a%20mathematical%20model%20of%20HIV%20outcomes%20among%20Rwandan%20adults%3A%20informing%20equitable%20achievement%20of%20targets%20in%20Rwanda%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22April%20D.%22%2C%22lastName%22%3A%22Kimmel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhongzhe%22%2C%22lastName%22%3A%22Pan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Muhoza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20We%20developed%20and%20calibrated%20the%20Central%20Africa-International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28CA-IeDEA%29%20HIV%20policy%20model%20to%20inform%20equitable%20achievement%20of%20global%20goals%2C%20overall%20and%20across%20sub-populations%2C%20in%20Rwanda.%5CnMETHODS%3A%20We%20created%20a%20deterministic%20dynamic%20model%20to%20project%20adult%20HIV%20epidemic%20and%20care%20continuum%20outcomes%2C%20overall%20and%20for%2025%20subpopulations%20%28age%20group%2C%20sex%2C%20HIV%20acquisition%20risk%2C%20urbanicity%29.%20Data%20came%20from%20the%20Rwanda%20cohort%20of%20CA-IeDEA%2C%202004-2020%3B%20Rwanda%20Demographic%20and%20Health%20Surveys%2C%202005%2C%202010%2C%202015%3B%20Rwanda%20Population-based%20HIV%20Impact%20Assessment%2C%202019%3B%20and%20the%20literature%20and%20reports.%20We%20calibrated%20the%20model%20to%2047%20targets%20by%20selecting%20the%2050%20best-fitting%20parameter%20sets%20among%2020%2C000%20simulations.%20Calibration%20targets%20reflected%20epidemic%20%28HIV%20prevalence%2C%20incidence%29%2C%20global%20goals%20%28percentage%20on%20antiretroviral%20therapy%20%28ART%29%20among%20diagnosed%2C%20percentage%20virally%20suppressed%20among%20on%20ART%29%20and%20other%20%28number%20on%20ART%2C%20percentage%20virally%20suppressed%29%20indicators%2C%20overall%20and%20by%20sex.%20Best-fitting%20sets%20minimized%20the%20summed%20absolute%20value%20of%20the%20percentage%20deviation%20%28AVPD%29%20between%20model%20projections%20and%20calibration%20targets.%20Good%20model%20performance%20was%20mean%20AVPD%20%5Cu22645%25%20across%20the%2050%20best-fitting%20sets%20and%5C%2For%20projections%20within%20the%20target%20confidence%20intervals%3B%20acceptable%20was%20mean%20AVPD%20%3E5%25%20and%20%5Cu226415%25.%5CnRESULTS%3A%20Across%20indicators%2C%201%2C841%20of%202%2C350%20%2878.3%25%29%20model%20projections%20were%20a%20good%20or%20acceptable%20fit%20to%20calibration%20targets.%20For%20HIV%20epidemic%20indicators%2C%20256%20of%20300%20%2885.3%25%29%20projections%20were%20a%20good%20fit%20to%20targets%2C%20with%20the%20model%20performing%20better%20for%20women%20%2883.3%25%20a%20good%20fit%29%20than%20for%20men%20%2871.7%25%20a%20good%20fit%29.%20For%20global%20goals%20indicators%2C%2096%20of%20100%20%2896.0%25%29%20projections%20were%20a%20good%20fit%3B%20model%20performance%20was%20similar%20for%20women%20and%20men.%20For%20other%20indicators%2C%20653%20of%20950%20%2868.7%25%29%20projections%20were%20a%20good%20or%20acceptable%20fit.%20Fit%20was%20better%20for%20women%20than%20for%20men%20%28percentage%20virally%20suppressed%20only%29%20and%20when%20restricting%20targets%20for%20number%20on%20ART%20to%202013%20and%20beyond.%5CnCONCLUSIONS%3A%20The%20CA-IeDEA%20HIV%20policy%20model%20fits%20historical%20data%20and%20can%20inform%20policy%20solutions%20for%20equitably%20achieving%20global%20goals%20to%20end%20the%20HIV%20epidemic%20in%20Rwanda.%20High-quality%2C%20unbiased%20population-based%20data%2C%20as%20well%20as%20novel%20approaches%20that%20account%20for%20calibration%20target%20quality%2C%20are%20critical%20to%20ongoing%20use%20of%20mathematical%20models%20for%20programmatic%20planning.%22%2C%22date%22%3A%222024-09-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2024.09.06.24313223%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222024-10-09T09%3A32%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22DH7Q539B%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zaniewski%20et%20al.%22%2C%22parsedDate%22%3A%222024-09-05%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZaniewski%2C%20Elizabeth%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESkrivankova%2C%20Veronika%20Whitesell%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrazier%2C%20Ellen%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAvihingsanon%2C%20Anchalee%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECardoso%2C%20Sandra%20Wagner%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Transition%20to%20dolutegravir-based%20ART%20in%2035%20low-%20and%20middle-income%20countries%3A%20a%20global%20survey%20of%20HIV%20care%20clinics.%20%3Ci%3EAIDS%20%28London%2C%20England%29%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000004007%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000004007%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Transition%20to%20dolutegravir-based%20ART%20in%2035%20low-%20and%20middle-income%20countries%3A%20a%20global%20survey%20of%20HIV%20care%20clinics%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Zaniewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronika%20Whitesell%22%2C%22lastName%22%3A%22Skrivankova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anchalee%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%20Wagner%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henri%22%2C%22lastName%22%3A%22Chenal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%20E.%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rossana%20A.%22%2C%22lastName%22%3A%22Ditangco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20Vanes%22%2C%22lastName%22%3A%22Ebasone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Eley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20George%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%22%2C%22lastName%22%3A%22Fatti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacqueline%20Madalitso%22%2C%22lastName%22%3A%22Huwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Lelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20Maria%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugene%20Kouassi%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%20Kla%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Muleebwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjay%22%2C%22lastName%22%3A%22Mundhe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Winnie%20R.%22%2C%22lastName%22%3A%22Muyindike%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%20Mahambou%22%2C%22lastName%22%3A%22Nsonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20M.%22%2C%22lastName%22%3A%22Obatsa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Odhiambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans%20Walter%22%2C%22lastName%22%3A%22Prozesky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Supattra%22%2C%22lastName%22%3A%22Rungmaitree%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%20Semwendero%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moussa%22%2C%22lastName%22%3A%22Seydi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nosisa%22%2C%22lastName%22%3A%22Sipambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tavitiya%22%2C%22lastName%22%3A%22Sudjaritruk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karl-G%5Cu00fcnter%22%2C%22lastName%22%3A%22Technau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20We%20studied%20the%20transition%20to%20dolutegravir-containing%20antiretroviral%20therapy%20%28ART%29%20at%20HIV%20treatment%20clinics%20within%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29.%5CnDESIGN%3A%20Site-level%20survey%20conducted%20in%202020-2021%20among%20HIV%20clinics%20in%20low-%20and%20middle-income%20countries%20%28LMICs%29.%5CnMETHODS%3A%20We%20assessed%20the%20status%20of%20dolutegravir%20rollout%20and%20viral%20load%20and%20drug%20resistance%20testing%20practices%20for%20patients%20on%20ART%20switching%20to%20dolutegravir-based%20regimens.%20We%20used%20generalized%20estimating%20equations%20to%20assess%20associations%20between%20clinic%20rollout%20of%20both%20first-%20and%20second-line%20dolutegravir-based%20ART%20regimens%20%28dual%20rollout%29%20and%20site-level%20factors.%5CnRESULTS%3A%20Of%20179%20surveyed%20clinics%2C%20175%20%2898%25%29%20participated%3B%20137%20%2878%25%29%20from%20Africa%2C%2030%20%2817%25%29%20from%20the%20Asia-Pacific%2C%20and%208%20%285%25%29%20from%20Latin%20America.%20Most%20clinics%20%2880%25%29%20were%20in%20low-%20or%20lower-middle-income%20countries%2C%20and%20there%20were%20a%20mix%20of%20primary-%2C%20secondary-%20and%20tertiary-level%20clinics.%20Ninety%20percent%20reported%20rollout%20of%20first-line%20dolutegravir%2C%2059%25%20of%20second-line%2C%2094%25%20of%20first-%20or%20second-line%20and%2055%25%20of%20dual%20rollout.%20The%20adjusted%20odds%20of%20dual%20rollout%20were%20higher%20among%20tertiary-level%20%28aOR%204.00%3B%2095%25%20CI%201.39%20to%2011.47%29%20and%20secondary-level%20clinics%20%28aOR%203.66%3B%2095%25%20CI%202.19%20to%206.11%29%20than%20in%20primary-level%20clinics.%20Over%20half%20%2859%25%29%20of%20clinics%20that%20introduced%20first-%20or%20second-line%20dolutegravir-based%20ART%20required%20recent%20viral%20load%20testing%20before%20switching%20to%20dolutegravir%2C%20and%2015%25%20performed%20genotypic%20resistance%20testing%20at%20switch.%5CnCONCLUSIONS%3A%20Dolutegravir-based%20ART%20was%20rolled%20out%20at%20nearly%20all%20IeDEA%20clinics%20in%20LMICs%2C%20yet%20many%20switched%20patients%20to%20dolutegravir%20without%20recent%20viral%20load%20testing%20and%20drug%20resistance%20testing%20was%20rarely%20performed.%20Without%20such%20testing%2C%20drug%20resistance%20among%20patient%20switching%20to%20dolutegravir%20may%20go%20undetected.%22%2C%22date%22%3A%222024-09-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000004007%22%2C%22ISSN%22%3A%221473-5571%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22369YB7BV%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222024-10-09T09%3A20%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22PEEEWISR%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Monroy%20et%20al.%22%2C%22parsedDate%22%3A%222024-09-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMonroy%2C%20Alexa%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGoodrich%2C%20Suzanne%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrown%2C%20Steven%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBalanos%2C%20Theofanis%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBakoyannis%2C%20Giorgos%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Effects%20of%20Alcohol%20Use%20on%20Patient%20Retention%20in%20HIV%20Care%20in%20East%20Africa.%20%3Ci%3EAIDS%20and%20Behavior%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-024-04483-z%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-024-04483-z%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effects%20of%20Alcohol%20Use%20on%20Patient%20Retention%20in%20HIV%20Care%20in%20East%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexa%22%2C%22lastName%22%3A%22Monroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Goodrich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20A.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theofanis%22%2C%22lastName%22%3A%22Balanos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giorgos%22%2C%22lastName%22%3A%22Bakoyannis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Winnie%22%2C%22lastName%22%3A%22Muyindike%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Kanyesigye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurice%22%2C%22lastName%22%3A%22Aluda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jayne%22%2C%22lastName%22%3A%22Lewis-Kulzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22East%20Africa%20International%20Epidemiologic%20Databases%20to%20Evaluate%20AIDS%20%28EA-IeDEA%29%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22We%20sought%20to%20investigate%20the%20association%20between%20hazardous%20alcohol%20use%20and%20gaps%20in%20care%20for%20people%20living%20with%20HIV%20over%20a%20long-term%20follow-up%20period.%20Adults%20who%20had%20participated%20in%20our%20previously%20published%20Phase%20I%20study%20of%20hazardous%20alcohol%20use%20at%20HIV%20programs%20in%20Kenya%20and%20Uganda%20were%20eligible%20at%20their%2042%20to%2048%5Cu00a0month%20follow-up%20visit.%20Those%20who%20re-enrolled%20were%20followed%20for%20an%20additional%5Cu2009~%5Cu200912%5Cu00a0months.%20Hazardous%20alcohol%20use%20behavior%20was%20measured%20using%20the%20Alcohol%20Use%20Disorders%20Identification%20Test%20%28AUDIT%29%20tool.%20Deidentified%20clinical%20data%20were%20used%20to%20assess%20gaps%20in%20care%20%28defined%20as%20failure%20to%20return%20to%20clinic%20within%2060%5Cu00a0days%20after%20a%20missed%20visit%29.%20The%20proportion%20of%20patients%20experiencing%20a%20gap%20in%20care%20at%20a%20specific%20time%20point%20was%20based%20on%20a%20nonparametric%20moment-based%20estimator.%20A%20semiparametric%20Cox%20proportional%20hazard%20model%20was%20used%20to%20determine%20the%20association%20between%20hazardous%20alcohol%20use%20at%20enrollment%20in%20Phase%20I%20%28AUDIT%20score%5Cu2009%5Cu2265%5Cu20098%29%20and%20gaps%20in%20care.%20Of%20the%20731%20study-eligible%20participants%20from%20Phase%20I%2C%205.5%25%20had%20died%2C%2010.1%25%20were%20lost%20to%20follow-up%2C%2039.5%25%20transferred%2C%207.5%25%20declined%5C%2Fnot%20approached%2C%20and%2037.3%25%20were%20enrolled.%20Phase%20II%20participants%20were%20older%2C%20had%20less%20hazardous%20drinking%20and%20had%20a%20lower%20WHO%20clinical%20stage%20than%20those%20not%20re-enrolled.%20Hazardous%20drinking%20in%20the%20re-enrolled%20was%20associated%20with%20a%20Hazard%20Ratio%20%28HR%29%20of%201.88%20%5Bp-value%5Cu2009%3D%5Cu20090.016%5D%20for%20a%20gap%20in%20care.%20Thus%2C%20hazardous%20alcohol%20use%20at%20baseline%20was%20associated%20with%20an%20increased%20risk%20of%20experiencing%20a%20gap%20in%20care%20and%20presents%20an%20early%20target%20for%20intervention.%22%2C%22date%22%3A%222024-09-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10461-024-04483-z%22%2C%22ISSN%22%3A%221573-3254%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222024-10-09T09%3A35%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22DYRPT4UX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Byakwaga%20et%20al.%22%2C%22parsedDate%22%3A%222024-08-28%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EByakwaga%2C%20Helen%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESemeere%2C%20Aggrey%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELaker-Oketta%2C%20Miriam%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBusakhala%2C%20Naftali%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFreeman%2C%20Esther%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Survival%20Following%20Diagnosis%20of%20HIV-Associated%20Kaposi%20Sarcoma%20Among%20Adults%20in%20East%20Africa%20in%20the%20%26%23x201C%3BTreat-All%26%23x201D%3B%20Era.%20%3Ci%3EMedRxiv%3A%20The%20Preprint%20Server%20for%20Health%20Sciences%3C%5C%2Fi%3E%2C%20S.%202024.08.26.24312536.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2024.08.26.24312536%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2024.08.26.24312536%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Survival%20Following%20Diagnosis%20of%20HIV-Associated%20Kaposi%20Sarcoma%20Among%20Adults%20in%20East%20Africa%20in%20the%20%5C%22Treat-All%5C%22%20Era%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miriam%22%2C%22lastName%22%3A%22Laker-Oketta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naftali%22%2C%22lastName%22%3A%22Busakhala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Esther%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elyne%22%2C%22lastName%22%3A%22Rotich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%22%2C%22lastName%22%3A%22Wenger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippa%22%2C%22lastName%22%3A%22Kadama-Makanga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Job%22%2C%22lastName%22%3A%22Kisuya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%22%2C%22lastName%22%3A%22Semakadde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bronia%22%2C%22lastName%22%3A%22Mwine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Kasozi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bwana%22%2C%22lastName%22%3A%22Mwebesa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Toby%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20V.%22%2C%22lastName%22%3A%22Glidden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Kambugu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%22%2C%22lastName%22%3A%22Martin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Despite%20widespread%20access%20to%20antiretroviral%20therapy%20%28ART%29%20in%20the%20%5C%22Treat%20All%5C%22%20era%2C%20HIV-associated%20Kaposi%20sarcoma%20%28KS%29%20remains%20among%20the%20most%20common%20malignancies%20in%20sub-Saharan%20Africa.%20Survival%20after%20KS%20diagnosis%20has%20historically%20been%20poor%20in%20Africa%2C%20but%20knowledge%20whether%20survival%20has%20changed%20at%20the%20population%20level%20in%20the%20contemporary%20era%20has%20been%20limited%20by%20lack%20of%20community-representative%20surveillance%20and%20monitoring%20systems.%5CnMETHODS%3A%20We%20identified%20all%20adult%20persons%20living%20with%20HIV%20%28PLWH%29%20with%20a%20new%20diagnosis%20of%20KS%20made%20between%202016%20and%202019%20during%20outpatient%20or%20inpatient%20care%20at%20prototypical%20primary%20care-providing%20medical%20facilities%20in%20Kenya%20and%20Uganda%20using%20rapid%20case%20ascertainment.%20Participants%20were%20subsequently%20followed%20for%20vital%20status%2C%20including%20community%20tracking%20for%20those%20who%20became%20lost%20to%20follow-up.%5CnFINDINGS%3A%20Among%20411%20participants%20with%20newly%20diagnosed%20KS%2C%2071%25%20were%20men%2C%20median%20age%20was%2034%20%28IQR%3A%2030%20to%2041%29%20years%2C%20and%2091%25%20had%20ACTG%20T1%20tumor%20extent.%20Over%20a%20median%20follow-up%20of%207.8%20%28IQR%3A%202.4%20to%2017.9%29%20months%2C%20cumulative%20incidence%20of%20death%20%2895%25%20CI%29%20at%20months%206%2C%2012%20and%2018%20were%2034%25%20%2830%25%20to%2039%25%29%2C%2041%25%20%2836%25%20to%2046%25%29%20and%2045%25%20%2840%25%20to%2051%25%29%2C%20respectively.%20Having%20the%20highest%20number%20of%20anatomic%20sites%20%2811%20to%2016%29%20harboring%20KS%20lesions%20%28hazard%20ratio%202.2%20%2895%25%20CI%3A%201.3-3.8%29%20compared%20to%201%20to%203%20sites%29%20and%20presence%20of%20oral%20KS%20lesions%20%28hazard%20ratio%202.2%20%2895%25%20CI%3A%201.4-3.3%29%29%20were%20independently%20associated%20with%20higher%20mortality.%20Lower%20hemoglobin%20and%20CD4%20count%20as%20well%20as%20higher%20plasma%20HIV%20RNA%20were%20also%20associated%20with%20higher%20mortality.%5CnINTERPRETATION%3A%20Among%20PLWH%20with%20newly%20diagnosed%20KS%20in%20East%20Africa%20in%20the%20%5C%22Treat%20All%5C%22%20era%2C%20survival%20was%20poor%20and%20related%20to%20mucocutaneous%20extent%20of%20KS.%20The%20findings%20emphasize%20the%20need%20for%20better%20control%20of%20KS%20in%20Africa%2C%20including%20novel%20approaches%20for%20earlier%20detection%2C%20better%20linkage%20to%20oncologic%20care%2C%20and%20more%20potent%20therapy.%22%2C%22date%22%3A%222024-08-28%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2024.08.26.24312536%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222024-10-09T09%3A34%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22XY975M2U%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Egger%20et%20al.%22%2C%22parsedDate%22%3A%222024-08-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEgger%2C%20Matthias%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESauermann%2C%20Mamatha%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELoosli%2C%20Tom%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHossmann%2C%20Stefanie%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERiedo%2C%20Selma%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20HIV-1%20subtype-specific%20drug%20resistance%20on%20dolutegravir-based%20antiretroviral%20therapy%3A%20protocol%20for%20a%20multicentre%20study%20%28DTG%20RESIST%29.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E14%3C%5C%2Fi%3E%20%288%29%2C%20S.%20e085819.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2024-085819%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2024-085819%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV-1%20subtype-specific%20drug%20resistance%20on%20dolutegravir-based%20antiretroviral%20therapy%3A%20protocol%20for%20a%20multicentre%20study%20%28DTG%20RESIST%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mamatha%22%2C%22lastName%22%3A%22Sauermann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Loosli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefanie%22%2C%22lastName%22%3A%22Hossmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Selma%22%2C%22lastName%22%3A%22Riedo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Niko%22%2C%22lastName%22%3A%22Beerenwinkel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Giandhari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%20D.%22%2C%22lastName%22%3A%22Kouyos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Lessells%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20HIV%20drug%20resistance%20poses%20a%20challenge%20to%20the%20United%20Nation%27s%20goal%20of%20ending%20the%20HIV%5C%2FAIDS%20epidemic.%20The%20integrase%20strand%20transfer%20inhibitor%20%28InSTI%29%20dolutegravir%2C%20which%20has%20a%20higher%20resistance%20barrier%2C%20was%20endorsed%20by%20the%20WHO%20in%202019%20for%20first-line%2C%20second-line%20and%20third-line%20antiretroviral%20therapy%20%28ART%29.%20This%20multiplicity%20of%20roles%20of%20dolutegravir%20in%20ART%20may%20facilitate%20the%20emergence%20of%20dolutegravir%20resistance.%5CnMETHODS%20AND%20ANALYSIS%3A%20Nested%20within%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%2C%20DTG%20RESIST%20is%20a%20multicentre%20study%20of%20adults%20and%20adolescents%20living%20with%20HIV%20in%20sub-Saharan%20Africa%2C%20Asia%2C%20and%20South%20and%20Central%20America%20who%20experienced%20virological%20failure%20on%20dolutegravir-based%20ART.%20At%20the%20time%20of%20virological%20failure%2C%20whole%20blood%20will%20be%20collected%20and%20processed%20to%20prepare%20plasma%20or%20dried%20blood%20spots.%20Laboratories%20in%20Durban%2C%20Mexico%20City%20and%20Bangkok%20will%20perform%20genotyping.%20Analyses%20will%20focus%20on%20%281%29%20individuals%20who%20experienced%20virological%20failure%20on%20dolutegravir%20and%20%282%29%20those%20who%20started%20or%20switched%20to%20such%20a%20regimen%20and%20were%20at%20risk%20of%20virological%20failure.%20For%20population%20%281%29%2C%20the%20outcome%20will%20be%20any%20InSTI%20drug%20resistance%20mutations%2C%20and%20for%20population%20%282%29%20virological%20failure%20is%20defined%20as%20a%20viral%20load%20%3E1000%20copies%5C%2FmL.%20Phenotypic%20testing%20will%20focus%20on%20non-B%20subtype%20viruses%20with%20major%20InSTI%20resistance%20mutations.%20Bayesian%20evolutionary%20models%20will%20explore%20and%20predict%20treatment%20failure%20genotypes.%20The%20study%20will%20have%20intermediate%20statistical%20power%20to%20detect%20differences%20in%20resistance%20mutation%20prevalence%20between%20major%20HIV-1%20subtypes%3B%20ample%20power%20to%20identify%20risk%20factors%20for%20virological%20failure%20and%20limited%20power%20for%20analysing%20factors%20associated%20with%20individual%20InSTI%20drug%20resistance%20mutations.%5CnETHICS%20AND%20DISSEMINATION%3A%20The%20research%20protocol%20was%20approved%20by%20the%20Biomedical%20Research%20Ethics%20Committee%20at%20the%20University%20of%20KwaZulu-Natal%2C%20South%20Africa%20and%20the%20Ethics%20Committee%20of%20the%20Canton%20of%20Bern%2C%20Switzerland.%20All%20sites%20participate%20in%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20and%20have%20obtained%20ethics%20approval%20from%20their%20local%20ethics%20committee%20to%20collect%20additional%20data.%5CnTRIAL%20REGISTRATION%20NUMBER%3A%20NCT06285110.%22%2C%22date%22%3A%222024-08-21%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2024-085819%22%2C%22ISSN%22%3A%222044-6055%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222024-09-02T06%3A39%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22D83PFGZI%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ross%20et%20al.%22%2C%22parsedDate%22%3A%222024-08-20%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERoss%2C%20Jonathan%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGasana%2C%20Josephine%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZotova%2C%20Natalia%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENdabakuranye%2C%20Giovanni%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMabano%2C%20Fabiola%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20PrEP%20in%20the%20key%20population%20community%3A%20a%20qualitative%20study%20of%20perspectives%20on%20pre-exposure%20prophylaxis%20by%20men%20who%20have%20sex%20with%20men%20and%20female%20sex%20workers%20in%20Kigali%2C%20Rwanda.%20%3Ci%3EMedRxiv%3A%20The%20Preprint%20Server%20for%20Health%20Sciences%3C%5C%2Fi%3E%2C%20S.%202024.08.20.24311545.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2024.08.20.24311545%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2024.08.20.24311545%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22PrEP%20in%20the%20key%20population%20community%3A%20a%20qualitative%20study%20of%20perspectives%20on%20pre-exposure%20prophylaxis%20by%20men%20who%20have%20sex%20with%20men%20and%20female%20sex%20workers%20in%20Kigali%2C%20Rwanda%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josephine%22%2C%22lastName%22%3A%22Gasana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalia%22%2C%22lastName%22%3A%22Zotova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Ndabakuranye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabiola%22%2C%22lastName%22%3A%22Mabano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Ingabire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adebola%22%2C%22lastName%22%3A%22Adedimeji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Viraj%20V.%22%2C%22lastName%22%3A%22Patel%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Men%20who%20have%20sex%20with%20men%20%28MSM%29%20and%20female%20sex%20workers%20%28FSW%29%20are%20increasingly%20and%20disproportionately%20impacted%20by%20HIV%20in%20sub-Saharan%20Africa%2C%20yet%20current%20PrEP%20care%20models%20in%20this%20region%20are%20not%20optimized%20for%20these%20communities.%20Limited%20data%20exist%20describing%20experiences%20and%20preferences%20of%20MSM%20and%20FSW%20with%20respect%20to%20accessing%20and%20using%20PrEP.%5CnMETHODS%3A%20We%20conducted%20qualitative%2C%20semi-structured%20interviews%20with%20MSM%20and%20FSW%20recruited%20from%20three%20health%20centers%20and%20seven%20community%20organizations%20in%20Kigali%2C%20Rwanda.%20Data%20were%20analyzed%20using%20a%20mixed%20deductive%20and%20inductive%20approach%20to%20describe%20key%20themes%20related%20to%20initiating%20and%20adhering%20to%20PrEP.%5CnRESULTS%3A%20Participants%20included%2018%20MSM%20and%2014%20FSW%3B%2012%20were%20using%20PrEP%20at%20the%20time%20of%20interview%2C%209%20had%20previously%20used%20PrEP%2C%20and%2011%20had%20never%20used%20it.%20Participants%20highlighted%20the%20central%20role%20of%20their%20social%20networks%20as%20key%20sources%20of%20information%20about%20and%20support%20for%20PrEP%20use%2C%20and%20described%20a%20strong%20motivation%20to%20use%20PrEP%20as%20a%20way%20to%20protect%20both%20themselves%20and%20their%20communities%20from%20HIV.%20While%20stigma%20and%20discrimination%20were%20pervasive%2C%20these%20were%20experienced%20differently%20by%20MSM%20and%20FSW.%20Participants%20suggested%20community%20access%20points%20that%20allowed%20more%20discreet%20and%20less%20frequent%20contact%20with%20health%20care%20workers%20as%20important%20and%20desired%20strategies%20to%20improve%20engagement.%5CnCONCLUSIONS%3A%20These%20findings%20suggest%20that%20leveraging%20community%20resources%20for%20disseminating%20information%20about%20HIV%20prevention%20and%20delivering%20PrEP%20could%20contribute%20to%20successful%20implementation%20of%20PrEP%20for%20MSM%20and%20FSW%20in%20Rwanda%20and%20other%20settings%20in%20SSA.%22%2C%22date%22%3A%222024-08-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2024.08.20.24311545%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222024-10-09T09%3A32%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22Z7ATF5ZM%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lang%20et%20al.%22%2C%22parsedDate%22%3A%222024-08-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELang%2C%20Raynell%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECoburn%2C%20Sally%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGill%2C%20M.%20John%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGrossman%2C%20Jennifer%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGebo%2C%20Kelly%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20THE%20ASSOCIATION%20OF%20ANEMIA%20WITH%20SURVIVAL%20AMONG%20PEOPLE%20WITH%20HIV%20FOLLOWING%20ANTIRETROVIRAL%20INITIATION%20IN%20THE%20NA-ACCORD%202007-2016.%20%3Ci%3EJournal%20of%20Acquired%20Immune%20Deficiency%20Syndromes%20%281999%29%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003502%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003502%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22THE%20ASSOCIATION%20OF%20ANEMIA%20WITH%20SURVIVAL%20AMONG%20PEOPLE%20WITH%20HIV%20FOLLOWING%20ANTIRETROVIRAL%20INITIATION%20IN%20THE%20NA-ACCORD%202007-2016%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raynell%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sally%20B.%22%2C%22lastName%22%3A%22Coburn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20John%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Grossman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%20A.%22%2C%22lastName%22%3A%22Gebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angel%20M.%22%2C%22lastName%22%3A%22Mayor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20C.%22%2C%22lastName%22%3A%22Justice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20J.%22%2C%22lastName%22%3A%22Bosch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20S.%22%2C%22lastName%22%3A%22Rabkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20E.%22%2C%22lastName%22%3A%22Thorne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22North%20American%20AIDS%20Cohort%20Collaboration%20on%20Research%20and%20Design%20%28NA-ACCORD%29%20of%20the%20International%20Epidemiologic%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Anemia%20is%20an%20independent%20predictor%20of%20mortality%2C%20which%20may%20be%20utilized%20as%20a%20signal%20of%20deteriorating%20health.%20We%20estimated%20the%20association%20between%20anemia%20severity%20categories%20and%20mortality%20following%20the%20initiation%20of%20antiretroviral%20therapy%20%28ART%29%20among%20people%20with%20HIV%20%28PWH%29%20in%20North%20America.%5CnMETHODS%3A%20Within%20the%20NA-ACCORD%2C%20annual%20median%20hemoglobin%20measurements%20between%2001%5C%2F01%5C%2F2007-12%5C%2F31%5C%2F2016%20were%20categorized%20using%20World%20Health%20Organization%20criteria%20into%20mild%20%2811.0-12.9g%5C%2FdL%20men%2C%2011.0-11.9g%5C%2FdL%20women%29%2C%20moderate%20%288.0-10.9g%5C%2FdL%20men%5C%2Fwomen%29%20and%20severe%20%28%3C8.0g%5C%2FdL%20men%5C%2Fwomen%29%20anemia.%20Discrete%20time-to-event%20analyses%20using%20complementary%20log-log%20link%20models%20estimated%20mortality%20hazards%20ratios%20adjusted%20for%20demographics%2C%20comorbidities%2C%20and%20HIV%20clinical%20markers%20with%2095%25%20confidence%20intervals%20for%20the%20association%20between%20anemia%20and%20mortality.%5CnRESULTS%3A%20Among%2067%2C228%20PWH%20contributing%20a%20total%20of%20320%2C261%20annual%20median%20hemoglobin%20measurements%2C%20257%2C293%20%2880%25%29%20demonstrated%20no%20anemia%2C%2044%2C041%20%2814%25%29%20mild%2C%2018%2C259%20%286%25%29%20moderate%2C%20and%20668%20%280.2%25%29%20severe%20anemia%20during%20follow-up.%20Mortality%20risk%20was%205.6-fold%20higher%20among%20PWH%20with%20%28vs.%20without%29%20anemia.%20The%20association%20was%20greater%20among%20males%20%28aHR%3D5.8%20%5B5.4%2C%206.2%5D%29%20versus%20females%20%28aHR%3D4.1%20%5B3.2%2C%205.4%5D%29.%20Mortality%20risk%20was%203.8-fold%20higher%20among%20PWH%20with%20mild%20anemia%2C%2013.7-fold%20higher%20with%20moderate%20anemia%2C%20and%2034.5-fold%20higher%20with%20severe%20anemia%20%28vs.%20no%20anemia%29.%20Median%20hemoglobin%20levels%20significantly%20declined%20within%204%20years%20prior%20to%20death%2C%20with%20the%20maximum%20decrease%20the%20year%20prior%20to%20death.%20Macrocytic%20anemia%20was%20associated%20with%20an%20increased%20and%20microcytic%20anemia%20a%20decreased%20mortality%20risk%20%28vs.%20normocytic%20anemia%29.%5CnCONCLUSIONS%3A%20Anemia%20among%20PWH%20who%20have%20initiated%20ART%20is%20an%20important%20predictive%20marker%20for%20mortality%20with%20macrocytic%20anemia%20having%20an%20increased%20and%20microcytic%20anemia%20a%20decreased%20association%20with%20mortality%20compared%20with%20normocytic%20anemia.%22%2C%22date%22%3A%222024-08-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003502%22%2C%22ISSN%22%3A%221944-7884%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222024-09-02T07%3A02%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22ZEPBWGGW%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rupasinghe%20et%20al.%22%2C%22parsedDate%22%3A%222024-08-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERupasinghe%2C%20Dhanushi%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChoi%2C%20Jun%20Yong%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKumarasamy%2C%20Nagalingeswaran%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPujari%2C%20Sanjay%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKhol%2C%20Vohith%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Post-Diagnosis%20HCV%20RNA%20Testing%20Rates%20Prior%20to%20HCV%20Treatment%20Among%20People%20Living%20With%20HIV%20With%20HCV%20Antibody%20Positivity%20in%20the%20Asia-Pacific%20Region.%20%3Ci%3EJournal%20of%20Viral%20Hepatitis%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjvh.13993%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjvh.13993%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Post-Diagnosis%20HCV%20RNA%20Testing%20Rates%20Prior%20to%20HCV%20Treatment%20Among%20People%20Living%20With%20HIV%20With%20HCV%20Antibody%20Positivity%20in%20the%20Asia-Pacific%20Region%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhanushi%22%2C%22lastName%22%3A%22Rupasinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jun%20Yong%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nagalingeswaran%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjay%22%2C%22lastName%22%3A%22Pujari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vohith%22%2C%22lastName%22%3A%22Khol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20Ketut%20Agus%22%2C%22lastName%22%3A%22Somia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Man%20Po%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thach%20Ngoc%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sasisopin%22%2C%22lastName%22%3A%22Kiertiburanakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cuong%20Duy%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anchalee%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Awachana%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Asia%5Cu2010Pacific%22%7D%5D%2C%22abstractNote%22%3A%22HCV%20RNA%20test%20determines%20current%20active%20infection%20and%20is%20a%20requirement%20prior%20to%20initiating%20HCV%20treatment.%20We%20investigated%20trends%20and%20factors%20associated%20with%20post-diagnosis%20HCV%20RNA%20testing%20rates%20prior%20to%20HCV%20treatment%2C%20and%20risk%20factors%20for%20first%20positive%20HCV%20RNA%20among%20people%20living%20with%20HIV%20%28PLHIV%29%20with%20HCV%20in%20the%20Asia-Pacific%20region.%20PLHIV%20with%20positive%20HCV%20antibody%20and%20in%20follow-up%20after%202010%20were%20included.%20Patients%20were%20considered%20HCV-antibody%20positive%20if%20they%20ever%20tested%20positive%20for%20HCV%20antibody%20%28HCVAb%29.%20Repeated%20measures%20Poisson%20regression%20model%20was%20used%20to%20analyse%20factors%20associated%20with%20post-diagnosis%20HCV%20RNA%20testing%20rates%20from%20positive%20HCVAb%20test.%20Factors%20associated%20with%20time%20to%20first%20positive%20HCV%20RNA%20from%20positive%20HCVAb%20test%20were%20analysed%20using%20Cox%20regression%20model.%20There%20were%20767%20HCVAb%20positive%20participants%20included%20%2887%25%20from%20LMICs%29%20of%20whom%2011%25%20had%20HCV%20RNA%20tests.%20With%20163%20HCV%20RNA%20tests%20post%20positive%20HCVAb%20test%2C%20the%20overall%20testing%20rate%20was%205.05%20per%20100%20person-years.%20Factors%20associated%20with%20increased%20testing%20rates%20included%20later%20calendar%20years%20of%20follow-up%2C%20HIV%20viral%20load%20%5Cu22651000%5Cu2009copies%5C%2FmL%20and%20higher%20income%20countries.%20Later%20calendar%20years%20of%20follow-up%2C%20ALT%20%3E5%20times%20its%20upper%20limit%20of%20normal%2C%20and%20higher%20income%20countries%20were%20associated%20with%20shorter%20time%20to%20first%20positive%20HCV%20RNA%20test.%20Testing%20patterns%20indicated%20that%20uptake%20was%20predominantly%20in%20high%20income%20countries%20possibly%20due%20to%20different%20strategies%20used%20to%20determine%20testing%20in%20LMICs.%20Expanding%20access%20to%20HCV%20RNA%2C%20such%20as%20through%20lower-cost%20point%20of%20care%20assays%2C%20will%20be%20required%20to%20achieve%20elimination%20of%20HCV%20as%20a%20public%20health%20issue.%22%2C%22date%22%3A%222024-08-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fjvh.13993%22%2C%22ISSN%22%3A%221365-2893%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222024-09-02T06%3A42%3A43Z%22%7D%7D%2C%7B%22key%22%3A%225KRLESRY%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lang%20et%20al.%22%2C%22parsedDate%22%3A%222024-08-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELang%2C%20Raynell%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECoburn%2C%20Sally%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGill%2C%20M.%20John%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJustice%2C%20Amy%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGrossman%2C%20Jennifer%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Evaluation%20of%20mean%20corpuscular%20volume%20among%20anemic%20people%20with%20HIV%20in%20North%20America%20following%20ART%20initiation.%20%3Ci%3EAIDS%20Research%20and%20Therapy%3C%5C%2Fi%3E%2C%20%3Ci%3E21%3C%5C%2Fi%3E%20%281%29%2C%20S.%2052.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12981-024-00641-4%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12981-024-00641-4%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20mean%20corpuscular%20volume%20among%20anemic%20people%20with%20HIV%20in%20North%20America%20following%20ART%20initiation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raynell%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sally%20B.%22%2C%22lastName%22%3A%22Coburn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20John%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20C.%22%2C%22lastName%22%3A%22Justice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Grossman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%20A.%22%2C%22lastName%22%3A%22Gebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angel%20M.%22%2C%22lastName%22%3A%22Mayor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathleen%20A.%22%2C%22lastName%22%3A%22McGinnis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenna%22%2C%22lastName%22%3A%22Hogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22North%20American%20AIDS%20Cohort%20Collaboration%20on%20Research%2C%20Design%20%28NA-ACCORD%29%20of%20the%20International%20Epidemiologic%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Anemia%20is%20common%20and%20associated%20with%20increased%20morbidity%20among%20people%20with%20HIV%20%28PWH%29.%20Classification%20of%20anemia%20using%20the%20mean%20corpuscular%20volume%20%28MCV%29%20can%20help%20investigate%20the%20underlying%20causative%20factors%20of%20anemia.%20We%20characterize%20anemia%20using%20MCV%20among%20PWH%20receiving%20antiretroviral%20therapy%20%28ART%29%2C%20and%20identify%20the%20risk%20factors%20for%20normocytic%2C%20macrocytic%2C%20and%20microcytic%20anemias.%5CnMETHODS%3A%20Including%20PWH%20with%20anemia%20%28hemoglobin%20measure%5Cu2009%3C%5Cu200912.9%5Cu00a0g%5C%2FdL%20among%20men%20and%5Cu2009%3C%5Cu200911.9%5Cu00a0g%5C%2FdL%20among%20women%29%20in%20the%20NA-ACCORD%20from%2001%5C%2F01%5C%2F2007%20to%2012%5C%2F31%5C%2F2017%2C%20we%20estimated%20the%20annual%20distribution%20of%20normocytic%20%2880-100%5Cu00a0femtolitre%20%28fL%29%29%2C%20macrocytic%20%28%3E%5Cu2009100%5Cu00a0fL%29%20or%20microcytic%20%28%3C%5Cu200980%5Cu00a0fL%29%20anemia%20based%20on%20the%20lowest%20hemoglobin%20within%20each%20year.%20Poisson%20regression%20models%20with%20robust%20variance%20and%20general%20estimating%20equations%20were%20used%20to%20estimate%20crude%20and%20adjusted%20prevalence%20ratios%20and%2095%25%20confidence%20intervals%20for%20risk%20factors%20for%20macrocytic%20%28vs.%20normocytic%29%20and%20microcytic%20%28vs.%20normocytic%29%20anemia%20stratified%20by%20sex.%5CnRESULTS%3A%20Among%2037%2C984%20hemoglobin%20measurements%20that%20identified%20anemia%20in%2014%2C590%20PWH%2C%2027%2C909%20%2874%25%29%20were%20normocytic%2C%204257%20%2811%25%29%20were%20microcytic%2C%20and%205818%20%2815%25%29%20were%20macrocytic.%20Of%20the%20anemic%20PWH%20included%20over%20the%20study%20period%2C%201910%20%2813%25%29%20experienced%20at%20least%20one%20measure%20of%20microcytic%20anemia%20and%203208%20%2822%25%29%20at%20least%20one%20measure%20of%20macrocytic%20anemia.%20Normocytic%20anemia%20was%20most%20common%20among%20both%20males%20and%20females%2C%20followed%20by%20microcytic%20among%20females%20and%20macrocytic%20among%20males.%20Over%20time%2C%20the%20proportion%20of%20anemic%20PWH%20who%20have%20macrocytosis%20decreased%20while%20microcytosis%20increased.%20Macrocytic%20%28vs.%20normocytic%29%20anemia%20is%20associated%20with%20increasing%20age%20and%20comorbidities.%20With%20increasing%20age%2C%20microcytic%20anemia%20decreased%20among%20females%20but%20not%20males.%20A%20greater%20proportion%20of%20PWH%20with%20normocytic%20anemia%20had%20CD4%20counts%20%5Cu2264%20200%5Cu00a0cells%5C%2Fmm3%20and%20had%20recently%20initiated%20ART.%5CnCONCLUSION%3A%20In%20anemic%20PWH%2C%20normocytic%20anemia%20was%20most%20common.%20Over%20time%20macrocytic%20anemia%20decreased%2C%20and%20microcytic%20anemia%20increased%20irrespective%20of%20sex.%20Normocytic%20anemia%20is%20often%20due%20to%20chronic%20disease%20and%20may%20explain%20the%20greater%20risk%20for%20normocytic%20anemia%20among%20those%20with%20lower%20CD4%20counts%20or%20recent%20ART%20initiation.%20Identified%20risk%20factors%20for%20type-specific%20anemias%20including%20sex%2C%20age%2C%20comorbidities%2C%20and%20HIV%20factors%2C%20can%20help%20inform%20targeted%20investigation%20into%20the%20underlying%20causes.%22%2C%22date%22%3A%222024-08-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12981-024-00641-4%22%2C%22ISSN%22%3A%221742-6405%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222024-09-02T07%3A03%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22SIYFL2NM%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nyakato%20et%20al.%22%2C%22parsedDate%22%3A%222024-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENyakato%2C%20Patience%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESchomaker%2C%20Michael%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBoulle%2C%20Andrew%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEuvrard%2C%20Jonathan%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWood%2C%20Robin%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Correcting%20mortality%20estimates%20among%20children%20and%20youth%20on%20antiretroviral%20therapy%20in%20southern%20Africa%3A%20A%20comparative%20analysis%20between%20a%20multi-country%20tracing%20study%20and%20linkage%20to%20a%20health%20information%20exchange.%20%3Ci%3ETropical%20Medicine%20%26amp%3B%20International%20Health%3A%20TM%20%26amp%3B%20IH%3C%5C%2Fi%3E%2C%20%3Ci%3E29%3C%5C%2Fi%3E%20%288%29%2C%20S.%20739%26%23x2013%3B751.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Ftmi.14030%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Ftmi.14030%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Correcting%20mortality%20estimates%20among%20children%20and%20youth%20on%20antiretroviral%20therapy%20in%20southern%20Africa%3A%20A%20comparative%20analysis%20between%20a%20multi-country%20tracing%20study%20and%20linkage%20to%20a%20health%20information%20exchange%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patience%22%2C%22lastName%22%3A%22Nyakato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Schomaker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Wood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Eley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans%22%2C%22lastName%22%3A%22Prozesky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benedikt%22%2C%22lastName%22%3A%22Christ%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nanina%22%2C%22lastName%22%3A%22Anderegg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irene%22%2C%22lastName%22%3A%22Ayakaka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Idiovino%22%2C%22lastName%22%3A%22Rafael%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cordelia%22%2C%22lastName%22%3A%22Kunzekwenyika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolyn%20B.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22van%20Lettow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cleophas%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Safari%22%2C%22lastName%22%3A%22Mbewe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morna%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20The%20objective%20of%20this%20study%20is%20to%20assess%20the%20outcomes%20of%20children%2C%20adolescents%20and%20young%20adults%20with%20HIV%20reported%20as%20lost%20to%20follow-up%2C%20correct%20mortality%20estimates%20for%20children%2C%20adolescents%20and%20young%20adults%20with%20HIV%20for%20unascertained%20outcomes%20in%20those%20loss%20to%20follow-up%20%28LTFU%29%20based%20on%20tracing%20and%20linkage%20data%20separately%20using%20data%20from%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20in%20Southern%20Africa.%5CnMETHODS%3A%20We%20included%20data%20from%20two%20different%20populations%20of%20children%2C%20adolescents%20and%20young%20adults%20with%20HIV%3B%20%281%29%20clinical%20data%20from%20children%2C%20adolescents%20and%20young%20adults%20with%20HIV%20aged%20%5Cu226424%5Cu2009years%20from%20Lesotho%2C%20Malawi%2C%20Mozambique%2C%20Zambia%20and%20Zimbabwe%3B%20%282%29%20clinical%20data%20from%20children%2C%20adolescents%20and%20young%20adults%20with%20HIV%20aged%20%5Cu226414%5Cu2009years%20from%20the%20Western%20Cape%20%28WC%29%20in%20South%20Africa.%20Outcomes%20of%20patients%20lost%20to%20follow-up%20were%20available%20from%20%281%29%20a%20tracing%20study%20and%20%282%29%20linkage%20to%20a%20health%20information%20exchange.%20For%20both%20populations%2C%20we%20compared%20six%20methods%20for%20correcting%20mortality%20estimates%20for%20all%20children%2C%20adolescents%20and%20young%20adults%20with%20HIV.%5CnRESULTS%3A%20We%20found%20substantial%20variations%20of%20mortality%20estimates%20among%20children%2C%20adolescents%20and%20young%20adults%20with%20HIV%20reported%20as%20lost%20to%20follow-up%20versus%20those%20retained%20in%20care.%20Ascertained%20mortality%20was%20higher%20among%20lost%20and%20traceable%20children%2C%20adolescents%20and%20young%20adults%20with%20HIV%20and%20lower%20among%20lost%20and%20linkable%20than%20those%20retained%20in%20care%20%28mortality%3A%2013.4%25%20%5Btraced%5D%20vs.%2012.6%25%20%5Bretained-other%20Southern%20Africa%20countries%5D%3B%203.4%25%20%5Blinked%5D%20vs.%209.4%25%20%5Bretained-WC%5D%29.%20A%20high%20proportion%20of%20lost%20to%20follow-up%20children%2C%20adolescents%20and%20young%20adults%20with%20HIV%20had%20self-transferred%20%2821.0%25%20and%2047.0%25%29%20in%20the%20traced%20and%20linked%20samples%2C%20respectively.%20The%20uncorrected%20method%20of%20non-informative%20censoring%20yielded%20the%20lowest%20mortality%20estimates%20among%20all%20methods%20for%20both%20tracing%20%286.0%25%29%20and%20linkage%20%284.0%25%29%20approaches%20at%202%5Cu2009years%20from%20ART%20start.%20Among%20corrected%20methods%20using%20ascertained%20data%2C%20multiple%20imputation%2C%20incorporating%20ascertained%20data%20%28MI%28asc.%29%29%20and%20inverse%20probability%20weighting%20with%20logistic%20weights%20were%20most%20robust%20for%20the%20tracing%20approach.%20In%20contrast%2C%20for%20the%20linkage%20approach%2C%20MI%28asc.%29%20was%20the%20most%20robust.%5CnCONCLUSIONS%3A%20Our%20findings%20emphasise%20that%20lost%20to%20follow-up%20is%20non-ignorable%20and%20both%20tracing%20and%20linkage%20improved%20outcome%20ascertainment%3A%20tracing%20identified%20substantial%20mortality%20in%20those%20reported%20as%20lost%20to%20follow-up%2C%20whereas%20linkage%20did%20not%20identify%20out-of-facility%20deaths%2C%20but%20showed%20that%20a%20large%20proportion%20of%20those%20reported%20as%20lost%20to%20follow-up%20were%20self-transfers.%22%2C%22date%22%3A%222024-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Ftmi.14030%22%2C%22ISSN%22%3A%221365-3156%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222024-09-02T06%3A52%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22MK8Q7EQF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kalk%20et%20al.%22%2C%22parsedDate%22%3A%222024-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKalk%2C%20Emma%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHeekes%2C%20Alexa%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELavies%2C%20Diane%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJacobs%2C%20Lizel%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESpencer%2C%20Careni%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Population-based%20prevalence%20of%20congenital%20defects%20in%20a%20routine%20sentinel%20site-based%20surveillance%20system%20in%20the%20Western%20Cape%2C%20South%20Africa.%20%3Ci%3EBirth%20Defects%20Research%3C%5C%2Fi%3E%2C%20%3Ci%3E116%3C%5C%2Fi%3E%20%288%29%2C%20S.%20e2388.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fbdr2.2388%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fbdr2.2388%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Population-based%20prevalence%20of%20congenital%20defects%20in%20a%20routine%20sentinel%20site-based%20surveillance%20system%20in%20the%20Western%20Cape%2C%20South%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Kalk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexa%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Lavies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lizel%22%2C%22lastName%22%3A%22Jacobs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Careni%22%2C%22lastName%22%3A%22Spencer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alison%22%2C%22lastName%22%3A%22Boutall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayesha%22%2C%22lastName%22%3A%22Osman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anika%22%2C%22lastName%22%3A%22van%20Niekerk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Fieggen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ushma%22%2C%22lastName%22%3A%22Mehta%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Lack%20of%20data%20on%20the%20burden%20and%20scope%20of%20congenital%20disorders%20%28CDs%29%20in%20South%20Africa%20undermines%20resource%20allocation%20and%20limits%20the%20ability%20to%20detect%20signals%20from%20potentially%20teratogenic%20pregnancy%20exposures.%5CnMETHODS%3A%20We%20used%20routine%20electronic%20data%20in%20the%20Western%20Cape%20Pregnancy%20Exposure%20Registry%20%28PER%29%20to%20determine%20the%20overall%20and%20individual%20prevalence%20of%20CD%20identified%20on%20neonatal%20surface%20examination%20at%20birth%20in%20the%20Western%20Cape%2C%20South%20Africa%2C%202016-2022.%20CD%20was%20confirmed%20by%20record%20review.%20The%20contribution%20of%20late%20%28%5Cu226424%5Cu2009months%29%20and%20antenatal%20diagnoses%20was%20assessed.%20We%20compared%20demographic%20and%20obstetric%20characteristics%20between%20women%20with%5C%2Fwithout%20pregnancies%20affected%20by%20CD.%5CnRESULTS%3A%20Women%20with%20a%20viable%20pregnancy%20%28%3E22%5Cu2009weeks%20gestation%3B%20birth%20weight%5Cu2009%5Cu2265%5Cu2009500%5Cu2009g%29%20%28n%5Cu2009%3D%5Cu200932%2C494%29%20were%20included.%20Of%201106%20potential%20CD%20identified%2C%2056.1%25%20were%20confirmed%20on%20folder%20review.%20When%20internal%20and%20minor%20CD%20were%20excluded%20the%20prevalence%20of%20major%20CD%20identified%20on%20surface%20examination%20at%20birth%20was%207.2%5C%2F1000%20births.%20When%20missed%5C%2Flate%20diagnoses%20on%20examination%20%2816.8%25%29%20and%20ultrasound%20%286.8%25%29%20were%20included%2C%20the%20prevalence%20was%209.2%5C%2F1000%20births%3A%208.9%5C%2F1000%20livebirths%20and%2021.5%5C%2F1000%20stillbirths.%20The%20PER%20did%20not%20detect%2021.5%25%20of%20major%20CD%20visible%20at%20birth.%20Older%20maternal%20age%20and%20diabetes%20mellitus%20were%20associated%20with%20an%20increased%20prevalence%20of%20CD.%20Women%20living%20with%5C%2Fwithout%20HIV%20%28or%20the%20timing%20of%20antiretroviral%20therapy%2C%20before%5C%2Fafter%20conception%29%2C%20hypertension%20or%20obesity%20did%20not%20significantly%20affect%20prevalence%20of%20CD.%5CnCONCLUSIONS%3A%20A%20surveillance%20system%20based%20on%20routine%20data%20successfully%20determined%20the%20prevalence%20of%20major%20CD%20identified%20on%20surface%20examination%20at%20birth%20at%20rates%20slightly%20higher%20than%20in%20equivalent%20studies.%20Overall%20rates%2C%20modeled%20at%20~2%25%2C%20are%20likely%20underestimated.%20Strengthening%20routine%20neonatal%20examination%20and%20clinical%20record-keeping%20could%20improve%20CD%20ascertainment.%22%2C%22date%22%3A%222024-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fbdr2.2388%22%2C%22ISSN%22%3A%222472-1727%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222024-09-02T07%3A00%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22BIDVG29V%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Barreto-Duarte%20et%20al.%22%2C%22parsedDate%22%3A%222024-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBarreto-Duarte%2C%20Beatriz%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVillalva-Serra%2C%20Klauss%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMiguez-Pinto%2C%20Jo%26%23xE3%3Bo%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAra%26%23xFA%3Bjo-Pereira%2C%20Mariana%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECampos%2C%20Vanessa%20M.%20S.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Retreatment%20and%20Anti-tuberculosis%20Therapy%20Outcomes%20in%20Brazil%20Between%202015%20and%202022%3A%20A%20Nationwide%20Study.%20%3Ci%3EOpen%20Forum%20Infectious%20Diseases%3C%5C%2Fi%3E%2C%20%3Ci%3E11%3C%5C%2Fi%3E%20%288%29%2C%20S.%20ofae416.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofae416%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofae416%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Retreatment%20and%20Anti-tuberculosis%20Therapy%20Outcomes%20in%20Brazil%20Between%202015%20and%202022%3A%20A%20Nationwide%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Klauss%22%2C%22lastName%22%3A%22Villalva-Serra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00e3o%20P.%22%2C%22lastName%22%3A%22Miguez-Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%20M.%20S.%22%2C%22lastName%22%3A%22Campos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Rosier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bet%5Cu00e2nia%20M.%20F.%22%2C%22lastName%22%3A%22Nogueira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonardo%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moreno%20M.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Adherence%20to%20anti-tuberculosis%20treatment%20%28ATT%29%20in%20Brazil%20remains%20a%20challenge%20in%20achieving%20the%20goals%20set%20by%20the%20World%20Health%20Organization%20%28WHO%29.%20Patients%20who%20are%20lost%20to%20follow-up%20during%20treatment%20pose%20a%20significant%20public%20health%20problem.%20This%20study%20aimed%20to%20investigate%20the%20factors%20associated%20with%20unfavorable%20ATT%20outcomes%20among%20those%20undergoing%20retreatment%20in%20Brazil.%5CnMETHODS%3A%20We%20conducted%20an%20observational%20study%20of%20patients%20aged%20%5Cu226518%20years%20with%20tuberculosis%20%28TB%29%20reported%20to%20the%20Brazilian%20National%20Notifiable%20Disease%20Information%20System%20between%202015%20and%202022.%20Clinical%20and%20epidemiologic%20variables%20were%20compared%20between%20the%20study%20groups%20%28new%20cases%20and%20retreatment%29.%20Regression%20models%20identified%20variables%20associated%20with%20unfavorable%20outcomes.%5CnRESULTS%3A%20Among%20743%20823%20reported%20TB%20cases%20in%20the%20study%20period%2C%20555%20632%20cases%20were%20eligible%2C%20consisting%20of%20462%20061%20new%20cases%20and%2093%20571%20undergoing%20retreatments%20%2844%20642%20recurrent%20and%2048%20929%20retreatments%20after%20loss%20to%20follow-up%20%5BRLTFU%5D%29.%20RLTFU%20%28odds%20ratio%20%5BOR%5D%2C%203.96%20%5B95%25%20confidence%20interval%20%7BCI%7D%2C%203.83-4.1%5D%29%20was%20a%20significant%20risk%20factor%20for%20any%20type%20of%20unfavorable%20ATT.%20Furthermore%2C%20RLTFU%20%28OR%2C%204.93%20%5B95%25%20CI%2C%204.76-5.11%5D%29%20was%20the%20main%20risk%20factor%20for%20subsequent%20LTFU.%20For%20death%2C%20aside%20from%20advanced%20age%2C%20living%20with%20HIV%20%28OR%2C%206.28%20%5B95%25%20CI%2C%206.03-6.54%5D%29%20was%20the%20top%20risk%20factor.%5CnCONCLUSIONS%3A%20Retreatment%20is%20a%20substantial%20risk%20factor%20for%20unfavorable%20ATT%20outcomes%2C%20especially%20after%20LTFU.%20The%20rates%20of%20treatment%20success%20in%20RLTFU%20are%20distant%20from%20the%20WHO%20End%20TB%20Strategy%20targets%20throughout%20Brazil.%20These%20findings%20underscore%20the%20need%20for%20targeted%20interventions%20to%20improve%20treatment%20adherence%20and%20outcomes%20in%20persons%20who%20experience%20RLTFU.%22%2C%22date%22%3A%222024-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofae416%22%2C%22ISSN%22%3A%222328-8957%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222024-09-02T06%3A49%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22HLPQKWNM%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rudolph%20et%20al.%22%2C%22parsedDate%22%3A%222024-07-30%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERudolph%2C%20Jacqueline%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECalkins%2C%20Keri%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZhang%2C%20Xueer%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZhou%2C%20Yiyi%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EXu%2C%20Xiaoqiang%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Retention%20in%20care%20and%20antiretroviral%20therapy%20adherence%20among%20Medicaid%20beneficiaries%20with%20HIV%2C%202001-2015.%20%3Ci%3EAIDS%20Care%3C%5C%2Fi%3E%2C%20S.%201%26%23x2013%3B13.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F09540121.2024.2383901%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F09540121.2024.2383901%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Retention%20in%20care%20and%20antiretroviral%20therapy%20adherence%20among%20Medicaid%20beneficiaries%20with%20HIV%2C%202001-2015%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacqueline%20E.%22%2C%22lastName%22%3A%22Rudolph%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20L.%22%2C%22lastName%22%3A%22Calkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xueer%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yiyi%22%2C%22lastName%22%3A%22Zhou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaoqiang%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eryka%20L.%22%2C%22lastName%22%3A%22Wentz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%20E.%22%2C%22lastName%22%3A%22Joshu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%22%2C%22lastName%22%3A%22Lau%22%7D%5D%2C%22abstractNote%22%3A%22Disparities%20in%20HIV%20care%20by%20socioeconomic%20status%2C%20place%20of%20residence%2C%20and%20race%5C%2Fethnicity%20prevent%20progress%20toward%20epidemic%20control.%20No%20study%20has%20comprehensively%20characterized%20the%20HIV%20care%20cascade%20among%20people%20with%20HIV%20enrolled%20in%20Medicaid%20-%20an%20insurance%20source%20for%20low-income%20individuals%20in%20the%20US.%20We%20analyzed%20data%20from%20246%2C127%20people%20with%20HIV%20enrolled%20in%20Medicaid%202001-2015%2C%20aged%2018-64%2C%20living%20in%2014%20US%20states.%20We%20estimated%20the%20monthly%20prevalence%20of%20four%20steps%20of%20the%20care%20cascade%3A%20retained%20in%20care%5C%2Fadherent%20to%20ART%3B%20retained%5C%2Fnot%20adherent%3B%20not%20retained%5C%2Fadherent%3B%20not%20retained%5C%2Fnot%20adherent.%20Beneficiaries%20were%20retained%20in%20care%20if%20they%20had%20an%20outpatient%20care%20encounter%20every%20six%20months.%20Adherence%20was%20based%20on%20medication%20possession%20ratio.%20We%20estimated%20prevalence%20using%20a%20non-parametric%20multi-state%20approach%2C%20accounting%20for%20death%20as%20a%20competing%20event%20and%20for%20Medicaid%20disenrollment%20using%20inverse%20probability%20of%20censoring%20weights.%20Across%202001-2015%2C%20the%20proportion%20of%20beneficiaries%20with%20HIV%20who%20were%20retained%5C%2FART%20adherent%20increased%2C%20overall%20and%20in%20all%20subgroups.%20By%202015%2C%20approximately%20half%20of%20beneficiaries%20were%20retained%20in%20care%2C%20and%2042%25%20of%20beneficiaries%20were%20ART%20adherent.%20We%20saw%20meaningful%20differences%20by%20race%5C%2Fethnicity%20and%20region.%20Our%20work%20highlights%20an%20important%20disparity%20in%20the%20HIV%20care%20cascade%20by%20insurance%20status%20during%20this%20time%20period.%22%2C%22date%22%3A%222024-07-30%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1080%5C%2F09540121.2024.2383901%22%2C%22ISSN%22%3A%221360-0451%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222024-09-02T07%3A04%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22SKNX7FXN%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Navuluri%20et%20al.%22%2C%22parsedDate%22%3A%222024-07-25%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENavuluri%2C%20Neelima%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZimo%2C%20Jessica%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EByrd%2C%20Kaitland%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELee%2C%20Kathleen%20Tiffany%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EViglianti%2C%20Elizabeth%3C%5C%2Fspan%3E%20%282024%29.%20The%20Impact%20of%20Dobbs%20v%20Jackson%20on%20Future%20Critical%20Care%20Workforce%20A%20Cross-Sectional%20Survey.%20%3Ci%3EChest%3C%5C%2Fi%3E%2C%20S.%20S0012-%203692%2824%2904844-%20X.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.chest.2024.07.142%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.chest.2024.07.142%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Impact%20of%20Dobbs%20v%20Jackson%20on%20Future%20Critical%20Care%20Workforce%20A%20Cross-Sectional%20Survey%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neelima%22%2C%22lastName%22%3A%22Navuluri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Zimo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaitland%22%2C%22lastName%22%3A%22Byrd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathleen%20Tiffany%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Viglianti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222024-07-25%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.chest.2024.07.142%22%2C%22ISSN%22%3A%221931-3543%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222024-09-02T06%3A51%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22DT22IEUB%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Moolla%20et%20al.%22%2C%22parsedDate%22%3A%222024-07-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMoolla%2C%20Haroon%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavies%2C%20Mary-Ann%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavies%2C%20Claire%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEuvrard%2C%20Jonathan%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EProzesky%2C%20Hans%20W.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20The%20effect%20of%20care%20interruptions%20on%20mortality%20in%20adults%20resuming%20antiretroviral%20therapy.%20%3Ci%3EAIDS%20%28London%2C%20England%29%3C%5C%2Fi%3E%2C%20%3Ci%3E38%3C%5C%2Fi%3E%20%288%29%2C%20S.%201198%26%23x2013%3B1205.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003859%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003859%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20effect%20of%20care%20interruptions%20on%20mortality%20in%20adults%20resuming%20antiretroviral%20therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Haroon%22%2C%22lastName%22%3A%22Moolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans%20W.%22%2C%22lastName%22%3A%22Prozesky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20P.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Orrell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Per%22%2C%22lastName%22%3A%22Von%20Groote%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leigh%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20Southern%20Africa%20%28IeDEA-SA%29%20Collaboration%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20estimate%20the%20relative%20rate%20of%20all-cause%20mortality%20amongst%20those%20on%20antiretroviral%20treatment%20%28ART%29%20with%20a%20history%20of%20interruptions%20compared%20with%20those%20with%20no%20previous%20interruptions%20in%20care.%5CnDESIGN%3A%20Retrospective%20cohort%20study.%5CnMETHODS%3A%20We%20used%20data%20from%20four%20South%20African%20cohorts%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20Southern%20Africa%20collaboration.%20We%20included%20adults%20who%20started%20ART%20between%202004%20and%202019.%20We%20defined%20a%20care%20interruption%20as%20a%20gap%20in%20contact%20longer%20than%20180%5Cu200adays.%20Observation%20time%20prior%20to%20interruption%20was%20allocated%20to%20a%20%27no%20interruption%27%20group.%20Observation%20time%20after%20interruption%20was%20allocated%20to%20one%20of%20two%20groups%20based%20on%20whether%20the%20first%20interruption%20started%20before%206%5Cu200amonths%20of%20ART%20%28%27early%20interruption%27%29%20or%20later%20%28%27late%20interruption%27%29.%20We%20used%20Cox%20regression%20to%20estimate%20hazard%20ratios.%5CnRESULTS%3A%20Sixty-three%20thousand%20six%20hundred%20and%20ninety-two%20participants%20contributed%20162%5Cu200a916%20person-years%20of%20observation.%20There%20were%203469%20deaths.%20Most%20participants%20were%20female%20individuals%20%2867.4%25%29%20and%20the%20median%20age%20at%20ART%20initiation%20was%2033.3%5Cu200ayears%20%28interquartile%20range%3A%2027.5-40.7%29.%20Seventeen%20thousand%20and%20eleven%20%2826.7%25%29%20participants%20experienced%20care%20interruptions.%20Those%20resuming%20ART%20experienced%20increased%20mortality%20compared%20with%20those%20with%20no%20interruptions%3A%20early%20interrupters%20had%20a%20hazard%20ratio%20of%204.37%20%2895%25%20confidence%20interval%20%28CI%29%203.87-4.95%29%20and%20late%20interrupters%20had%20a%20hazard%20ratio%20of%202.74%20%2895%25%20CI%202.39-3.15%29.%20In%20sensitivity%20analyses%2C%20effect%20sizes%20were%20found%20to%20be%20proportional%20to%20the%20length%20of%20time%20used%20to%20define%20interruptions.%5CnCONCLUSION%3A%20Our%20findings%20highlight%20the%20need%20to%20improve%20retention%20in%20care%2C%20regardless%20of%20treatment%20duration.%20Programmes%20to%20encourage%20return%20to%20care%20also%20need%20to%20be%20strengthened.%22%2C%22date%22%3A%222024-07-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003859%22%2C%22ISSN%22%3A%221473-5571%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A47%3A21Z%22%7D%7D%2C%7B%22key%22%3A%226QYKYZZ3%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bakoyannis%20et%20al.%22%2C%22parsedDate%22%3A%222024-07-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBakoyannis%2C%20Giorgos%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EElul%2C%20Batya%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWools-Kaloustian%2C%20Kara%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrown%2C%20Steven%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESemeere%2C%20Aggrey%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Modeling%20the%20HIV%20Cascade%20of%20Care%20Using%20Routinely%20Collected%20Clinical%20Data%20to%20Guide%20Programmatic%20Interventions%20and%20Policy%20Decisions.%20%3Ci%3EJournal%20of%20Acquired%20Immune%20Deficiency%20Syndromes%20%281999%29%3C%5C%2Fi%3E%2C%20%3Ci%3E96%3C%5C%2Fi%3E%20%283%29%2C%20S.%20223%26%23x2013%3B230.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003413%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003413%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Modeling%20the%20HIV%20Cascade%20of%20Care%20Using%20Routinely%20Collected%20Clinical%20Data%20to%20Guide%20Programmatic%20Interventions%20and%20Policy%20Decisions%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giorgos%22%2C%22lastName%22%3A%22Bakoyannis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Batya%22%2C%22lastName%22%3A%22Elul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%20K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Castelnuovo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gertrude%22%2C%22lastName%22%3A%22Nakigozi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rita%22%2C%22lastName%22%3A%22Lyamuya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22East%20Africa%20IeDEA%20Regional%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20HIV%20care%20cascade%20is%20a%20framework%20to%20examine%20effectiveness%20of%20HIV%20programs%20and%20progress%20toward%20global%20targets%20to%20end%20the%20epidemic%20but%20has%20been%20conceptualized%20as%20a%20unidirectional%20process%20that%20ignores%20cyclical%20care%20patterns.%20We%20present%20a%20dynamic%20cascade%20that%20accounts%20for%20patient%20%5C%22churn%5C%22%20and%20apply%20novel%20analytic%20techniques%20to%20readily%20available%20clinical%20data%20to%20robustly%20estimate%20program%20outcomes%20and%20efficiently%20assess%20progress%20toward%20global%20targets.%5CnMETHODS%3A%20Data%20were%20assessed%20for%2035%2C649%20people%20living%20with%20HIV%20and%20receiving%20care%20at%2078%20clinics%20in%20East%20Africa%20between%202014%20and%202020.%20Patients%20were%20aged%20%5Cu226515%20years%20and%20had%20%5Cu22651%20viral%20load%20measurements.%20We%20used%20multi-state%20models%20to%20estimate%20the%20probability%20of%20being%20in%201%20of%205%20states%20of%20a%20dynamic%20HIV%20cascade%3A%20%281%29%20in%20HIV%20care%20but%20not%20on%20antiretroviral%20therapy%20%28ART%29%2C%20%282%29%20on%20ART%2C%20%283%29%20virally%20suppressed%2C%20%284%29%20in%20a%20gap-in-care%2C%20and%20%285%29%20deceased%20and%20compared%20these%20among%20subgroups.%20To%20assess%20progress%20toward%20global%20targets%2C%20we%20summed%20those%20probabilities%20across%20patients%20and%20generated%20population-level%20proportions%20of%20patients%20on%20ART%20and%20virally%20suppressed%20in%20mid-2020.%5CnRESULTS%3A%20One%20year%20after%20enrollment%2C%202.8%25%20of%20patients%20had%20not%20initiated%20ART%2C%2086.7%25%20were%20receiving%20ART%2C%2057.4%25%20were%20virally%20suppressed%2C%2010.2%25%20were%20disengaged%20from%20care%2C%20and%200.3%25%20had%20died.%20At%205%20years%2C%20the%20proportion%20on%20ART%20remained%20steady%20but%20viral%20suppression%20increased%20to%2077.2%25.%20Of%20those%20aged%2015-25%2C%20%3E20%25%20had%20disengaged%20from%20care%20and%20%3C60%25%20were%20virally%20suppressed.%20In%20mid-2020%2C%2090.1%25%20of%20the%20cohort%20was%20on%20ART%2C%2090.7%25%20of%20whom%20had%20suppressed%20virus.%5CnCONCLUSIONS%3A%20Novel%20analytic%20approaches%20can%20characterize%20patient%20movement%20through%20a%20dynamic%20HIV%20cascade%20and%2C%20importantly%2C%20by%20capitalizing%20on%20readily%20available%20data%20from%20clinical%20cohorts%2C%20offer%20an%20efficient%20approach%20to%20estimate%20population-level%20proportions%20of%20patients%20on%20ART%20and%20virally%20suppressed.%20Significant%20progress%20toward%20global%20targets%20was%20observed%20in%20our%20cohort%20but%20challenges%20remain%20among%20younger%20patients.%22%2C%22date%22%3A%222024-07-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003413%22%2C%22ISSN%22%3A%221944-7884%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A42%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22NMND3SBE%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Asangbeh-Kerman%20et%20al.%22%2C%22parsedDate%22%3A%222024-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAsangbeh-Kerman%2C%20Serra%20Lem%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavidovi%26%23x107%3B%2C%20Ma%26%23x161%3Ba%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETaghavi%2C%20Katayoun%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDhokotera%2C%20Tafadzwa%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EManasyan%2C%20Albert%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Cervical%20cancer%20prevention%20and%20care%20in%20HIV%20clinics%20across%20sub-Saharan%20Africa%3A%20results%20of%20a%20facility-based%20survey.%20%3Ci%3EJournal%20of%20the%20International%20AIDS%20Society%3C%5C%2Fi%3E%2C%20%3Ci%3E27%3C%5C%2Fi%3E%20%287%29%2C%20S.%20e26303.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26303%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26303%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cervical%20cancer%20prevention%20and%20care%20in%20HIV%20clinics%20across%20sub-Saharan%20Africa%3A%20results%20of%20a%20facility-based%20survey%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serra%20Lem%22%2C%22lastName%22%3A%22Asangbeh-Kerman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ma%5Cu0161a%22%2C%22lastName%22%3A%22Davidovi%5Cu0107%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katayoun%22%2C%22lastName%22%3A%22Taghavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tafadzwa%22%2C%22lastName%22%3A%22Dhokotera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Manasyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anjali%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christella%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cleophas%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hannock%22%2C%22lastName%22%3A%22Tweya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josephine%22%2C%22lastName%22%3A%22Muhairwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karl-Gunter%22%2C%22lastName%22%3A%22Technau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marielle%22%2C%22lastName%22%3A%22Jousse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oliver%22%2C%22lastName%22%3A%22Ezechi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Omenge%22%2C%22lastName%22%3A%22Orang%27o%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Bosomprah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Pierre%20Boni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Partha%22%2C%22lastName%22%3A%22Basu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Bohlius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20To%20eliminate%20cervical%20cancer%20%28CC%29%2C%20access%20to%20and%20quality%20of%20prevention%20and%20care%20services%20must%20be%20monitored%2C%20particularly%20for%20women%20living%20with%20HIV%20%28WLHIV%29.%20We%20assessed%20implementation%20practices%20in%20HIV%20clinics%20across%20sub-Saharan%20Africa%20%28SSA%29%20to%20identify%20gaps%20in%20the%20care%20cascade%20and%20used%20aggregated%20patient%20data%20to%20populate%20cascades%20for%20WLHIV%20attending%20HIV%20clinics.%5CnMETHODS%3A%20Our%20facility-based%20survey%20was%20administered%20between%20November%202020%20and%20July%202021%20in%2030%20HIV%20clinics%20across%20SSA%20that%20participate%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%20We%20performed%20a%20qualitative%20site-level%20assessment%20of%20CC%20prevention%20and%20care%20services%20and%20analysed%20data%20from%20routine%20care%20of%20WLHIV%20in%20SSA.%5CnRESULTS%3A%20Human%20papillomavirus%20%28HPV%29%20vaccination%20was%20offered%20in%2033%25%20of%20sites.%20Referral%20for%20CC%20diagnosis%20%2842%25%29%20and%20treatment%20%2870%25%29%20was%20common%2C%20but%20not%20free%20at%20about%2050%25%20of%20sites.%20Most%20sites%20had%20electronic%20health%20information%20systems%20%2890%25%29%2C%20but%20data%20to%20inform%20indicators%20to%20monitor%20global%20targets%20for%20CC%20elimination%20in%20WLHIV%20were%20not%20routinely%20collected%20in%20these%20sites.%20Data%20were%20collected%20routinely%20in%20only%2036%25%20of%20sites%20that%20offered%20HPV%20vaccination%2C%2033%25%20of%20sites%20that%20offered%20cervical%20screening%20and%2020%25%20of%20sites%20that%20offered%20pre-cancer%20and%20CC%20treatment.%5CnCONCLUSIONS%3A%20Though%20CC%20prevention%20and%20care%20services%20have%20long%20been%20available%20in%20some%20HIV%20clinics%20across%20SSA%2C%20patient%20and%20programme%20monitoring%20need%20to%20be%20improved.%20Countries%20should%20consider%20leveraging%20their%20existing%20health%20information%20systems%20and%20use%20monitoring%20tools%20provided%20by%20the%20World%20Health%20Organization%20to%20improve%20CC%20prevention%20programmes%20and%20access%2C%20and%20to%20track%20their%20progress%20towards%20the%20goal%20of%20eliminating%20CC.%22%2C%22date%22%3A%222024-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26303%22%2C%22ISSN%22%3A%221758-2652%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A42%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22FPFPK64D%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pirsl%20et%20al.%22%2C%22parsedDate%22%3A%222024-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPirsl%2C%20Filip%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKeruly%2C%20Jeanne%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMoore%2C%20Richard%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELau%2C%20Bryan%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJoshu%2C%20Corinne%20E.%3C%5C%2Fspan%3E%20%282024%29.%20Determinants%20of%20receipt%20of%20prostate%20cancer%20screening%20among%20men%20living%20with%20HIV%20enrolled%20in%20an%20urban%20HIV%20Clinic%20in%20the%20United%20States%20over%20the%20period%20of%202000-2020.%20%3Ci%3EPreventive%20Medicine%3C%5C%2Fi%3E%2C%20%3Ci%3E184%3C%5C%2Fi%3E%2C%20S.%20108000.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ypmed.2024.108000%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ypmed.2024.108000%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Determinants%20of%20receipt%20of%20prostate%20cancer%20screening%20among%20men%20living%20with%20HIV%20enrolled%20in%20an%20urban%20HIV%20Clinic%20in%20the%20United%20States%20over%20the%20period%20of%202000-2020%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Filip%22%2C%22lastName%22%3A%22Pirsl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeanne%20C.%22%2C%22lastName%22%3A%22Keruly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%22%2C%22lastName%22%3A%22Lau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%20E.%22%2C%22lastName%22%3A%22Joshu%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Prostate%20cancer%20is%20projected%20to%20account%20for%20the%20greatest%20proportion%20of%20cancer-related%20burden%20among%20men%20with%20HIV.%20However%2C%20incidence%20is%20reportedly%20lower%20than%20in%20men%20without%20HIV%2C%20potentially%20due%20to%20differences%20in%20screening.%20Factors%20influencing%20receipt%20of%20screening%20in%20men%20with%20HIV%20are%20unknown.%20We%20described%20receipt%20of%20prostate-specific%20antigen%20%28PSA%29%20testing%20and%20assessed%20factors%20for%20association%20with%20receipt%20of%20PSA%20test.%5CnMETHODS%3A%20Demographics%2C%20measures%20of%20HIV%20and%20related%20care%2C%20and%20non-HIV%20care%20were%20assessed%20for%20association%20with%20receipt%20of%20first%20PSA%20test%20in%20men%20%5Cu226540%5Cu00a0years%20old%20each%20calendar%20year%20in%202000-2020%20using%20univariable%20and%20multivariable%20Poisson%20regression.%20Models%20were%20additionally%20stratified%20by%20calendar%20period%20to%20identify%20changes%20in%20determinants%20of%20PSA%20test%20as%20prostate%20cancer%20screening%20guidelines%20changed.%5CnRESULTS%3A%20Men%20%28n%5Cu00a0%3D%5Cu00a02%2C063%29%2072%25%20Non-Hispanic%20Black%2C%20median%20age%20of%2047%20%28IQR%3A%2041%2C%2053%29%2C%20contributed%20median%20of%204.7%5Cu00a0years%20%28IQR%3A%202.3%2C%2010.0%29%20of%20follow-up.%20Receipt%20of%20antiretroviral%20therapy%20%28aIRR%5Cu00a0%3D%5Cu00a01.33%3B%2095%25%20CI%3A%201.14%2C%201.55%29%2C%20engagement%20in%20HIV%20care%20%28aIRR%5Cu00a0%3D%5Cu00a02.09%3B%2095%25%20CI%3A%201.66%2C%202.62%29%2C%20history%20of%20testosterone-replacement%20therapy%20%28aIRR%5Cu00a0%3D%5Cu00a01.34%3B%2095%25%20CI%3A%201.19%2C%201.50%29%2C%20urologist%20evaluation%20%28aIRR%5Cu00a0%3D%5Cu00a01.66%3B%2095%25%20CI%3A%201.35%2C%202.05%29%2C%20and%20receipt%20of%20PSA%20test%20in%20preceding%20two%20years%20%28no%20elevated%20PSA%20aIRR%5Cu00a0%3D%5Cu00a02.37%3B%2095%25%20CI%3A%202.16%2C%202.61%3B%20elevated%20PSA%20aIRR%5Cu00a0%3D%5Cu00a04.35%3B%2095%25%20CI%3A%203.24%2C%205.84%29%20were%20associated%20with%20PSA%20testing%20in%20men%20aged%2050%20or%20older.%20Associations%20varied%20across%20calendar%20time.%5CnCONCLUSION%3A%20Findings%20suggest%20men%20with%20greater%20interaction%20with%20healthcare%20are%20more%20likely%20to%20receive%20PSA%20test.%20Measures%20of%20control%20of%20HIV%20did%20not%20appear%20to%20influence%20the%20decision%20to%20screen.%22%2C%22date%22%3A%222024-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ypmed.2024.108000%22%2C%22ISSN%22%3A%221096-0260%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A59%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22VNPED45I%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Shafi%20et%20al.%22%2C%22parsedDate%22%3A%222024-06-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShafi%2C%20Jenine%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVirk%2C%20Maneet%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKalk%2C%20Emma%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECarlucci%2C%20James%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChepkemoi%2C%20Audrey%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Pharmacovigilance%20in%20Pregnancy%20Studies%2C%20Exposures%20and%20Outcomes%20Ascertainment%2C%20and%20Findings%20from%20Low-%20and%20Middle-Income%20Countries%3A%20A%20Scoping%20Review.%20%3Ci%3EDrug%20Safety%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40264-024-01445-1%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40264-024-01445-1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pharmacovigilance%20in%20Pregnancy%20Studies%2C%20Exposures%20and%20Outcomes%20Ascertainment%2C%20and%20Findings%20from%20Low-%20and%20Middle-Income%20Countries%3A%20A%20Scoping%20Review%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jenine%22%2C%22lastName%22%3A%22Shafi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maneet%20K.%22%2C%22lastName%22%3A%22Virk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Kalk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20G.%22%2C%22lastName%22%3A%22Carlucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Chepkemoi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caitlin%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%20S.%22%2C%22lastName%22%3A%22McHenry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edwin%22%2C%22lastName%22%3A%22Were%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Humphrey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ushma%20C.%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rena%20C.%22%2C%22lastName%22%3A%22Patel%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Pharmacovigilance%20%28PV%29%2C%20or%20the%20ongoing%20safety%20monitoring%20after%20a%20medication%20has%20been%20licensed%2C%20plays%20a%20crucial%20role%20in%20pregnancy%2C%20as%20clinical%20trials%20often%20exclude%20pregnant%20people.%20It%20is%20important%20to%20understand%20how%20pregnancy%20PV%20projects%20operate%20in%20low-%20and%20middle-income%20countries%20%28LMICs%29%2C%20where%20there%20is%20a%20disproportionate%20lack%20of%20PV%20data%20yet%20a%5Cu00a0high%20burden%20of%20adverse%20pregnancy%20outcomes.%20We%20conducted%20a%20scoping%20review%20to%20assess%20how%20exposures%20and%20outcomes%20were%20measured%20in%20recently%20published%20pregnancy%20PV%20projects%20in%20LMICs.%5CnMETHODS%3A%20We%20utilized%20a%20search%20string%2C%20secondary%20review%2C%20and%20team%20knowledge%20to%20review%20publications%20focusing%20on%20therapeutic%20or%20vaccine%20exposures%20among%20pregnant%20people%20in%20LMICs.%20We%20screened%20abstracts%20for%20relevance%20before%20conducting%20a%20full%20text%20review%2C%20and%20documented%20measurements%20of%20exposures%20and%20outcomes%20%28categorized%20as%20maternal%2C%20birth%2C%20or%20neonatal%5C%2Finfant%29%20among%20other%20factors%2C%20including%20study%20topic%2C%20setting%2C%20and%20design%2C%20comparator%20groups%2C%20and%20funding%20sources.%5CnRESULTS%3A%20We%20identified%2031%20PV%20publications%20spanning%20at%20least%2024%20LMICs%2C%20all%20focusing%20on%20therapeutics%20or%20vaccines%20for%20infectious%20diseases%2C%20including%20HIV%20%28n%20%3D%2017%29%2C%20tuberculosis%20%28TB%3B%20n%20%3D%209%29%2C%20malaria%20%28n%20%3D%207%29%2C%20pertussis%2C%20tetanus%2C%20and%20diphtheria%20%28n%20%3D%201%29%2C%20and%20influenza%20%28n%20%3D%203%29.%20As%20for%20outcomes%2C%20n%20%3D%2015%2C%20n%20%3D%2031%2C%20and%20n%20%3D%2020%20of%20the%20publications%20covered%20maternal%2C%20birth%2C%20and%20neonatal%5C%2Finfant%20outcomes%2C%20respectively.%20Among%20HIV-specific%20publications%2C%20the%20primary%20exposure-outcome%20relationship%20of%20focus%20was%20exposure%20to%20maternal%20antiretroviral%20therapy%20and%20adverse%20outcomes.%20For%20TB-specific%20publications%2C%20the%20main%20exposures%20of%20interest%20were%20second-line%20drug-resistant%20TB%20and%20isoniazid-based%20prevention%20therapeutics%20for%20pregnant%20people%20living%20with%20HIV.%20For%20malaria-specific%20publications%2C%20the%20primary%20exposure-outcome%20relationship%20of%20interest%20was%20antimalarial%20medication%20exposure%20during%20pregnancy%20and%20adverse%20outcomes.%20Among%20vaccine-focused%20publications%2C%20the%20exposure%20was%20assessed%20during%20a%20specific%20time%20during%20pregnancy%2C%20with%20an%20overall%20interest%20in%20vaccine%20safety%20and%5C%2For%20efficacy.%20The%20study%20settings%20were%20frequently%20from%20Africa%2C%20designs%20varied%20from%20cohort%20or%20cross-sectional%20studies%20to%20clinical%20trials%2C%20and%20funding%20sources%20were%20largely%20from%20high-income%20countries.%5CnCONCLUSION%3A%20The%20published%20pregnancy%20PV%20projects%20were%20largely%20centered%20in%20Africa%20and%20concerned%20with%20infectious%20diseases.%20This%20may%20reflect%20the%20disease%20burden%20in%20LMICs%20but%20also%20funding%20priorities%20from%20high-income%20countries.%20As%20the%20prevalence%20of%20non-communicable%20diseases%20increases%20in%20LMICs%2C%20PV%20projects%20will%20have%20to%20broaden%20their%20scope.%20Birth%20and%20neonatal%5C%2Finfant%20outcomes%20were%20most%20reported%2C%20with%20fewer%20reporting%20on%20maternal%20outcomes%20and%20none%20on%20longer-term%20child%20outcomes%3B%20additionally%2C%20heterogeneity%20existed%20in%20definitions%20and%20ascertainment%20of%20specific%20measures.%20Notably%2C%20almost%20all%20projects%20covered%20a%20single%20therapeutic%20exposure%2C%20missing%20an%20opportunity%20to%20leverage%20their%20projects%20to%20cover%20additional%20exposures%2C%20add%20scientific%20rigor%2C%20create%20uniformity%20across%20health%20services%2C%20and%20bolster%20existing%20health%20systems.%20For%20many%20publications%2C%20the%20timing%20of%20exposure%2C%20specifically%20by%20trimester%2C%20was%20crucial%20to%20maternal%20and%20neonatal%20safety.%20While%20currently%20published%20pregnancy%20PV%20literature%20offer%20insights%20into%20the%20PV%20landscape%20in%20LMICs%2C%20further%20work%20is%20needed%20to%20standardize%20definitions%20and%20measurements%2C%20integrate%20PV%20projects%20across%20health%20services%2C%20and%20establish%20longer-term%20monitoring.%22%2C%22date%22%3A%222024-06-21%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs40264-024-01445-1%22%2C%22ISSN%22%3A%221179-1942%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A43%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22QF8IHYPK%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vinikoor%20et%20al.%22%2C%22parsedDate%22%3A%222024-06-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVinikoor%2C%20Michael%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHamusonde%2C%20Kalongo%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMuula%2C%20Guy%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAsombang%2C%20Mah%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERiebensahm%2C%20Carlotta%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Long-term%20Hepatitis%20B%20and%20Liver%20Outcomes%20Among%20Adults%20Taking%20Tenofovir-Containing%20Antiretroviral%20Therapy%20for%20HBV%5C%2FHIV%20Coinfection%20in%20Zambia.%20%3Ci%3EClinical%20Infectious%20Diseases%3A%20An%20Official%20Publication%20of%20the%20Infectious%20Diseases%20Society%20of%20America%3C%5C%2Fi%3E%2C%20%3Ci%3E78%3C%5C%2Fi%3E%20%286%29%2C%20S.%201583%26%23x2013%3B1590.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad654%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad654%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20Hepatitis%20B%20and%20Liver%20Outcomes%20Among%20Adults%20Taking%20Tenofovir-Containing%20Antiretroviral%20Therapy%20for%20HBV%5C%2FHIV%20Coinfection%20in%20Zambia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Vinikoor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kalongo%22%2C%22lastName%22%3A%22Hamusonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Muula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mah%22%2C%22lastName%22%3A%22Asombang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlotta%22%2C%22lastName%22%3A%22Riebensahm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Chitundu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronica%22%2C%22lastName%22%3A%22Sunkuntu-Sichizya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Debika%22%2C%22lastName%22%3A%22Bhattacharya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edford%22%2C%22lastName%22%3A%22Sinkala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georg%22%2C%22lastName%22%3A%22Lauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raymond%22%2C%22lastName%22%3A%22Chung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wilson%22%2C%22lastName%22%3A%22Mbewe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Bosomprah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Wandeler%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Long-term%20outcomes%20of%20tenofovir-containing%20antiretroviral%20therapy%20%28ART%29%20for%20hepatitis%20B%20virus%20%28HBV%29%5C%2Fhuman%20immunodeficiency%20virus%20%28HIV%29%20coinfection%20were%20evaluated%20in%20Zambia.%5CnMETHODS%3A%20A%20prospective%20cohort%20of%20adults%20with%20HIV%20and%20hepatitis%20B%20surface%20antigen%20%28HBsAg%29-positivity%20was%20enrolled%20at%20ART%20initiation.%20On%20tenofovir-containing%20ART%2C%20we%20ascertained%20HBV%20viral%20load%20%28VL%29%20non-suppression%2C%20alanine%20aminotransferase%20%28ALT%29%20elevation%2C%20serologic%20end-points%2C%20progression%20of%20liver%20fibrosis%20based%20on%20elastography%2C%20and%20hepatocellular%20carcinoma%20%28HCC%29%20incidence.%20We%20also%20described%20a%20subgroup%20%28low%20HBV%20VL%20and%20no%5C%2Fminimal%20fibrosis%20at%20baseline%29%20that%2C%20under%20current%20international%20guidelines%2C%20would%20not%20have%20been%20treated%20in%20the%20absence%20of%20their%20HIV%20infection.%5CnRESULTS%3A%20Among%20289%20participants%20at%20ART%20start%2C%20median%20age%20was%2034%20years%2C%2040.1%25%20were%20women%2C%20median%20CD4%20count%20was%20191%20cells%5C%2Fmm3%2C%2044.2%25%20were%20hepatitis%20B%20e%20antigen-positive%2C%20and%2028.4%25%20had%20liver%20fibrosis%5C%2Fcirrhosis.%20Over%20median%205.91%20years%20of%20ART%2C%2013.6%25%20developed%20HBV%20viral%20non-suppression%2C%20which%20was%20associated%20with%20advanced%20HIV%20disease.%20ALT%20elevation%20on%20ART%20was%20linked%20with%20HBV%20VL%20non-suppression.%20Regression%20of%20fibrosis%20and%20cirrhosis%20were%20common%2C%20progression%20to%20cirrhosis%20was%20absent%2C%20and%20no%20cases%20of%20HCC%20were%20ascertained.%20HBsAg%20seroclearance%20was%209.4%25%20at%202%20and%2015.4%25%20at%205%20years%2C%20with%20higher%20rates%20among%20patients%20with%20low%20baseline%20HBV%20replication%20markers.%5CnCONCLUSIONS%3A%20Reassuring%20long-term%20liver%20outcomes%20were%20ascertained%20during%20tenofovir-based%20ART%20for%20HBV%5C%2FHIV%20coinfection%20in%20Zambia.%20Higher%20than%20expected%20HBsAg%20seroclearance%20during%20ART%20underscores%20the%20need%20to%20include%20people%20with%20HIV%20in%20HBV%20cure%20research.%22%2C%22date%22%3A%222024-06-14%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciad654%22%2C%22ISSN%22%3A%221537-6591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222024-07-26T08%3A30%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22EI8FELZ2%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vakaniaki%20et%20al.%22%2C%22parsedDate%22%3A%222024-06-13%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVakaniaki%2C%20Emmanuel%20Hasivirwe%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKacita%2C%20Cris%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKinganda-Lusamaki%2C%20Eddy%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EO%26%23x2019%3BToole%2C%20%26%23xC1%3Bine%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWawina-Bokalanga%2C%20Tony%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Sustained%20human%20outbreak%20of%20a%20new%20MPXV%20clade%20I%20lineage%20in%20eastern%20Democratic%20Republic%20of%20the%20Congo.%20%3Ci%3ENature%20Medicine%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41591-024-03130-3%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41591-024-03130-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sustained%20human%20outbreak%20of%20a%20new%20MPXV%20clade%20I%20lineage%20in%20eastern%20Democratic%20Republic%20of%20the%20Congo%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%20Hasivirwe%22%2C%22lastName%22%3A%22Vakaniaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cris%22%2C%22lastName%22%3A%22Kacita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eddy%22%2C%22lastName%22%3A%22Kinganda-Lusamaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c1ine%22%2C%22lastName%22%3A%22O%27Toole%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tony%22%2C%22lastName%22%3A%22Wawina-Bokalanga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Mukadi-Bamuleka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrienne%22%2C%22lastName%22%3A%22Amuri-Aziza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Malyamungu-Bubala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franklin%22%2C%22lastName%22%3A%22Mweshi-Kumbana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9andre%22%2C%22lastName%22%3A%22Mutimbwa-Mambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Freddy%22%2C%22lastName%22%3A%22Belesi-Siangoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Mujula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edyth%22%2C%22lastName%22%3A%22Parker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline-Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Muswamba-Kayembe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabin%20S.%22%2C%22lastName%22%3A%22Nundu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20S.%22%2C%22lastName%22%3A%22Lushima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Claude%22%2C%22lastName%22%3A%22Makangara-Cigolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Noella%22%2C%22lastName%22%3A%22Mulopo-Mukanya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Pukuta-Simbu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Prince%22%2C%22lastName%22%3A%22Akil-Bandali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Kavunga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ombotimbe%22%2C%22lastName%22%3A%22Abdramane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabel%22%2C%22lastName%22%3A%22Brosius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugene%22%2C%22lastName%22%3A%22Bangwen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Koen%22%2C%22lastName%22%3A%22Vercauteren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%20A.%22%2C%22lastName%22%3A%22Sam-Agudu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20J.%22%2C%22lastName%22%3A%22Mills%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Tshiani-Mbaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%20A.%22%2C%22lastName%22%3A%22Hoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%20W.%22%2C%22lastName%22%3A%22Rimoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%20E.%22%2C%22lastName%22%3A%22Hensley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jason%22%2C%22lastName%22%3A%22Kindrachuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cheryl%22%2C%22lastName%22%3A%22Baxter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tulio%22%2C%22lastName%22%3A%22de%20Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahidjo%22%2C%22lastName%22%3A%22Ayouba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Peeters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delaporte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steve%22%2C%22lastName%22%3A%22Ahuka-Mundeke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%20L.%22%2C%22lastName%22%3A%22Mohr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%20J.%22%2C%22lastName%22%3A%22Sullivan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Muyembe-Tamfum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20B.%22%2C%22lastName%22%3A%22Nachega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Rambaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurens%22%2C%22lastName%22%3A%22Liesenborghs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Placide%22%2C%22lastName%22%3A%22Mbala-Kingebeni%22%7D%5D%2C%22abstractNote%22%3A%22Outbreaks%20of%20monkeypox%20%28mpox%29%20have%20historically%20resulted%20from%20zoonotic%20spillover%20of%20clade%20I%20monkeypox%20virus%20%28MPXV%29%20in%20Central%20Africa%20and%20clade%20II%20MPXV%20in%20West%20Africa.%20In%202022%2C%20subclade%20IIb%20caused%20a%20global%20epidemic%20linked%20to%20transmission%20through%20sexual%20contact.%20Here%20we%20describe%20the%20epidemiological%20and%20genomic%20features%20of%20an%20mpox%20outbreak%20in%20a%20mining%20region%20in%20eastern%20Democratic%20Republic%20of%20the%20Congo%2C%20caused%20by%20clade%20I%20MPXV.%20Surveillance%20data%20collected%20between%20September%202023%20and%20January%202024%20identified%20241%20suspected%20cases.%20Genomic%20analysis%20demonstrates%20a%20distinct%20clade%20I%20lineage%20divergent%20from%20previously%20circulating%20strains%20in%20the%20Democratic%20Republic%20of%20the%20Congo.%20Of%20the%20108%20polymerase%20chain%20reaction-confirmed%20mpox%20cases%2C%20the%20median%20age%20of%20individuals%20was%2022%5Cu2009years%2C%2051.9%25%20were%20female%20and%2029%25%20were%20sex%20workers%2C%20suggesting%20a%20potential%20role%20for%20sexual%20transmission.%20The%20predominance%20of%20APOBEC3-type%20mutations%20and%20the%20estimated%20emergence%20time%20around%20mid-September%202023%20imply%20recent%20sustained%20human-to-human%20transmission.%22%2C%22date%22%3A%222024-06-13%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41591-024-03130-3%22%2C%22ISSN%22%3A%221546-170X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A36%3A47Z%22%7D%7D%2C%7B%22key%22%3A%224VTZ6XT2%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kassanjee%20et%20al.%22%2C%22parsedDate%22%3A%222024-06-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKassanjee%2C%20Reshma%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavies%2C%20Mary-Ann%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHeekes%2C%20Alexa%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMahomed%2C%20Hassan%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHawkridge%2C%20Anthony%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20COVID-19%20Vaccine%20Uptake%20and%20Effectiveness%20by%20Time%20since%20Vaccination%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%3A%20An%20Observational%20Cohort%20Study%20during%202020-2022.%20%3Ci%3EVaccines%3C%5C%2Fi%3E%2C%20%3Ci%3E12%3C%5C%2Fi%3E%20%286%29%2C%20S.%20628.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fvaccines12060628%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fvaccines12060628%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22COVID-19%20Vaccine%20Uptake%20and%20Effectiveness%20by%20Time%20since%20Vaccination%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%3A%20An%20Observational%20Cohort%20Study%20during%202020-2022%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reshma%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexa%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hassan%22%2C%22lastName%22%3A%22Mahomed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%20J.%22%2C%22lastName%22%3A%22Hawkridge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erna%22%2C%22lastName%22%3A%22Morden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theuns%22%2C%22lastName%22%3A%22Jacobs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cheryl%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harry%22%2C%22lastName%22%3A%22Moultrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20J.%22%2C%22lastName%22%3A%22Lessells%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolette%22%2C%22lastName%22%3A%22Van%20Der%20Walt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juanita%20O.%22%2C%22lastName%22%3A%22Arendse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Wolter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sibongile%22%2C%22lastName%22%3A%22Walaza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Waasila%22%2C%22lastName%22%3A%22Jassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22von%20Gottberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20L.%22%2C%22lastName%22%3A%22Hannan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20R.%22%2C%22lastName%22%3A%22Feikin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%22%2C%22lastName%22%3A%22Cloete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Boulle%22%7D%5D%2C%22abstractNote%22%3A%22There%20are%20few%20data%20on%20the%20real-world%20effectiveness%20of%20COVID-19%20vaccines%20and%20boosting%20in%20Africa%2C%20which%20experienced%20widespread%20SARS-CoV-2%20infection%20before%20vaccine%20availability.%20We%20assessed%20the%20association%20between%20vaccination%20and%20severe%20COVID-19%20in%20the%20Western%20Cape%2C%20South%20Africa%2C%20in%20an%20observational%20cohort%20study%20of%20%3E2%20million%20adults%20during%202020-2022.%20We%20described%20SARS-CoV-2%20testing%2C%20COVID-19%20outcomes%2C%20and%20vaccine%20uptake%20over%20time.%20We%20used%20multivariable%20cox%20models%20to%20estimate%20the%20association%20of%20BNT162b2%20and%20Ad26.COV2.S%20vaccination%20with%20COVID-19-related%20hospitalization%20and%20death%2C%20adjusting%20for%20demographic%20characteristics%2C%20underlying%20health%20conditions%2C%20socioeconomic%20status%20proxies%2C%20and%20healthcare%20utilization.%20We%20found%20that%20by%20the%20end%20of%202022%2C%2041%25%20of%20surviving%20adults%20had%20completed%20vaccination%20and%208%25%20had%20received%20a%20booster%20dose.%20Recent%20vaccination%20was%20associated%20with%20notable%20reductions%20in%20severe%20COVID-19%20during%20periods%20dominated%20by%20Delta%2C%20and%20Omicron%20BA.1%5C%2F2%20and%20BA.4%5C%2F5%20%28sub%29lineages.%20During%20the%20latest%20Omicron%20BA.4%5C%2F5%20wave%2C%20within%203%20months%20of%20vaccination%20or%20boosting%2C%20BNT162b2%20and%20Ad26.COV2.S%20were%20each%2084%25%20effective%20against%20death%20%2895%25%20CIs%3A%2057-94%20and%2049-95%2C%20respectively%29.%20However%2C%20distinct%20reductions%20of%20effectiveness%20occurred%20at%20longer%20times%20post%20completing%20or%20boosting%20vaccination.%20Results%20highlight%20the%20importance%20of%20continued%20emphasis%20on%20COVID-19%20vaccination%20and%20boosting%20for%20those%20at%20high%20risk%20of%20severe%20COVID-19%2C%20even%20in%20settings%20with%20widespread%20infection-induced%20immunity.%22%2C%22date%22%3A%222024-06-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fvaccines12060628%22%2C%22ISSN%22%3A%222076-393X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A46%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22AQRXVE7I%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hutchinson%20et%20al.%22%2C%22parsedDate%22%3A%222024-06-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHutchinson%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENeesgard%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKowalska%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGrabmeier-Pfistershammer%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJohnson%2C%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Clinical%20characteristics%20of%20women%20with%20HIV%20in%20the%20RESPOND%20cohort%3A%20A%20descriptive%20analysis%20and%20comparison%20to%20men.%20%3Ci%3EHIV%20Medicine%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhiv.13662%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhiv.13662%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20characteristics%20of%20women%20with%20HIV%20in%20the%20RESPOND%20cohort%3A%20A%20descriptive%20analysis%20and%20comparison%20to%20men%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Hutchinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Neesgard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Kowalska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Grabmeier-Pfistershammer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Kusejko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22De%20Wit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Wit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Mussini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Castagna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Stecher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Pradier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Domingo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Carlander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Wasmuth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Chkhartishvili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Uzdaviniene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Haberl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22d%27Arminio%20Monforte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Garges%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Gallant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Said%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Schmied%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22van%20der%20Valk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Konopnicki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Jaschinski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mocroft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Greenberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Burns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Ryom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Petoumenos%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Women%20with%20HIV%20are%20globally%20underrepresented%20in%20clinical%20research.%20Existing%20studies%20often%20focus%20on%20reproductive%20outcomes%2C%20seldom%20focus%20on%20older%20women%2C%20and%20are%20often%20underpowered%20to%20assess%20sex%5C%2Fgender%20differences.%20We%20describe%20CD4%2C%20HIV%20viral%20load%20%28VL%29%2C%20clinical%20characteristics%2C%20comorbidity%20burden%2C%20and%20use%20of%20antiretroviral%20therapy%20%28ART%29%20among%20women%20with%20HIV%20in%20the%20RESPOND%20study%20and%20compare%20them%20with%20those%20of%20the%20men%20in%20RESPOND.%5CnMETHODS%3A%20RESPOND%20is%20a%20prospective%2C%20multi-cohort%20collaboration%20including%20over%2034%5Cu2009000%20people%20with%20HIV%20from%20across%20Europe%20and%20Australia.%20Demographic%20and%20clinical%20characteristics%2C%20including%20CD4%5C%2FVL%2C%20comorbidity%20burden%2C%20and%20ART%20are%20presented%20at%20baseline%2C%20defined%20as%20the%20latter%20of%201%20January%202012%20or%20enrolment%20into%20the%20local%20cohort%2C%20stratified%20by%20age%20and%20sex%5C%2Fgender.%20We%20further%20stratify%20men%20by%20reported%20mode%20of%20HIV%20acquisition%2C%20men%20who%20have%20sex%20with%20men%20%28MSM%29%20and%20non-MSM.%5CnRESULTS%3A%20Women%20account%20for%2026.0%25%20%28n%5Cu2009%3D%5Cu20099019%29%20of%20the%20cohort%2C%20with%20a%20median%20age%20of%2042.2%5Cu2009years%20%28interquartile%20range%20%5BIQR%5D%2034.7-49.1%29.%20The%20majority%20%2859.3%25%29%20of%20women%20were%20white%2C%20followed%20by%2030.3%25%20Black.%20Most%20women%20%2875.8%25%29%20had%20acquired%20HIV%20heterosexually%20and%2015.9%25%20via%20injecting%20drug%20use.%20Nearly%20half%20%2844.8%25%29%20were%20receiving%20a%20boosted%20protease%20inhibitor%2C%2031.4%25%20a%20non-nucleoside%20reverse%20transcriptase%20inhibitor%2C%20and%207.8%25%20an%20integrase%20strand%20transfer%20inhibitor.%20The%20baseline%20year%20was%202012%20for%2073.2%25%20of%20women%20and%20%3E2019%20for%204.2%25.%20Median%20CD4%20was%20523%20%28IQR%20350-722%29%20cells%5C%2F%5Cu03bcl%2C%20and%2073.6%25%20of%20women%20had%20a%20VL%5Cu2009%3C200%20copies%5C%2FmL.%20Among%20the%20ART-na%5Cu00efve%20population%2C%20women%20were%20more%20likely%20than%20MSM%20but%20less%20likely%20than%20non-MSM%20%28p%20%3C%5Cu20090.001%29%20to%20have%20CD4%5Cu2009%3C200%20cells%5C%2F%5Cu03bcL%20and%20less%20likely%20than%20both%20MSM%20and%20non-MSM%20%28p%5Cu2009%3C%5Cu20090.001%29%20to%20have%20VL%20%5Cu2265100%5Cu2009000%20copies%5C%2FmL.%20Women%20were%20also%20more%20likely%20to%20be%20free%20of%20comorbidity%20than%20were%20both%20MSM%20and%20non-MSM%20%28p%5Cu2009%3C%5Cu20090.0001%29.%5CnCONCLUSION%3A%20RESPOND%20women%20are%20diverse%20in%20age%2C%20ethnicity%5C%2Frace%2C%20CD4%5C%2FVL%2C%20and%20comorbidity%20burden%2C%20with%20important%20differences%20relative%20to%20men.%20This%20work%20highlights%20the%20importance%20of%20stratification%20by%20sex%5C%2Fgender%20for%20future%20research%20that%20may%20help%20improve%20screening%20and%20management%20guidelines%20specifically%20for%20women%20with%20HIV.%22%2C%22date%22%3A%222024-06-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fhiv.13662%22%2C%22ISSN%22%3A%221468-1293%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A32%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22NGF8UMV6%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ebasone%20et%20al.%22%2C%22parsedDate%22%3A%222024-06-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEbasone%2C%20Peter%20Vanes%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDzudie%2C%20Anastase%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPeer%2C%20Nasheeta%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHoover%2C%20Donald%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShi%2C%20Qiuhu%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Coprevalence%20and%20associations%20of%20diabetes%20mellitus%20and%20hypertension%20among%20people%20living%20with%20HIV%5C%2FAIDS%20in%20Cameroon.%20%3Ci%3EAIDS%20Research%20and%20Therapy%3C%5C%2Fi%3E%2C%20%3Ci%3E21%3C%5C%2Fi%3E%20%281%29%2C%20S.%2036.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12981-024-00624-5%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12981-024-00624-5%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Coprevalence%20and%20associations%20of%20diabetes%20mellitus%20and%20hypertension%20among%20people%20living%20with%20HIV%5C%2FAIDS%20in%20Cameroon%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20Vanes%22%2C%22lastName%22%3A%22Ebasone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anastase%22%2C%22lastName%22%3A%22Dzudie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nasheeta%22%2C%22lastName%22%3A%22Peer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Donald%22%2C%22lastName%22%3A%22Hoover%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qiuhu%22%2C%22lastName%22%3A%22Shi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hae-Young%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rogers%22%2C%22lastName%22%3A%22Ajeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andre%20Pascal%22%2C%22lastName%22%3A%22Kengne%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20association%20between%20HIV%20infection%20and%20increased%20cardiometabolic%20risk%2C%20attributed%20to%20chronic%20inflammation%20in%20people%20living%20with%20HIV%20%28PLWH%29%20and%5C%2For%20antiretroviral%20therapy%20%28ART%29%20effects%2C%20has%20been%20inconsistent.%20In%20this%20study%2C%20we%20aimed%20to%20assess%20the%20associations%20of%20HIV-related%20factors%20with%20hypertension%20%28HTN%29%20and%20type-2%20diabetes%20mellitus%20%28T2DM%29%2C%20and%20the%20potential%20mediation%20effects%20of%20body%20mass%20index%20%28BMI%29%20in%20the%20associations%20between%20ART%20use%20and%20HTN%20or%20T2DM%20in%20PLWH%20in%20Cameroon.%5CnMETHODS%3A%20A%20cross-sectional%20study%20was%20conducted%20with%2014%2C119%20adult%20PLWH%20from%20Cameroon%20enrolled%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20between%202016%20and%202021.%20HTN%20was%20defined%20as%20systolic%5C%2Fdiastolic%20blood%20pressure%5Cu2009%5Cu2265%5Cu2009140%5C%2F90%5Cu00a0mmHg%20and%5C%2For%20current%20use%20of%20antihypertensive%20medication%2C%20while%20T2DM%20was%20defined%20as%20fasting%20blood%20sugar%5Cu2009%5Cu2265%5Cu2009126%5Cu00a0mg%5C%2FdL%20and%5C%2For%20use%20of%20antidiabetic%20medications.%20Univariable%20and%20multivariable%20multinomial%20logistic%20regression%20analyses%20examined%20the%20associations%20of%20factors%20with%20HTN%20alone%2C%20T2DM%20alone%2C%20and%20both%20%28HTN%5Cu2009%2B%5Cu2009T2DM%29.%20Mediation%20analyses%20were%20conducted%20to%20assess%20the%20potential%20mediation%20roles%20of%20BMI%2C%20while%20controlling%20for%20age%2C%20sex%2C%20and%20smoking.%5CnRESULTS%3A%20Of%20the%2014%2C119%20participants%2C%209177%20%2865%25%29%20were%20women%2C%20with%20a%20median%20age%20of%2042%20%2825th-75th%20percentiles%3A%2035-51%29%20years.%20Age%5Cu2009%3E%5Cu200950%5Cu00a0years%20was%20associated%20with%20HTN%20alone%2C%20T2DM%20alone%2C%20and%20HTN%5Cu2009%2B%5Cu2009T2DM%20compared%20to%20the%20age%20group%2019-29%5Cu00a0years.%20Men%20had%20higher%20odds%20of%20having%20HTN%5Cu2009%2B%5Cu2009T2DM.%20Overweight%20and%20obesity%20were%20predictors%20of%20HTN%20alone%20compared%20to%20being%20underweight.%20WHO%20stages%20II%20and%20III%20HIV%20disease%20were%20inversely%20associated%20with%20HTN%20alone%20compared%20to%20stage%20I.%20The%20odds%20of%20diabetes%20alone%20were%20lower%20with%20ART%20use.%20BMI%20partially%20mediated%20the%20association%20between%20ART%20use%20and%20hypertension%2C%20with%20a%20proportion%20of%20mediation%20effect%20of%2049.6%25%20%28all%20p%5Cu2009%3C%5Cu20090.02%29.%20However%2C%20BMI%20did%20not%20mediate%20the%20relationship%20between%20ART%20use%20and%20diabetes.%5CnCONCLUSIONS%3A%20Traditional%20cardiovascular%20risk%20factors%20were%20strongly%20associated%20with%20hypertension%20among%20PLWH%2C%20while%20HIV-related%20exposures%20had%20smaller%20associations.%20BMI%20partially%20mediated%20the%20association%20between%20ART%20use%20and%20hypertension.%20This%20study%20emphasizes%20the%20importance%20of%20screening%2C%20monitoring%2C%20and%20managing%20HTN%20and%20T2DM%20in%20older%2C%20male%2C%20and%20overweight%5C%2Fobese%20PLWH.%20Further%20research%20on%20the%20associations%20of%20HIV%20disease%20stage%20and%20ART%20use%20with%20HTN%20and%20T2DM%20is%20warranted.%22%2C%22date%22%3A%222024-06-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12981-024-00624-5%22%2C%22ISSN%22%3A%221742-6405%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A39%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22YRXXW78T%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gorsline%20et%20al.%22%2C%22parsedDate%22%3A%222024-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGorsline%2C%20Chelsea%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELotspeich%2C%20Sarah%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBelaunzar%26%23xE1%3Bn-Zamudio%2C%20Pablo%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMejia%2C%20Fernando%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECortes%2C%20Claudia%20P.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20The%20impact%20of%20earthquakes%20in%20Latin%20America%20on%20the%20continuity%20of%20HIV%20care%3A%20A%20retrospective%20observational%20cohort%20study.%20%3Ci%3EPublic%20Health%20in%20Practice%20%28Oxford%2C%20England%29%3C%5C%2Fi%3E%2C%20%3Ci%3E7%3C%5C%2Fi%3E%2C%20S.%20100479.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.puhip.2024.100479%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.puhip.2024.100479%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20impact%20of%20earthquakes%20in%20Latin%20America%20on%20the%20continuity%20of%20HIV%20care%3A%20A%20retrospective%20observational%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chelsea%20A.%22%2C%22lastName%22%3A%22Gorsline%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20C.%22%2C%22lastName%22%3A%22Lotspeich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20F.%22%2C%22lastName%22%3A%22Belaunzar%5Cu00e1n-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mejia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damocles%20Patrice%22%2C%22lastName%22%3A%22Severe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20As%20earthquakes%20occur%20frequently%20in%20Latin%20America%20and%20can%20cause%20significant%20disruptions%20in%20HIV%20care%2C%20we%20sought%20to%20analyze%20patterns%20of%20HIV%20care%20for%20adults%20at%20Latin%20American%20clinical%20sites%20experiencing%20a%20significant%20earthquake%20within%20the%20past%20two%20decades.%5CnSTUDY%20DESIGN%3A%20Retrospective%20clinical%20cohort%20study.%5CnMETHODS%3A%20Adults%20receiving%20HIV%20care%20at%20sites%20experiencing%20at%20least%20a%20%5C%22moderate%20intensity%5C%22%20%28Modified%20Mercalli%20scale%29%20earthquake%20in%20the%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%20contributed%20data%20from%202003%20to%202017.%20Interrupted%20Time%20Series%20models%20were%20fit%20with%20discontinuities%20at%20site-specific%20earthquake%20dates%20%28Sept.%2016%2C%202015%20in%20Chile%3B%20Apr.%2018%2C%202014%20and%20Sept.%2019%2C%202017%20in%20Mexico%3B%20and%20Aug.%2015%2C%202007%20in%20Peru%29%20to%20assess%20clinical%20visit%2C%20CD4%20measure%2C%20viral%20load%20lab%2C%20and%20ART%20initiation%20rates%203-%20and%206-months%20after%20versus%20before%20earthquakes.%5CnRESULTS%3A%20Comparing%20post-to%20pre-earthquake%20periods%2C%20there%20was%20a%20sharp%20drop%20in%20median%20visit%20%28incidence%20rate%20ratio%20%5BIRR%5D%5Cu00a0%3D%5Cu00a00.79%2C%2095%25%20confidence%20interval%20%5BCI%5D%3A%200.68-0.91%29%20and%20viral%20load%20lab%20%28IRR%5Cu00a0%3D%5Cu00a00.78%2C%2095%25%20CI%3A%200.62-0.99%29%20rates%20per%20week%2C%20using%20a%203-month%20window.%20CD4%20measurement%20rates%20also%20decreased%20%28IRR%5Cu00a0%3D%5Cu00a00.43%3B%2095%25%20CI%3A%200.37-0.51%29%2C%20though%20only%20using%20a%206-month%20window.%5CnCONCLUSIONS%3A%20Given%20that%20earthquakes%20occur%20frequently%20in%20Latin%20America%2C%20disaster%20preparedness%20plans%20must%20be%20more%20broadly%20implemented%20to%20avoid%20disruptions%20in%20HIV%20care%20and%20attendant%20poor%20outcomes.%22%2C%22date%22%3A%222024-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.puhip.2024.100479%22%2C%22ISSN%22%3A%222666-5352%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222024-04-12T12%3A43%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22VKQAH9Z4%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pirsl%20et%20al.%22%2C%22parsedDate%22%3A%222024-05-25%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPirsl%2C%20Filip%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECalkins%2C%20Keri%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERudolph%2C%20Jacqueline%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWentz%2C%20Eryka%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EXu%2C%20Xiaoqiang%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Incidence%20of%20prostate%20cancer%20in%20Medicaid%20beneficiaries%20with%20and%20without%20HIV%20in%202001-2015%20in%2014%20states.%20%3Ci%3EMedRxiv%3A%20The%20Preprint%20Server%20for%20Health%20Sciences%3C%5C%2Fi%3E%2C%20S.%202024.05.24.24307676.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2024.05.24.24307676%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2024.05.24.24307676%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Incidence%20of%20prostate%20cancer%20in%20Medicaid%20beneficiaries%20with%20and%20without%20HIV%20in%202001-2015%20in%2014%20states%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Filip%22%2C%22lastName%22%3A%22Pirsl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%22%2C%22lastName%22%3A%22Calkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacqueline%20E.%22%2C%22lastName%22%3A%22Rudolph%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eryka%22%2C%22lastName%22%3A%22Wentz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaoqiang%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%22%2C%22lastName%22%3A%22Lau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%20E.%22%2C%22lastName%22%3A%22Joshu%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Prostate%20cancer%20is%20projected%20to%20be%20the%20most%20common%20cancer%20among%20people%20living%20with%20HIV%3B%20however%2C%20incidence%20of%20prostate%20cancer%20has%20been%20reported%20to%20be%20lower%20in%20men%20with%20HIV%20compared%20to%20men%20without%20HIV%20with%20little%20evidence%20to%20explain%20this%20difference.%20We%20describe%20prostate%20cancer%20incidence%20by%20HIV%20status%20in%20Medicaid%20beneficiaries%2C%20allowing%20for%20comparison%20of%20men%20with%20and%20without%20HIV%20who%20are%20similar%20with%20respect%20to%20socioeconomic%20characteristics%20and%20access%20to%20healthcare.%5CnMETHODS%3A%20Medicaid%20beneficiaries%20%28N%3D15%2C167%2C636%29%20aged%2018-64%20with%20%5Cu22657%20months%20of%20continuous%20enrollment%20during%202001-2015%20in%2014%20US%20states%20were%20retained%20for%20analysis.%20Diagnoses%20of%20HIV%20and%20prostate%20cancer%20were%20identified%20using%20inpatient%20and%20other%20non-drug%20claims.%20We%20estimated%20cause-specific%20%28csHR%29%20and%20sub-distribution%20hazard%20ratios%20comparing%20incidence%20of%20prostate%20cancer%20by%20HIV%20status%2C%20adjusted%20for%20age%2C%20race-ethnicity%2C%20state%20of%20residence%2C%20year%20of%20enrollment%2C%20and%20comorbid%20conditions.%20Models%20were%20additionally%20stratified%20by%20age%20and%20race-ethnicity.%5CnRESULTS%3A%20There%20were%20366%20cases%20of%20prostate%20cancer%20observed%20over%20299%2C976%20person-years%20among%20beneficiaries%20with%20HIV%20and%2017%2C224%20cases%20over%2022%2C298%2C914%20person-years%20in%20beneficiaries%20without%20HIV.%20The%20hazard%20of%20prostate%20cancer%20was%20lower%20in%20men%20with%20HIV%20than%20men%20without%20HIV%20%28csHR%3D0.89%3B%2095%25%20CI%3A%200.80%2C%200.99%29%2C%20but%20varied%20by%20race-ethnicity%2C%20with%20similar%20observations%20among%20non-Hispanic%20Black%20%28csHR%3D0.79%3B%2095%25%20CI%3A%200.69%2C%200.91%29%20and%20Hispanic%20%28csHR%3D0.85%3B%2095%25%20CI%3A%200.67%2C%201.09%29%2C%20but%20not%20non-Hispanic%20white%20men%20%28csHR%3D1.17%3B%2095%25%20CI%3A%200.91%2C%201.50%29.%20Results%20were%20similar%20in%20models%20restricted%20to%20ages%2050-64%20and%2040-49%2C%20except%20for%20a%20higher%20hazard%20of%20prostate%20cancer%20in%20Hispanic%20men%20with%20HIV%20in%20their%2040s%2C%20while%20the%20hazard%20of%20prostate%20cancer%20was%20higher%20in%20men%20with%20HIV%20across%20all%20models%20for%20men%20aged%2018-39.%5CnCONCLUSION%3A%20Reported%20deficits%20in%20prostate%20cancer%20incidence%20by%20HIV%20status%20may%20be%20restricted%20to%20specific%20groups%20defined%20by%20age%20and%20race-ethnicity.%22%2C%22date%22%3A%222024-05-25%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2024.05.24.24307676%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A57%3A27Z%22%7D%7D%2C%7B%22key%22%3A%229RZS3LVI%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rodrigues%20et%20al.%22%2C%22parsedDate%22%3A%222024-05-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERodrigues%2C%20Moreno%20M.%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBarreto-Duarte%2C%20Beatriz%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVinhaes%2C%20Caian%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAra%26%23xFA%3Bjo-Pereira%2C%20Mariana%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFukutani%2C%20Eduardo%20R.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Machine%20learning%20algorithms%20using%20national%20registry%20data%20to%20predict%20loss%20to%20follow-up%20during%20tuberculosis%20treatment.%20%3Ci%3EBMC%20Public%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E24%3C%5C%2Fi%3E%20%281%29%2C%20S.%201385.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-024-18815-0%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-024-18815-0%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Machine%20learning%20algorithms%20using%20national%20registry%20data%20to%20predict%20loss%20to%20follow-up%20during%20tuberculosis%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moreno%20M.%20S.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20R.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keityane%20Bone%22%2C%22lastName%22%3A%22Bergamaschi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%22%2C%22lastName%22%3A%22Kristki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Identifying%20patients%20at%20increased%20risk%20of%20loss%20to%20follow-up%20%28LTFU%29%20is%20key%20to%20developing%20strategies%20to%20optimize%20the%20clinical%20management%20of%20tuberculosis%20%28TB%29.%20The%20use%20of%20national%20registry%20data%20in%20prediction%20models%20may%20be%20a%20useful%20tool%20to%20inform%20healthcare%20workers%20about%20risk%20of%20LTFU.%20Here%20we%20developed%20a%20score%20to%20predict%20the%20risk%20of%20LTFU%20during%20anti-TB%20treatment%20%28ATT%29%20in%20a%20nationwide%20cohort%20of%20cases%20using%20clinical%20data%20reported%20to%20the%20Brazilian%20Notifiable%20Disease%20Information%20System%20%28SINAN%29.%5CnMETHODS%3A%20We%20performed%20a%20retrospective%20study%20of%20all%20TB%20cases%20reported%20to%20SINAN%20between%202015%20and%202022%3B%20excluding%20children%20%28%3C%5Cu200918%20years-old%29%2C%20vulnerable%20groups%20or%20drug-resistant%20TB.%20For%20the%20score%2C%20data%20before%20treatment%20initiation%20were%20used.%20We%20trained%20and%20internally%20validated%20three%20different%20prediction%20scoring%20systems%2C%20based%20on%20Logistic%20Regression%2C%20Random%20Forest%2C%20and%20Light%20Gradient%20Boosting.%20Before%20applying%20our%20models%20we%20splitted%20our%20data%20into%20training%20%28~%5Cu200980%25%20data%29%20and%20test%20%28~%5Cu200920%25%29%20sets%2C%20and%20then%20compared%20the%20model%20metrics%20using%20the%20test%20data%20set.%5CnRESULTS%3A%20Of%20the%20243%2C726%20cases%20included%2C%2041%2C373%20experienced%20LTFU%20whereas%20202%2C353%20were%20successfully%20treated.%20The%20groups%20were%20different%20with%20regards%20to%20several%20clinical%20and%20sociodemographic%20characteristics.%20The%20directly%20observed%20treatment%20%28DOT%29%20was%20unbalanced%20between%20the%20groups%20with%20lower%20prevalence%20in%20those%20who%20were%20LTFU.%20Three%20models%20were%20developed%20to%20predict%20LTFU%20using%208%20features%20%28prior%20TB%2C%20drug%20use%2C%20age%2C%20sex%2C%20HIV%20infection%20and%20schooling%20level%29%20with%20different%20score%20composition%20approaches.%20Those%20prediction%20scoring%20systems%20exhibited%20an%20area%20under%20the%20curve%20%28AUC%29%20ranging%20between%200.71%20and%200.72.%20The%20Light%20Gradient%20Boosting%20technique%20resulted%20in%20the%20best%20prediction%20performance%2C%20weighting%20specificity%20and%20sensitivity.%20A%20user-friendly%20web%20calculator%20app%20was%20developed%20%28%20https%3A%5C%2F%5C%2Ftbprediction.herokuapp.com%5C%2F%20%29%20to%20facilitate%20implementation.%5CnCONCLUSIONS%3A%20Our%20nationwide%20risk%20score%20predicts%20the%20risk%20of%20LTFU%20during%20ATT%20in%20Brazilian%20adults%20prior%20to%20treatment%20commencement%20utilizing%20schooling%20level%2C%20sex%2C%20age%2C%20prior%20TB%20status%2C%20and%20substance%20use%20%28drug%2C%20alcohol%2C%20and%5C%2For%20tobacco%29.%20This%20is%20a%20potential%20tool%20to%20assist%20in%20decision-making%20strategies%20to%20guide%20resource%20allocation%2C%20DOT%20indications%2C%20and%20improve%20TB%20treatment%20adherence.%22%2C%22date%22%3A%222024-05-23%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12889-024-18815-0%22%2C%22ISSN%22%3A%221471-2458%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A40%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22FC8ZI5CX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rudolph%20et%20al.%22%2C%22parsedDate%22%3A%222024-05-13%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERudolph%2C%20Jacqueline%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECalkins%2C%20Keri%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZhang%2C%20Xueer%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZhou%2C%20Yiyi%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EXu%2C%20Xiaoqiang%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Retention%20in%20care%20and%20antiretroviral%20therapy%20adherence%20among%20Medicaid%20beneficiaries%20with%20HIV%2C%202001-2015.%20%3Ci%3EMedRxiv%3A%20The%20Preprint%20Server%20for%20Health%20Sciences%3C%5C%2Fi%3E%2C%20S.%202024.05.13.24307278.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2024.05.13.24307278%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2024.05.13.24307278%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Retention%20in%20care%20and%20antiretroviral%20therapy%20adherence%20among%20Medicaid%20beneficiaries%20with%20HIV%2C%202001-2015%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacqueline%20E.%22%2C%22lastName%22%3A%22Rudolph%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20L.%22%2C%22lastName%22%3A%22Calkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xueer%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yiyi%22%2C%22lastName%22%3A%22Zhou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaoqiang%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eryka%20L.%22%2C%22lastName%22%3A%22Wentz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%20E.%22%2C%22lastName%22%3A%22Joshu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%22%2C%22lastName%22%3A%22Lau%22%7D%5D%2C%22abstractNote%22%3A%22Disparities%20in%20HIV%20care%20by%20socioeconomic%20status%2C%20place%20of%20residence%2C%20and%20race%5C%2Fethnicity%20prevent%20progress%20toward%20epidemic%20control.%20No%20study%20has%20comprehensively%20characterized%20the%20HIV%20care%20cascade%20among%20people%20with%20HIV%20enrolled%20in%20Medicaid%20-%20an%20insurance%20source%20for%20low-income%20individuals%20in%20the%20US.%20We%20analyzed%20data%20from%20246%2C127%20people%20with%20HIV%20enrolled%20in%20Medicaid%202001-2015%2C%20aged%2018-64%2C%20living%20in%2014%20US%20states.%20We%20estimated%20monthly%20prevalence%20of%20four%20steps%20of%20the%20care%20cascade%3A%20retained%20in%20care%5C%2Fadherent%20to%20ART%3B%20retained%5C%2Fnot%20adherent%3B%20not%20retained%5C%2Fadherent%3B%20not%20retained%5C%2Fnot%20adherent.%20Beneficiaries%20were%20retained%20in%20care%20if%20they%20had%20an%20outpatient%20care%20encounter%20every%20six%20months.%20Adherence%20was%20based%20on%20medication%20possession%20ratio.%20We%20estimated%20prevalence%20using%20a%20non-parametric%20multi-state%20approach%2C%20accounting%20for%20death%20as%20a%20competing%20event%20and%20for%20Medicaid%20disenrollment%20using%20inverse%20probability%20of%20censoring%20weights.%20Across%202001-2015%2C%20the%20proportion%20of%20beneficiaries%20with%20HIV%20who%20were%20retained%5C%2FART%20adherent%20increased%2C%20overall%20and%20in%20all%20subgroups.%20By%202015%2C%20approximately%20half%20of%20beneficiaries%20were%20retained%20in%20care%2C%20and%2042%25%20of%20beneficiaries%20were%20ART%20adherent.%20We%20saw%20meaningful%20differences%20by%20race%5C%2Fethnicity%20and%20region.%20Our%20work%20highlights%20an%20important%20disparity%20in%20the%20HIV%20care%20cascade%20by%20insurance%20status%20during%20this%20time%20period.%22%2C%22date%22%3A%222024-05-13%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2024.05.13.24307278%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A58%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22FMT5562Q%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ssemasaazi%20et%20al.%22%2C%22parsedDate%22%3A%222024-05-13%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESsemasaazi%2C%20Amutuhaire%20Judith%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKalyesubula%2C%20Robert%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EManabe%2C%20Yukari%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMbabazi%2C%20Phoebe%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENaikooba%2C%20Susan%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Higher%20prevalence%20of%20kidney%20function%20impairment%20among%20older%20people%20living%20with%20HIV%20in%20Uganda.%20%3Ci%3EResearch%20Square%3C%5C%2Fi%3E%2C%20S.%20rs.3.rs-4364155.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21203%5C%2Frs.3.rs-4364155%5C%2Fv1%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21203%5C%2Frs.3.rs-4364155%5C%2Fv1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Higher%20prevalence%20of%20kidney%20function%20impairment%20among%20older%20people%20living%20with%20HIV%20in%20Uganda%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amutuhaire%20Judith%22%2C%22lastName%22%3A%22Ssemasaazi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Kalyesubula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yukari%20C.%22%2C%22lastName%22%3A%22Manabe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Phoebe%22%2C%22lastName%22%3A%22Mbabazi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%22%2C%22lastName%22%3A%22Naikooba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faizo%22%2C%22lastName%22%3A%22Ssekindi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Esther%22%2C%22lastName%22%3A%22Nasuuna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%20Byakika%22%2C%22lastName%22%3A%22Kibwika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Castelnuovo%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20People%20living%20with%20HIV%20%28PLWH%29%20are%20at%20risk%20of%20kidney%20function%20impairment%20due%20to%20HIV-related%20inflammation%2C%20antiretroviral%20therapy%20%28ART%29%2C%20diabetes%20mellitus%2C%20and%20hypertension.%20Older%20persons%20may%20experience%20a%20higher%20burden%20of%20chronic%20kidney%20disease%20%28CKD%29%20as%20kidney%20function%20declines%20with%20increasing%20age.%20There%20is%20a%20paucity%20of%20data%20comparing%20the%20prevalence%20of%20kidney%20function%20impairment%20in%20older%20PLWH%20to%20that%20in%20HIV-uninfected%20people%20in%20sub-Saharan%20Africa.%5CnMETHODS%3A%20We%20conducted%20a%20cross-sectional%20study%20among%20people%20aged%20%5Cu2265%2060%20years%20living%20with%20and%20without%20HIV%20in%20Kampala%2C%20Uganda%20who%20were%20matched%201%3A1%20by%20community%20location.%20We%20collected%20data%20on%20sociodemographics%2C%20comorbidities%2C%20and%20HIV-related%20clinical%20characteristics.%20We%20defined%20kidney%20function%20impairment%20as%20an%20estimated%20glomerular%20filtration%20rate%28eGFR%29%20%3C%2060mls%5C%2Fmin%5C%2F1.73m2%20with%20or%20without%20proteinuria.%20We%20constructed%20multivariable%20logistic%20regression%20models%20to%20study%20associations%20between%20participant%20characteristics%20and%20kidney%20function%20impairment.%5CnRESULTS%3A%20We%20enrolled%20278%20people%20%28median%20age%2066%20years%29%3B%2050%25%20were%20PLWH%2C%20and%2051.8%25%20were%20female.%20Overall%2C%20the%20prevalence%20of%20kidney%20function%20impairment%20was%2023.0%25%20%2895%25%20CI%3A18.4%25-28.4%25%29%3B%2033.1%25%20%2895%25%20CI%3A%2025.7%25-41.4%25%29%20versus%2012.9%25%20%2895%25%20CI%3A%208.3%25-19.7%25%29%20among%20people%20living%20with%20and%20without%20HIV%20%28p-value%20%3C%200.01%29.%20The%20prevalence%20of%20proteinuria%20among%20PLWH%20versus%20people%20without%20HIV%20was%2043.9%25%20%2895%25%20CI%3A35.8%25-52.3%25%29%20versus%2019.4%25%20%2895%25%20CI%3A13.6%25-26.9%25%29%20p-value%20%3C%200.01.%20Living%20with%20HIV%20%28OR%20%3D%203.89%2895%25%20CI%3A%202.04-7.41%29%2C%20p-value%20%3C%200.01%29%2C%20older%20age%20%28OR%20%3D%201.13%2C%20%2895%25%20CI%3A1.07-1.20%29%2C%20p-value%20%3C%200.01%29%2C%20female%20sex%20%28OR%20%3D%201.95%2C%20%2895%25%20CI%3A1.06-3.62%29%2C%20p-value%20%3D%200.03%29%20and%20a%20prior%20diagnosis%20of%20hypertension%20%28OR%20%3D%202.19%2895%25%20CI%3A1.02-4.67%29%2C%20p-value%20%3D%200.04%29%20were%20significantly%20associated%20with%20kidney%20function%20impairment.%5CnCONCLUSIONS%3A%20HIV%20infection%20is%20strongly%20associated%20with%20kidney%20function%20impairment%20among%20older%20PLWH.%20Prioritizing%20routine%20measurements%20of%20kidney%20function%20and%20proteinuria%20in%20older%20PLWH%20will%20enable%20early%20detection%20and%20institution%20of%20measures%20to%20reduce%20the%20progression%20of%20kidney%20disease.%22%2C%22date%22%3A%222024-05-13%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.21203%5C%2Frs.3.rs-4364155%5C%2Fv1%22%2C%22ISSN%22%3A%222693-5015%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A43%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22Y8G2RMUC%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Yiannoutsos%20et%20al.%22%2C%22parsedDate%22%3A%222024-05-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EYiannoutsos%2C%20Constantin%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWools-Kaloustian%2C%20Kara%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMusick%2C%20Beverly%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKosgei%2C%20Rose%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKimaiyo%2C%20Sylvester%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Assessing%20HIV-infected%20patient%20retention%20in%20a%20program%20of%20differentiated%20care%20in%20sub-Saharan%20Africa%3A%20a%20G-estimation%20approach.%20%3Ci%3EThe%20International%20Journal%20of%20Biostatistics%3C%5C%2Fi%3E%2C%20%3Ci%3E20%3C%5C%2Fi%3E%20%281%29%2C%20S.%20279%26%23x2013%3B291.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1515%5C%2Fijb-2023-0031%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1515%5C%2Fijb-2023-0031%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessing%20HIV-infected%20patient%20retention%20in%20a%20program%20of%20differentiated%20care%20in%20sub-Saharan%20Africa%3A%20a%20G-estimation%20approach%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%20S.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rose%22%2C%22lastName%22%3A%22Kosgei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvester%22%2C%22lastName%22%3A%22Kimaiyo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abraham%22%2C%22lastName%22%3A%22Siika%22%7D%5D%2C%22abstractNote%22%3A%22Differentiated%20care%20delivery%20aims%20to%20simplify%20care%20of%20people%20living%20with%20HIV%2C%20reflect%20their%20preferences%2C%20reduce%20burdens%20on%20the%20healthcare%20system%2C%20maintain%20care%20quality%20and%20preserve%20resources.%20However%2C%20assessing%20program%20effectiveness%20using%20observational%20data%20is%20difficult%20due%20to%20confounding%20by%20indication%20and%20randomized%20trials%20may%20be%20infeasible.%20Also%2C%20benefits%20can%20reach%20patients%20directly%2C%20through%20enrollment%20in%20the%20program%2C%20and%20indirectly%2C%20by%20increasing%20quality%20of%20and%20accessibility%20to%20care.%20Low-risk%20express%20care%20%28LREC%29%2C%20the%20program%20under%20evaluation%2C%20is%20a%20nurse-centered%20model%20which%20assigns%20patients%20stable%20on%20ART%20to%20a%20nurse%20every%20two%20months%20and%20a%20clinician%20every%20third%20visit%2C%20reducing%20annual%20clinician%20visits%20by%20two%20thirds.%20Study%20population%20is%20comprised%20of%2016%2C832%20subjects%20from%2015%20clinics%20in%20Kenya.%20We%20focus%20on%20patient%20retention%20in%20care%20based%20on%20whether%20the%20LREC%20program%20is%20available%20at%20a%20clinic%20and%20whether%20the%20patient%20is%20enrolled%20in%20LREC.%20We%20use%20G-estimation%20to%20assess%20the%20effect%20on%20retention%20of%20two%20%5C%22strategies%5C%22%3A%20%28i%29%20program%20availability%20but%20no%20enrollment%3B%20%28ii%29%20enrollment%20at%20an%20available%20program%3B%20versus%20no%20program%20availability.%20Compared%20to%20no%20availability%2C%20LREC%20results%20in%20a%20non-significant%20increase%20in%20patient%20retention%2C%20among%20patients%20not%20enrolled%20in%20the%20program%20%28indirect%20effect%29%2C%20while%20enrollment%20in%20LREC%20is%20associated%20with%20a%20significant%20extension%20of%20the%20time%20retained%20in%20care%20%28direct%20effect%29.%20G-estimation%20provides%20an%20analytical%20framework%20useful%20to%20the%20assessment%20of%20similar%20programs%20using%20observational%20data.%22%2C%22date%22%3A%222024-05-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1515%5C%2Fijb-2023-0031%22%2C%22ISSN%22%3A%221557-4679%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A44%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22ZNXT7F89%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tiendrebeogo%20et%20al.%22%2C%22parsedDate%22%3A%222024-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETiendrebeogo%2C%20Thierry%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMalateste%2C%20Karen%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPoda%2C%20Armel%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMinga%2C%20Albert%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMessou%2C%20Eugene%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Sex-Based%20Disparities%20in%20the%20Transition%20to%20Dolutegravir-Based%20Antiretroviral%20Therapy%20in%20West%20African%20HIV%20Cohorts.%20%3Ci%3EOpen%20Forum%20Infectious%20Diseases%3C%5C%2Fi%3E%2C%20%3Ci%3E11%3C%5C%2Fi%3E%20%285%29%2C%20S.%20ofae139.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofae139%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofae139%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sex-Based%20Disparities%20in%20the%20Transition%20to%20Dolutegravir-Based%20Antiretroviral%20Therapy%20in%20West%20African%20HIV%20Cohorts%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Malateste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armel%22%2C%22lastName%22%3A%22Poda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugene%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henri%22%2C%22lastName%22%3A%22Chenal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oliver%22%2C%22lastName%22%3A%22Ezechi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%20K.%22%2C%22lastName%22%3A%22Ekouevi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Igho%22%2C%22lastName%22%3A%22Ofotokun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%20West%20Africa%20Collaboration%22%7D%5D%2C%22abstractNote%22%3A%22Transition%20to%20dolutegravir%20among%2021%20167%20individuals%20experienced%20in%20antiretroviral%20therapy%20in%20West%20Africa%20showed%20heterogeneous%20timelines%20and%20patterns.%20Initially%20reported%20sex%20disparities%20tended%20to%20catch%20up%20over%20time%20with%20persisting%20disparities%2C%20according%20to%20contributing%20HIV%20clinics.%20Key%20factors%20facilitating%20dolutegravir%20switch%20were%20male%20sex%2C%20age%20%3C50%20years%2C%20viral%20suppression%2C%20and%20regimens%20not%20based%20on%20protease%20inhibitors.%22%2C%22date%22%3A%222024-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofae139%22%2C%22ISSN%22%3A%222328-8957%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A45%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22MQLWR6BS%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Euvrard%20et%20al.%22%2C%22parsedDate%22%3A%222024-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEuvrard%2C%20Jonathan%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETimmerman%2C%20Venessa%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKeene%2C%20Claire%20Marriott%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPhelanyane%2C%20Florence%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHeekes%2C%20Alexa%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20The%20cyclical%20cascade%20of%20HIV%20care%3A%20Temporal%20care%20engagement%20trends%20within%20a%20population-wide%20cohort.%20%3Ci%3EPLoS%20Medicine%3C%5C%2Fi%3E%2C%20%3Ci%3E21%3C%5C%2Fi%3E%20%285%29%2C%20S.%20e1004407.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004407%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004407%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20cyclical%20cascade%20of%20HIV%20care%3A%20Temporal%20care%20engagement%20trends%20within%20a%20population-wide%20cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Venessa%22%2C%22lastName%22%3A%22Timmerman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%20Marriott%22%2C%22lastName%22%3A%22Keene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Phelanyane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexa%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%20D.%22%2C%22lastName%22%3A%22Rice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Grimsrud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Ehrenkranz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Boulle%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20traditional%20HIV%20treatment%20cascade%20aims%20to%20visualise%20the%20journey%20of%20each%20person%20living%20with%20HIV%20from%20diagnosis%2C%20through%20initiation%20on%20antiretroviral%20therapy%20%28ART%29%20to%20treatment%20success%2C%20represented%20by%20virological%20suppression.%20This%20representation%20has%20been%20a%20pivotal%20tool%20in%20highlighting%20and%20quantifying%20sequential%20gaps%20along%20the%20care%20continuum.%20There%20is%20longstanding%20recognition%2C%20however%2C%20that%20this%20may%20oversimplify%20the%20complexity%20of%20real-world%20engagement%20with%20HIV%20services%20in%20settings%20with%20mature%20high-burden%20HIV%20epidemics.%20A%20complementary%20%5C%22cyclical%5C%22%20cascade%20has%20been%20proposed%20to%20represent%20the%20processes%20of%20disengagement%20at%20different%20points%20on%20the%20care%20continuum%2C%20with%20multiple%20pathways%20to%20re-engagement%2C%20although%20the%20feasibility%20of%20implementing%20this%20at%20scale%20has%20been%20uncertain.%20This%20study%20aimed%20to%20populate%2C%20refine%2C%20and%20explore%20the%20utility%20of%20a%20cyclical%20representation%20of%20the%20HIV%20cascade%2C%20using%20routine%20data%20from%20a%20high-burden%20HIV%20setting.%5CnMETHODS%20AND%20FINDINGS%3A%20This%20observational%20cohort%20study%20leveraged%20person-level%20data%20on%20all%20people%20living%20with%20HIV%20in%20the%20Western%20Cape%20%28WC%29%2C%20South%20Africa%2C%20who%20accessed%20public%20health%20services%20in%20the%202%20years%20prior%20to%2031%20December%202023.%20Programme%20data%20from%20disease%20registers%20were%20complemented%20by%20data%20from%20pharmacy%20and%20laboratory%20systems.%20At%20study%20closure%2C%20494%20370%20people%20were%20included%2C%20constituting%2093%25%20of%20those%20of%20those%20estimated%20to%20be%20living%20with%20HIV%20in%20the%20province%2C%20of%20whom%20355%20104%20were%20on%20ART.%20Substantial%20disengagement%20from%20HIV%20care%20was%20evident%20at%20every%20point%20on%20the%20cascade.%20Early%20treatment%20emerged%20as%20a%20period%20of%20higher%20risk%20of%20disengagement%2C%20but%20it%20did%20not%20account%20for%20the%20majority%20of%20disengagement.%20Almost%20all%20those%20currently%20disengaged%20had%20prior%20experience%20of%20treatment.%20While%20re-engagement%20was%20also%20common%2C%20overall%20treatment%20coverage%20had%20increased%20slowly%20over%205%20years.%20The%20transition%20to%20dolutegravir-based%20regimens%20was%20dramatic%20with%20good%20virological%20outcomes%20for%20those%20in%20care%2C%20notwithstanding%20a%20clearly%20discernible%20impact%20of%20the%20Coronavirus%20Disease%202019%20%28COVID-19%29%20pandemic%20on%20viral%20load%20%28VL%29%20testing.%20People%20currently%20engaged%20and%20disengaged%20in%20care%20are%20similar%20with%20respect%20to%20age%20and%20gender.%20Those%20who%20died%20or%20disengaged%20recently%20were%20previously%20distributed%20across%20a%20range%20of%20cascade%20statuses%2C%20and%20a%20substantial%20proportion%20of%20those%20newly%20initiating%20and%20re-initiating%20treatment%20were%20no%20longer%20on%20treatment%206%20months%20later.%20The%20main%20limitation%20of%20this%20study%20was%20incomplete%20evidence%20of%20HIV%20testing%2C%20linkage%20to%20HIV-specific%20services%2C%20and%20out-of-facility%20mortality.%5CnCONCLUSIONS%3A%20Using%20routine%20data%2C%20it%20was%20possible%20to%20populate%20and%20automate%20a%20cyclical%20cascade%20of%20HIV%20care%20that%20continuously%20captured%20the%20nonlinear%20care%20journeys%20of%20individuals%20living%20with%20HIV.%20In%20this%20generalised%20mature%20HIV%20epidemic%2C%20most%20people%20are%20treatment%20experienced.%20Disengagement%20is%20common%20and%20occurs%20at%20various%20points%20along%20the%20cascade%2C%20making%20it%20challenging%20to%20identify%20high-impact%20intervention%20opportunities.%20While%20historical%20HIV%20cascades%20remain%20valuable%20for%20target%20setting%20and%20service%20monitoring%2C%20they%20can%20be%20complemented%20with%20insights%20from%20more%20detailed%20cyclical%20cascades.%22%2C%22date%22%3A%222024-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pmed.1004407%22%2C%22ISSN%22%3A%221549-1676%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A44%3A22Z%22%7D%7D%2C%7B%22key%22%3A%224FWVC8ZR%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Grimes%20et%20al.%22%2C%22parsedDate%22%3A%222024-04-24%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGrimes%2C%20Kathryn%20E.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEbasone%2C%20Peter%20Vanes%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDzudie%2C%20Anastase%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENash%2C%20Denis%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWainberg%2C%20Milton%20L.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Factors%20influencing%20integration%20of%20mental%20health%20screening%20and%20treatment%20at%20HIV%20clinic%20settings%20in%20Cameroon%3A%20a%20qualitative%20study%20of%20health%20providers%26%23x2019%3B%20perspectives.%20%3Ci%3EBMC%20Health%20Services%20Research%3C%5C%2Fi%3E%2C%20%3Ci%3E24%3C%5C%2Fi%3E%20%281%29%2C%20S.%20519.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12913-024-10775-w%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12913-024-10775-w%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Factors%20influencing%20integration%20of%20mental%20health%20screening%20and%20treatment%20at%20HIV%20clinic%20settings%20in%20Cameroon%3A%20a%20qualitative%20study%20of%20health%20providers%27%20perspectives%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%20E.%20L.%22%2C%22lastName%22%3A%22Grimes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20Vanes%22%2C%22lastName%22%3A%22Ebasone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anastase%22%2C%22lastName%22%3A%22Dzudie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milton%20L.%22%2C%22lastName%22%3A%22Wainberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%20W.%22%2C%22lastName%22%3A%22Pence%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clare%22%2C%22lastName%22%3A%22Barrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Pefura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nsame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rogers%22%2C%22lastName%22%3A%22Ajeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annereke%22%2C%22lastName%22%3A%22Nyenti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%20M.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Mental%20disorders%20are%20common%20among%20people%20with%20HIV%20%28PWH%29%20and%20are%20associated%20with%20poor%20HIV%20outcomes.%20Despite%20high%20unmet%20mental%20health%20needs%20among%20PWH%2C%20use%20of%20evidence-based%20mental%20health%20screening%20and%20treatment%20protocols%20remains%20limited%20at%20HIV%20treatment%20facilities%20across%20low-resource%20settings.%20Integrating%20mental%20health%20services%20into%20HIV%20care%20can%20reduce%20this%20gap.%20This%20study%27s%20objective%20was%20to%20explore%20factors%20that%20influence%20integration%20of%20mental%20health%20screening%20and%20treatment%20into%20HIV%20clinics%20in%20Cameroon.%5CnMETHODS%3A%20We%20analyzed%2014%20in-depth%20interviews%20with%20clinic%20staff%20supporting%20PWH%20at%20three%20urban%20HIV%20treatment%20clinics%20in%20Cameroon.%20Interviews%20focused%20on%20current%20processes%2C%20barriers%20and%20facilitators%2C%20and%20types%20of%20support%20needed%20to%20integrate%20mental%20health%20care%20into%20HIV%20care.%20Interviews%20were%20recorded%20and%20transcribed.%20French%20transcripts%20were%20translated%20into%20English.%20We%20used%20thematic%20analysis%20to%20identify%20factors%20that%20influence%20integration%20of%20mental%20health%20screening%20and%20treatment%20into%20HIV%20care%20in%20these%20settings.%20Ethical%20review%20boards%20in%20the%20United%20States%20and%20Cameroon%20approved%20this%20study.%5CnRESULTS%3A%20Respondents%20discussed%20a%20lack%20of%20standardized%20mental%20health%20screening%20processes%20in%20HIV%20treatment%20facilities%20and%20generally%20felt%20ill-equipped%20to%20conduct%20mental%20health%20screening.%20Low%20community%20awareness%20about%20mental%20disorders%2C%20mental%20health-related%20stigma%2C%20limited%20physical%20space%2C%20and%20high%20clinic%20volume%20affected%20providers%27%20ability%20to%20screen%20clients%20for%20mental%20disorders.%20Providers%20indicated%20that%20better%20coordination%20and%20communication%20were%20needed%20to%20support%20client%20referral%20to%20mental%20health%20care.%20Despite%20these%20barriers%2C%20providers%20were%20motivated%20to%20screen%20clients%20for%20mental%20disorders%20and%20believed%20that%20mental%20health%20service%20provision%20could%20improve%20quality%20of%20HIV%20care%20and%20treatment%20outcomes.%20All%20providers%20interviewed%20said%20they%20would%20feel%20more%20confident%20screening%20for%20mental%20disorders%20with%20additional%20training%20and%20resources.%20Providers%20recommended%20community%20sensitization%2C%20training%20or%20hiring%20additional%20staff%2C%20improved%20coordination%20to%20manage%20referrals%2C%20and%20leadership%20buy-in%20at%20multiple%20levels%20of%20the%20health%20system%20to%20support%20sustainable%20integration%20of%20mental%20health%20screening%20and%20treatment%20into%20HIV%20clinics%20in%20Cameroon.%5CnCONCLUSIONS%3A%20Providers%20reported%20enthusiasm%20to%20integrate%20mental%20health%20services%20into%20HIV%20care%20but%20need%20more%20support%20and%20training%20to%20do%20so%20in%20an%20effective%20and%20sustainable%20manner.%22%2C%22date%22%3A%222024-04-24%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12913-024-10775-w%22%2C%22ISSN%22%3A%221472-6963%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A40%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22Q8FT48GL%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mujwara%20et%20al.%22%2C%22parsedDate%22%3A%222024-04-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMujwara%2C%20Deo%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKelvin%2C%20Elizabeth%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDahman%2C%20Bassam%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGeorge%2C%20Gavin%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENixon%2C%20Daniel%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20The%20economic%20costs%20and%20cost-effectiveness%20of%20HIV%20self-testing%20among%20truck%20drivers%20in%20Kenya.%20%3Ci%3EHealth%20Policy%20and%20Planning%3C%5C%2Fi%3E%2C%20%3Ci%3E39%3C%5C%2Fi%3E%20%284%29%2C%20S.%20355%26%23x2013%3B362.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fheapol%5C%2Fczae013%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fheapol%5C%2Fczae013%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20economic%20costs%20and%20cost-effectiveness%20of%20HIV%20self-testing%20among%20truck%20drivers%20in%20Kenya%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deo%22%2C%22lastName%22%3A%22Mujwara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20A.%22%2C%22lastName%22%3A%22Kelvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bassam%22%2C%22lastName%22%3A%22Dahman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gavin%22%2C%22lastName%22%3A%22George%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Nixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tilahun%22%2C%22lastName%22%3A%22Adera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Mwai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22April%20D.%22%2C%22lastName%22%3A%22Kimmel%22%7D%5D%2C%22abstractNote%22%3A%22HIV%20status%20awareness%20is%20critical%20for%20ending%20the%20HIV%20epidemic%20but%20remains%20low%20in%20high-HIV-risk%20and%20hard-to-reach%20sub-populations.%20Targeted%2C%20efficient%20interventions%20are%20needed%20to%20improve%20HIV%20test-uptake.%20We%20examined%20the%20incremental%20cost-effectiveness%20of%20offering%20the%20choice%20of%20self-administered%20oral%20HIV-testing%20%28HIVST-Choice%29%20compared%20with%20provider-administered%20testing%20only%20%5Bstandard-of-care%20%28SOC%29%5D%20among%20long-distance%20truck%20drivers.%20Effectiveness%20data%20came%20from%20a%20randomized-controlled%20trial%20conducted%20at%20two%20roadside%20wellness%20clinics%20in%20Kenya%20%28HIVST-Choice%20arm%2C%20n%5Cu2009%3D%5Cu2009150%3B%20SOC%20arm%2C%20n%5Cu2009%3D%5Cu2009155%29.%20Economic%20cost%20data%20came%20from%20the%20literature%2C%20reflected%20a%20societal%20perspective%20and%20were%20reported%20in%202020%20international%20dollars%20%28I%24%29%2C%20a%20hypothetical%20currency%20with%20equivalent%20purchasing%20power%20as%20the%20US%20dollar.%20Generalized%20Poisson%20and%20linear%20gamma%20regression%20models%20were%20used%20to%20estimate%20effectiveness%20and%20incremental%20costs%2C%20respectively%3B%20incremental%20effectiveness%20was%20reported%20as%20the%20number%20of%20long-distance%20truck%20drivers%20needing%20to%20receive%20HIVST-Choice%20for%20an%20additional%20HIV%20test-uptake.%20We%20calculated%20the%20incremental%20cost-effectiveness%20ratio%20%28ICER%29%20of%20HIVST-Choice%20compared%20with%20SOC%20and%20estimated%2095%25%20confidence%20intervals%20%28CIs%29%20using%20non-parametric%20bootstrapping.%20Uncertainty%20was%20assessed%20using%20deterministic%20sensitivity%20analysis%20and%20the%20cost-effectiveness%20acceptability%20curve.%20HIV%20test-uptake%20was%2023%25%20more%20likely%20for%20HIVST-Choice%2C%20with%20six%20individuals%20needing%20to%20be%20offered%20HIVST-Choice%20for%20an%20additional%20HIV%20test-uptake.%20The%20mean%20per-patient%20cost%20was%20nearly%204-fold%20higher%20in%20HIVST-Choice%20%28I%2439.28%29%20versus%20SOC%20%28I%2410.80%29%2C%20with%20an%20ICER%20of%20I%24174.51%2C%2095%25%20CI%20%5B165.72%2C%20194.59%5D%20for%20each%20additional%20test-uptake.%20HIV%20self-test%20kit%20and%20cell%20phone%20service%20costs%20were%20the%20main%20drivers%20of%20the%20ICER%2C%20although%20findings%20were%20robust%20even%20at%20highest%20possible%20costs.%20The%20probability%20of%20cost-effectiveness%20approached%201%20at%20a%20willingness-to-pay%20of%20I%24200%20for%20each%20additional%20HIV%20test-uptake.%20HIVST-Choice%20improves%20HIV-test-uptake%20among%20truck%20drivers%20at%20low%20willingness-to-pay%20thresholds%2C%20suggesting%20that%20HIV%20self-testing%20is%20an%20efficient%20use%20of%20resources.%20Policies%20supporting%20HIV%20self-testing%20in%20similar%20high%20risk%2C%20hard-to-reach%20sub-populations%20may%20expedite%20achievement%20of%20international%20targets.%22%2C%22date%22%3A%222024-04-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fheapol%5C%2Fczae013%22%2C%22ISSN%22%3A%221460-2237%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222024-04-16T08%3A00%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22EDIV7L8F%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kebede%20et%20al.%22%2C%22parsedDate%22%3A%222024-04-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKebede%2C%20Samuel%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrazier%2C%20Ellen%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFreeman%2C%20Aimee%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMuwonge%2C%20Timothy%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChoi%2C%20Jun%20Yong%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Preexposure%20prophylaxis%20availability%20among%20health%20facilities%20participating%20in%20the%20global%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%20%3Ci%3EAIDS%20%28London%2C%20England%29%3C%5C%2Fi%3E%2C%20%3Ci%3E38%3C%5C%2Fi%3E%20%285%29%2C%20S.%20751%26%23x2013%3B756.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003824%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003824%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Preexposure%20prophylaxis%20availability%20among%20health%20facilities%20participating%20in%20the%20global%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Kebede%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aimee%20M.%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Muwonge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jun%20Yong%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renee%22%2C%22lastName%22%3A%22de%20Waal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armel%22%2C%22lastName%22%3A%22Poda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Athanase%22%2C%22lastName%22%3A%22Munyaneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Kasozi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20Kristoffer%20U.%22%2C%22lastName%22%3A%22Pasayan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alisho%22%2C%22lastName%22%3A%22Shongo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Low%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Ekouevi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdil%5Cu00e9a%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20While%20recognized%20as%20a%20key%20HIV%20prevention%20strategy%2C%20preexposure%20prophylaxis%20%28PrEP%29%20availability%20and%20accessibility%20are%20not%20well%20documented%20globally.%20We%20aimed%20to%20describe%20PrEP%20drug%20registration%20status%20and%20the%20availability%20of%20PrEP%20services%20across%20HIV%20care%20sites%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20research%20consortium.%5CnMETHODS%3A%20We%20used%20country-level%20PrEP%20drug%20registration%20status%20from%20the%20AIDS%20Vaccine%20Advocacy%20Coalition%20and%20data%20from%20IeDEA%20surveys%20conducted%20in%202014%2C%202017%20and%202020%20among%20participating%20HIV%20clinics%20in%20seven%20global%20regions.%20We%20used%20descriptive%20statistics%20to%20assess%20PrEP%20availability%20across%20IeDEA%20sites%20serving%20adult%20patients%20in%202020%20and%20examined%20trends%20in%20PrEP%20availability%20among%20sites%20that%20responded%20to%20all%20three%20surveys.%5CnRESULTS%3A%20Of%20199%20sites%20that%20completed%20the%202020%20survey%2C%20PrEP%20was%20available%20in%20161%20%2881%25%29.%20PrEP%20availability%20was%20highest%20at%20sites%20in%20North%20America%20%2829%5C%2F30%3B%2097%25%29%20and%20East%20Africa%20%2870%5C%2F74%3B%2095%25%29%20and%20lowest%20at%20sites%20in%20Central%20%2810%5C%2F20%3B%2050%25%29%20and%20West%20Africa%20%281%5C%2F6%3B%2017%25%29.%20PrEP%20availability%20was%20higher%20among%20sites%20in%20countries%20where%20PrEP%20was%20officially%20registered%20%28146%5C%2F161%3B%2091%25%29%20than%20where%20it%20was%20not%20%2814%5C%2F32%3B%2044%25%29.%20Availability%20was%20higher%20at%20health%20centers%20%28109%5C%2F120%3B%2090%25%29%20and%20district%20hospitals%20%2814%5C%2F16%3B%2088%25%29%20compared%20to%20regional%5C%2Fteaching%20hospitals%20%2836%5C%2F63%29.%20Among%20the%2094%20sites%20that%20responded%20to%20all%20three%20surveys%2C%20PrEP%20availability%20increased%20from%2047%25%20in%202014%20to%2060%25%20in%202017%20and%2076%25%20in%202020.%5CnCONCLUSION%3A%20PrEP%20availability%20has%20substantially%20increased%20since%202014%20and%20is%20now%20available%20at%20most%20IeDEA%20sites.%20However%2C%20PrEP%20service%20provision%20varies%20markedly%20across%20global%20regions.%22%2C%22date%22%3A%222024-04-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003824%22%2C%22ISSN%22%3A%221473-5571%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222024-04-12T12%3A44%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22Y6NAACJN%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Phillips%20et%20al.%22%2C%22parsedDate%22%3A%222024-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPhillips%2C%20Tamsin%20Kate%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKassanjee%2C%20Reshma%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMaxwell%2C%20Nicola%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAnderson%2C%20Kim%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJohnson%2C%20Leigh%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20ART%20history%20prior%20to%20conception%3A%20trends%20and%20association%20with%20postpartum%20disengagement%20from%20HIV%20care%20in%20Khayelitsha%2C%20South%20Africa%20%282013-2019%29%3A%20a%20retrospective%20cohort%20study.%20%3Ci%3EJournal%20of%20the%20International%20AIDS%20Society%3C%5C%2Fi%3E%2C%20%3Ci%3E27%3C%5C%2Fi%3E%20%284%29%2C%20S.%20e26236.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26236%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26236%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22ART%20history%20prior%20to%20conception%3A%20trends%20and%20association%20with%20postpartum%20disengagement%20from%20HIV%20care%20in%20Khayelitsha%2C%20South%20Africa%20%282013-2019%29%3A%20a%20retrospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tamsin%20Kate%22%2C%22lastName%22%3A%22Phillips%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reshma%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Maxwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leigh%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Haroon%22%2C%22lastName%22%3A%22Moolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Landon%22%2C%22lastName%22%3A%22Myer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%20H.%22%2C%22lastName%22%3A%22Chi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morna%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renee%22%2C%22lastName%22%3A%22de%20Waal%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20In%20recent%20years%2C%20the%20expansion%20of%20HIV%20treatment%20eligibility%20has%20resulted%20in%20an%20increase%20in%20people%20with%20antiretroviral%20therapy%20%28ART%29%20experience%20prior%20to%20pregnancy%20but%20little%20is%20known%20about%20postpartum%20engagement%20in%20care%20in%20this%20population.%20We%20examined%20differences%20in%20disengagement%20from%20HIV%20care%20after%20delivery%20by%20maternal%20ART%20history%20before%20conception.%5CnMETHODS%3A%20We%20analysed%20data%20from%20people%20living%20with%20HIV%20%28aged%2015-49%29%20in%20Khayelitsha%2C%20South%20Africa%2C%20with%20%5Cu22651%20live%20birth%20between%20April%202013%20and%20March%202019.%20We%20described%20trends%20over%20time%20in%20ART%20history%20prior%20to%20estimated%20conception%2C%20classifying%20ART%20history%20groups%20as%3A%20%28A%29%20on%20ART%20with%20no%20disengagement%20%28%3E270%20days%20with%20no%20evidence%20of%20HIV%20care%29%3B%20%28B%29%20returned%20before%20pregnancy%20following%20disengagement%3B%20%28C%29%20restarted%20ART%20in%20pregnancy%20after%20disengagement%3B%20and%20%28D%29%20ART%20new%20start%20in%20pregnancy.%20We%20used%20Kaplan-Meier%20curves%20and%20proportional-hazards%20models%20%28adjusted%20for%20maternal%20age%2C%20number%20of%20pregnancy%20records%20and%20year%20of%20delivery%29%20to%20examine%20the%20time%20to%20disengagement%20from%20delivery%20to%202%20years%20postpartum.%5CnRESULTS%3A%20Among%207309%20pregnancies%20%28in%206680%20individuals%29%2C%20the%20proportion%20on%20ART%20%28A%29%20increased%20from%2019%25%20in%202013%20to%2041%25%20in%202019.%20The%20proportions%20of%20those%20who%20returned%20%28B%29%20and%20restarted%20%28C%29%20increased%20from%202%25%20to%2013%25%20and%20from%202%25%20to%2010%25%2C%20respectively.%20There%20was%20a%20corresponding%20decline%20in%20the%20proportion%20of%20new%20starts%20%28D%29%20from%2077%25%20in%202013%20to%2036%25%20in%202019.%20In%20the%20first%20recorded%20pregnancy%20per%20person%20in%20the%20study%20period%2C%2026%25%20%2895%25%20CI%2025-27%25%29%20had%20disengaged%20from%20care%20by%201%20year%20and%2034%25%20%2895%25%20CI%2033-36%25%29%20by%202%20years%20postpartum.%20Individuals%20who%20returned%20%28B%3A%20aHR%202.10%2C%2095%25%20CI%201.70-2.60%29%2C%20restarted%20%28C%3A%20aHR%203.32%2C%2095%25%20CI%202.70-4.09%29%20and%20newly%20started%20ART%20%28D%3A%20aHR%202.41%2C%2095%25%20CI%202.12-2.74%29%20had%20increased%20hazards%20of%20postpartum%20disengagement%20compared%20to%20those%20on%20ART%20%28A%29.%5CnCONCLUSIONS%3A%20There%20is%20a%20growing%20population%20of%20people%20with%20ART%20experience%20prior%20to%20conception%20and%20postpartum%20disengagement%20varies%20substantially%20by%20ART%20history.%20Antenatal%20care%20presents%20an%20important%20opportunity%20to%20understand%20prior%20ART%20experiences%20and%20an%20entry%20into%20interventions%20for%20strengthened%20engagement%20in%20HIV%20care.%22%2C%22date%22%3A%222024-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26236%22%2C%22ISSN%22%3A%221758-2652%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222024-07-25T14%3A48%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22GNS9IMDT%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Plaisy%20et%20al.%22%2C%22parsedDate%22%3A%222024-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPlaisy%2C%20Marie%20Kerbie%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMinga%2C%20Albert%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWandeler%2C%20Gilles%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMurenzi%2C%20Gad%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESamala%2C%20Niharika%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Metabolic%20causes%20of%20liver%20disease%20among%20adults%20living%20with%20HIV%20from%20low-%20and%20middle-income%20countries%3A%20a%20cross-sectional%20study.%20%3Ci%3EJournal%20of%20the%20International%20AIDS%20Society%3C%5C%2Fi%3E%2C%20%3Ci%3E27%3C%5C%2Fi%3E%20%284%29%2C%20S.%20e26238.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26238%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26238%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Metabolic%20causes%20of%20liver%20disease%20among%20adults%20living%20with%20HIV%20from%20low-%20and%20middle-income%20countries%3A%20a%20cross-sectional%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20Kerbie%22%2C%22lastName%22%3A%22Plaisy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%20K.%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Niharika%22%2C%22lastName%22%3A%22Samala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ephrem%22%2C%22lastName%22%3A%22Mensah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ren%5Cu00e9e%22%2C%22lastName%22%3A%22de%20Waal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20H.%22%2C%22lastName%22%3A%22Kuniholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonali%22%2C%22lastName%22%3A%22Salvi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Attia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ardele%22%2C%22lastName%22%3A%22Mandiriri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Shumbusho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Goodrich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhanushi%22%2C%22lastName%22%3A%22Rupasinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%22%2C%22lastName%22%3A%22Alarcon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Perrazo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Sentinel%20Research%20Network%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Liver%20disease%20is%20a%20leading%20cause%20of%20morbidity%20and%20mortality%20among%20persons%20living%20with%20HIV%20%28PLHIV%29.%20While%20chronic%20viral%20hepatitis%20has%20been%20extensively%20studied%20in%20low-%20and%20middle-income%20countries%20%28LMICs%29%2C%20there%20is%20limited%20information%20about%20the%20burden%20of%20metabolic%20disorders%20on%20liver%20disease%20in%20PLHIV.%5CnMETHODS%3A%20We%20conducted%20a%20cross-sectional%20analysis%20of%20baseline%20data%20collected%20between%20October%202020%20and%20July%202022%20from%20the%20IeDEA-Sentinel%20Research%20Network%2C%20a%20prospective%20cohort%20enrolling%20PLHIV%20%5Cu226540%20years%20on%20antiretroviral%20treatment%20%28ART%29%20for%20%5Cu22656%20months%20from%20eight%20clinics%20in%20Asia%2C%20Americas%2C%20and%20central%2C%20East%2C%20southern%20and%20West%20Africa.%20Clinical%20assessments%2C%20laboratory%20testing%20on%20fasting%20blood%20samples%20and%20liver%20stiffness%20measurement%20%28LSM%29%5C%2Fcontrolled%20attenuation%20parameter%20%28CAP%29%20by%20vibration-controlled%20transient%20elastography%20were%20performed.%20Multivariable%20logistic%20regression%20models%20assessed%20factors%20associated%20with%20liver%20fibrosis%20%28LSM%20%5Cu22657.1%20kPa%29%20and%20steatosis%20%28CAP%20%5Cu2265248%20dB%5C%2Fm%29.%20Population%20attributable%20fraction%20%28PAF%29%20of%20each%20variable%20associated%20with%20significant%20liver%20fibrosis%20was%20estimated%20using%20Levin%27s%20formula.%5CnRESULTS%3A%20Overall%2C%202120%20PLHIV%20%2856%25%20female%2C%20median%20age%2050%20%5Binterquartile%20range%3A%2045-56%5D%20years%29%20were%20included.%20The%20prevalence%20of%20obesity%20was%2019%25%2C%2012%25%20had%20type%202%20diabetes%20mellitus%20%28T2DM%29%2C%2029%25%20had%20hypertension%20and%2053%25%20had%20dyslipidaemia.%20The%20overall%20prevalence%20of%20liver%20fibrosis%20and%20steatosis%20was%207.6%25%20%2895%25%20confidence%20interval%20%5BCI%5D%206.1-8.4%29%20and%2028.4%25%20%2895%25%20CI%2026.5-30.7%29%2C%20respectively%2C%20with%20regional%20variability.%20Male%20sex%20at%20birth%20%28odds%20ratio%20%5BOR%5D%201.62%2C%20CI%201.10-2.40%29%2C%20overweight%5C%2Fobesity%20%28OR%20%3D%202.50%2C%2095%25%20CI%201.69-3.75%29%2C%20T2DM%20%28OR%202.26%2C%2095%25%20CI%201.46-3.47%29%20and%20prolonged%20exposure%20to%20didanosine%20%28OR%203.13%2C%2095%25%20CI%201.46-6.49%29%20were%20associated%20with%20liver%20fibrosis.%20Overweight%5C%2Fobesity%20and%20T2DM%20accounted%20for%2042%25%20and%2011%25%20of%20the%20PAF%20for%20liver%20fibrosis%2C%20while%20HBsAg%20and%20anti-HCV%20accounted%20for%203%25%20and%201%25%2C%20respectively.%20Factors%20associated%20with%20steatosis%20included%20overweight%5C%2Fobesity%20%28OR%204.25%2C%2095%25%20CI%203.29-5.51%29%2C%20T2DM%20%28OR%202.06%2C%2095%25%20CI%201.47-2.88%29%2C%20prolonged%20exposure%20to%20stavudine%20%28OR%201.69%2C%2095%25%20CI%201.27-2.26%29%20and%20dyslipidaemia%20%28OR%201.68%2C%2095%25%20CI%201.31-2.16%29.%5CnCONCLUSIONS%3A%20Metabolic%20disorders%20were%20significant%20risk%20factors%20for%20liver%20disease%20among%20PLHIV%20in%20LMICs.%20Early%20recognition%20of%20metabolic%20disorders%20risk%20factors%20might%20be%20helpful%20to%20guide%20clinical%20and%20lifestyle%20interventions.%20Further%20prospective%20studies%20are%20needed%20to%20determine%20the%20causative%20natures%20of%20these%20findings.%22%2C%22date%22%3A%222024-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26238%22%2C%22ISSN%22%3A%221758-2652%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222024-04-16T08%3A00%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22L9HJN877%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Baker%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBaker%2C%20Paul%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBohrer%2C%20Andrea%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECastro%2C%20Ehydel%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAmaral%2C%20Eduardo%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESnow-Smith%2C%20Maryonne%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20The%20inflammatory%20microenvironment%20of%20the%20lung%20at%20the%20time%20of%20infection%20governs%20innate%20control%20of%20SARS-CoV-2%20replication.%20%3Ci%3EBioRxiv%3A%20The%20Preprint%20Server%20for%20Biology%3C%5C%2Fi%3E%2C%20S.%202024.03.27.586885.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2024.03.27.586885%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2024.03.27.586885%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20inflammatory%20microenvironment%20of%20the%20lung%20at%20the%20time%20of%20infection%20governs%20innate%20control%20of%20SARS-CoV-2%20replication%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20J.%22%2C%22lastName%22%3A%22Baker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%20C.%22%2C%22lastName%22%3A%22Bohrer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ehydel%22%2C%22lastName%22%3A%22Castro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20P.%22%2C%22lastName%22%3A%22Amaral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maryonne%22%2C%22lastName%22%3A%22Snow-Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flor%22%2C%22lastName%22%3A%22Torres-Ju%5Cu00e1rez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sydnee%20T.%22%2C%22lastName%22%3A%22Gould%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20R.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cassandra%20M.%22%2C%22lastName%22%3A%22Jordan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaspal%20S.%22%2C%22lastName%22%3A%22Khillan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kyoungin%22%2C%22lastName%22%3A%22Cho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20L.%22%2C%22lastName%22%3A%22Barber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reed%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kerry%20L.%22%2C%22lastName%22%3A%22Hilligan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katrin%20D.%22%2C%22lastName%22%3A%22Mayer-Barber%22%7D%5D%2C%22abstractNote%22%3A%22SARS-CoV-2%20infection%20leads%20to%20vastly%20divergent%20clinical%20outcomes%20ranging%20from%20asymptomatic%20infection%20to%20fatal%20disease.%20Co-morbidities%2C%20sex%2C%20age%2C%20host%20genetics%20and%20vaccine%20status%20are%20known%20to%20affect%20disease%20severity.%20Yet%2C%20how%20the%20inflammatory%20milieu%20of%20the%20lung%20at%20the%20time%20of%20SARS-CoV-2%20exposure%20impacts%20the%20control%20of%20viral%20replication%20remains%20poorly%20understood.%20We%20demonstrate%20here%20that%20immune%20events%20in%20the%20mouse%20lung%20closely%20preceding%20SARS-CoV-2%20infection%20significantly%20impact%20viral%20control%20and%20we%20identify%20key%20innate%20immune%20pathways%20required%20to%20limit%20viral%20replication.%20A%20diverse%20set%20of%20pulmonary%20inflammatory%20stimuli%2C%20including%20resolved%20antecedent%20respiratory%20infections%20with%20S.%20aureus%20or%20influenza%2C%20ongoing%20pulmonary%20M.%20tuberculosis%20infection%2C%20ovalbumin%5C%2Falum-induced%20asthma%20or%20airway%20administration%20of%20defined%20TLR%20ligands%20and%20recombinant%20cytokines%2C%20all%20establish%20an%20antiviral%20state%20in%20the%20lung%20that%20restricts%20SARS-CoV-2%20replication%20upon%20infection.%20In%20addition%20to%20antiviral%20type%20I%20interferons%2C%20the%20broadly%20inducible%20inflammatory%20cytokines%20TNF%5Cu03b1%20and%20IL-1%20precondition%20the%20lung%20for%20enhanced%20viral%20control.%20Collectively%2C%20our%20work%20shows%20that%20SARS-CoV-2%20may%20benefit%20from%20an%20immunologically%20quiescent%20lung%20microenvironment%20and%20suggests%20that%20heterogeneity%20in%20pulmonary%20inflammation%20that%20precedes%20or%20accompanies%20SARS-CoV-2%20exposure%20may%20be%20a%20significant%20factor%20contributing%20to%20the%20population-wide%20variability%20in%20COVID-19%20disease%20outcomes.%22%2C%22date%22%3A%222024-03-27%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2024.03.27.586885%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222024-04-12T12%3A32%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22B7CFQDVE%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jacob%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJacob%2C%20Nisha%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERice%2C%20Brian%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHeekes%2C%20Alexa%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJohnson%2C%20Leigh%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrinkmann%2C%20Samantha%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Exploring%20the%20validity%20of%20routine%20individuated%20service%20data%20for%20antenatal%20HIV%20surveillance%20in%20the%20Western%20Cape.%20%3Ci%3EResearch%20Square%3C%5C%2Fi%3E%2C%20S.%20rs.3.rs-4065819.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21203%5C%2Frs.3.rs-4065819%5C%2Fv1%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21203%5C%2Frs.3.rs-4065819%5C%2Fv1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Exploring%20the%20validity%20of%20routine%20individuated%20service%20data%20for%20antenatal%20HIV%20surveillance%20in%20the%20Western%20Cape%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nisha%22%2C%22lastName%22%3A%22Jacob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Rice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexa%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leigh%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samantha%22%2C%22lastName%22%3A%22Brinkmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tendesayi%22%2C%22lastName%22%3A%22Kufa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrian%22%2C%22lastName%22%3A%22Puren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Boulle%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20In%20the%20Western%20Cape%2C%20South%20Africa%2C%20public-sector%20individual-level%20routine%20data%20are%20consolidated%20from%20multiple%20sources%20through%20the%20Provincial%20Health%20Data%20Centre%20%28PHDC%29.%20This%20enables%20the%20description%20of%20temporal%20changes%20in%20population-wide%20antenatal%20HIV%20seroprevalence.%20We%20evaluated%20the%20validity%20of%20these%20data%20compared%20to%20aggregated%20program%20data%20and%20population-wide%20sentinel%20antenatal%20HIV%20seroprevalence%20surveys%20for%20the%20Western%20Cape%20province.%5CnMETHODS%3A%20We%20conducted%20a%20retrospective%20cohort%20analysis%20of%20all%20pregnancies%20identified%20in%20the%20PHDC%20from%20January%202011%20to%20December%202020.%20Evidence%20of%20antenatal%20and%20HIV%20care%20from%20electronic%20platforms%20were%20linked%20using%20a%20unique%20patient%20identifier.%20HIV%20prevalence%20estimates%20were%20triangulated%20and%20compared%20with%20available%20survey%20estimates%20and%20aggregated%20programmatic%20data%20from%20registers%20as%20recorded%20in%20the%20District%20Health%20Information%20System.%20Provincial%2C%20district-level%20and%20age-group%20HIV%20prevalence%20estimates%20were%20compared%20between%20data%20systems%20using%20correlation%20coefficients%2C%20absolute%20differences%20and%20trend%20analysis.%5CnRESULTS%3A%20Of%20the%20977800%20pregnancies%20ascertained%2C%20PHDC%20HIV%20prevalence%20estimates%20from%202011-2013%20were%20widely%20disparate%20from%20aggregate%20and%20survey%20data%20%28due%20to%20incomplete%20electronic%20data%29%2C%20whereas%20from%202014%20onwards%2C%20estimates%20were%20within%20the%2095%25%20confidence%20interval%20of%20survey%20estimates%2C%20and%20closely%20correlated%20to%20aggregate%20data%20estimates%20%28r%20%3D%200.8%3B%20p%20%3D%200.01%29%2C%20with%20an%20average%20prevalence%20difference%20of%200.4%25.%20PHDC%20data%20show%20a%20slow%20but%20steady%20increase%20in%20provincial%20HIV%20prevalence%20from%2016.7%25%20in%202015%20to%2018.6%25%20in%202020.%20The%20highest%20HIV%20prevalence%20was%20in%20the%20Cape%20Metro%20district%20%2820.3%25%29%20Prevalence%20estimates%20by%20age%20group%20were%20comparable%20between%20sentinel%20surveys%20and%20PHDC%20from%202015%20onwards%2C%20with%20prevalence%20estimates%20stable%20over%20time%20among%20younger%20age-groups%20%2815-24%20years%29%20but%20increased%20among%20older%20age-groups%20%28%3E%2034%20years%29.%5CnCONCLUSIONS%3A%20This%20study%20compares%20sentinel%20seroprevalence%20surveys%20with%20both%20register-based%20aggregate%20data%20and%20consolidated%20individuated%20administrative%20data.%20We%20show%20that%20in%20this%20setting%20linked%20individuated%20data%20may%20be%20reliably%20used%20for%20HIV%20surveillance%20and%20provide%20more%20granular%20estimates%20with%20greater%20efficiency%20than%20seroprevalence%20surveys%20and%20register-based%20aggregate%20data.%22%2C%22date%22%3A%222024-03-21%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.21203%5C%2Frs.3.rs-4065819%5C%2Fv1%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222024-04-16T07%3A47%3A39Z%22%7D%7D%2C%7B%22key%22%3A%2234J9LGNY%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Haw%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHaw%2C%20Nel%20Jason%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELesko%2C%20Catherine%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENg%2C%20Derek%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELam%2C%20Jennifer%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELang%2C%20Raynell%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Incidence%20of%20non-AIDS%20defining%20comorbidities%20among%20young%20adults%20with%20perinatally-acquired%20HIV%20in%20North%20America%2C%202000-2019.%20%3Ci%3EAIDS%20%28London%2C%20England%29%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003892%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003892%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Incidence%20of%20non-AIDS%20defining%20comorbidities%20among%20young%20adults%20with%20perinatally-acquired%20HIV%20in%20North%20America%2C%202000-2019%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nel%20Jason%20L.%22%2C%22lastName%22%3A%22Haw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20R.%22%2C%22lastName%22%3A%22Lesko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Derek%20K.%22%2C%22lastName%22%3A%22Ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Lam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raynell%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mari%20M.%22%2C%22lastName%22%3A%22Kitahata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heidi%22%2C%22lastName%22%3A%22Crane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Eron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20John%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maile%22%2C%22lastName%22%3A%22Karris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mona%22%2C%22lastName%22%3A%22Loutfy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathleen%20A.%22%2C%22lastName%22%3A%22Mcginnis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allison%22%2C%22lastName%22%3A%22Agwu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22North%20American%20AIDS%20Cohort%20Collaboration%20on%20Research%20and%20Design%20%28NA-ACCORD%29%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20describe%20the%20incidence%20of%20diabetes%20mellitus%20type%202%20%28T2DM%29%2C%20hypercholesterolemia%2C%20hypertriglyceridemia%2C%20hypertension%2C%20and%20chronic%20kidney%20disease%20%28CKD%29%20from%202000%20to%202019%20among%20North%20American%20adults%20with%20perinatally-acquired%20HIV%20%28PHIV%29%20aged%2018%20to%2030.%5CnDESIGN%3A%20Description%20of%20outcomes%20based%20on%20electronic%20health%20records%20for%20a%20cohort%20of%20375%20young%20adults%20with%20PHIV%20enrolled%20in%20routine%20HIV%20care%20at%20clinics%20contributing%20data%20to%20the%20North%20American%20AIDS%20Cohort%20Collaboration%20on%20Research%20and%20Design%20%28NA-ACCORD%29.%5CnMETHODS%3A%20We%20estimated%20overall%2C%20sex-%2C%20and%20race-stratified%20cumulative%20incidences%20using%20Turnbull%20estimation%2C%20and%20incidence%20rates%20using%20quasi-Poisson%20regression.%20T2DM%20was%20defined%20as%20glycosylated%20hemoglobin%20%3E6.5%25%20or%20based%20on%20clinical%20diagnosis%20and%20medication%20use.%20Hypercholesterolemia%20was%20based%20on%20medication%20use%20or%20total%20cholesterol%20%5Cu2265200%5Cu200amg%5C%2FdL.%20Hypertriglyceridemia%20was%20based%20on%20medication%20use%20or%20fasting%20triglyceride%20%5Cu2265150%5Cu200amg%5C%2FdL%20or%20non-fasting%20%5Cu2265200%5Cu200amg%5C%2FdL.%20Hypertension%20was%20based%20on%20clinical%20diagnosis.%20CKD%20was%20defined%20as%20estimated%20glomerular%20filtration%20rates%20%3C90%5Cu200aml%5C%2Fmi%7C1.73%5Cu200am2%20for%20%5Cu22653%5Cu200amonths.%5CnRESULTS%3A%20Cumulative%20incidence%20by%20age%2030%20and%20incidence%20rates%20from%20age%2018%20to%2030%20%28per%20100%20person-years%29%20were%3A%20T2DM%3A%2019%25%2C%202.9%3B%20hypercholesterolemia%3A%2040%25%2C%204.6%3B%20hypertriglyceridemia%3A%2050%25%2C%205.6%3B%20hypertension%3A%2022%25%2C%202.0%3B%20and%20CKD%3A%2025%25%2C%203.3.%20Non-Black%20females%20had%20the%20highest%20incidence%20of%20hypercholesterolemia%20and%20hypertriglyceridemia%2C%20Black%20adults%20had%20the%20highest%20hypertension%20incidence%2C%20and%20Black%20males%20had%20the%20highest%20CKD%20incidence.%5CnCONCLUSION%3A%20There%20was%20a%20high%20incidence%20of%20five%20chronic%20comorbidities%20among%20people%20with%20PHIV.%20Earlier%20screening%20at%20younger%20ages%20might%20be%20considered%20for%20this%20unique%20population%20to%20strengthen%20prevention%20strategies%20and%20initiate%20treatment%20in%20a%20timely%20way.%22%2C%22date%22%3A%222024-03-19%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003892%22%2C%22ISSN%22%3A%221473-5571%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222024-04-16T07%3A51%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22Y9257EJM%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vinhaes%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVinhaes%2C%20Caian%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFukutani%2C%20Eduardo%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESantana%2C%20Gabriel%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EArriaga%2C%20Mar%26%23xED%3Ba%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBarreto-Duarte%2C%20Beatriz%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20An%20integrative%20multi-omics%20approach%20to%20characterize%20interactions%20between%20tuberculosis%20and%20diabetes%20mellitus.%20%3Ci%3EIScience%3C%5C%2Fi%3E%2C%20%3Ci%3E27%3C%5C%2Fi%3E%20%283%29%2C%20S.%20109135.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.isci.2024.109135%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.isci.2024.109135%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22An%20integrative%20multi-omics%20approach%20to%20characterize%20interactions%20between%20tuberculosis%20and%20diabetes%20mellitus%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20R.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%20C.%22%2C%22lastName%22%3A%22Santana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mateus%22%2C%22lastName%22%3A%22Maggitti-Bezerril%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%20M.%20S.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ginger%20L.%22%2C%22lastName%22%3A%22Milne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kristki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT%20Brazil%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22Tuberculosis-diabetes%20mellitus%20%28TB-DM%29%20is%20linked%20to%20a%20distinct%20inflammatory%20profile%2C%20which%20can%20be%20assessed%20using%20multi-omics%20analyses.%20Here%2C%20a%20machine%20learning%20algorithm%20was%20applied%20to%20multi-platform%20data%2C%20including%20cytokines%20and%20gene%20expression%20in%20peripheral%20blood%20and%20eicosanoids%20in%20urine%2C%20in%20a%20Brazilian%20multi-center%20TB%20cohort.%20There%20were%20four%20clinical%20groups%3A%20TB-DM%28n%5Cu00a0%3D%2024%29%2C%20TB%20only%28n%5Cu00a0%3D%2028%29%2C%20DM%28HbA1c%20%5Cu2265%206.5%25%29%20only%28n%5Cu00a0%3D%2011%29%2C%20and%20a%20control%20group%20of%20close%20TB%20contacts%20who%20did%20not%20have%20TB%20or%20DM%28n%5Cu00a0%3D%2013%29.%20After%5Cu00a0cross-validation%2C%20baseline%20expression%20or%20abundance%20of%20MMP-28%2C%20LTE-4%2C%2011-dTxB2%2C%20PGDM%2C%20FBXO6%2C%20SECTM1%2C%20and%20LINCO2009%20differentiated%20the%20four%20patient%20groups.%20A%20distinct%20multi-omic-derived%2C%20dimensionally%20reduced%2C%20signature%20was%20associated%20with%20TB%2C%20regardless%20of%20glycemic%20status.%20SECTM1%20and%20FBXO6%20mRNA%20levels%20were%20positively%20correlated%20with%20sputum%20acid-fast%20bacilli%20grade%20in%20TB-DM.%20Values%20of%20the%20biomarkers%20decreased%20during%20the%20course%20of%20anti-TB%20therapy.%20Our%20study%20identified%20several%20markers%20associated%20with%20the%20pathophysiology%20of%20TB-DM%20that%20could%20be%20evaluated%20in%20future%20mechanistic%20investigations.%22%2C%22date%22%3A%222024-03-15%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.isci.2024.109135%22%2C%22ISSN%22%3A%222589-0042%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222024-04-12T12%3A38%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22784IN2BU%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ridolfi%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERidolfi%2C%20Felipe%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAmorim%2C%20Gustavo%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPeetluk%2C%20Lauren%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHaas%2C%20David%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStaats%2C%20Cody%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Prediction%20Models%20for%20Adverse%20Drug%20Reactions%20During%20Tuberculosis%20Treatment%20in%20Brazil.%20%3Ci%3EThe%20Journal%20of%20Infectious%20Diseases%3C%5C%2Fi%3E%2C%20%3Ci%3E229%3C%5C%2Fi%3E%20%283%29%2C%20S.%20813%26%23x2013%3B823.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiae025%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiae025%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prediction%20Models%20for%20Adverse%20Drug%20Reactions%20During%20Tuberculosis%20Treatment%20in%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felipe%22%2C%22lastName%22%3A%22Ridolfi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20S.%22%2C%22lastName%22%3A%22Peetluk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20W.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cody%22%2C%22lastName%22%3A%22Staats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Regional%20Prospective%20Observational%20Research%20in%20Tuberculosis%20%28RePORT%29%5Cu2013Brazil%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Tuberculosis%20%28TB%29%20treatment-related%20adverse%20drug%20reactions%20%28TB-ADRs%29%20can%20negatively%20affect%20adherence%20and%20treatment%20success%20rates.%5CnMETHODS%3A%20We%20developed%20prediction%20models%20for%20TB-ADRs%2C%20considering%20participants%20with%20drug-susceptible%20pulmonary%20TB%20who%20initiated%20standard%20TB%20therapy.%20TB-ADRs%20were%20determined%20by%20the%20physician%20attending%20the%20participant%2C%20assessing%20causality%20to%20TB%20drugs%2C%20the%20affected%20organ%20system%2C%20and%20grade.%20Potential%20baseline%20predictors%20of%20TB-ADR%20included%20concomitant%20medication%20%28CM%29%20use%2C%20human%20immunodeficiency%20virus%20%28HIV%29%20status%2C%20glycated%20hemoglobin%20%28HbA1c%29%2C%20age%2C%20body%20mass%20index%20%28BMI%29%2C%20sex%2C%20substance%20use%2C%20and%20TB%20drug%20metabolism%20variables%20%28NAT2%20acetylator%20profiles%29.%20The%20models%20were%20developed%20through%20bootstrapped%20backward%20selection.%20Cox%20regression%20was%20used%20to%20evaluate%20TB-ADR%20risk.%5CnRESULTS%3A%20There%20were%20156%20TB-ADRs%20among%20102%20of%20the%20945%20%2811%25%29%20participants%20included.%20Most%20TB-ADRs%20were%20hepatic%20%28n%20%3D%2082%20%5B53%25%5D%29%2C%20of%20moderate%20severity%20%28grade%202%3B%20n%20%3D%20121%20%5B78%25%5D%29%2C%20and%20occurred%20in%20NAT2%20slow%20acetylators%20%28n%20%3D%2062%20%5B61%25%5D%29.%20The%20main%20prediction%20model%20included%20CM%20use%2C%20HbA1c%2C%20alcohol%20use%2C%20HIV%20seropositivity%2C%20BMI%2C%20and%20age%2C%20with%20robust%20performance%20%28c-statistic%20%3D%200.79%20%5B95%25%20confidence%20interval%20%7BCI%7D%2C%20.74-.83%29%20and%20fit%20%28optimism-corrected%20slope%20and%20intercept%20of%20-0.09%20and%200.94%2C%20respectively%29.%20An%20alternative%20model%20replacing%20BMI%20with%20NAT2%20had%20similar%20performance.%20HIV%20seropositivity%20%28hazard%20ratio%20%5BHR%5D%2C%202.68%20%5B95%25%20CI%2C%201.75-4.09%5D%29%20and%20CM%20use%20%28HR%2C%205.26%20%5B95%25%20CI%2C%202.63-10.52%5D%29%20increased%20TB-ADR%20risk.%5CnCONCLUSIONS%3A%20The%20models%2C%20with%20clinical%20variables%20and%20with%20NAT2%2C%20were%20highly%20predictive%20of%20TB-ADRs.%22%2C%22date%22%3A%222024-03-14%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Finfdis%5C%2Fjiae025%22%2C%22ISSN%22%3A%221537-6613%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222024-04-12T12%3A38%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22IKXYYDYT%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ben%20Farhat%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBen%20Farhat%2C%20Jihane%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETiendrebeogoMD%2C%20Thierry%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMalateste%2C%20Karen%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPoda%2C%20Armel%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMinga%2C%20Albert%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Effects%20of%20the%20Covid-19%20pandemic%20on%20ART%20initiation%20and%20access%20to%20HIV%20viral%20load%20monitoring%20in%20adults%20living%20with%20HIV%20in%20West%20Africa%3A%20a%20regression%20discontinuity%20analysis.%20%3Ci%3EJournal%20of%20Acquired%20Immune%20Deficiency%20Syndromes%20%281999%29%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003404%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003404%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effects%20of%20the%20Covid-19%20pandemic%20on%20ART%20initiation%20and%20access%20to%20HIV%20viral%20load%20monitoring%20in%20adults%20living%20with%20HIV%20in%20West%20Africa%3A%20a%20regression%20discontinuity%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jihane%22%2C%22lastName%22%3A%22Ben%20Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22TiendrebeogoMD%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Malateste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armel%22%2C%22lastName%22%3A%22Poda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eug%5Cu00e8ne%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henri%22%2C%22lastName%22%3A%22Chenal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oliver%22%2C%22lastName%22%3A%22Ezechi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Igho%22%2C%22lastName%22%3A%22Ofotokun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%20K.%22%2C%22lastName%22%3A%22Ekouevi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Barger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20Efforts%20to%20control%20the%20COVID-19%20pandemic%20have%20potentially%20compromised%20the%20availability%20and%5C%2For%20quality%20of%20HIV%20services.%20We%20aimed%20to%20assess%20the%20pandemic%27s%20impact%20on%20ART%20initiation%20and%20HIV%20viral%20load%20%28VL%29%20monitoring%20in%20three%20West%20African%20countries.%5CnMETHODS%3A%20We%20used%20routinely%20collected%20data%20from%20five%20clinics%20contributing%20to%20the%20IeDEA%20collaboration%20in%20Burkina%20Faso%2C%20C%5Cu00f4te%20d%27Ivoire%20and%20Nigeria.%20We%20included%20ART-na%5Cu00efve%20adults%20living%20with%20HIV%20%28ALWH%29%20initiating%20ART%20from%2001%5C%2F01%5C%2F2018.%20We%20conducted%20regression%20discontinuity%20analysis%20to%20estimate%20changes%20in%20the%20number%20of%20ART%20initiations%20and%20VL%20measures%20per%20week%2C%20before%20and%20during%20the%20pandemic%20period%20in%20each%20country.%5CnRESULTS%3A%20In%20clinics%20in%20Burkina%20Faso%20and%20C%5Cu00f4te%20d%27Ivoire%2C%20ART%20initiations%20per%20week%20remained%20constant%20throughout%20the%20studied%20periods%20%28-0.24%20points%20%28p%29%20of%20ART%20initiations%5C%2Fweek%2095%25CI%20-5.5%2C%205.9%2C%20-0.9%20p%2095%25CI%20-8.5%2C8.6%2C%20respectively%29%2C%20whereas%20in%20Nigeria%27s%20clinic%2C%20they%20decreased%20significantly%20%28-6.3%20p%2C%2095%25%20CI%20-10.8%2C%20-1.7%29%20after%20the%20beginning%20of%20the%20pandemic.%20The%20volume%20of%20VL%20tests%20performed%20decreased%20significantly%20in%20all%20three%20countries%20%28-17.0%20p%2095%25CI%20-25.3%2C%20-8.6%20in%20Burkina%20Faso%2C%20-118.4%20p%2095%25CI%20-171.1%2C%20-65.8%20in%20C%5Cu00f4te%20d%27Ivoire%20and%20-169.1p%2095%25CI-282.6%2C%20-55.6%20in%20Nigeria%29.%5CnCONCLUSIONS%3A%20Access%20to%20ART%20was%20maintained%20for%20newly%20diagnosed%20ALWH%20despite%20pandemic-related%20physical%5C%2Fsocial%20distancing%20measures.%20However%2C%20VL%20monitoring%20was%20severely%20disrupted%20and%20did%20not%20return%20to%20pre-pandemic%20levels%20approximately%20one%20year%20after%20the%20beginning%20of%20the%20pandemic.%20While%20HIV%20services%20in%20West%20Africa%20appear%20rather%20resilient%2C%20the%20impact%20of%20disruptions%20in%20VL%20monitoring%20on%20virological%20and%20clinical%20outcomes%20should%20continue%20to%20be%20monitored.%22%2C%22date%22%3A%222024-03-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003404%22%2C%22ISSN%22%3A%221944-7884%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222024-04-16T08%3A01%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22JDX3XTED%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nabukalu%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENabukalu%2C%20Dorean%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EYiannoutsos%2C%20Constantin%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESemeere%2C%20Aggrey%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMusick%2C%20Beverly%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMurungi%2C%20Teddy%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Mortality%20Among%20HIV-Infected%20Adults%20on%20Antiretroviral%20Therapy%20in%20Southern%20Uganda.%20%3Ci%3EJournal%20of%20Acquired%20Immune%20Deficiency%20Syndromes%20%281999%29%3C%5C%2Fi%3E%2C%20%3Ci%3E95%3C%5C%2Fi%3E%20%283%29%2C%20S.%20268%26%23x2013%3B274.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003330%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003330%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mortality%20Among%20HIV-Infected%20Adults%20on%20Antiretroviral%20Therapy%20in%20Southern%20Uganda%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dorean%22%2C%22lastName%22%3A%22Nabukalu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%20S.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Teddy%22%2C%22lastName%22%3A%22Murungi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jane%20Viola%22%2C%22lastName%22%3A%22Namulindwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francis%22%2C%22lastName%22%3A%22Waswa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gertrude%22%2C%22lastName%22%3A%22Nakigozi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelson%20K.%22%2C%22lastName%22%3A%22Sewankambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20J.%22%2C%22lastName%22%3A%22Reynolds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lutalo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fredrick%22%2C%22lastName%22%3A%22Makumbi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Godfrey%22%2C%22lastName%22%3A%22Kigozi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fred%22%2C%22lastName%22%3A%22Nalugoda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Monitoring%20and%20evaluation%20of%20clinical%20programs%20requires%20assessing%20patient%20outcomes.%20Numerous%20challenges%20complicate%20these%20efforts%2C%20the%20most%20insidious%20of%20which%20is%20loss%20to%20follow-up%20%28LTFU%29.%20LTFU%20is%20a%20composite%20outcome%2C%20including%20individuals%20out%20of%20care%2C%20undocumented%20transfers%2C%20and%20unreported%20deaths.%20Incorporation%20of%20vital%20status%20information%20from%20routine%20patient%20outreach%20may%20improve%20the%20mortality%20estimates%20for%20those%20LTFU.%5CnSETTINGS%3A%20We%20analyzed%20routinely%20collected%20clinical%20and%20patient%20tracing%20data%20for%20individuals%20%2815%20years%20or%20older%29%20initiating%20antiretroviral%20treatment%20between%20January%202014%20and%20December%202018%20at%202%20public%20HIV%20care%20clinics%20in%20greater%20Rakai%2C%20Uganda.%5CnMETHODS%3A%20We%20derived%20unadjusted%20mortality%20estimates%20using%20Kaplan-Meier%20methods.%20Estimates%2C%20adjusted%20for%20unreported%20deaths%2C%20applied%20weighting%20through%20the%20Frangakis%20and%20Rubin%20method%20to%20represent%20outcomes%20among%20LTFU%20patients%20who%20were%20successfully%20traced%20and%20for%20whom%20vital%20status%20was%20ascertained.%20Confidence%20intervals%20were%20determined%20through%20bootstrap%20methods.%5CnRESULTS%3A%20Of%201969%20patients%20with%20median%20age%20at%20antiretroviral%20treatment%20initiation%20of%2031%20years%20%28interquartile%20range%3A%2025-38%29%2C%201126%20%2857.2%25%29%20were%20female%20patients%20and%20808%20%2841%25%29%20were%20lost.%20Of%20the%20lost%20patients%2C%20640%20patient%20files%20%2879.2%25%29%20were%20found%20and%20reviewed%2C%20of%20which%20204%20%2831.8%25%29%20had%20a%20tracing%20attempt.%20Within%20the%20electronic%20health%20records%20of%20the%20program%2C%2028%20deaths%20were%20identified%20with%20an%20estimated%20unadjusted%20mortality%201%20year%20after%20antiretroviral%20treatment%20initiation%20of%202.5%25%20%2895%25%20CI%3A%201.8%25%20to%203.3%25%29.%20Using%20chart%20review%20and%20patient%20tracing%20data%2C%20an%20additional%2024%20deaths%20%28total%2052%29%20were%20discovered%20with%20an%20adjusted%201-year%20mortality%20of%203.8%25%20%2895%25%20CI%3A%202.6%25%20to%205.0%25%29.%5CnCONCLUSIONS%3A%20Data%20from%20routine%20outreach%20efforts%20by%20HIV%20care%20and%20treatment%20programs%20can%20be%20used%20to%20support%20plausible%20adjustments%20to%20estimates%20of%20client%20mortality.%20Mortality%20estimates%20without%20active%20ascertainment%20of%20vital%20status%20of%20LTFU%20patients%20may%20significantly%20underestimate%20program%20mortality.%22%2C%22date%22%3A%222024-03-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003330%22%2C%22ISSN%22%3A%221944-7884%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222024-03-18T10%3A40%3A41Z%22%7D%7D%2C%7B%22key%22%3A%226EZFH9QC%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Anderson%20et%20al.%22%2C%22parsedDate%22%3A%222024-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAnderson%2C%20Kim%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKalk%2C%20Emma%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHeekes%2C%20Alexa%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPhelanyane%2C%20Florence%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJacob%2C%20Nisha%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Factors%20associated%20with%20vertical%20transmission%20of%20HIV%20in%20the%20Western%20Cape%2C%20South%20Africa%3A%20a%20retrospective%20cohort%20analysis.%20%3Ci%3EJournal%20of%20the%20International%20AIDS%20Society%3C%5C%2Fi%3E%2C%20%3Ci%3E27%3C%5C%2Fi%3E%20%283%29%2C%20S.%20e26235.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26235%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26235%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Factors%20associated%20with%20vertical%20transmission%20of%20HIV%20in%20the%20Western%20Cape%2C%20South%20Africa%3A%20a%20retrospective%20cohort%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Kalk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexa%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Phelanyane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nisha%22%2C%22lastName%22%3A%22Jacob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ushma%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reshma%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gayathri%22%2C%22lastName%22%3A%22Sridhar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leigh%22%2C%22lastName%22%3A%22Ragone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vani%22%2C%22lastName%22%3A%22Vannappagari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Monitoring%20mother-infant%20pairs%20with%20HIV%20exposure%20is%20needed%20to%20assess%20the%20effectiveness%20of%20vertical%20transmission%20%28VT%29%20prevention%20programmes%20and%20progress%20towards%20VT%20elimination.%5CnMETHODS%3A%20We%20used%20routinely%20collected%20data%20on%20infants%20with%20HIV%20exposure%2C%20born%20May%202018-April%202021%20in%20the%20Western%20Cape%2C%20South%20Africa%2C%20with%20follow-up%20through%20mid-2022.%20We%20assessed%20the%20proportion%20of%20infants%20diagnosed%20with%20HIV%20at%20birth%20%28%5Cu22647%20days%29%2C%2010%20weeks%20%28%3E1%20to%2014%20weeks%29%20and%20%3E14%20weeks%20as%20proxies%20for%20intrauterine%2C%20intrapartum%5C%2Fearly%20breastfeeding%20and%20late%20breastfeeding%20transmission%2C%20respectively.%20We%20used%20mixed-effects%20Poisson%20regression%20to%20assess%20factors%20associated%20with%20VT%20in%20mothers%20known%20with%20HIV%20by%20delivery.%5CnRESULTS%3A%20We%20included%2050%2C461%20infants%20born%20to%20mothers%20known%20with%20HIV%20by%20delivery.%20HIV%20was%20diagnosed%20in%20894%20%281.8%25%29%20infants.%20Among%20mothers%2C%2051%25%20started%20antiretroviral%20treatment%20%28ART%29%20before%20and%2027%25%20during%20pregnancy%3B%2017%25%20restarted%20during%20pregnancy%20after%20%5Cu22656%20months%20interruption%3B%20and%206%25%20had%20no%20recorded%20ART%20during%20pregnancy.%20Most%20pregnancy%20ART%20regimens%20included%20non-nucleoside%20reverse%20transcriptase%20inhibitors%20%2883%25%29.%20Of%20mothers%20with%20available%20results%20%2890%25%20with%20viral%20load%20%5BVL%5D%3B%2070%25%20with%20CD4%29%2C%20VL%20nearest%20delivery%20was%20%3C100%20copies%5C%2Fml%20in%2078%25%20and%20CD4%20count%20%5Cu2265350%20cells%5C%2F%5Cu03bcl%20in%2062%25.%20HIV-PCR%20results%20were%20available%20for%2086%25%2C%2067%25%20and%2048%25%20of%20eligible%20infants%20at%20birth%2C%2010%20weeks%20and%20%3E14%20weeks.%20Among%20these%20infants%2C%200.9%25%2C%200.4%25%20and%201.5%25%20were%20diagnosed%20positive%20at%20birth%2C%2010%20weeks%20and%20%3E14%20weeks%2C%20respectively.%20Among%20infants%20diagnosed%20with%20HIV%2C%2043%25%2C%2016%25%20and%2041%25%20were%20diagnosed%20at%20these%20respective%20time%20periods.%20Among%20mothers%20with%20VL%3C100%2C%20100-999%2C%201000-99%2C000%20and%20%5Cu2265100%2C000%20copies%5C%2Fml%20nearest%20delivery%2C%20infant%20HIV%20diagnosis%20incidence%20was%200.4%25%2C%202.3%25%2C%206.6%25%20and%2018.4%25%2C%20respectively.%20Increased%20VT%20was%20strongly%20associated%20with%20recent%20elevated%20maternal%20VL%20with%20a%20seven-fold%20increased%20rate%20with%20even%20modestly%20elevated%20VL%20%28100-999%20vs.%20%3C100%20copies%5C%2Fml%29.%20VT%20was%20also%20associated%20with%20unknown%5C%2Flow%20maternal%20CD4%2C%20maternal%20age%20%3C20%20years%2C%20no%20antenatal%20ART%2C%20later%20maternal%20ART%20start%5C%2Frestart%20in%20pregnancy%20and%20ART%20gaps.%5CnCONCLUSIONS%3A%20Despite%20high%20maternal%20ART%20coverage%20and%20routine%20postnatal%20prophylaxis%2C%20ongoing%20VT%20remains%20a%20concern.%20Timing%20of%20infant%20HIV%20diagnoses%20suggests%20intrapartum%20and%5C%2For%20breastfeeding%20transmission%20in%20nearly%2060%25.%20Interventions%20to%20ensure%20retention%20on%20ART%20and%20sustained%20maternal%20viral%20suppression%20are%20needed%20to%20reduce%20VT.%22%2C%22date%22%3A%222024-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26235%22%2C%22ISSN%22%3A%221758-2652%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222024-04-16T07%3A55%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22EKX688G4%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brazier%20et%20al.%22%2C%22parsedDate%22%3A%222024-03%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrazier%2C%20Ellen%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETymejczyk%2C%20Olga%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWools-Kaloustian%2C%20Kara%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJiamsakul%2C%20Awachana%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETorres%2C%20Marco%20Tulio%20Luque%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282024%29.%20Long-term%20HIV%20care%20outcomes%20under%20universal%20HIV%20treatment%20guidelines%3A%20A%20retrospective%20cohort%20study%20in%2025%20countries.%20%3Ci%3EPLoS%20Medicine%3C%5C%2Fi%3E%2C%20%3Ci%3E21%3C%5C%2Fi%3E%20%283%29%2C%20S.%20e1004367.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004367%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004367%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20HIV%20care%20outcomes%20under%20universal%20HIV%20treatment%20guidelines%3A%20A%20retrospective%20cohort%20study%20in%2025%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Tymejczyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Awachana%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Tulio%20Luque%22%2C%22lastName%22%3A%22Torres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20S.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Abuogi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vohith%22%2C%22lastName%22%3A%22Khol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mej%5Cu00eda%20Cordero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20G.%22%2C%22lastName%22%3A%22Law%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20While%20national%20adoption%20of%20universal%20HIV%20treatment%20guidelines%20has%20led%20to%20improved%2C%20timely%20uptake%20of%20antiretroviral%20therapy%20%28ART%29%2C%20longer-term%20care%20outcomes%20are%20understudied.%20There%20is%20little%20data%20from%20real-world%20service%20delivery%20settings%20on%20patient%20attrition%2C%20viral%20load%20%28VL%29%20monitoring%2C%20and%20viral%20suppression%20%28VS%29%20at%2024%20and%2036%20months%20after%20HIV%20treatment%20initiation.%5CnMETHODS%20AND%20FINDINGS%3A%20For%20this%20retrospective%20cohort%20analysis%2C%20we%20used%20observational%20data%20from%2025%20countries%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%27s%20Asia-Pacific%2C%20Central%20Africa%2C%20East%20Africa%2C%20Central%5C%2FSouth%20America%2C%20and%20North%20America%20regions%20for%20patients%20who%20were%20ART%20na%5Cu00efve%20and%20aged%20%5Cu226515%20years%20at%20care%20enrollment%20between%2024%20months%20before%20and%2012%20months%20after%20national%20adoption%20of%20universal%20treatment%20guidelines%2C%20occurring%202012%20to%202018.%20We%20estimated%20crude%20cumulative%20incidence%20of%20loss-to-clinic%20%28CI-LTC%29%20at%2012%2C%2024%2C%20and%2036%20months%20after%20enrollment%20among%20patients%20enrolling%20in%20care%20before%20and%20after%20guideline%20adoption%20using%20competing%20risks%20regression.%20Guideline%20change-associated%20hazard%20ratios%20of%20LTC%20at%20each%20time%20point%20after%20enrollment%20were%20estimated%20via%20cause-specific%20Cox%20proportional%20hazards%20regression%20models.%20Modified%20Poisson%20regression%20was%20used%20to%20estimate%20relative%20risks%20of%20retention%2C%20VL%20monitoring%2C%20and%20VS%20at%2012%2C%2024%2C%20and%2036%20months%20after%20ART%20initiation.%20There%20were%2066%2C963%20patients%20enrolling%20in%20HIV%20care%20at%20109%20clinics%20with%20%5Cu226512%20months%20of%20follow-up%20time%20after%20enrollment%20%2846%2C484%20%5B69.4%25%5D%20enrolling%20before%20guideline%20adoption%20and%2020%2C479%20%5B30.6%25%5D%20enrolling%20afterwards%29.%20More%20than%20half%20%2854.9%25%29%20were%20females%2C%20and%20median%20age%20was%2034%20years%20%28interquartile%20range%20%5BIQR%5D%3A%2027%20to%2043%29.%20Mean%20follow-up%20time%20was%2051%20months%20%28standard%20deviation%3A%2017%20months%3B%20range%3A%2012%2C%20110%20months%29.%20Among%20patients%20enrolling%20before%20guideline%20adoption%2C%20crude%20CI-LTC%20was%2023.8%25%20%2895%25%20confidence%20interval%20%5B95%25%20CI%5D%2023.4%2C%2024.2%29%20at%2012%20months%2C%2031.0%25%20%2895%25%20CI%20%5B30.6%2C%2031.5%5D%29%20at%2024%20months%2C%20and%2037.2%25%20%2895%25%20%5BCI%2036.8%2C%2037.7%5D%29%20at%2036%20months%20after%20enrollment.%20Adjusting%20for%20sex%2C%20age%20group%2C%20enrollment%20CD4%2C%20clinic%20location%20and%20type%2C%20and%20country%20income%20level%2C%20enrolling%20in%20care%20and%20initiating%20ART%20after%20guideline%20adoption%20was%20associated%20with%20increased%20hazard%20of%20LTC%20at%2012%20months%20%28adjusted%20hazard%20ratio%20%5BaHR%5D%201.25%20%5B95%25%20CI%201.08%2C%201.44%5D%3B%20p%20%3D%200.003%29%3B%2024%20months%20%28aHR%201.38%20%5B95%25%20CI%201.19%2C%201.59%5D%3B%20p%20%3C%20.001%29%3B%20and%2036%20months%20%28aHR%201.34%20%5B95%25%20CI%201.18%2C%201.53%5D%2C%20p%20%3C%20.001%29%20compared%20with%20enrollment%20before%20guideline%20adoption%2C%20with%20no%20before-after%20differences%20among%20patients%20with%20no%20record%20of%20ART%20initiation%20by%20end%20of%20follow-up.%20Among%20patients%20retained%20after%20ART%20initiation%2C%20VL%20monitoring%20was%20low%2C%20with%20marginal%20improvements%20associated%20with%20guideline%20adoption%20only%20at%2012%20months%20after%20ART%20initiation.%20Among%20those%20with%20VL%20monitoring%2C%20VS%20was%20high%20at%20each%20time%20point%20among%20patients%20enrolling%20before%20guideline%20adoption%20%2886.0%25%20to%2088.8%25%29%20and%20afterwards%20%2886.2%25%20to%2090.3%25%29%2C%20with%20no%20substantive%20difference%20associated%20with%20guideline%20adoption.%20Study%20limitations%20include%20lags%20in%20and%20potential%20underascertainment%20of%20care%20outcomes%20in%20real-world%20service%20delivery%20data%20and%20potential%20lack%20of%20generalizability%20beyond%20IeDEA%20sites%20and%20regions%20included%20in%20this%20analysis.%5CnCONCLUSIONS%3A%20In%20this%20study%2C%20adoption%20of%20universal%20HIV%20treatment%20guidelines%20was%20associated%20with%20lower%20retention%20after%20ART%20initiation%20out%20to%2036%20months%20of%20follow-up%2C%20with%20little%20change%20in%20VL%20monitoring%20or%20VS%20among%20retained%20patients.%20Monitoring%20long-term%20HIV%20care%20outcomes%20remains%20critical%20to%20identify%20and%20address%20causes%20of%20attrition%20and%20gaps%20in%20HIV%20care%20quality.%22%2C%22date%22%3A%222024-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pmed.1004367%22%2C%22ISSN%22%3A%221549-1676%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222024-04-16T08%3A01%3A22Z%22%7D%7D%5D%7D
Parcesepe, Angela M.; Stockton, Melissa; Bernard, Charlotte; Kanguya, Tukiya; Kwobah, Edith Kamaru et al. (2024). Prevalence and co-occurrence of symptoms of mental and substance use disorders among people with HIV age 40 and older in low- and middle-income countries: a cross-sectional study. Journal of the International AIDS Society, 27 (10), S. e26359. http://doi.org/10.1002/jia2.26359.
Ssemasaazi, Amutuhaire Judith; Kalyesubula, Robert; Manabe, Yukari C.; Mbabazi, Phoebe; Naikooba, Susan et al. (2024). Higher prevalence of kidney function impairment among older people living with HIV in Uganda. BMC Nephrology, 25 (1), S. 321. http://doi.org/10.1186/s12882-024-03761-1.
Technau, Karl-Günter; Maskew, Mhairi; Nattey, Cornelius; Hwang, Candice; van Dongen, Nicola et al. (2024). Cohort profile: Rahima Moosa Mother and Child Hospital maternal HIV cohort, Johannesburg, South Africa. BMJ Open, 14 (9), S. e085082. http://doi.org/10.1136/bmjopen-2024-085082.
Kuniholm, Mark H.; Murenzi, Gad; Shumbusho, Fabienne; Brazier, Ellen; Plaisy, Marie K. et al. (2024). Association of cardiovascular disease risk with liver steatosis and fibrosis in people living with hiv in low- and middle-income countries. AIDS (London, England). http://doi.org/10.1097/QAD.0000000000004012.
Kimmel, April D.; Pan, Zhongzhe; Brazier, Ellen; Murenzi, Gad; Muhoza, Benjamin et al. (2024). Development and calibration of a mathematical model of HIV outcomes among Rwandan adults: informing equitable achievement of targets in Rwanda. MedRxiv: The Preprint Server for Health Sciences, S. 2024.09.06.24313223. http://doi.org/10.1101/2024.09.06.24313223.
Zaniewski, Elizabeth; Skrivankova, Veronika Whitesell; Brazier, Ellen; Avihingsanon, Anchalee; Cardoso, Sandra Wagner et al. (2024). Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics. AIDS (London, England). http://doi.org/10.1097/QAD.0000000000004007.
Monroy, Alexa; Goodrich, Suzanne; Brown, Steven A.; Balanos, Theofanis; Bakoyannis, Giorgos et al. (2024). Effects of Alcohol Use on Patient Retention in HIV Care in East Africa. AIDS and Behavior. http://doi.org/10.1007/s10461-024-04483-z.
Byakwaga, Helen; Semeere, Aggrey; Laker-Oketta, Miriam; Busakhala, Naftali; Freeman, Esther et al. (2024). Survival Following Diagnosis of HIV-Associated Kaposi Sarcoma Among Adults in East Africa in the “Treat-All” Era. MedRxiv: The Preprint Server for Health Sciences, S. 2024.08.26.24312536. http://doi.org/10.1101/2024.08.26.24312536.
Egger, Matthias; Sauermann, Mamatha; Loosli, Tom; Hossmann, Stefanie; Riedo, Selma et al. (2024). HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre study (DTG RESIST). BMJ Open, 14 (8), S. e085819. http://doi.org/10.1136/bmjopen-2024-085819.
Ross, Jonathan; Gasana, Josephine; Zotova, Natalia; Ndabakuranye, Giovanni; Mabano, Fabiola et al. (2024). PrEP in the key population community: a qualitative study of perspectives on pre-exposure prophylaxis by men who have sex with men and female sex workers in Kigali, Rwanda. MedRxiv: The Preprint Server for Health Sciences, S. 2024.08.20.24311545. http://doi.org/10.1101/2024.08.20.24311545.
Lang, Raynell; Coburn, Sally B.; Gill, M. John; Grossman, Jennifer; Gebo, Kelly A. et al. (2024). THE ASSOCIATION OF ANEMIA WITH SURVIVAL AMONG PEOPLE WITH HIV FOLLOWING ANTIRETROVIRAL INITIATION IN THE NA-ACCORD 2007-2016. Journal of Acquired Immune Deficiency Syndromes (1999). http://doi.org/10.1097/QAI.0000000000003502.
Rupasinghe, Dhanushi; Choi, Jun Yong; Kumarasamy, Nagalingeswaran; Pujari, Sanjay; Khol, Vohith et al. (2024). Post-Diagnosis HCV RNA Testing Rates Prior to HCV Treatment Among People Living With HIV With HCV Antibody Positivity in the Asia-Pacific Region. Journal of Viral Hepatitis. http://doi.org/10.1111/jvh.13993.
Lang, Raynell; Coburn, Sally B.; Gill, M. John; Justice, Amy C.; Grossman, Jennifer et al. (2024). Evaluation of mean corpuscular volume among anemic people with HIV in North America following ART initiation. AIDS Research and Therapy, 21 (1), S. 52. http://doi.org/10.1186/s12981-024-00641-4.
Nyakato, Patience; Schomaker, Michael; Boulle, Andrew; Euvrard, Jonathan; Wood, Robin et al. (2024). Correcting mortality estimates among children and youth on antiretroviral therapy in southern Africa: A comparative analysis between a multi-country tracing study and linkage to a health information exchange. Tropical Medicine & International Health: TM & IH, 29 (8), S. 739–751. http://doi.org/10.1111/tmi.14030.
Kalk, Emma; Heekes, Alexa; Lavies, Diane; Jacobs, Lizel; Spencer, Careni et al. (2024). Population-based prevalence of congenital defects in a routine sentinel site-based surveillance system in the Western Cape, South Africa. Birth Defects Research, 116 (8), S. e2388. http://doi.org/10.1002/bdr2.2388.
Barreto-Duarte, Beatriz; Villalva-Serra, Klauss; Miguez-Pinto, João P.; Araújo-Pereira, Mariana; Campos, Vanessa M. S. et al. (2024). Retreatment and Anti-tuberculosis Therapy Outcomes in Brazil Between 2015 and 2022: A Nationwide Study. Open Forum Infectious Diseases, 11 (8), S. ofae416. http://doi.org/10.1093/ofid/ofae416.
Rudolph, Jacqueline E.; Calkins, Keri L.; Zhang, Xueer; Zhou, Yiyi; Xu, Xiaoqiang et al. (2024). Retention in care and antiretroviral therapy adherence among Medicaid beneficiaries with HIV, 2001-2015. AIDS Care, S. 1–13. http://doi.org/10.1080/09540121.2024.2383901.
Navuluri, Neelima; Zimo, Jessica; Byrd, Kaitland; Lee, Kathleen Tiffany & Viglianti, Elizabeth (2024). The Impact of Dobbs v Jackson on Future Critical Care Workforce A Cross-Sectional Survey. Chest, S. S0012- 3692(24)04844- X. http://doi.org/10.1016/j.chest.2024.07.142.
Moolla, Haroon; Davies, Mary-Ann; Davies, Claire; Euvrard, Jonathan; Prozesky, Hans W. et al. (2024). The effect of care interruptions on mortality in adults resuming antiretroviral therapy. AIDS (London, England), 38 (8), S. 1198–1205. http://doi.org/10.1097/QAD.0000000000003859.
Bakoyannis, Giorgos; Elul, Batya; Wools-Kaloustian, Kara K.; Brown, Steven; Semeere, Aggrey et al. (2024). Modeling the HIV Cascade of Care Using Routinely Collected Clinical Data to Guide Programmatic Interventions and Policy Decisions. Journal of Acquired Immune Deficiency Syndromes (1999), 96 (3), S. 223–230. http://doi.org/10.1097/QAI.0000000000003413.
Asangbeh-Kerman, Serra Lem; Davidović, Maša; Taghavi, Katayoun; Dhokotera, Tafadzwa; Manasyan, Albert et al. (2024). Cervical cancer prevention and care in HIV clinics across sub-Saharan Africa: results of a facility-based survey. Journal of the International AIDS Society, 27 (7), S. e26303. http://doi.org/10.1002/jia2.26303.
Pirsl, Filip; Keruly, Jeanne C.; Moore, Richard D.; Lau, Bryan & Joshu, Corinne E. (2024). Determinants of receipt of prostate cancer screening among men living with HIV enrolled in an urban HIV Clinic in the United States over the period of 2000-2020. Preventive Medicine, 184, S. 108000. http://doi.org/10.1016/j.ypmed.2024.108000.
Shafi, Jenine; Virk, Maneet K.; Kalk, Emma; Carlucci, James G.; Chepkemoi, Audrey et al. (2024). Pharmacovigilance in Pregnancy Studies, Exposures and Outcomes Ascertainment, and Findings from Low- and Middle-Income Countries: A Scoping Review. Drug Safety. http://doi.org/10.1007/s40264-024-01445-1.
Vinikoor, Michael J.; Hamusonde, Kalongo; Muula, Guy; Asombang, Mah; Riebensahm, Carlotta et al. (2024). Long-term Hepatitis B and Liver Outcomes Among Adults Taking Tenofovir-Containing Antiretroviral Therapy for HBV/HIV Coinfection in Zambia. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 78 (6), S. 1583–1590. http://doi.org/10.1093/cid/ciad654.
Vakaniaki, Emmanuel Hasivirwe; Kacita, Cris; Kinganda-Lusamaki, Eddy; O’Toole, Áine; Wawina-Bokalanga, Tony et al. (2024). Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. Nature Medicine. http://doi.org/10.1038/s41591-024-03130-3.
Kassanjee, Reshma; Davies, Mary-Ann; Heekes, Alexa; Mahomed, Hassan; Hawkridge, Anthony J. et al. (2024). COVID-19 Vaccine Uptake and Effectiveness by Time since Vaccination in the Western Cape Province, South Africa: An Observational Cohort Study during 2020-2022. Vaccines, 12 (6), S. 628. http://doi.org/10.3390/vaccines12060628.
Hutchinson, J.; Neesgard, B.; Kowalska, J.; Grabmeier-Pfistershammer, K.; Johnson, M. et al. (2024). Clinical characteristics of women with HIV in the RESPOND cohort: A descriptive analysis and comparison to men. HIV Medicine. http://doi.org/10.1111/hiv.13662.
Ebasone, Peter Vanes; Dzudie, Anastase; Peer, Nasheeta; Hoover, Donald; Shi, Qiuhu et al. (2024). Coprevalence and associations of diabetes mellitus and hypertension among people living with HIV/AIDS in Cameroon. AIDS Research and Therapy, 21 (1), S. 36. http://doi.org/10.1186/s12981-024-00624-5.
Gorsline, Chelsea A.; Lotspeich, Sarah C.; Belaunzarán-Zamudio, Pablo F.; Mejia, Fernando; Cortes, Claudia P. et al. (2024). The impact of earthquakes in Latin America on the continuity of HIV care: A retrospective observational cohort study. Public Health in Practice (Oxford, England), 7, S. 100479. http://doi.org/10.1016/j.puhip.2024.100479.
Pirsl, Filip; Calkins, Keri; Rudolph, Jacqueline E.; Wentz, Eryka; Xu, Xiaoqiang et al. (2024). Incidence of prostate cancer in Medicaid beneficiaries with and without HIV in 2001-2015 in 14 states. MedRxiv: The Preprint Server for Health Sciences, S. 2024.05.24.24307676. http://doi.org/10.1101/2024.05.24.24307676.
Rodrigues, Moreno M. S.; Barreto-Duarte, Beatriz; Vinhaes, Caian L.; Araújo-Pereira, Mariana; Fukutani, Eduardo R. et al. (2024). Machine learning algorithms using national registry data to predict loss to follow-up during tuberculosis treatment. BMC Public Health, 24 (1), S. 1385. http://doi.org/10.1186/s12889-024-18815-0.
Rudolph, Jacqueline E.; Calkins, Keri L.; Zhang, Xueer; Zhou, Yiyi; Xu, Xiaoqiang et al. (2024). Retention in care and antiretroviral therapy adherence among Medicaid beneficiaries with HIV, 2001-2015. MedRxiv: The Preprint Server for Health Sciences, S. 2024.05.13.24307278. http://doi.org/10.1101/2024.05.13.24307278.
Ssemasaazi, Amutuhaire Judith; Kalyesubula, Robert; Manabe, Yukari C.; Mbabazi, Phoebe; Naikooba, Susan et al. (2024). Higher prevalence of kidney function impairment among older people living with HIV in Uganda. Research Square, S. rs.3.rs-4364155. http://doi.org/10.21203/rs.3.rs-4364155/v1.
Yiannoutsos, Constantin T.; Wools-Kaloustian, Kara; Musick, Beverly S.; Kosgei, Rose; Kimaiyo, Sylvester et al. (2024). Assessing HIV-infected patient retention in a program of differentiated care in sub-Saharan Africa: a G-estimation approach. The International Journal of Biostatistics, 20 (1), S. 279–291. http://doi.org/10.1515/ijb-2023-0031.
Tiendrebeogo, Thierry; Malateste, Karen; Poda, Armel; Minga, Albert; Messou, Eugene et al. (2024). Sex-Based Disparities in the Transition to Dolutegravir-Based Antiretroviral Therapy in West African HIV Cohorts. Open Forum Infectious Diseases, 11 (5), S. ofae139. http://doi.org/10.1093/ofid/ofae139.
Euvrard, Jonathan; Timmerman, Venessa; Keene, Claire Marriott; Phelanyane, Florence; Heekes, Alexa et al. (2024). The cyclical cascade of HIV care: Temporal care engagement trends within a population-wide cohort. PLoS Medicine, 21 (5), S. e1004407. http://doi.org/10.1371/journal.pmed.1004407.
Grimes, Kathryn E. L.; Ebasone, Peter Vanes; Dzudie, Anastase; Nash, Denis; Wainberg, Milton L. et al. (2024). Factors influencing integration of mental health screening and treatment at HIV clinic settings in Cameroon: a qualitative study of health providers’ perspectives. BMC Health Services Research, 24 (1), S. 519. http://doi.org/10.1186/s12913-024-10775-w.
Mujwara, Deo; Kelvin, Elizabeth A.; Dahman, Bassam; George, Gavin; Nixon, Daniel et al. (2024). The economic costs and cost-effectiveness of HIV self-testing among truck drivers in Kenya. Health Policy and Planning, 39 (4), S. 355–362. http://doi.org/10.1093/heapol/czae013.
Kebede, Samuel; Brazier, Ellen; Freeman, Aimee M.; Muwonge, Timothy R.; Choi, Jun Yong et al. (2024). Preexposure prophylaxis availability among health facilities participating in the global International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. AIDS (London, England), 38 (5), S. 751–756. http://doi.org/10.1097/QAD.0000000000003824.
Phillips, Tamsin Kate; Kassanjee, Reshma; Maxwell, Nicola; Anderson, Kim; Johnson, Leigh et al. (2024). ART history prior to conception: trends and association with postpartum disengagement from HIV care in Khayelitsha, South Africa (2013-2019): a retrospective cohort study. Journal of the International AIDS Society, 27 (4), S. e26236. http://doi.org/10.1002/jia2.26236.
Plaisy, Marie Kerbie; Minga, Albert K.; Wandeler, Gilles; Murenzi, Gad; Samala, Niharika et al. (2024). Metabolic causes of liver disease among adults living with HIV from low- and middle-income countries: a cross-sectional study. Journal of the International AIDS Society, 27 (4), S. e26238. http://doi.org/10.1002/jia2.26238.
Baker, Paul J.; Bohrer, Andrea C.; Castro, Ehydel; Amaral, Eduardo P.; Snow-Smith, Maryonne et al. (2024). The inflammatory microenvironment of the lung at the time of infection governs innate control of SARS-CoV-2 replication. BioRxiv: The Preprint Server for Biology, S. 2024.03.27.586885. http://doi.org/10.1101/2024.03.27.586885.
Jacob, Nisha; Rice, Brian; Heekes, Alexa; Johnson, Leigh F.; Brinkmann, Samantha et al. (2024). Exploring the validity of routine individuated service data for antenatal HIV surveillance in the Western Cape. Research Square, S. rs.3.rs-4065819. http://doi.org/10.21203/rs.3.rs-4065819/v1.
Haw, Nel Jason L.; Lesko, Catherine R.; Ng, Derek K.; Lam, Jennifer; Lang, Raynell et al. (2024). Incidence of non-AIDS defining comorbidities among young adults with perinatally-acquired HIV in North America, 2000-2019. AIDS (London, England). http://doi.org/10.1097/QAD.0000000000003892.
Vinhaes, Caian L.; Fukutani, Eduardo R.; Santana, Gabriel C.; Arriaga, María B.; Barreto-Duarte, Beatriz et al. (2024). An integrative multi-omics approach to characterize interactions between tuberculosis and diabetes mellitus. IScience, 27 (3), S. 109135. http://doi.org/10.1016/j.isci.2024.109135.
Ridolfi, Felipe; Amorim, Gustavo; Peetluk, Lauren S.; Haas, David W.; Staats, Cody et al. (2024). Prediction Models for Adverse Drug Reactions During Tuberculosis Treatment in Brazil. The Journal of Infectious Diseases, 229 (3), S. 813–823. http://doi.org/10.1093/infdis/jiae025.
Ben Farhat, Jihane; TiendrebeogoMD, Thierry; Malateste, Karen; Poda, Armel; Minga, Albert et al. (2024). Effects of the Covid-19 pandemic on ART initiation and access to HIV viral load monitoring in adults living with HIV in West Africa: a regression discontinuity analysis. Journal of Acquired Immune Deficiency Syndromes (1999). http://doi.org/10.1097/QAI.0000000000003404.
Nabukalu, Dorean; Yiannoutsos, Constantin T.; Semeere, Aggrey; Musick, Beverly S.; Murungi, Teddy et al. (2024). Mortality Among HIV-Infected Adults on Antiretroviral Therapy in Southern Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 95 (3), S. 268–274. http://doi.org/10.1097/QAI.0000000000003330.
Anderson, Kim; Kalk, Emma; Heekes, Alexa; Phelanyane, Florence; Jacob, Nisha et al. (2024). Factors associated with vertical transmission of HIV in the Western Cape, South Africa: a retrospective cohort analysis. Journal of the International AIDS Society, 27 (3), S. e26235. http://doi.org/10.1002/jia2.26235.
Brazier, Ellen; Tymejczyk, Olga; Wools-Kaloustian, Kara; Jiamsakul, Awachana; Torres, Marco Tulio Luque et al. (2024). Long-term HIV care outcomes under universal HIV treatment guidelines: A retrospective cohort study in 25 countries. PLoS Medicine, 21 (3), S. e1004367. http://doi.org/10.1371/journal.pmed.1004367.
2023
2775998
GXCKG69T
2023
1
padagogische-hochschule-bern-institut-vorschulstufe-und-primarstufe
50
date
desc
1194
https://www.iedea.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A50%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%229LM6AC8B%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Banholzer%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-30%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBanholzer%2C%20Nicolas%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJent%2C%20Philipp%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBittel%2C%20Pascal%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZ%26%23xFC%3Brcher%2C%20Kathrin%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFurrer%2C%20Lavinia%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Air%20cleaners%20and%20respiratory%20infections%20in%20schools%3A%20A%20modeling%20study%20using%20epidemiological%2C%20environmental%2C%20and%20molecular%20data.%20%3Ci%3EMedRxiv%3A%20The%20Preprint%20Server%20for%20Health%20Sciences%3C%5C%2Fi%3E%2C%20S.%202023.12.29.23300635.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2023.12.29.23300635%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2023.12.29.23300635%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Air%20cleaners%20and%20respiratory%20infections%20in%20schools%3A%20A%20modeling%20study%20using%20epidemiological%2C%20environmental%2C%20and%20molecular%20data%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Banholzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipp%22%2C%22lastName%22%3A%22Jent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Bittel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathrin%22%2C%22lastName%22%3A%22Z%5Cu00fcrcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lavinia%22%2C%22lastName%22%3A%22Furrer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Bertschinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ernest%22%2C%22lastName%22%3A%22Weingartner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alban%22%2C%22lastName%22%3A%22Ramette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tina%22%2C%22lastName%22%3A%22Hascher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukas%22%2C%22lastName%22%3A%22Fenner%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Using%20a%20multiple-measurement%20approach%2C%20we%20examined%20the%20real-world%20effectiveness%20of%20portable%20HEPA-air%20filtration%20devices%20%28air%20cleaners%29%20in%20a%20school%20setting.%5CnMETHODS%3A%20We%20collected%20environmental%20%28CO2%2C%20particle%20concentrations%29%2C%20epidemiological%20%28absences%20related%20to%20respiratory%20infections%29%2C%20audio%20%28coughing%29%2C%20and%20molecular%20data%20%28bioaerosol%20and%20saliva%20samples%29%20over%20seven%20weeks%20during%20winter%202022%5C%2F2023%20in%20two%20Swiss%20secondary%20school%20classes.%20Using%20a%20cross-over%20study%20design%2C%20we%20compared%20particle%20concentrations%2C%20coughing%2C%20and%20the%20risk%20of%20infection%20with%20vs%20without%20air%20cleaners.%5CnRESULTS%3A%20All%2038%20students%20%28age%2013-15%20years%29%20participated.%20With%20air%20cleaners%2C%20mean%20particle%20concentration%20decreased%20by%2077%25%20%2895%25%20credible%20interval%2063%25-86%25%29.%20There%20were%20no%20differences%20in%20CO2%20levels.%20Absences%20related%20to%20respiratory%20infections%20were%2022%20without%20vs%2013%20with%20air%20cleaners.%20Bayesian%20modeling%20suggested%20a%20reduced%20risk%20of%20infection%2C%20with%20a%20posterior%20probability%20of%2091%25%20and%20a%20relative%20risk%20of%200.73%20%2895%25%20credible%20interval%200.44-1.18%29.%20Coughing%20also%20tended%20to%20be%20less%20frequent%20%28posterior%20probability%2093%25%29.%20Molecular%20analysis%20detected%20mainly%20non-SARS-CoV-2%20viruses%20in%20saliva%20%2850%5C%2F448%20positive%29%2C%20but%20not%20in%20bioaerosols%20%282%5C%2F105%20positive%29%20or%20HEPA-filters%20%284%5C%2F160%29.%20The%20detection%20rate%20was%20similar%20with%20vs%20without%20air%20cleaners.%20Spatiotemporal%20analysis%20of%20positive%20saliva%20samples%20identified%20several%20likely%20transmissions.%5CnCONCLUSIONS%3A%20Air%20cleaners%20improved%20air%20quality%2C%20showed%20a%20potential%20benefit%20in%20reducing%20respiratory%20infections%2C%20and%20were%20associated%20with%20less%20coughing.%20Airborne%20detection%20of%20non-SARS-CoV-2%20viruses%20was%20rare%2C%20suggesting%20that%20these%20viruses%20may%20be%20more%20difficult%20to%20detect%20in%20the%20air.%20Future%20studies%20should%20examine%20the%20importance%20of%20close%20contact%20and%20long-range%20transmission%2C%20and%20the%20cost-effectiveness%20of%20using%20air%20cleaners.%22%2C%22date%22%3A%222023-12-30%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2023.12.29.23300635%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222024-03-18T10%3A50%3A02Z%22%7D%7D%2C%7B%22key%22%3A%222HTNPKKX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Trickey%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETrickey%2C%20Adam%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJohnson%2C%20Leigh%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFung%2C%20Fai%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBonifacio%2C%20Rogerio%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EIwuji%2C%20Collins%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Associations%20of%20inter-annual%20rainfall%20decreases%20with%20subsequent%20HIV%20outcomes%20for%20persons%20with%20HIV%20on%20antiretroviral%20therapy%20in%20Southern%20Africa%3A%20a%20collaborative%20analysis%20of%20cohort%20studies.%20%3Ci%3EBMC%20Infectious%20Diseases%3C%5C%2Fi%3E%2C%20%3Ci%3E23%3C%5C%2Fi%3E%20%281%29%2C%20S.%20889.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-023-08902-9%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-023-08902-9%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Associations%20of%20inter-annual%20rainfall%20decreases%20with%20subsequent%20HIV%20outcomes%20for%20persons%20with%20HIV%20on%20antiretroviral%20therapy%20in%20Southern%20Africa%3A%20a%20collaborative%20analysis%20of%20cohort%20studies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%22%2C%22lastName%22%3A%22Trickey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leigh%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fai%22%2C%22lastName%22%3A%22Fung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rogerio%22%2C%22lastName%22%3A%22Bonifacio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Collins%22%2C%22lastName%22%3A%22Iwuji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Biraro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Bosomprah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%22%2C%22lastName%22%3A%22Chirimuta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%22%2C%22lastName%22%3A%22Fatti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20P.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Per%22%2C%22lastName%22%3A%22Von%20Groote%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joe%22%2C%22lastName%22%3A%22Gumulira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Howard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Jennings%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnes%22%2C%22lastName%22%3A%22Kiragga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Muula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22Tanser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thorsten%22%2C%22lastName%22%3A%22Wagener%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Low%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vickerman%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Periods%20of%20droughts%20can%20lead%20to%20decreased%20food%20security%2C%20and%20altered%20behaviours%2C%20potentially%20affecting%20outcomes%20on%20antiretroviral%20therapy%20%28ART%29%20among%20persons%20with%20HIV%20%28PWH%29.%20We%20investigated%20whether%20decreased%20rainfall%20is%20associated%20with%20adverse%20outcomes%20among%20PWH%20on%20ART%20in%20Southern%20Africa.%5CnMETHODS%3A%20Data%20were%20combined%20from%2011%20clinical%20cohorts%20of%20PWH%20in%20Lesotho%2C%20Malawi%2C%20Mozambique%2C%20South%20Africa%2C%20Zambia%2C%20and%20Zimbabwe%2C%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20Southern%20Africa%20%28IeDEA-SA%29%20collaboration.%20Adult%20PWH%20who%20had%20started%20ART%20prior%20to%2001%5C%2F06%5C%2F2016%20and%20were%20in%20follow-up%20in%20the%20year%20prior%20to%2001%5C%2F06%5C%2F2016%20were%20included.%20Two-year%20rainfall%20from%20June%202014%20to%20May%202016%20at%20the%20location%20of%20each%20HIV%20centre%20was%20summed%20and%20ranked%20against%20historical%202-year%20rainfall%20amounts%20%281981-2016%29%20to%20give%20an%20empirical%20relative%20percentile%20rainfall%20estimate.%20The%20IeDEA-SA%20and%20rainfall%20data%20were%20combined%20using%20each%20HIV%20centre%27s%20latitude%5C%2Flongitude.%20In%20individual-level%20analyses%2C%20multivariable%20Cox%20or%20generalized%20estimating%20equation%20regression%20models%20%28GEEs%29%20assessed%20associations%20between%20decreased%20rainfall%20versus%20historical%20levels%20and%20four%20separate%20outcomes%20%28mortality%2C%20CD4%20counts%5Cu2009%3C%5Cu2009200%20cells%5C%2Fmm3%2C%20viral%20loads%5Cu2009%3E%5Cu2009400%20copies%5C%2FmL%2C%20and%5Cu2009%3E%5Cu200912-month%20gaps%20in%20follow-up%29%20in%20the%20two%20years%20following%20the%20rainfall%20period.%20GEEs%20were%20used%20to%20investigate%20the%20association%20between%20relative%20rainfall%20and%20monthly%20numbers%20of%20unique%20visitors%20per%20HIV%20centre.%5CnRESULTS%3A%20Among%20270%2C708%20PWH%20across%20386%20HIV%20centres%20%2867%25%20female%2C%20median%20age%2039%20%5BIQR%3A%2032-46%5D%29%2C%20lower%20rainfall%20than%20usual%20was%20associated%20with%20higher%20mortality%20%28adjusted%20Hazard%20Ratio%3A%201.18%20%5B95%25CI%3A%201.07-1.32%5D%20per%2010%20percentile%20rainfall%20rank%20decrease%29%20and%20unsuppressed%20viral%20loads%20%28adjusted%20Odds%20Ratio%3A%201.05%20%5B1.01-1.09%5D%29.%20Levels%20of%20rainfall%20were%20not%20strongly%20associated%20with%20CD4%20counts%5Cu2009%3C%5Cu2009200%20cell%5C%2Fmm3%20or%5Cu2009%3E%5Cu200912-month%20gaps%20in%20care.%20HIV%20centres%20in%20areas%20with%20less%20rainfall%20than%20usual%20had%20lower%20numbers%20of%20PWH%20visiting%20them%20%28adjusted%20Rate%20Ratio%3A%200.80%20%5B0.66-0.98%5D%20per%2010%20percentile%20rainfall%20rank%20decrease%29.%5CnCONCLUSIONS%3A%20Decreased%20rainfall%20could%20negatively%20impact%20on%20HIV%20treatment%20behaviours%20and%20outcomes.%20Further%20research%20is%20needed%20to%20explore%20the%20reasons%20for%20these%20effects.%20Interventions%20to%20mitigate%20the%20health%20impact%20of%20severe%20weather%20events%20are%20required.%22%2C%22date%22%3A%222023-12-19%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12879-023-08902-9%22%2C%22ISSN%22%3A%221471-2334%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222024-01-12T13%3A20%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22BNKIBKQZ%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hill%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHill%2C%20Sarah%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZhang%2C%20Chenshu%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERemera%2C%20Eric%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EIngabire%2C%20Charles%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EUmwiza%2C%20Francine%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Association%20Between%20Clinical%20Encounter%20Frequency%20and%20HIV-Related%20Stigma%20Among%20Newly-Diagnosed%20People%20Living%20with%20HIV%20in%20Rwanda.%20%3Ci%3EAIDS%20and%20Behavior%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-023-04226-6%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-023-04226-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20Between%20Clinical%20Encounter%20Frequency%20and%20HIV-Related%20Stigma%20Among%20Newly-Diagnosed%20People%20Living%20with%20HIV%20in%20Rwanda%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20E.%22%2C%22lastName%22%3A%22Hill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chenshu%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Remera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Ingabire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francine%22%2C%22lastName%22%3A%22Umwiza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Athanase%22%2C%22lastName%22%3A%22Munyaneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Muhoza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gallican%22%2C%22lastName%22%3A%22Rwibasira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ross%22%7D%5D%2C%22abstractNote%22%3A%22HIV-related%20stigma%20in%20healthcare%20settings%20remains%20a%20key%20barrier%20to%20engaging%20people%20living%20with%20HIV%20%28PLHIV%29%20in%20care.%20This%20study%20investigated%20the%20association%20between%20clinical%20encounter%20frequency%20and%20HIV-related%20anticipated%2C%20enacted%2C%20and%20internalized%20stigma%20among%20newly-diagnosed%20PLHIV%20in%20Rwanda.%20From%20October%202020%20to%20May%202022%2C%20we%20collected%20data%20from%20adult%20PLHIV%20on%20antiretroviral%20therapy%20%28ART%29%20in%20Kigali%2C%20Rwanda%20who%20were%20participating%20in%20a%20randomized%2C%20controlled%20trial%20testing%20early%20entry%20into%20differentiated%20care%20at%206%20months%20after%20ART%20initiation.%20We%20measured%20anticipated%20HIV%20stigma%20with%20five-point%20Likert%20HIV%20Stigma%20Framework%20measures%2C%20enacted%20stigma%20with%20the%20four-point%20Likert%20HIV%5C%2FAIDS%20Stigma%20Instrument%2C%20and%20internalized%20stigma%20with%20the%20four-point%20Likert%20HIV%5C%2FAIDS%20Stigma%20Instrument.%20We%20used%20multivariable%20linear%20regression%20to%20test%20the%20associations%20between%20clinical%20encounter%20frequency%20%28average%20inter-visit%20interval%5Cu2009%5Cu2265%5Cu200950%20days%20vs.%5Cu2009%3C%5Cu200950%20days%29%20and%20change%20in%20mean%20anticipated%2C%20enacted%20and%20internalized%20HIV%20stigma%20over%20the%20first%2012%20months%20in%20care.%20Among%2093%20individuals%20enrolled%2C%2076%20had%20complete%20data%20on%20encounter%20frequency%20and%20stigma%20measurements%20and%20were%20included%20in%20the%20present%20analysis.%20Mean%20internalized%20stigma%20scores%20of%20all%20participants%20decreased%20over%20the%20first%2012%20months%20in%20care.%20Anticipated%20and%20enacted%20stigma%20scores%20were%20low%20and%20did%20not%20change%20significantly%20over%20time.%20There%20was%20no%20association%20between%20encounter%20frequency%20and%20change%20in%20internalized%20stigma.%20In%20this%20pilot%20study%20of%20newly-diagnosed%20Rwandan%20PLHIV%20with%20relatively%20low%20levels%20of%20HIV-related%20stigma%2C%20clinical%20encounter%20frequency%20was%20not%20associated%20with%20change%20in%20stigma.%20Additional%20research%20in%20diverse%20settings%20and%20with%20larger%20samples%20is%20necessary%20to%20further%20explore%20this%20relationship.%22%2C%22date%22%3A%222023-12-19%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10461-023-04226-6%22%2C%22ISSN%22%3A%221573-3254%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222024-01-12T13%3A08%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22I5QF6ZNX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Skrivankova%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESkrivankova%2C%20Veronika%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHossmann%2C%20Stefanie%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECornell%2C%20Morna%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBallif%2C%20Marie%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDupont%2C%20Carole%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Authorship%20inequalities%20in%20global%20health%20research%3A%20the%20IeDEA%20Southern%20Africa%20collaboration.%20%3Ci%3EBMJ%20Global%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E8%3C%5C%2Fi%3E%20%2812%29%2C%20S.%20e013316.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgh-2023-013316%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgh-2023-013316%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Authorship%20inequalities%20in%20global%20health%20research%3A%20the%20IeDEA%20Southern%20Africa%20collaboration%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronika%20W.%22%2C%22lastName%22%3A%22Skrivankova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefanie%22%2C%22lastName%22%3A%22Hossmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morna%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%22%2C%22lastName%22%3A%22Dupont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacqueline%22%2C%22lastName%22%3A%22Huwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Konstantinos%22%2C%22lastName%22%3A%22Seintaridis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thokozani%22%2C%22lastName%22%3A%22Kalua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reshma%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karl-Gunter%22%2C%22lastName%22%3A%22Technau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukas%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Low%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20conducts%20research%20in%20several%20regions%2C%20including%20in%20Southern%20Africa.%20We%20assessed%20authorship%20inequalities%20for%20the%20Southern%20African%20region%2C%20which%20is%20led%20by%20South%20African%20and%20Swiss%20investigators.%5CnMETHODS%3A%20We%20analysed%20authorships%20of%20publications%20from%202007%20to%202020%20by%20gender%2C%20country%20income%20group%2C%20time%20and%20citation%20impact.%20We%20used%202020%20World%20Bank%20categories%20to%20define%20income%20groups%20and%20the%20relative%20citation%20ratio%20%28RCR%29%20to%20assess%20citation%20impact.%20Authorship%20parasitism%20was%20defined%20as%20articles%20without%20authors%20from%20the%20countries%20where%20the%20study%20was%20conducted.%20A%20regression%20model%20examined%20the%20probability%20of%20different%20authorship%20positions.%5CnRESULTS%3A%20We%20included%20313%20articles.%20Of%20the%201064%20contributing%20authors%2C%20547%20%2851.4%25%29%20were%20women%2C%20and%20223%20%2821.0%25%29%20were%20from%2032%20low-income%5C%2Flower%20middle-income%20countries%20%28LLMICs%29%2C%20269%20%2825.3%25%29%20were%20from%2013%20upper%20middle-income%20countries%20and%20572%20%2853.8%25%29%20were%20from%2025%20high-income%20countries%20%28HICs%29.%20Most%20articles%20%28150%5C%2F157%2C%2095.5%25%29%20reporting%20data%20from%20Southern%20Africa%20included%20authors%20from%20all%20participating%20countries.%20Women%20were%20more%20likely%20to%20be%20the%20first%20author%20than%20men%20%28OR%201.74%3B%2095%25%5Cu2009CI%201.06%20to%202.83%29%20but%20less%20likely%20to%20be%20last%20authors%20%28OR%200.63%3B%2095%25%5Cu2009CI%200.40%20to%200.99%29.%20Compared%20with%20HIC%2C%20LLMIC%20authors%20were%20less%20likely%20to%20publish%20as%20first%20%28OR%200.21%3B%2095%25%5Cu2009CI%200.11%20to%200.41%29%20or%20last%20author%20%28OR%200.20%3B%2095%25%5Cu2009CI%200.09%20to%200.42%29.%20The%20proportion%20of%20women%20and%20LLMIC%20first%20and%20last%20authors%20increased%20over%20time.%20The%20RCR%20tended%20to%20be%20higher%2C%20indicating%20greater%20impact%2C%20if%20first%20or%20last%20authors%20were%20from%20HIC%20%28p%3D0.06%29.%5CnCONCLUSIONS%3A%20This%20analysis%20of%20a%20global%20health%20collaboration%20co-led%20by%20South%20African%20and%20Swiss%20investigators%20showed%20little%20evidence%20of%20authorship%20parasitism.%20There%20were%20stark%20inequalities%20in%20authorship%20position%2C%20with%20women%20occupying%20more%20first%20and%20men%20more%20last%20author%20positions%20and%20researchers%20from%20LLMIC%20being%20%27stuck%20in%20the%20middle%27%20on%20the%20byline.%20Global%20health%20research%20collaborations%20should%20monitor%2C%20analyse%20and%20address%20authorship%20inequalities.%22%2C%22date%22%3A%222023-12-16%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjgh-2023-013316%22%2C%22ISSN%22%3A%222059-7908%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222024-01-12T13%3A22%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22RJA7XYYM%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chammartin%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-13%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChammartin%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Brique%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMocroft%2C%20Amanda%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEgle%2C%20Alexander%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZangerle%2C%20Robert%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESmith%2C%20Colette%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Measures%20of%20Longitudinal%20Immune%20Dysfunction%20and%20Risk%20of%20AIDS%20and%20Non-AIDS%20Defining%20Malignancies%20in%20Antiretroviral%20Treated%20People%20With%20Human%20Immunodeficiency%20Virus%20%28HIV%29.%20%3Ci%3EClinical%20Infectious%20Diseases%3A%20An%20Official%20Publication%20of%20the%20Infectious%20Diseases%20Society%20of%20America%3C%5C%2Fi%3E%2C%20S.%20ciad671.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad671%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad671%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Measures%20of%20Longitudinal%20Immune%20Dysfunction%20and%20Risk%20of%20AIDS%20and%20Non-AIDS%20Defining%20Malignancies%20in%20Antiretroviral%20Treated%20People%20With%20Human%20Immunodeficiency%20Virus%20%28HIV%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Chammartin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%22%2C%22lastName%22%3A%22Mocroft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Egle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Zangerle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Colette%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Mussini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ferdinand%22%2C%22lastName%22%3A%22Wit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00f6rg%20Janne%22%2C%22lastName%22%3A%22Vehreschild%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonella%22%2C%22lastName%22%3A%22d%27Arminio%20Monforte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonella%22%2C%22lastName%22%3A%22Castagna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Bailly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Bogner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22de%20Wit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raimonda%22%2C%22lastName%22%3A%22Matulionyte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%22%2C%22lastName%22%3A%22Law%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronica%22%2C%22lastName%22%3A%22Svedhem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joan%22%2C%22lastName%22%3A%22Tallada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harmony%20P.%22%2C%22lastName%22%3A%22Garges%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Marongiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c1lvaro%20H.%22%2C%22lastName%22%3A%22Borges%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Jaschinski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastian%22%2C%22lastName%22%3A%22Neesgaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lene%22%2C%22lastName%22%3A%22Ryom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heiner%20C.%22%2C%22lastName%22%3A%22Bucher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RESPOND%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Human%20immunodeficiency%20virus%20%28HIV%29%20infection%20leads%20to%20chronic%20immune%20activation%5C%2Finflammation%20that%20can%20persist%20in%20virally%20suppressed%20persons%20on%20fully%20active%20antiretroviral%20therapy%20%28ART%29%20and%20increase%20risk%20of%20malignancies.%20The%20prognostic%20role%20of%20low%20CD4%3ACD8%20ratio%20and%20elevated%20CD8%20cell%20counts%20on%20the%20risk%20of%20cancer%20remains%20unclear.%5CnMETHODS%3A%20We%20investigated%20the%20association%20of%20CD4%3ACD8%20ratio%20on%20the%20hazard%20of%20non-AIDS%20defining%20malignancy%20%28NADM%29%2C%20AIDS-defining%20malignancy%20%28ADM%29%20and%20most%20frequent%20group%20of%20cancers%20in%20ART-treated%20people%20with%20HIV%20%28PWH%29%20with%20a%20CD4%20and%20CD8%20cell%20counts%20and%20viral%20load%20measurements%20at%20baseline.%20We%20developed%20Cox%20proportional%20hazard%20models%20with%20adjustment%20for%20known%20confounders%20of%20cancer%20risk%20and%20time-dependent%20cumulative%20and%20lagged%20exposures%20of%20CD4%3ACD8%20ratio%20to%20account%20for%20time-evolving%20risk%20factors%20and%20avoid%20reverse%20causality.%5CnRESULTS%3A%20CD4%3ACD8%20ratios%20below%200.5%2C%20compared%20to%20above%201.0%2C%20were%20independently%20associated%20with%20a%2012-month%20time-lagged%20higher%20risk%20of%20ADM%20and%20infection-related%20malignancies%20%28adjusted%20hazard%20ratio%202.61%20%5B95%25%20confidence%20interval%20%7BCI%20%7D1.10-6.19%5D%20and%202.03%20%5B95%25%20CI%201.24-3.33%5D%2C%20respectively%29.%20CD4%20cell%20counts%20below%20350%20cells%5C%2F%5Cu03bcL%20were%20associated%20with%20an%20increased%20risk%20of%20NADMs%20and%20ADMs%2C%20as%20did%20infection%2C%20smoking%2C%20and%20body%20mass%20index-related%20malignancies.%5CnCONCLUSIONS%3A%20In%20ART-treated%20PWH%20low%20CD4%3ACD8%20ratios%20were%20associated%20with%20ADM%20and%20infection-related%20cancers%20independently%20from%20CD4%20and%20CD8%20cell%20counts%20and%20may%20alert%20clinicians%20for%20cancer%20screening%20and%20prevention%20of%20NADM.%22%2C%22date%22%3A%222023-12-13%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciad671%22%2C%22ISSN%22%3A%221537-6591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222024-01-12T12%3A55%3A35Z%22%7D%7D%2C%7B%22key%22%3A%227SWCRYX4%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rodrigues%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERodrigues%2C%20Moreno%20M.%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBarreto-Duarte%2C%20Beatriz%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVinhaes%2C%20Caian%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAra%26%23xFA%3Bjo-Pereira%2C%20Mariana%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFukutani%2C%20Eduardo%20R.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Machine%20learning%20algorithms%20using%20national%20registry%20data%20to%20predict%20loss%20to%20follow-%20up%20during%20tuberculosis%20treatment.%20%3Ci%3EResearch%20Square%3C%5C%2Fi%3E%2C%20S.%20rs.3.rs-3706875.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21203%5C%2Frs.3.rs-3706875%5C%2Fv1%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21203%5C%2Frs.3.rs-3706875%5C%2Fv1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Machine%20learning%20algorithms%20using%20national%20registry%20data%20to%20predict%20loss%20to%20follow-%20up%20during%20tuberculosis%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moreno%20M.%20S.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20R.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keityane%20Bone%22%2C%22lastName%22%3A%22Bergamaschi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%22%2C%22lastName%22%3A%22Kristki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Identifying%20patients%20at%20increased%20risk%20of%20loss%20to%20follow-up%20%28LTFU%29%20is%20key%20to%20developing%20strategies%20to%20optimize%20the%20clinical%20management%20of%20tuberculosis%20%28TB%29.%20The%20use%20of%20national%20registry%20data%20in%20prediction%20models%20may%20be%20a%20useful%20tool%20to%20inform%20healthcare%20workers%20about%20risk%20of%20LTFU.%20Here%20we%20developed%20a%20score%20to%20predict%20the%20risk%20of%20LTFU%20during%20anti-TB%20treatment%20%28ATT%29%20in%20a%20nationwide%20cohort%20of%20cases%20using%20clinical%20data%20reported%20to%20the%20Brazilian%20Notifiable%20Disease%20Information%20System%20%28SINAN%29.%5CnMETHODS%3A%20We%20performed%20a%20retrospective%20study%20of%20all%20TB%20cases%20reported%20to%20SINAN%20between%202015-2022%3B%20excluding%20children%20%28%3C18%20years-old%29%2C%20vulnerable%20groups%20or%20drug-resistant%20TB.%20For%20the%20score%2C%20data%20before%20treatment%20initiation%20were%20used.%20We%20trained%20and%20internally%20validated%20three%20different%20prediction%20scoring%20systems%2C%20based%20on%20Logistic%20Regression%2C%20Random%20Forest%2C%20and%20Light%20Gradient%20Boosting.%20Before%20applying%20our%20models%20we%20split%20our%20data%20into%20train%20%28~80%25%20data%29%20and%20test%20%28~20%25%29%2C%20and%20then%20we%20compare%20model%20metrics%20using%20a%20test%20data%20set.%5CnRESULTS%3A%20Of%20the%20243%2C726%20cases%20included%2C%2041%2C373%20experienced%20LTFU%20whereas%20202%2C353%20were%20successfully%20treated%20and%20cured.%20The%20groups%20were%20different%20with%20regards%20to%20several%20clinical%20and%20sociodemographic%20characteristics.%20The%20directly%20observed%20treatment%20%28DOT%29%20was%20unbalanced%20between%20the%20groups%20with%20lower%20prevalence%20in%20those%20who%20were%20LTFU.%20Three%20models%20were%20developed%20to%20predict%20LTFU%20using%208%20features%20%28prior%20TB%2C%20drug%20use%2C%20age%2C%20sex%2C%20HIV%20infection%20and%20schooling%20level%29%20with%20different%20score%20composition%20approaches.%20Those%20prediction%20scoring%20system%20exhibited%20an%20area%20under%20the%20curve%20%28AUC%29%20ranging%20between%200.71%20and%200.72.%20The%20Light%20Gradient%20Boosting%20technique%20resulted%20in%20the%20best%20prediction%20performance%2C%20weighting%20specificity%2C%20and%20sensibility.%20A%20user-friendly%20web%20calculator%20app%20was%20created%20%28https%3A%5C%2F%5C%2Ftbprediction.herokuapp.com%5C%2F%29%20to%20facilitate%20implementation.%5CnCONCLUSIONS%3A%20Our%20nationwide%20risk%20score%20predicts%20the%20risk%20of%20LTFU%20during%20ATT%20in%20Brazilian%20adults%20prior%20to%20treatment%20commencement.%20This%20is%20a%20potential%20tool%20to%20assist%20in%20decision-making%20strategies%20to%20guide%20resource%20allocation%2C%20DOT%20indications%2C%20and%20improve%20TB%20treatment%20adherence.%22%2C%22date%22%3A%222023-12-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.21203%5C%2Frs.3.rs-3706875%5C%2Fv1%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222024-01-12T13%3A02%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22CUA4BYIU%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Grinsztejn%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGrinsztejn%2C%20Eduarda%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECardoso%2C%20Sandra%20Wagner%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVelasque%2C%20Luciane%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHoagland%2C%20Brenda%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDos%20Santos%2C%20Desiree%20Gomes%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Impact%20of%20Latent%20M.%20tuberculosis%20Infection%20Treatment%20on%20Time%20to%20CD4%5C%2FCD8%20Recovery%20in%20Acute%2C%20Recent%2C%20and%20Chronic%20HIV%20Infection.%20%3Ci%3EJournal%20of%20Acquired%20Immune%20Deficiency%20Syndromes%20%281999%29%3C%5C%2Fi%3E%2C%20%3Ci%3E94%3C%5C%2Fi%3E%20%284%29%2C%20S.%20355%26%23x2013%3B363.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003284%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003284%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20Latent%20M.%20tuberculosis%20Infection%20Treatment%20on%20Time%20to%20CD4%5C%2FCD8%20Recovery%20in%20Acute%2C%20Recent%2C%20and%20Chronic%20HIV%20Infection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduarda%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%20Wagner%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luciane%22%2C%22lastName%22%3A%22Velasque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Hoagland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Desiree%20Gomes%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolina%22%2C%22lastName%22%3A%22Coutinho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%20da%20Costa%22%2C%22lastName%22%3A%22Cruz%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandro%20Coutinho%22%2C%22lastName%22%3A%22Nazer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%20Cristina%20Garcia%22%2C%22lastName%22%3A%22Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdilea%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20In%20people%20living%20with%20HIV%2C%20active%20and%20latent%20tuberculosis%20%28TB%29%20coinfections%20are%20associated%20with%20immune%20activation%20that%20correlate%20with%20HIV%20progression%20and%20mortality.%20We%20investigated%20the%20effect%20of%20initiating%20antiretroviral%20therapy%20%28ART%29%20during%20acute%20%28AHI%29%2C%20recent%20%28RHI%29%2C%20or%20chronic%20HIV%20infection%20%28CHI%29%20on%20CD4%5C%2FCD8%20ratio%20normalization%20and%20associated%20factors%2C%20the%20impact%20of%20latent%20TB%20infection%20treatment%2C%20and%20prior%5C%2Fconcomitant%20TB%20diagnosis%20at%20the%20time%20of%20ART%20initiation.%5CnMETHODS%3A%20We%20included%20sex%20with%20men%20and%20transgender%20women%20individuals%20initiating%20ART%20with%20AHI%2C%20RHI%20and%20CHI%20between%202013%20and%202019%2C%20from%20a%20prospective%20cohort%20in%20Brazil.%20We%20compared%20time%20from%20ART%20initiation%20to%20the%20first%20normal%20CD4%5C%2FCD8%20ratio%20%28CD4%5C%2FCD8%20%5Cu22651%29%20using%20Kaplan-Meier%20curves%20and%20multivariable%20Cox%20proportional%20hazards%20models.%20Sociodemographic%20and%20clinical%20variables%20were%20explored.%20Variables%20with%20P%20-values%20%3C0.20%20in%20univariable%20analyses%20were%20included%20in%20multivariable%20analyses.%5CnRESULTS%3A%20Five%20hundred%20fifty%20participants%20were%20included%2C%2011.8%25%20classified%20as%20AHI%20and%206.4%25%20as%20RHI%2C%2046.7%25%20with%20CHI-CD4%20cell%20counts%20%5Cu2265350%20cells%5C%2Fmm%203%20and%2035.1%25%20with%20CHI-CD4%20cell%20counts%20%3C350%20cells%5C%2Fmm%203%20.%20Time%20to%20normalization%20was%20shortest%20among%20AHI%20patients%2C%20followed%20by%20RHI%20and%20CHI%20individuals%20with%20higher%20baseline%20CD4.%20In%20the%20multivariable%20model%2C%20AHI%20was%20associated%20with%20a%20six-fold%20increased%20likelihood%20of%20achieving%20a%20CD4%5C%2FCD8%20ratio%20%5Cu22651%20%28hazard%20ratio%20%5BHR%5D%3A%206.03%3B%2095%25%20confidence%20interval%20%5BCI%5D%3A%203.70%20to%209.82%3B%20P%20%3C%200.001%29%2C%20RHI%20with%20HR%3A%204.47%20%2895%25%20CI%3A%202.57%20to%207.76%3B%20P%20%3C%200.001%29%2C%20and%20CHI%20CD4%20%5Cu2265350%20cells%5C%2Fmm%203%20with%20HR%3A%201.87%20%2895%25%20CI%3A%201.24%20to%202.84%3B%20P%20%3D%200.003%29.%20Latent%20TB%20infection%20treatment%20was%20significantly%20associated%20with%20a%20higher%20likelihood%20of%20the%20outcome%20%28HR%3A%201.79%3B%2095%25%20CI%3A%201.22%20to%202.62%3B%20P%20%3D%200.003%29.%20Previous%20history%20or%20concomitant%20active%20TB%20at%20ART%20initiation%20was%20associated%20with%20a%20lower%20likelihood%20of%20the%20outcome%20%28HR%3A%200.41%3B%2095%25%20CI%3A%200.16%20to%201.02%3B%20P%20%3D%200.054%29.%5CnCONCLUSIONS%3A%20Initiating%20ART%20early%20during%20AHI%20may%20offer%20an%20opportunity%20to%20mitigate%20immune%20damage.%20Efforts%20to%20implement%20HIV%20diagnosis%20and%20ART%20initiation%20during%20AHI%20are%20critical%20to%20amplify%20ART%20benefits.%22%2C%22date%22%3A%222023-12-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003284%22%2C%22ISSN%22%3A%221944-7884%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222024-01-12T13%3A25%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22ERBK5K5S%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22DeLong%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDeLong%2C%20Stephanie%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EXu%2C%20Yizhen%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGenberg%2C%20Becky%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENyambura%2C%20Monicah%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGoodrich%2C%20Suzanne%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Population-Based%20Estimates%20and%20Predictors%20of%20Child%20and%20Adolescent%20Linkage%20to%20HIV%20Care%20or%20Death%20in%20Western%20Kenya.%20%3Ci%3EJournal%20of%20Acquired%20Immune%20Deficiency%20Syndromes%20%281999%29%3C%5C%2Fi%3E%2C%20%3Ci%3E94%3C%5C%2Fi%3E%20%284%29%2C%20S.%20281%26%23x2013%3B289.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003288%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003288%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Population-Based%20Estimates%20and%20Predictors%20of%20Child%20and%20Adolescent%20Linkage%20to%20HIV%20Care%20or%20Death%20in%20Western%20Kenya%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%20M.%22%2C%22lastName%22%3A%22DeLong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yizhen%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Becky%20L.%22%2C%22lastName%22%3A%22Genberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monicah%22%2C%22lastName%22%3A%22Nyambura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Goodrich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carren%22%2C%22lastName%22%3A%22Tarus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samson%22%2C%22lastName%22%3A%22Ndege%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20W.%22%2C%22lastName%22%3A%22Hogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%22%2C%22lastName%22%3A%22Braitstein%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Population-level%20estimates%20of%20linkage%20to%20HIV%20care%20among%20children%20and%20adolescents%20%28CAs%29%20can%20facilitate%20progress%20toward%2095-95-95%20goals.%5CnSETTING%3A%20This%20study%20was%20conducted%20in%20Bunyala%2C%20Chulaimbo%2C%20and%20Teso%20North%20subcounties%2C%20Western%20Kenya.%5CnMETHODS%3A%20Linkage%20to%20care%20was%20defined%20among%20CAs%20diagnosed%20with%20HIV%20through%20Academic%20Model%20Providing%20Access%20to%20Healthcare%20%28AMPATH%29%27s%20home-based%20counseling%20and%20testing%20initiative%20%28HBCT%29%20by%20merging%20HBCT%20and%20AMPATH%20Medical%20Record%20System%20data.%20Using%20follow-up%20data%20from%20Bunyala%2C%20we%20examined%20factors%20associated%20with%20linkage%20or%20death%2C%20using%20weighted%20multinomial%20logistic%20regression%20to%20account%20for%20selection%20bias%20from%20double-sampled%20visits.%20Based%20on%20the%20estimated%20model%2C%20we%20imputed%20the%20trajectory%20for%20each%20person%20in%203%20subcounties%20until%20a%20simulated%20linkage%20or%20death%20occurred%20or%20until%20the%20end%20of%208%20years%20when%20an%20individual%20was%20simulated%20to%20be%20censored.%5CnRESULTS%3A%20Of%20720%20CAs%20in%20the%20analytic%20sample%2C%2068%25%20were%20between%200%20and%209%20years%20and%2059%25%20were%20female.%20Probability%20of%20linkage%20among%20CAs%20in%20the%20combined%203%20subcounties%20was%2048%25-49%25%20at%202%20years%20and%2064%25-78%25%20at%208%20years%20while%20probability%20of%20death%20was%2013%25%20at%202%20years%20and%2019%25%20at%208%20years.%20Single%20or%20double%20orphanhood%20predicted%20linkage%20%28adjusted%20odds%20ratio%20%5BaOR%5D%3A%202.66%2C%2095%25%20confidence%20interval%20%5BCI%5D%3A%201.33%20to%205.32%29%20and%20death%20%28aOR%3A%209.85%20%5B95%25%20CI%3A%202.21%20to%2044.01%5D%29.%20Having%20a%20mother%20known%20to%20be%20HIV-positive%20also%20predicted%20linkage%20%28aOR%20%3D%201.94%2C%2095%25%20CI%3A%200.97%20to%203.86%29%20and%20death%20%28aOR%3A%2014.49%2C%2095%25%20CI%3A%203.32%20to%2063.19%29.%5CnCONCLUSION%3A%20HIV%20testers%5C%2Fcounselors%20should%20continue%20to%20ensure%20linkage%20among%20orphans%20and%20CAs%20with%20mothers%20known%20to%20be%20HIV-positive%20and%20also%20to%20support%20other%20CAs%20to%20link%20to%20HIV%20care.%22%2C%22date%22%3A%222023-12-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003288%22%2C%22ISSN%22%3A%221944-7884%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-11-08T09%3A45%3A55Z%22%7D%7D%2C%7B%22key%22%3A%225BRPIT3J%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bourgi%20et%20al.%22%2C%22parsedDate%22%3A%222023-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBourgi%2C%20Kassem%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOfner%2C%20Susan%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMusick%2C%20Beverly%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWools-Kaloustian%2C%20Kara%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHumphrey%2C%20John%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Preswitch%20Regimens%20Influence%20the%20Rate%20of%20Weight%20Gain%20After%20Switch%20to%20Tenofovir%20Disoproxil%20Fumarate%2C%20Lamivudine%2C%20and%20Dolutegravir%20%28TLD%29%3A%20Study%20From%20an%20East%20African%20Cohort.%20%3Ci%3EOpen%20Forum%20Infectious%20Diseases%3C%5C%2Fi%3E%2C%20%3Ci%3E10%3C%5C%2Fi%3E%20%2812%29%2C%20S.%20ofad581.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofad581%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofad581%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Preswitch%20Regimens%20Influence%20the%20Rate%20of%20Weight%20Gain%20After%20Switch%20to%20Tenofovir%20Disoproxil%20Fumarate%2C%20Lamivudine%2C%20and%20Dolutegravir%20%28TLD%29%3A%20Study%20From%20an%20East%20African%20Cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kassem%22%2C%22lastName%22%3A%22Bourgi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%22%2C%22lastName%22%3A%22Ofner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20M.%22%2C%22lastName%22%3A%22Humphrey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samir%20K.%22%2C%22lastName%22%3A%22Gupta%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Switching%20from%20non-nucleoside%20reverse%20transcriptase%20inhibitor%20%28NNRTI%29-based%20regimens%20to%20dolutegravir%20%28DTG%29%20has%20been%20associated%20with%20greater%20weight%20gain.%5CnMETHODS%3A%20We%20conducted%20our%20analysis%20using%20a%20longitudinal%20cohort%20of%20people%20with%20HIV%20%28PWH%29%20in%20Western%20Kenya.%20We%20evaluated%20changes%20in%20the%20rate%20of%20weight%20gain%20among%20treatment-experienced%2C%20virally%20suppressed%20PWH%20who%20switched%20from%20NNRTI%20to%20tenofovir%20disoproxil%20fumarate%2C%20lamivudine%2C%20and%20dolutegravir%20%28TLD%29.%20We%20modeled%20the%20weights%20pre-%20and%20postswitch%20using%20a%202-phase%20model%20with%20linear%20trend%20preswitch%20and%20an%20inverted%20exponential%20function%20postswitch.%20We%20estimated%20an%2018-month%20excess%20weight%20gain%20by%20comparing%20the%20projected%20weight%20with%20that%20expected%20using%20the%20preswitch%20rate.%5CnRESULTS%3A%20A%20total%20of%2018%20662%20individuals%20were%20included%20in%20our%20analysis%2C%20with%2055%25%20switching%20from%20efavirenz%20%28EFV%29%20and%2045%25%20from%20nevirapine%20%28NVP%29.%20Of%20the%20studied%20individuals%2C%2051%25%20were%20female%2C%20and%20the%20median%20age%20and%20body%20mass%20index%20%28BMI%29%20were%2051%20years%20and%2022%5Cu2005kg%5C%2Fm2%2C%20respectively.%20For%20the%20overall%20population%2C%20the%20rate%20of%20weight%20gain%20increased%20from%200.47%5Cu2005kg%5C%2Fyear%20preswitch%20to%200.77%5Cu2005kg%5C%2Fyear%2C%20with%20higher%20increases%20for%20females%20%280.57%5Cu2005kg%5C%2Fyear%20to%200.96%5Cu2005kg%5C%2Fyear%29%20than%20males%20%280.34%5Cu2005kg%5C%2Fyear%20to%200.62%5Cu2005kg%5C%2Fyear%29.%20The%20rate%20of%20weight%20gain%20for%20individuals%20switching%20from%20EFV-based%20regimens%20significantly%20increased%20from%200.57%5Cu2005kg%5C%2Fyear%20preswitch%20to%201.11%5Cu2005kg%5C%2Fyear%20postswitch%20but%20remained%20stable%20at%200.35%5Cu2005kg%5C%2Fyear%20preswitch%20vs%200.32%5Cu2005kg%5C%2Fyear%20postswitch%20for%20individuals%20switching%20from%20NVP-based%20regimens.%5CnCONCLUSIONS%3A%20Switching%20from%20NNRTI-based%20regimens%20to%20TLD%20is%20associated%20with%20a%20modest%20increase%20in%20the%20rate%20of%20weight%20gain%2C%20with%20the%20preswitch%20NNRTI%20being%20the%20key%20determinant%20of%20the%20amount%20of%20weight%20gain%20experienced%20postswitch.%22%2C%22date%22%3A%222023-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofad581%22%2C%22ISSN%22%3A%222328-8957%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222024-02-06T15%3A15%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22C8REYNX4%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Meireles%20et%20al.%22%2C%22parsedDate%22%3A%222023-12%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMeireles%2C%20Glaucia%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENobre%2C%20Aline%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECardoso%2C%20Sandra%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVelasque%2C%20Luciane%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVeloso%2C%20Valdilea%20G.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Real-world%20effectiveness%20of%20WHO%20recommended%20first-line%20antiretroviral%20therapies%3A%20a%20cohort%20study%20from%20a%20middle-income%20country.%20%3Ci%3EAIDS%20Care%3C%5C%2Fi%3E%2C%20%3Ci%3E35%3C%5C%2Fi%3E%20%2812%29%2C%20S.%201891%26%23x2013%3B1903.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F09540121.2023.2190954%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F09540121.2023.2190954%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Real-world%20effectiveness%20of%20WHO%20recommended%20first-line%20antiretroviral%20therapies%3A%20a%20cohort%20study%20from%20a%20middle-income%20country%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Glaucia%22%2C%22lastName%22%3A%22Meireles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%20A.%22%2C%22lastName%22%3A%22Nobre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%20W.%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luciane%22%2C%22lastName%22%3A%22Velasque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdilea%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%5D%2C%22abstractNote%22%3A%22We%20estimate%20the%20effectiveness%20of%20antiretroviral%20therapy%20%28ART%29%20among%20individuals%20receiving%20HIV%20care%20in%20Rio%20de%20Janeiro%2C%20Brazil.%20Adults%20%2818y%2B%29%20initiating%20ART%20between%20Jan%5C%2F2008%20and%20Dec%5C%2F2018%20%28follow-up%20through%20Dec%5C%2F2020%29%20were%20included.%20First-line%20ART%20%28two%20nucleoside%20reverse%20transcriptase%20inhibitors%20plus%20one%20antiretroviral%20from%20another%20class%29%20was%20categorized%20into%20four%20categories%3A%20non-nucleoside%20reverse%20transcriptase%20inhibitor%5C%2FNNRTI-based%2C%20protease%20inhibitor%5C%2FPI-based%2C%20integrase%20strand%20transfer%20inhibitor%5C%2FINSTI-based%2C%20and%20single-tablet%20regimen%20%28STR%2C%20Tenofovir%20300mg%5Cu2009%2B%5Cu2009Lamivudine%20300mg%5Cu2009%2B%5Cu2009Efavirenz%20600mg%29.%20Effectiveness%20%28viral%20load%20%5Cu226450%20copies%5C%2F%5Cu00b5L%29%20was%20evaluated%20at%206%283-9%29%20and%2012%289-15%29%20months%20from%20ART%20initiation.%20Bayesian%20logistic%20regression%20models%20were%20used%20to%20quantify%20the%20association%20between%20exposure%20and%20outcomes%20while%20accounting%20for%20missing%20data.%20Overall%2C%201863%2857%25%29%2C%20652%2819.9%25%29%2C%20412%2812.6%25%29%2C%20and%20342%2810.5%25%29%20individuals%20used%2C%20respectively%2C%20NNRTI-based%2C%20PI-based%2C%20INSTI-based%20regimens%2C%20and%20STR.%20Compared%20to%20NNRTIs%2C%20the%20odds%20of%20viral%20suppression%20with%20INSTI-based%20regimens%20was%2076%25%20higher%20%28adjusted%20OR%3A1.76%2C%2095%25CI%3A1.23-2.51%29%20at%20six%20months%20but%20no%20higher%20at%2012%20months.%20Older%20age%2C%20higher%20education%2C%20CD4%20count%20%5Cu2265500%20cells%5C%2Fmm3%20and%20viral%20load%20%3C100%2C000%20copies%5C%2F%5Cu00b5L%20at%20ART%20initiation%20increased%20the%20odds%20of%20viral%20suppression.%20Viral%20suppression%20at%20six%20months%20was%20the%20strongest%20predictor%20of%20viral%20suppression%20at%2012%20months.%20These%20results%20highlight%20population%20groups%20that%20could%20benefit%20from%20close%20monitoring%20during%20the%20first%20year%20of%20ART.%22%2C%22date%22%3A%222023-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1080%5C%2F09540121.2023.2190954%22%2C%22ISSN%22%3A%221360-0451%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-12-01T10%3A43%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22LAIYZ48S%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sornillo%20et%20al.%22%2C%22parsedDate%22%3A%222023-12%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESornillo%2C%20Johanna%20Beulah%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDitangco%2C%20Rossana%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELumbiganon%2C%20Pagakrong%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVu%2C%20Thien%20An%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELe%2C%20Oanh%20Ngoc%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Disclosure%20of%20HIV%20status%20and%20associated%20clinical%20outcomes%20of%20children%20and%20adolescents%20living%20with%20HIV%20in%20Asia.%20%3Ci%3EAIDS%20Care%3C%5C%2Fi%3E%2C%20%3Ci%3E35%3C%5C%2Fi%3E%20%2812%29%2C%20S.%201928%26%23x2013%3B1937.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F09540121.2023.2176424%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F09540121.2023.2176424%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Disclosure%20of%20HIV%20status%20and%20associated%20clinical%20outcomes%20of%20children%20and%20adolescents%20living%20with%20HIV%20in%20Asia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanna%20Beulah%22%2C%22lastName%22%3A%22Sornillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rossana%22%2C%22lastName%22%3A%22Ditangco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pagakrong%22%2C%22lastName%22%3A%22Lumbiganon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thien%20An%22%2C%22lastName%22%3A%22Vu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oanh%20Ngoc%22%2C%22lastName%22%3A%22Le%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khanh%20Huu%22%2C%22lastName%22%3A%22Truong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lam%20Van%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Viet%20Chau%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pradthana%22%2C%22lastName%22%3A%22Ounchanum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dewi%20Kumara%22%2C%22lastName%22%3A%22Wati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thanyawee%22%2C%22lastName%22%3A%22Puthanakit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nia%22%2C%22lastName%22%3A%22Kurniati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keswadee%22%2C%22lastName%22%3A%22Lapphra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tavitiya%22%2C%22lastName%22%3A%22Sudjaritruk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nagalingeswaran%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thahira%20A.%22%2C%22lastName%22%3A%22Jamal%20Mohamed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nik%20Khairulddin%22%2C%22lastName%22%3A%22Nik%20Yusoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Siew%20Moy%22%2C%22lastName%22%3A%22Fong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Revathy%20A.%22%2C%22lastName%22%3A%22Nallusamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annette%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Azar%22%2C%22lastName%22%3A%22Kariminia%22%7D%5D%2C%22abstractNote%22%3A%22Disclosure%20of%20HIV%20status%20is%20an%20important%20part%20of%20pediatric%20care.%20We%20studied%20disclosure%20and%20clinical%20outcomes%20in%20a%20multi-country%20Asian%20cohort%20of%20children%20and%20adolescents%20with%20HIV.%20Those%206-19%20years%20of%20age%20who%20initiated%20combination%20antiretroviral%20therapy%20%28cART%29%20between%202008%20and%202018%2C%20and%20who%20had%20at%20least%20one%20follow-up%20clinic%20visit%20were%20included.%20Data%20up%20to%20December%202019%20were%20analyzed.%20Cox%20and%20competing%20risk%20regression%20analyses%20were%20used%20to%20assess%20the%20effect%20of%20disclosure%20on%20disease%20progression%20%28WHO%20clinical%20stage%203%20or%204%29%2C%20loss%20to%20follow-up%20%28LTFU%3B%5Cu2009%3E%5Cu200912%20months%29%2C%20and%20death.%20Of%201913%20children%20and%20adolescents%20%2848%25%20female%3B%20median%20%5BIQR%5D%20age%2011.5%20%5B9.2-14.7%5D%20years%20at%20last%20clinic%20visit%29%2C%20795%20%2842%25%29%20were%20disclosed%20to%20about%20their%20HIV%20status%20at%20a%20median%20age%20of%2012.9%20years%20%28IQR%3A%2011.8-14.1%29.%20During%20follow-up%2C%20207%20%2811%25%29%20experienced%20disease%20progression%2C%2075%20%283.9%25%29%20were%20LTFU%2C%20and%2059%20%283.1%25%29%20died.%20There%20were%20lower%20hazards%20of%20disease%20progression%20%28adjusted%20hazard%20ratio%20%5BaHR%5D%200.43%20%5B0.28-0.66%5D%29%20and%20death%20%28aHR%200.36%20%5B0.17-0.79%5D%29%20for%20those%20disclosed%20to%20compared%20with%20those%20who%20were%20not.%20Disclosure%20and%20its%20appropriate%20implementation%20should%20be%20promoted%20in%20pediatric%20HIV%20clinics%20in%20resource-limited%20settings.%22%2C%22date%22%3A%222023-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1080%5C%2F09540121.2023.2176424%22%2C%22ISSN%22%3A%221360-0451%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222024-01-12T13%3A25%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22NFL64P9Z%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Morgan%20et%20al.%22%2C%22parsedDate%22%3A%222023-11-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMorgan%2C%20Camille%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENgimbi%2C%20Patrick%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBoisson-Walsh%2C%20Alix%20Jn%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENtambua%2C%20Sarah%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMatondo%2C%20Jolie%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Hepatitis%20B%20virus%20prevalence%20and%20transmission%20in%20the%20households%20of%20pregnant%20women%20in%20Kinshasa%2C%20Democratic%20Republic%20of%20Congo.%20%3Ci%3EMedRxiv%3A%20The%20Preprint%20Server%20for%20Health%20Sciences%3C%5C%2Fi%3E%2C%20S.%202023.11.27.23298863.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2023.11.27.23298863%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2023.11.27.23298863%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hepatitis%20B%20virus%20prevalence%20and%20transmission%20in%20the%20households%20of%20pregnant%20women%20in%20Kinshasa%2C%20Democratic%20Republic%20of%20Congo%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%20E.%22%2C%22lastName%22%3A%22Morgan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Ngimbi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alix%20Jn%22%2C%22lastName%22%3A%22Boisson-Walsh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Ntambua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jolie%22%2C%22lastName%22%3A%22Matondo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Tabala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melchior%20Mwandaglirwa%22%2C%22lastName%22%3A%22Kashamuka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Emch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessie%20K.%22%2C%22lastName%22%3A%22Edwards%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kimberly%20A.%22%2C%22lastName%22%3A%22Powers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%22%2C%22lastName%22%3A%22James%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nana%22%2C%22lastName%22%3A%22Mbonze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Mampunza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peyton%22%2C%22lastName%22%3A%22Thompson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20B.%22%2C%22lastName%22%3A%22Parr%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Despite%20routine%20infant%20vaccination%20and%20blood%20donor%20screening%2C%20the%20Democratic%20Republic%20of%20Congo%20%28DRC%29%20has%20high%20hepatitis%20B%20virus%20%28HBV%29%20prevalence%20compared%20to%20the%20United%20States%20and%20Europe.%20Through%20the%20cross-sectional%20Horizontal%20and%20Vertical%20Transmission%20of%20Hepatitis%20B%20%28HOVER-HBV%29%20study%2C%20we%20characterized%20household%20prevalence%20in%20DRC%27s%20capital%2C%20Kinshasa%2C%20to%20inform%20additional%20prevention%20efforts.%5CnMETHODS%3A%20We%20introduced%20HBV%20surface%20antigen%20%28HBsAg%29%20screening%20alongside%20existing%20HIV%20screening%20as%20part%20of%20routine%20antenatal%20care%20%28ANC%29%20in%20high-volume%20maternity%20clinics%20in%20Kinshasa.%20We%20recruited%20households%20of%20pregnant%20women%20who%20were%20HBsAg-positive%20and%20HBsAg-negative%2C%20defining%20households%20as%20%5C%22exposed%5C%22%20and%20%5C%22unexposed%2C%5C%22%20respectively.%20Household%20members%20underwent%20HBsAg%20testing%20and%20an%20epidemiological%20survey.%20We%20evaluated%20HBsAg%20prevalence%20and%20potential%20transmission%20correlates.%5CnRESULTS%3A%20We%20enrolled%201%2C006%20participants%20from%20200%20households%20%28100%20exposed%2C%20100%20unexposed%29%20across%20Kinshasa.%20HBsAg%20prevalence%20was%20more%20than%20twice%20as%20high%20in%20exposed%20households%20%285.0%25%3B%2095%25%20CI%3A%202.8%25-7.1%25%29%20as%20in%20unexposed%20households%20%281.9%25%3B%200.6%25-3.2%25%29.%20Exposed%20direct%20offspring%20had%203.3%20%280.9%2C%2011.8%29%20times%20the%20prevalence%20of%20unexposed%20direct%20offspring.%20Factors%20associated%20with%20HBsAg-positivity%20included%20older%20age%2C%20marriage%2C%20and%20having%20multiple%20recent%20partners%20or%20any%20new%20sexual%20partners%20among%20index%20mothers%3B%20and%20older%20age%2C%20lower%20household%20wealth%2C%20sharing%20nail%20clippers%2C%20and%20using%20street%20salons%20among%20exposed%20offspring.%5CnCONCLUSIONS%3A%20Vertical%20and%20horizontal%20HBV%20transmission%20within%20households%20is%20ongoing%20in%20Kinshasa.%20Factors%20associated%20with%20infection%20reveal%20opportunities%20for%20HBV%20prevention%20efforts%2C%20including%20perinatal%20prevention%2C%20protection%20during%20sexual%20contact%2C%20and%20sanitation%20of%20shared%20personal%20items.%22%2C%22date%22%3A%222023-11-27%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2023.11.27.23298863%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222024-01-12T13%3A07%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22L5PY7ZP3%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Amorim%20et%20al.%22%2C%22parsedDate%22%3A%222023-11-21%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAmorim%2C%20Gustavo%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETao%2C%20Ran%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELotspeich%2C%20Sarah%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShaw%2C%20Pamela%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELumley%2C%20Thomas%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Three-phase%20generalized%20raking%20and%20multiple%20imputation%20estimators%20to%20address%20error-prone%20data.%20%3Ci%3EStatistics%20in%20Medicine%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fsim.9967%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fsim.9967%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Three-phase%20generalized%20raking%20and%20multiple%20imputation%20estimators%20to%20address%20error-prone%20data%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ran%22%2C%22lastName%22%3A%22Tao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Lotspeich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%20A.%22%2C%22lastName%22%3A%22Shaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Lumley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rena%20C.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%5D%2C%22abstractNote%22%3A%22Validation%20studies%20are%20often%20used%20to%20obtain%20more%20reliable%20information%20in%20settings%20with%20error-prone%20data.%20Validated%20data%20on%20a%20subsample%20of%20subjects%20can%20be%20used%20together%20with%20error-prone%20data%20on%20all%20subjects%20to%20improve%20estimation.%20In%20practice%2C%20more%20than%20one%20round%20of%20data%20validation%20may%20be%20required%2C%20and%20direct%20application%20of%20standard%20approaches%20for%20combining%20validation%20data%20into%20analyses%20may%20lead%20to%20inefficient%20estimators%20since%20the%20information%20available%20from%20intermediate%20validation%20steps%20is%20only%20partially%20considered%20or%20even%20completely%20ignored.%20In%20this%20paper%2C%20we%20present%20two%20novel%20extensions%20of%20multiple%20imputation%20and%20generalized%20raking%20estimators%20that%20make%20full%20use%20of%20all%20available%20data.%20We%20show%20through%20simulations%20that%20incorporating%20information%20from%20intermediate%20steps%20can%20lead%20to%20substantial%20gains%20in%20efficiency.%20This%20work%20is%20motivated%20by%20and%20illustrated%20in%20a%20study%20of%20contraceptive%20effectiveness%20among%2083%5Cu2009671%20women%20living%20with%20HIV%2C%20whose%20data%20were%20originally%20extracted%20from%20electronic%20medical%20records%2C%20of%20whom%204732%20had%20their%20charts%20reviewed%2C%20and%20a%20subsequent%201210%20also%20had%20a%20telephone%20interview%20to%20validate%20key%20study%20variables.%22%2C%22date%22%3A%222023-11-21%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fsim.9967%22%2C%22ISSN%22%3A%221097-0258%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-12-01T10%3A45%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22KM8A3363%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Boni%20et%20al.%22%2C%22parsedDate%22%3A%222023-11-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBoni%2C%20Simon%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETenet%2C%20Vanessa%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHoro%2C%20Apollinaire%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHeideman%2C%20Dani%26%23xEB%3Blle%20A.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBleeker%2C%20Maaike%20C.%20G.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20High-risk%20human%20papillomavirus%20distribution%20according%20to%20human%20immunodeficiency%20virus%20status%20among%20women%20with%20cervical%20cancer%20in%20Abidjan%2C%20C%26%23xF4%3Bte%20d%26%23x2019%3BIvoire%2C%202018%20to%202020.%20%3Ci%3EInternational%20Journal%20of%20Cancer%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.34774%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.34774%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22High-risk%20human%20papillomavirus%20distribution%20according%20to%20human%20immunodeficiency%20virus%20status%20among%20women%20with%20cervical%20cancer%20in%20Abidjan%2C%20C%5Cu00f4te%20d%27Ivoire%2C%202018%20to%202020%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%20P.%22%2C%22lastName%22%3A%22Boni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Tenet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Apollinaire%22%2C%22lastName%22%3A%22Horo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dani%5Cu00eblle%20A.%20M.%22%2C%22lastName%22%3A%22Heideman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maaike%20C.%20G.%22%2C%22lastName%22%3A%22Bleeker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aristophane%22%2C%22lastName%22%3A%22Tanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Boston%22%2C%22lastName%22%3A%22Mian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isidore%20D.%22%2C%22lastName%22%3A%22Mohenou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%20K.%22%2C%22lastName%22%3A%22Ekouevi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tarik%22%2C%22lastName%22%3A%22Gheit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judith%22%2C%22lastName%22%3A%22Didi-Kouko%20Coulibaly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Boris%20K.%22%2C%22lastName%22%3A%22Tchounga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Innocent%22%2C%22lastName%22%3A%22Adoubi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gary%20M.%22%2C%22lastName%22%3A%22Clifford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20The%20IeDEA%20West%20Africa%20Collaboration%22%7D%5D%2C%22abstractNote%22%3A%22As%20human%20papillomavirus%20%28HPV%29%20immunisation%20and%20HPV-based%20cervical%20cancer%20%28CC%29%20screening%20programmes%20expand%20across%20sub-Saharan%20Africa%2C%20we%20investigated%20the%20potential%20impact%20of%20human%20immunodeficiency%20virus%20%28HIV%29%20status%20on%20high-risk%20%28HR%29-HPV%20distribution%20among%20women%20with%20CC%20in%20C%5Cu00f4te%20d%27Ivoire.%20From%20July%202018%20to%20June%202020%2C%20paraffin-embedded%20CC%20specimens%20diagnosed%20in%20Abidjan%2C%20C%5Cu00f4te%20d%27Ivoire%20were%20systematically%20collected%20and%20tested%20for%20HR-HPV%20DNA.%20Type-specific%20HR-HPV%20prevalence%20was%20compared%20according%20to%20HIV%20status.%20Of%20the%20170%20CC%20specimens%20analysed%20%28median%20age%2052%5Cu2009years%2C%20interquartile%20range%3A%20%5B43.0-60.0%5D%29%2C%2043%20%2825.3%25%29%20were%20from%20women%20living%20with%20HIV%20%28WLHIV%29%20with%20a%20median%20CD4%20count%20of%20526%20%5B373-833%5D%20cells%5C%2Fmm3%20and%2086%25%20were%20on%20antiretroviral%20therapy%20%28ART%29.%20The%20overall%20HR-HPV%20prevalence%20was%2089.4%25%20%5B95%25%20CI%3A%2084.7-94.1%5D.%20All%20were%20single%20HR-HPV%20infections%20with%20no%20differences%20according%20to%20HIV%20status%20%28P%5Cu2009%3D%5Cu2009.8%29.%20Among%20HR-HPV-positive%20CC%20specimens%2C%20the%20most%20prevalent%20HR-HPV%20types%20were%20HPV16%20%2857.2%25%29%2C%20HPV18%20%2819.7%25%29%2C%20HPV45%20%288.6%25%29%20and%20HPV35%20%284.6%25%29%2C%20with%20no%20significant%20differences%20according%20to%20HIV%20status.%20Altogether%2C%20infection%20with%20HPV16%5C%2F18%20accounted%20for%2071.1%25%20%5B95%25%20CI%3A%2055.9-86.2%5D%20of%20CC%20cases%20in%20WLHIV%20vs%2078.9%25%20%5B95%25%20CI%3A%2071.3-86.5%5D%20in%20women%20without%20HIV%20%28P%5Cu2009%3D%5Cu2009.3%29.%20The%20study%20confirms%20the%20major%20role%20of%20HPV16%5C%2F18%20in%20CC%20in%20C%5Cu00f4te%20d%27Ivoire%20and%20should%20support%20a%20regional%20scale-up%20of%20HPV16%5C%2F18%20vaccination%20programmes%20regardless%20of%20HIV%20status.%20However%2C%20vaccines%20targeting%20additional%20HR-HPV%20types%2C%20including%20HPV45%20and%20HPV35%2C%20could%20further%20decrease%20future%20CC%20incidence%20in%20C%5Cu00f4te%20d%27Ivoire%2C%20both%20for%20WLHIV%20and%20women%20without%20HIV.%22%2C%22date%22%3A%222023-11-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fijc.34774%22%2C%22ISSN%22%3A%221097-0215%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222024-01-12T13%3A25%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22MYPZC62H%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Muula%20et%20al.%22%2C%22parsedDate%22%3A%222023-11-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMuula%2C%20Guy%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBosomprah%2C%20Samuel%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESinkala%2C%20Edford%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENsokolo%2C%20Bright%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMusonda%2C%20Taonga%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Hepatitis%20B%20viral%20replication%20markers%20and%20hepatic%20fibrosis%20in%20untreated%20chronic%20hepatitis%20B%20virus%20infection%20with%20and%20without%20HIV%20coinfection%20in%20Zambia.%20%3Ci%3EAIDS%20%28London%2C%20England%29%3C%5C%2Fi%3E%2C%20%3Ci%3E37%3C%5C%2Fi%3E%20%2813%29%2C%20S.%202015%26%23x2013%3B2020.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003659%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003659%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hepatitis%20B%20viral%20replication%20markers%20and%20hepatic%20fibrosis%20in%20untreated%20chronic%20hepatitis%20B%20virus%20infection%20with%20and%20without%20HIV%20coinfection%20in%20Zambia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%20K.%22%2C%22lastName%22%3A%22Muula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Bosomprah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edford%22%2C%22lastName%22%3A%22Sinkala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bright%22%2C%22lastName%22%3A%22Nsokolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Taonga%22%2C%22lastName%22%3A%22Musonda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kalongo%22%2C%22lastName%22%3A%22Hamusonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Debika%22%2C%22lastName%22%3A%22Bhattacharya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georg%22%2C%22lastName%22%3A%22Lauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raymond%20T.%22%2C%22lastName%22%3A%22Chung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lloyd%20B.%22%2C%22lastName%22%3A%22Mulenga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Vinikoor%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20To%20inform%20novel%20therapies%2C%20a%20more%20nuanced%20understanding%20of%20HIV%27s%20impact%20on%20hepatitis%20B%20virus%20%28HBV%29%20natural%20history%20is%20needed%2C%20particularly%20in%20high%20burden%20countries.%5CnMETHODS%3A%20In%20Lusaka%2C%20Zambia%2C%20we%20compared%20prospectively%20recruited%20adults%20%2818%2B%20years%29%20with%20chronic%20HBV%20infection%2C%20with%20and%20without%20HIV.%20We%20excluded%20those%20with%20prior%20antiviral%20treatment%20experience%20or%20HBV%20diagnosis%20due%20to%20clinical%20suspicion%20%28rather%20than%20routine%20testing%29.%20We%20assessed%20HBV%20DNA%20levels%2C%20hepatitis%20B%20e%20antigen%20%28HBeAg%29%2C%20CD4%20%2B%20%28if%20HIV%20coinfection%29%2C%20and%20liver%20disease%20%28transient%20elastography%2C%20serum%20alanine%20aminotransferase%29.%20In%20multivariable%20analyses%2C%20we%20evaluated%20the%20association%20of%20HIV%20overall%20and%20by%20level%20of%20CD4%20%2B%20count%20on%20these%20markers.%5CnRESULTS%3A%20Among%20713%20adults%20analyzed%2C%20median%20age%20was%2033%5Cu200ayears%2C%2063%25%20were%20male%2C%20and%20433%20had%20HBV%5C%2FHIV%20coinfection.%20Median%20CD4%20%2B%20count%20was%20200%5Cu200acells%5C%2F%5Cu03bcl.%20HBV%20DNA%20was%20greater%20than%202000%5Cu200aIU%5C%2Fml%20for%20311%20%2851.0%25%29%20and%20227%20%2832.5%25%29%20were%20HBeAg-positive.%2015.5%25%20had%20advanced%20fibrosis%20or%20cirrhosis.%20HIV%20coinfection%20was%20associated%20with%20five-fold%20increased%20HBV%20DNA%20levels%20%5Badjusted%20geometric%20mean%20ratio%2C%205.78%3B%2095%25%20confidence%20interval%20%28CI%29%2C%202.29-14.62%5D%20and%20two%20times%20the%20odds%20of%20HBeAg-positivity%20%28adjusted%20odds%20ratio%2C%202.54%3B%2095%25%20CI%2C%201.59-4.08%29.%20These%20associations%20were%20significant%20only%20at%20CD4%20%2B%20counts%20100-350%20and%20%3C100%5Cu200acells%5C%2F%5Cu03bcl.%20HIV%20was%20not%20associated%20with%20markers%20of%20fibrosis%20or%20ALT.%5CnDISCUSSION%3A%20HIV%27s%20impact%20on%20HBV%20natural%20history%20likely%20depends%20on%20the%20degree%20and%20duration%20of%20immune%20suppression.%20There%20is%20strong%20rationale%20to%20monitor%20HBV%20DNA%20in%20people%20with%20HBV%5C%2FHIV%20coinfection%20and%20immune%20suppression.%20A%20better%20understanding%20is%20needed%20of%20mechanisms%20of%20increased%20liver-related%20mortality%20in%20people%20with%20HBV%5C%2FHIV%20coinfection.%22%2C%22date%22%3A%222023-11-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003659%22%2C%22ISSN%22%3A%221473-5571%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-11-08T09%3A56%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22MGI477IL%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ruffieux%20et%20al.%22%2C%22parsedDate%22%3A%222023-11-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERuffieux%2C%20Yann%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWettstein%2C%20Anja%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMaartens%2C%20Gary%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFolb%2C%20Naomi%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMesa-Vieira%2C%20Cristina%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Life%20years%20lost%20associated%20with%20mental%20illness%3A%20A%20cohort%20study%20of%20beneficiaries%20of%20a%20South%20African%20medical%20insurance%20scheme.%20%3Ci%3EJournal%20of%20Affective%20Disorders%3C%5C%2Fi%3E%2C%20%3Ci%3E340%3C%5C%2Fi%3E%2C%20S.%20204%26%23x2013%3B212.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jad.2023.08.013%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jad.2023.08.013%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Life%20years%20lost%20associated%20with%20mental%20illness%3A%20A%20cohort%20study%20of%20beneficiaries%20of%20a%20South%20African%20medical%20insurance%20scheme%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Ruffieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anja%22%2C%22lastName%22%3A%22Wettstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gary%22%2C%22lastName%22%3A%22Maartens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naomi%22%2C%22lastName%22%3A%22Folb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Mesa-Vieira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christiane%22%2C%22lastName%22%3A%22Didden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mpho%22%2C%22lastName%22%3A%22Tlali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chanwyn%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morna%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Schomaker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leigh%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20A.%22%2C%22lastName%22%3A%22Joska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20People%20with%20mental%20illness%20have%20a%20reduced%20life%20expectancy%2C%20but%20the%20extent%20of%20the%20mortality%20gap%20and%20the%20contribution%20of%20natural%20and%20unnatural%20causes%20to%20excess%20mortality%20among%20people%20with%20mental%20illness%20in%20South%20Africa%20are%20unknown.%5CnMETHODS%3A%20We%20analysed%20reimbursement%20claims%20from%20South%20African%20medical%20insurance%20scheme%20beneficiaries%20aged%2015-85%5Cu00a0years.%20We%20estimated%20excess%20life%20years%20lost%20%28LYL%29%20associated%20with%20organic%2C%20substance%20use%2C%20psychotic%2C%20mood%2C%20anxiety%2C%20eating%2C%20personality%2C%20developmental%20or%20any%20mental%20disorders.%5CnRESULTS%3A%20We%20followed%201%2C070%2C183%20beneficiaries%20for%20a%20median%20of%20three%20years%2C%20of%20whom%20282%2C926%20%2826.4%5Cu00a0%25%29%20received%20mental%20health%20diagnoses.%20Men%20with%20a%20mental%20health%20diagnosis%20lost%203.83%20life%20years%20%2895%5Cu00a0%25%20CI%203.58-4.10%29%20compared%20to%20men%20without.%20Women%20with%20a%20mental%20health%20diagnosis%20lost%202.19%20life%20years%20%281.97-2.41%29%20compared%20to%20women%20without.%20Excess%20mortality%20varied%20by%20sex%20and%20diagnosis%2C%20from%2011.50%20LYL%20%2895%5Cu00a0%25%20CI%209.79-13.07%29%20among%20men%20with%20alcohol%20use%20disorder%20to%200.87%20LYL%20%280.40-1.43%29%20among%20women%20with%20generalised%20anxiety%20disorder.%20Most%20LYL%20were%20attributable%20to%20natural%20causes%20%28men%3A%203.42%2C%20women%3A%201.94%29.%20A%20considerable%20number%20of%20LYL%20were%20attributable%20to%20unnatural%20causes%20among%20men%20with%20bipolar%20%281.52%29%20or%20substance%20use%20%282.45%29%20disorder.%5CnLIMITATIONS%3A%20Mental%20diagnoses%20are%20based%20on%20reimbursement%20claims.%5CnCONCLUSIONS%3A%20Premature%20mortality%20among%20South%20African%20individuals%20with%20mental%20disorders%20is%20high.%20Our%20findings%20support%20interventions%20for%20the%20prevention%2C%20early%20detection%2C%20and%20treatment%20of%20physical%20comorbidities%20in%20this%20population.%20Targeted%20programs%20for%20suicide%20prevention%20and%20substance%20use%20treatment%2C%20particularly%20among%20men%2C%20can%20help%20reduce%20excess%20mortality%20from%20unnatural%20causes.%22%2C%22date%22%3A%222023-11-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jad.2023.08.013%22%2C%22ISSN%22%3A%221573-2517%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-11-08T10%3A06%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22RSD8GVHK%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Loosli%20et%20al.%22%2C%22parsedDate%22%3A%222023-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELoosli%2C%20Tom%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHossmann%2C%20Stefanie%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EIngle%2C%20Suzanne%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOkhai%2C%20Hajra%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKusejko%2C%20Katharina%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20HIV-1%20drug%20resistance%20in%20people%20on%20dolutegravir-based%20antiretroviral%20therapy%3A%20a%20collaborative%20cohort%20analysis.%20%3Ci%3EThe%20Lancet.%20HIV%3C%5C%2Fi%3E%2C%20%3Ci%3E10%3C%5C%2Fi%3E%20%2811%29%2C%20S.%20e733%26%23x2013%3Be741.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2823%2900228-X%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2823%2900228-X%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV-1%20drug%20resistance%20in%20people%20on%20dolutegravir-based%20antiretroviral%20therapy%3A%20a%20collaborative%20cohort%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Loosli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefanie%22%2C%22lastName%22%3A%22Hossmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%20M.%22%2C%22lastName%22%3A%22Ingle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hajra%22%2C%22lastName%22%3A%22Okhai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katharina%22%2C%22lastName%22%3A%22Kusejko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Mouton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pantxika%22%2C%22lastName%22%3A%22Bellecave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ard%22%2C%22lastName%22%3A%22van%20Sighem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melanie%22%2C%22lastName%22%3A%22Stecher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonella%22%2C%22lastName%22%3A%22d%27Arminio%20Monforte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20John%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%20A.%22%2C%22lastName%22%3A%22Sabin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gary%22%2C%22lastName%22%3A%22Maartens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Huldrych%20F.%22%2C%22lastName%22%3A%22G%5Cu00fcnthard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20A.%20C.%22%2C%22lastName%22%3A%22Sterne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Lessells%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%20D.%22%2C%22lastName%22%3A%22Kouyos%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20widespread%20use%20of%20the%20integrase%20strand%20transfer%20inhibitor%20%28INSTI%29%20dolutegravir%20in%20first-line%20and%20second-line%20antiretroviral%20therapy%20%28ART%29%20might%20facilitate%20emerging%20resistance.%20The%20DTG%20RESIST%20study%20combined%20data%20from%20HIV%20cohorts%20to%20examine%20patterns%20of%20drug%20resistance%20mutations%20%28DRMs%29%20and%20identify%20risk%20factors%20for%20dolutegravir%20resistance.%5CnMETHODS%3A%20We%20included%20cohorts%20with%20INSTI%20resistance%20data%20from%20two%20collaborations%20%28ART%20Cohort%20Collaboration%2C%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20in%20Southern%20Africa%29%2C%20and%20the%20UK%20Collaborative%20HIV%20Cohort.%20Eight%20cohorts%20from%20Canada%2C%20France%2C%20Germany%2C%20Italy%2C%20the%20Netherlands%2C%20Switzerland%2C%20South%20Africa%2C%20and%20the%20UK%20contributed%20data%20on%20individuals%20who%20were%20viraemic%20on%20dolutegravir-based%20ART%20and%20underwent%20genotypic%20resistance%20testing.%20Individuals%20with%20unknown%20dolutegravir%20initiation%20date%20were%20excluded.%20Resistance%20levels%20were%20categorised%20using%20the%20Stanford%20algorithm.%20We%20identified%20risk%20factors%20for%20resistance%20using%20mixed-effects%20ordinal%20logistic%20regression%20models.%5CnFINDINGS%3A%20We%20included%20599%20people%20with%20genotypic%20resistance%20testing%20on%20dolutegravir-based%20ART%20between%20May%2022%2C%202013%2C%20and%20Dec%2020%2C%202021.%20Most%20had%20HIV-1%20subtype%20B%20%28n%3D351%2C%2059%25%29%2C%20a%20third%20had%20been%20exposed%20to%20first-generation%20INSTIs%20%28n%3D193%2C%2032%25%29%2C%2070%20%2812%25%29%20were%20on%20dolutegravir%20dual%20therapy%2C%20and%2018%20%283%25%29%20were%20on%20dolutegravir%20monotherapy.%20INSTI%20DRMs%20were%20detected%20in%2086%20%2814%25%29%20individuals%3B%2020%20%283%25%29%20had%20more%20than%20one%20mutation.%20Most%20%28n%3D563%2C%2094%25%29%20were%20susceptible%20to%20dolutegravir%2C%20seven%20%281%25%29%20had%20potential%20low%2C%20six%20%281%25%29%20low%2C%2017%20%283%25%29%20intermediate%2C%20and%20six%20%281%25%29%20high-level%20dolutegravir%20resistance.%20The%20risk%20of%20dolutegravir%20resistance%20was%20higher%20on%20dolutegravir%20monotherapy%20%28adjusted%20odds%20ratio%20%5BaOR%5D%2034%5Cu00b71%2C%2095%25%20CI%209%5Cu00b793-117%29%20and%20dolutegravir%20plus%20lamivudine%20dual%20therapy%20%28aOR%209%5Cu00b721%2C%202%5Cu00b720-38%5Cu00b76%29%20compared%20with%20combination%20ART%2C%20and%20in%20the%20presence%20of%20potential%20low%20or%20low%20%28aOR%205%5Cu00b723%2C%201%5Cu00b732-20%5Cu00b77%29%20or%20intermediate%20or%20high-level%20%28aOR%2013%5Cu00b74%2C%204%5Cu00b755-39%5Cu00b77%29%20nucleoside%20reverse%20transcriptase%20inhibitor%20%28NRTI%29%20resistance.%5CnINTERPRETATION%3A%20Among%20people%20with%20viraemia%20on%20dolutegravir-based%20ART%2C%20INSTI%20DRMs%20and%20dolutegravir%20resistance%20were%20rare.%20NRTI%20resistance%20substantially%20increased%20the%20risk%20of%20dolutegravir%20resistance%2C%20which%20is%20of%20concern%2C%20notably%20in%20resource-limited%20settings.%20Monitoring%20is%20important%20to%20prevent%20resistance%20at%20the%20individual%20and%20population%20level%20and%20ensure%20the%20long-term%20sustainability%20of%20ART.%5CnFUNDING%3A%20US%20National%20Institutes%20of%20Health%2C%20Swiss%20National%20Science%20Foundation.%22%2C%22date%22%3A%222023-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS2352-3018%2823%2900228-X%22%2C%22ISSN%22%3A%222352-3018%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222024-07-26T10%3A08%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22T8YENW77%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Boni%20et%20al.%22%2C%22parsedDate%22%3A%222023-11%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBoni%2C%20Simon%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHoro%2C%20Apollinaire%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDidi-Kouko-Coulibaly%2C%20Judith%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETanon%2C%20Aristophane%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETchounga%2C%20Boris%20K.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Impact%20of%20HIV%20infection%20on%20access%20to%20cancer%20care%20and%20survival%20among%20women%20with%20invasive%20cervical%20cancer%20in%20C%26%23xF4%3Bte%20d%26%23x2019%3BIvoire%3A%20A%20prospective%20cohort%20study.%20%3Ci%3EInternational%20Journal%20of%20Gynaecology%20and%20Obstetrics%3A%20The%20Official%20Organ%20of%20the%20International%20Federation%20of%20Gynaecology%20and%20Obstetrics%3C%5C%2Fi%3E%2C%20%3Ci%3E163%3C%5C%2Fi%3E%20%282%29%2C%20S.%20392%26%23x2013%3B401.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijgo.14925%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijgo.14925%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20HIV%20infection%20on%20access%20to%20cancer%20care%20and%20survival%20among%20women%20with%20invasive%20cervical%20cancer%20in%20C%5Cu00f4te%20d%27Ivoire%3A%20A%20prospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%20P.%22%2C%22lastName%22%3A%22Boni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Apollinaire%22%2C%22lastName%22%3A%22Horo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judith%22%2C%22lastName%22%3A%22Didi-Kouko-Coulibaly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aristophane%22%2C%22lastName%22%3A%22Tanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Boris%20K.%22%2C%22lastName%22%3A%22Tchounga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20A.%22%2C%22lastName%22%3A%22Coffie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Claude%22%2C%22lastName%22%3A%22Comoe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raoul%20D.%22%2C%22lastName%22%3A%22Moh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Dabis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Innocent%22%2C%22lastName%22%3A%22Adoubi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%20West%20Africa%20Collaboration%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20assess%20the%20impact%20of%20HIV%20on%20access%20to%20invasive%20cervical%20cancer%20%28ICC%29%20care%20and%20overall%20survival%20%28OS%29%20in%20a%20time%20of%20universal%20access%20to%20antiretroviral%20therapy%20%28ART%29.%5CnMETHODS%3A%20A%20cohort%20of%20women%20prospectively%20diagnosed%20with%20ICC%20was%20consecutively%20recruited%20from%202018%20to%202020%20in%20public%5C%2Fprivate%20cancer%20centers%20in%20C%5Cu00f4te%20d%27Ivoire.%20Follow-up%20data%20were%20collected%20through%20facility-%20and%20phone-based%20approaches.%20Logistic%20and%20Cox%20regression%20models%20allowed%20analysis%20of%20factors%20associated%20with%20access%20to%20cancer%20care%20and%20OS%2C%20respectively.%5CnRESULTS%3A%20Overall%2C%20294%20women%20with%20ICC%20aged%2050%5Cu2009years%20%28interquartile%20range%20%5BIQR%5D%2043-60%29%20were%20enrolled%2C%20including%2021.4%25%20of%20women%20living%20with%20HIV%20%28WLHIV%29%2C%2087%25%20being%20on%20ART.%20An%20advanced%20ICC%20clinical%20stage%20%28III-IV%29%20was%20less%20frequent%20in%20WLHIV%20%2863.5%25%20vs.%2077.1%25%20in%20HIV-uninfected%20women%3B%20P%5Cu2009%3D%5Cu20090.029%29.%20Cancer%20care%20was%20initiated%20in%20124%20%2842.2%25%29%20women%20%2854.0%25%20in%20WLHIV%3B%2039.0%25%20in%20HIV-uninfected%3B%20P%5Cu2009%3D%5Cu20090.030%29.%20Factors%20independently%20associated%20with%20access%20to%20cancer%20care%20were%20International%20Federation%20of%20Gynecology%20and%20Obstetrics%20%28FIGO%29%20stage%20I-II%20%28adjusted%20odds%20ratio%20%5BaOR%5D%203.58%2C%2095%25%20CI%202.01-6.38%29%20and%20no%20treatment%20by%20traditional%20healers%20prior%20to%20ICC%20diagnosis%20%28aOR%203.69%2C%2095%25%20CI%201.96-6.96%29.%20The%202-year%20OS%20was%2037.9%25%20%2895%25%20CI%2030.0-47.9%29.%20HIV%20status%20was%20not%20predictive%20of%20mortality%20%28adjusted%20hazard%20ratio%20%5BaHR%5D%200.98%2C%2095%25%20CI%200.60-1.69%29.%20An%20advanced%20clinical%20stage%20was%20the%20only%20measured%20predictor%20of%20death%20%28aHR%201.59%2C%2095%25%20CI%201.02-2.47%29.%5CnCONCLUSION%3A%20In%20a%20time%20of%20universal%20access%20to%20ART%2C%20HIV%20infection%20was%20not%20associated%20with%20OS%20among%20women%20with%20ICC%20in%20C%5Cu00f4te%20d%27Ivoire.%20Higher%20access%20to%20cancer%20care%20in%20WLHIV%20might%20be%20mediated%20by%20enhanced%20access%20to%20ICC%20screening%20services%2C%20supporting%20the%20need%20to%20expand%20these%20services%20to%20other%20types%20of%20healthcare%20facilities.%22%2C%22date%22%3A%222023-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fijgo.14925%22%2C%22ISSN%22%3A%221879-3479%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-11-08T10%3A05%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22ERL2BAJB%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lesko%20et%20al.%22%2C%22parsedDate%22%3A%222023-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELesko%2C%20Catherine%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFalade-Nwulia%2C%20Oluwaseun%20O.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPytell%2C%20Jarratt%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHutton%2C%20Heidi%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFojo%2C%20Anthony%20T.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Joint%20effects%20of%20substance%20use%20disorders%20and%20recent%20substance%20use%20on%20HIV%20viral%20non-suppression%20among%20people%20engaged%20in%20HIV%20care%20in%20an%20urban%20clinic%2C%202014-2019.%20%3Ci%3EAddiction%20%28Abingdon%2C%20England%29%3C%5C%2Fi%3E%2C%20%3Ci%3E118%3C%5C%2Fi%3E%20%2811%29%2C%20S.%202193%26%23x2013%3B2202.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fadd.16301%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fadd.16301%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Joint%20effects%20of%20substance%20use%20disorders%20and%20recent%20substance%20use%20on%20HIV%20viral%20non-suppression%20among%20people%20engaged%20in%20HIV%20care%20in%20an%20urban%20clinic%2C%202014-2019%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20R.%22%2C%22lastName%22%3A%22Lesko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oluwaseun%20O.%22%2C%22lastName%22%3A%22Falade-Nwulia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jarratt%20D.%22%2C%22lastName%22%3A%22Pytell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heidi%20E.%22%2C%22lastName%22%3A%22Hutton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%20T.%22%2C%22lastName%22%3A%22Fojo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeanne%20C.%22%2C%22lastName%22%3A%22Keruly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geetanjali%22%2C%22lastName%22%3A%22Chander%22%7D%5D%2C%22abstractNote%22%3A%22AIMS%3A%20To%20estimate%20the%20joint%20effects%20of%20substance%20use%20disorder%20%28SUD%29%20and%20recent%20substance%20use%20on%20human%20immunodeficiency%20virus%20%28HIV%29%20non-suppression.%5CnDESIGN%3A%20Retrospective%20clinical%20cohort%20study%20with%20repeated%20observations%20within%20individuals.%5CnSETTING%3A%20Baltimore%2C%20Maryland%2C%20United%20States.%5CnPARTICIPANTS%3A%201881%20patients%20contributed%2010%5Cu2009794%20observations.%5CnMEASUREMENTS%3A%20The%20primary%20independent%20variable%20was%20the%20combination%20of%20history%20of%20SUD%20and%20recent%20substance%20use.%20History%20of%20SUD%20was%20defined%20as%20any%20prior%20International%20Classification%20of%20Diseases%209%5C%2F10%20code%20for%20cocaine%20or%20opioid%20disorder.%20Recent%20substance%20use%20was%20defined%20as%20the%20self-report%20of%20cocaine%20or%20non-prescribed%20opioid%20use%20on%20the%20National%20Institute%20of%20Drug%20Abuse-modified%20Alcohol%2C%20Smoking%20and%20Substance%20Involvement%20Screening%20Test%20or%20clinician-documented%20cocaine%20or%20opioid%20use%20abstracted%20from%20the%20medical%20record.%20The%20outcome%20was%20viral%20non-suppression%2C%20defined%20as%20HIV%20RNA%20%3E200%5Cu2009copies%5C%2FmL%20on%20the%20first%20viral%20load%20measurement%20within%201%5Cu00a0year%20subsequent%20to%20each%20observation%20of%20substance%20use.%20We%20adjusted%20for%20birth%20sex%2C%20Black%20race%2C%20age%2C%20HIV%20acquisition%20risk%20factors%2C%20years%20in%20care%20and%20CD4%20cell%20count.%20In%20secondary%20analyses%2C%20we%20also%20adjusted%20for%20depressive%2C%20anxiety%20and%20panic%20symptoms%2C%20cannabis%20use%20and%20cannabis%20use%20disorder.%5CnFINDINGS%3A%20On%20their%20first%20observation%2C%2031%25%20of%20patients%20had%20a%20history%20of%20an%20SUD%20and%2018%25%20had%20recent%20substance%20use.%20Relative%20to%20no%20history%20of%20SUD%20and%20no%20recent%20substance%20use%2C%20the%201-year%20fully%20adjusted%20risk%20difference%20%28RD%29%20for%20viral%20non-suppression%20associated%20with%20cocaine%20and%20opioid%20use%20disorder%20and%20recent%20substance%20use%20was%207.7%25%20%2895%25%20CI%20%3D%205.3%25-10.0%25%29%2C%20the%20RD%20was%205.5%25%20%2895%25%20CI%20%3D%201.2%25-9.7%25%29%20for%20history%20of%20cocaine%20use%20disorder%20without%20recent%20substance%20use%2C%20and%20the%20RD%20was%204.6%25%20%2895%25%20CI%20%3D%202.7%25-6.5%25%29%20for%20recent%20substance%20use%20without%20a%20SUD.%5CnCONCLUSIONS%3A%20Substance%20use%20and%20substance%20use%20disorders%20appear%20to%20be%20highly%20prevalent%20among%2C%20and%20independently%20associated%20with%2C%20viral%20non-suppression%20among%20people%20with%20HIV.%22%2C%22date%22%3A%222023-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fadd.16301%22%2C%22ISSN%22%3A%221360-0443%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-11-08T09%3A47%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22XLBPKKGG%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zotova%20et%20al.%22%2C%22parsedDate%22%3A%222023-10-23%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZotova%2C%20Natalia%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMunyaneza%2C%20Athanase%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMurenzi%2C%20Gad%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKubwimana%2C%20Gallican%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAdedimeji%2C%20Adebola%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Low%20birth%20weight%20among%20infants%20and%20pregnancy%20outcomes%20among%20women%20living%20with%20HIV%20and%20HIV-negative%20women%20in%20Rwanda.%20%3Ci%3EResearch%20Square%3C%5C%2Fi%3E%2C%20S.%20rs.3.rs-3467879.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21203%5C%2Frs.3.rs-3467879%5C%2Fv1%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21203%5C%2Frs.3.rs-3467879%5C%2Fv1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Low%20birth%20weight%20among%20infants%20and%20pregnancy%20outcomes%20among%20women%20living%20with%20HIV%20and%20HIV-negative%20women%20in%20Rwanda%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalia%22%2C%22lastName%22%3A%22Zotova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Athanase%22%2C%22lastName%22%3A%22Munyaneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gallican%22%2C%22lastName%22%3A%22Kubwimana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adebola%22%2C%22lastName%22%3A%22Adedimeji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ca-IeDEA%22%2C%22lastName%22%3A%22Ca-IeDEA%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20In%20utero%20exposure%20to%20HIV%20and%5C%2For%20triple%20antiretroviral%20therapy%20%28ART%29%20have%20been%20shown%20to%20be%20associated%20with%20preterm%20births%20and%20low%20birth%20weight%20%28LBW%29%2C%20but%20data%20from%20low-resources%20settings%20with%20high%20burden%20of%20HIV%20remain%20limited.%20This%20study%20utilized%20retrospective%20data%20to%20describe%20pregnancy%20outcomes%20among%20Rwandan%20women%20living%20with%20HIV%20%28WLHIV%29%20and%20HIV-negative%20women%20and%20to%20assess%20the%20association%20of%20HIV%20and%20ART%20with%20LBW.%5CnMETHODS%3A%20This%20study%20used%20data%20from%20a%20large%20cohort%20of%20WLHIV%20and%20HIV-negative%20women%20in%20Rwanda%20for%20a%20cross-sectional%20analysis.%20Retrospective%20data%20were%20collected%20from%20antenatal%20care%20%28ANC%29%2C%20delivery%2C%20and%20Prevention%20of%20Mother%20to%20Child%20Transmission%20%28PMTCT%29%20registries%20within%20the%20Central%20Africa%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28CA-IeDEA%29%20in%20Rwanda.%20Data%20from%20women%20with%20documented%20HIV%20test%20results%20and%20known%20pregnancy%20outcomes%20were%20included%20in%20the%20analysis.%20Analyses%20for%20predictors%20of%20LBW%20%28%3C%202%2C500%20g%29%20were%20restricted%20to%20singleton%20live%20births.%20Logistic%20models%20were%20used%20to%20identify%20independent%20predictors%20and%20estimate%20the%20odd%20ratios%20%28OR%29%20and%2095%25%20confidence%20intervals%20%28CI%29%20measuring%20the%20strength%20of%20their%20association%20with%20LBW.%5CnRESULTS%20AND%20DISCUSSION%3A%20Out%20of%2010%2C608%20women%20with%20known%20HIV%20status%20and%20with%20documented%20pregnancy%20outcomes%2C%209.7%25%20%28n%20%3D%201%2C024%29%20were%20WLHIV.%20We%20restricted%20the%20sample%20to%2010%2C483%20women%20who%20had%20singleton%20live%20births%20for%20the%20analysis%20of%20the%20primary%20outcome%2C%20LBW.%20Compared%20with%20HIV-negative%20women%2C%20WLHIV%20had%20higher%20rates%20of%20stillbirth%2C%20preterm%20births%2C%20and%20LBW%20babies.%20Multivariable%20model%20showed%20that%20WLHIV%20and%20primigravidae%20had%20higher%20odds%20of%20LBW.%20Lower%20maternal%20weight%20and%20primigravidae%20status%20were%20associated%20with%20greater%20odds%20of%20LBW.%20Among%20WLHIV%2C%20the%20use%20of%20ART%20was%20associated%20with%20significantly%20lower%20odds%20of%20LBW%20in%20a%20bivariate%20analysis.%20Even%20in%20a%20sample%20of%20relatively%20healthier%20uncomplicated%20pregnancies%20and%20women%20who%20delivered%20in%20low-risk%20settings%2C%20WLHIV%20still%20had%20higher%20rates%20of%20poor%20pregnancy%20outcomes%20and%20to%20have%20LBW%20infants%20compared%20to%20women%20without%20HIV.%20Lower%20maternal%20weight%20and%20primigravidae%20status%20were%20independently%20associated%20with%20LBW.%20Given%20that%20supplementary%20nutrition%20to%20malnourished%20pregnant%20women%20is%20known%20to%20decrease%20the%20incidence%20of%20LBW%2C%20providing%20such%20supplements%20to%20lower-weight%20WLHIV%2C%20especially%20primigravidae%20women%2C%20might%20help%20reduce%20LBW.%22%2C%22date%22%3A%222023-10-23%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.21203%5C%2Frs.3.rs-3467879%5C%2Fv1%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222023-12-01T10%3A44%3A16Z%22%7D%7D%2C%7B%22key%22%3A%228JN7GFW9%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Metekoua%20et%20al.%22%2C%22parsedDate%22%3A%222023-10-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMetekoua%2C%20Carole%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERuffieux%2C%20Yann%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOlago%2C%20Victor%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDhokotera%2C%20Tafadzwa%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEgger%2C%20Matthias%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Decreasing%20incidence%20of%20conjunctival%20squamous%20cell%20carcinoma%20in%20people%20with%20HIV%20in%20South%20Africa.%20%3Ci%3EJournal%20of%20the%20National%20Cancer%20Institute%3C%5C%2Fi%3E%2C%20%3Ci%3E115%3C%5C%2Fi%3E%20%2810%29%2C%20S.%201213%26%23x2013%3B1219.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjnci%5C%2Fdjad119%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjnci%5C%2Fdjad119%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Decreasing%20incidence%20of%20conjunctival%20squamous%20cell%20carcinoma%20in%20people%20with%20HIV%20in%20South%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%22%2C%22lastName%22%3A%22Metekoua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Ruffieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%22%2C%22lastName%22%3A%22Olago%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tafadzwa%22%2C%22lastName%22%3A%22Dhokotera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Bohlius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%22%2C%22lastName%22%3A%22Rohner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mazvita%22%2C%22lastName%22%3A%22Muchengeti%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20main%20risk%20factors%20for%20squamous%20cell%20carcinoma%20of%20the%20conjunctiva%20%28SCCC%29%20are%20immunodeficiency%20and%20exposure%20to%20ultraviolet%20radiation.%20Little%20is%20known%20about%20SCCC%20epidemiology%20among%20people%20with%20HIV%20%28PWH%29%20in%20South%20Africa.%5CnMETHODS%3A%20We%20used%20data%20from%20the%20South%20African%20HIV%20Cancer%20Match%20study%2C%20a%20nation-wide%20cohort%20of%20PWH%20in%20South%20Africa%2C%20created%20through%20a%20privacy-preserving%20probabilistic%20record%20linkage%20of%20HIV-related%20laboratory%20records%20from%20the%20National%20Health%20Laboratory%20Service%20and%20cancer%20records%20from%20the%20National%20Cancer%20Registry%20from%202004%20to%202014.%20We%20calculated%20crude%20incidence%20rates%2C%20analyzed%20trends%20using%20joinpoint%20models%2C%20and%20estimated%20hazard%20ratios%20for%20different%20risk%20factors%20using%20Royston-Parmar%20flexible%20parametric%20survival%20models.%5CnRESULTS%3A%20Among%205%5Cu200a247%5Cu200a968%20PWH%2C%201059%20cases%20of%20incident%20SCCC%20were%20diagnosed%2C%20for%20a%20crude%20overall%20SCCC%20incidence%20rate%20of%206.8%20per%20100%5Cu200a000%20person-years.%20The%20SCCC%20incidence%20rate%20decreased%20between%202004%20and%202014%2C%20with%20an%20annual%20percentage%20change%20of%20%5Cu201210.9%25%20%2895%25%20confidence%20interval%3A%20%5Cu201213.3%20to%20%5Cu20128.3%29.%20PWH%20residing%20within%20latitudes%2030%5Cu00b0S%20to%2034%5Cu00b0S%20had%20a%2049%25%20lower%20SCCC%20risk%20than%20those%20residing%20at%20less%20than%2025%5Cu00b0S%20latitude%20%28adjusted%20hazard%20ratio%5Cu2009%3D%5Cu20090.67%3B%2095%25%20confidence%20interval%3A%200.55%20to%200.82%29.%20Other%20risk%20factors%20for%20SCCC%20were%20lower%20CD4%20counts%20and%20middle%20age.%20There%20was%20no%20evidence%20for%20an%20association%20of%20sex%20or%20settlement%20type%20with%20SCCC%20risk.%5CnCONCLUSIONS%3A%20An%20increased%20risk%20of%20developing%20SCCC%20was%20associated%20with%20lower%20CD4%20counts%20and%20residence%20closer%20to%20the%20equator%2C%20indicative%20of%20higher%20ultraviolet%20radiation%20exposure.%20Clinicians%20and%20PWH%20should%20be%20educated%20on%20known%20SCCC%20preventive%20measures%2C%20such%20as%20maintaining%20high%20CD4%20counts%20and%20protection%20from%20ultraviolet%20radiation%20through%20sunglasses%20and%20sunhats%20when%20outdoors.%22%2C%22date%22%3A%222023-10-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fjnci%5C%2Fdjad119%22%2C%22ISSN%22%3A%221460-2105%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-11-08T10%3A00%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22CMUXNS8B%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rudolph%20et%20al.%22%2C%22parsedDate%22%3A%222023-10-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERudolph%2C%20Jacqueline%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECalkins%2C%20Keri%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EXu%2C%20Xiaoqiang%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWentz%2C%20Eryka%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPirsl%2C%20Filip%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Comparing%20cancer%20incidence%20in%20an%20observational%20cohort%20of%20Medicaid%20beneficiaries%20with%20and%20without%20HIV%2C%202001-2015.%20%3Ci%3EJournal%20of%20Acquired%20Immune%20Deficiency%20Syndromes%20%281999%29%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003318%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003318%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparing%20cancer%20incidence%20in%20an%20observational%20cohort%20of%20Medicaid%20beneficiaries%20with%20and%20without%20HIV%2C%202001-2015%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacqueline%20E.%22%2C%22lastName%22%3A%22Rudolph%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%22%2C%22lastName%22%3A%22Calkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaoqiang%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eryka%22%2C%22lastName%22%3A%22Wentz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Filip%22%2C%22lastName%22%3A%22Pirsl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kala%22%2C%22lastName%22%3A%22Visvanathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%22%2C%22lastName%22%3A%22Lau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Joshu%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Life%20expectancy%20among%20people%20with%20HIV%20%28PWH%29%20is%20increasing%2C%20making%20chronic%20conditions-including%20cancer-increasingly%20relevant.%20Among%20PWH%2C%20cancer%20burden%20has%20shifted%20from%20AIDS-defining%20cancers%20%28ADCs%29%20toward%20non-AIDS-defining%20cancers%20%28NADCs%29.%5CnSETTING%3A%20We%20described%20incidence%20of%20cancer%20in%20a%20claims-based%20cohort%20of%20Medicaid%20beneficiaries.%20We%20included%2043%2C426%2C043%20Medicaid%20beneficiaries%20%28180%2C058%20with%20HIV%29%20from%2014%20US%20states%2C%20aged%2018-64%2C%20with%20%3E6%20months%20of%20enrollment%20%28with%20no%20dual%20enrollment%20in%20another%20insurance%29%20and%20no%20evidence%20of%20a%20prior%20cancer.%5CnMETHODS%3A%20We%20estimated%20cumulative%20incidence%20of%20site-specific%20cancers%2C%20NADCs%2C%20and%20ADCs%20by%20baseline%20HIV%20status%2C%20using%20age%20as%20the%20time%20scale%20and%20accounting%20for%20death%20as%20a%20competing%20risk.%20We%20compared%20cumulative%20incidence%20across%20HIV%20status%20to%20estimate%20risk%20differences.%20We%20examined%20cancer%20incidence%20overall%20and%20by%20sex%2C%20race%5C%2Fethnicity%2C%20and%20calendar%20period.%5CnRESULTS%3A%20PWH%20had%20a%20higher%20incidence%20of%20ADCs%2C%20infection-related%20NADCs%2C%20and%20death.%20For%20NADCs%20like%20breast%2C%20prostate%2C%20and%20colon%20cancer%2C%20incidence%20was%20similar%20or%20higher%20among%20PWH%20below%20age%2050%20but%20higher%20among%20those%20without%20HIV%20by%20age%2065.%20Incidence%20of%20lung%20and%20head%20and%20neck%20cancer%20was%20always%20higher%20for%20female%20beneficiaries%20with%20HIV%2C%20while%20the%20curves%20crossed%20for%20male%20beneficiaries.%20We%20saw%20only%20small%20differences%20in%20incidence%20trends%20by%20race%5C%2Fethnicity.%5CnCONCLUSION%3A%20Our%20findings%20suggest%20an%20increased%20risk%20of%20certain%20NADCs%20at%20younger%20ages%20among%20PWH%2C%20even%20when%20compared%20against%20other%20Medicaid%20beneficiaries%2C%20and%20highlight%20the%20importance%20of%20monitoring%20PWH%20for%20ADCs%20and%20NADCs.%20Future%20work%20should%20explore%20possible%20mechanisms%20explaining%20the%20differences%20in%20incidence%20for%20specific%20cancer%20types.%22%2C%22date%22%3A%222023-10-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003318%22%2C%22ISSN%22%3A%221944-7884%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-11-08T09%3A48%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22Q3RQA5TS%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dantuluri%20et%20al.%22%2C%22parsedDate%22%3A%222023-10%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDantuluri%2C%20Meghana%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERubin%2C%20Leah%20H.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EManabe%2C%20Yukari%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMoore%2C%20Richard%20D.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAlthoff%2C%20Keri%20N.%3C%5C%2Fspan%3E%20%282023%29.%20Selection%20of%20cognitive%20impairment%20screening%20tools%20for%20longitudinal%20implementation%20in%20an%20HIV%20clinical%20care%20setting.%20%3Ci%3EAIDS%20Care%3C%5C%2Fi%3E%2C%20%3Ci%3E35%3C%5C%2Fi%3E%20%2810%29%2C%20S.%201619%26%23x2013%3B1627.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F09540121.2023.2165614%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F09540121.2023.2165614%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Selection%20of%20cognitive%20impairment%20screening%20tools%20for%20longitudinal%20implementation%20in%20an%20HIV%20clinical%20care%20setting%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meghana%20L.%22%2C%22lastName%22%3A%22Dantuluri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leah%20H.%22%2C%22lastName%22%3A%22Rubin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yukari%20C.%22%2C%22lastName%22%3A%22Manabe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%5D%2C%22abstractNote%22%3A%22To%20address%20and%20slow%20the%20increasing%20burden%20of%20cognitive%20impairment%20in%20people%20surviving%20to%20older%20ages%20with%20HIV%20requires%20longitudinal%20monitoring%20of%20cognition.%20We%20conducted%20a%20structured%20literature%20review%20to%20identify%20peer-reviewed%20studies%20employing%20validated%20cognitive%20impairment%20screening%20tools%20in%20adult%20populations%20of%20people%20with%20HIV.%20We%20identified%20three%20key%20criteria%20for%20selection%20and%20ranking%20of%20a%20tool%3A%20%28a%29%20strength%20of%20validity%20of%20the%20tool%3B%20%28b%29%20acceptability%20and%20feasibility%20of%20the%20tool%3B%20%28c%29%20ownership%20of%20the%20data%20from%20the%20assessment.%20From%20our%20structured%20review%20of%20105%2C%2029%20studies%20met%20our%20inclusion%20criteria%2C%20within%20which%2010%20cognitive%20impairment%20screening%20measurement%20tools%20were%20validated%20in%20a%20population%20of%20people%20with%20HIV.%20The%20BRACE%2C%20NeuroScreen%20and%20NCAD%20tools%20were%20ranked%20highly%20when%20compared%20with%20the%20other%20seven%20tools.%20Additionally%2C%20patient%20population%20and%20clinical%20setting%20characteristics%20%28such%20as%20availability%20of%20quiet%20space%2C%20timing%20of%20assessment%2C%20security%20of%20electronic%20resources%2C%20and%20ease%20of%20linkage%20to%20electronic%20health%20records%29%20were%20included%20in%20our%20framework%20for%20selection%20of%20tools.%20Numerous%20validated%20cognitive%20impairment%20screening%20tools%20are%20available%20to%20monitor%20for%20cognitive%20changes%20in%20the%20HIV%20clinical%20care%20setting%2C%20detecting%20opportunities%20for%20earlier%20intervention%20to%20reduce%20cognitive%20decline%20and%20preserve%20quality%20of%20life.%22%2C%22date%22%3A%222023-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1080%5C%2F09540121.2023.2165614%22%2C%22ISSN%22%3A%221360-0451%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-11-08T10%3A05%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22XACIV894%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Eden%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-27%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEden%2C%20Svetlana%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELi%2C%20Chun%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShepherd%2C%20Bryan%20E.%3C%5C%2Fspan%3E%20%282023%29.%20Spearman-like%20correlation%20measure%20adjusting%20for%20covariates%20in%20bivariate%20survival%20data.%20%3Ci%3EBiometrical%20Journal.%20Biometrische%20Zeitschrift%3C%5C%2Fi%3E%2C%20S.%20e2200137.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fbimj.202200137%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fbimj.202200137%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Spearman-like%20correlation%20measure%20adjusting%20for%20covariates%20in%20bivariate%20survival%20data%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Svetlana%20K.%22%2C%22lastName%22%3A%22Eden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chun%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%5D%2C%22abstractNote%22%3A%22We%20propose%20an%20extension%20of%20Spearman%27s%20correlation%20for%20censored%20continuous%20and%20discrete%20data%20that%20permits%20covariate%20adjustment.%20Previously%20proposed%20nonparametric%20and%20semiparametric%20Spearman%27s%20correlation%20estimators%20require%20either%20nonparametric%20estimation%20of%20the%20bivariate%20survival%20surface%20or%20parametric%20assumptions%20about%20the%20dependence%20structure.%20In%20practice%2C%20nonparametric%20estimation%20of%20the%20bivariate%20survival%20surface%20is%20difficult%2C%20and%20parametric%20assumptions%20about%20the%20correlation%20structure%20may%20not%20be%20satisfied.%20Therefore%2C%20we%20propose%20a%20method%20that%20requires%20neither%20and%20uses%20only%20the%20marginal%20survival%20distributions.%20Our%20method%20estimates%20the%20correlation%20of%20probability-scale%20residuals%2C%20which%20has%20been%20shown%20to%20equal%20Spearman%27s%20correlation%20when%20there%20is%20no%20censoring.%20Because%20this%20method%20relies%20only%20on%20marginal%20distributions%2C%20it%20tends%20to%20be%20less%20variable%20than%20the%20previously%20suggested%20nonparametric%20estimators%2C%20and%20the%20confidence%20intervals%20are%20easily%20constructed.%20Although%20under%20censoring%2C%20it%20is%20biased%20for%20Spearman%27s%20correlation%20as%20our%20simulations%20show%2C%20it%20performs%20well%20under%20moderate%20censoring%2C%20with%20a%20smaller%20mean%20squared%20error%20than%20nonparametric%20approaches.%20We%20also%20extend%20it%20to%20partial%20%28adjusted%29%2C%20conditional%2C%20and%20partial-conditional%20correlation%2C%20which%20makes%20it%20particularly%20relevant%20for%20practical%20applications.%20We%20apply%20our%20method%20to%20estimate%20the%20correlation%20between%20time%20to%20viral%20failure%20and%20time%20to%20regimen%20change%20in%20a%20multisite%20cohort%20of%20persons%20living%20with%20HIV%20in%20Latin%5Cu00a0America.%22%2C%22date%22%3A%222023-09-27%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fbimj.202200137%22%2C%22ISSN%22%3A%221521-4036%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-10-10T11%3A47%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22JZH89YZU%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kasaie%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKasaie%2C%20Parastu%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStewart%2C%20Cameron%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHumes%2C%20Elizabeth%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGerace%2C%20Lucas%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHyle%2C%20Emily%20P.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Impact%20of%20subgroup-specific%20heterogeneities%20and%20dynamic%20changes%20in%20mortality%20rates%20on%20forecasted%20population%20size%2C%20deaths%2C%20and%20age%20distribution%20of%20persons%20receiving%20antiretroviral%20treatment%20in%20the%20United%20States%3A%20a%20computer%20simulation%20study.%20%3Ci%3EAnnals%20of%20Epidemiology%3C%5C%2Fi%3E%2C%20S.%20S1047-%202797%2823%2900171-%200.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annepidem.2023.09.005%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annepidem.2023.09.005%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20subgroup-specific%20heterogeneities%20and%20dynamic%20changes%20in%20mortality%20rates%20on%20forecasted%20population%20size%2C%20deaths%2C%20and%20age%20distribution%20of%20persons%20receiving%20antiretroviral%20treatment%20in%20the%20United%20States%3A%20a%20computer%20simulation%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Parastu%22%2C%22lastName%22%3A%22Kasaie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cameron%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Humes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucas%22%2C%22lastName%22%3A%22Gerace%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emily%20P.%22%2C%22lastName%22%3A%22Hyle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20C.%22%2C%22lastName%22%3A%22Zalla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20A.%22%2C%22lastName%22%3A%22Rubtsova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashleigh%20J.%22%2C%22lastName%22%3A%22Rich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%22%2C%22lastName%22%3A%22Gebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20R.%22%2C%22lastName%22%3A%22Lesko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%20T.%22%2C%22lastName%22%3A%22Fojo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raynell%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessie%20K.%22%2C%22lastName%22%3A%22Edwards%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Model-based%20forecasts%20of%20population%20size%2C%20deaths%2C%20and%20age%20distribution%20of%20people%20with%20HIV%20%28PWH%29%20are%20helpful%20for%20public%20health%20and%20clinical%20services%20planning%20but%20are%20influenced%20by%20subgroup-specific%20heterogeneities%20and%20changes%20in%20mortality%20rates.%5CnMETHODS%3A%20Using%20an%20agent-based%20simulation%20of%20PWH%20in%20the%20United%20States%2C%20we%20examined%20the%20impact%20of%20distinct%20approaches%20to%20parametrizing%20mortality%20rates%20on%20forecasted%20epidemiology%20of%20PWH%20on%20antiretroviral%20treatment%20%28ART%29.%20We%20first%20estimated%20mortality%20rates%20among%20%281%29%20all%20PWH%2C%20%282%29%20sex-specific%2C%20%283%29%20sex-and-race%5C%2Fethnicity-specific%2C%20and%20%284%29%20sex-race%5C%2Fethnicity-and-HIV-acquisition-risk-specific%20subgroups.%20We%20then%20assessed%20each%20scenario%20by%20%281%29%20allowing%20unrestricted%20reductions%20in%20age-specific%20mortality%20rates%20over%20time%20and%20%282%29%20restricting%20the%20mortality%20rates%20among%20PWH%20to%20subgroup-specific%20mortality%20thresholds%20from%20the%20general%20population.%5CnRESULTS%3A%20Among%20the%20eight%20scenarios%20examined%2C%20those%20lacking%20subgroup-specific%20heterogeneities%20and%20those%20allowing%20unrestricted%20reductions%20in%20future%20mortality%20rates%20forecasted%20the%20lowest%20number%20of%20deaths%20among%20all%20PWH%20and%209%20of%20the%2015%20subgroups%20through%202030.%20The%20forecasted%20overall%20number%20and%20age%20distribution%20of%20people%20with%20a%20history%20of%20injection%20drug%20use%20were%20sensitive%20to%20inclusion%20of%20subgroup-specific%20mortality%20rates.%5CnCONCLUSIONS%3A%20Our%20results%20underscore%20the%20potential%20risk%20of%20underestimating%20future%20deaths%20by%20models%20lacking%20subgroup-specific%20heterogeneities%20in%20mortality%20rates%2C%20and%20those%20allowing%20unrestricted%20reductions%20in%20future%20mortality%20rates.%22%2C%22date%22%3A%222023-09-22%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annepidem.2023.09.005%22%2C%22ISSN%22%3A%221873-2585%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%5D%2C%22dateModified%22%3A%222023-11-08T09%3A53%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22I4UVBT6Y%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ingabire%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EIngabire%2C%20Charles%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWatnick%2C%20Dana%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGasana%2C%20Josephine%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EUmwiza%2C%20Francine%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMunyaneza%2C%20Athanase%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Experiences%20of%20stigma%20and%20HIV%20care%20engagement%20in%20the%20context%20of%20Treat%20All%20in%20Rwanda%3A%20a%20qualitative%20study.%20%3Ci%3EBMC%20Public%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E23%3C%5C%2Fi%3E%20%281%29%2C%20S.%201817.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-023-16752-y%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-023-16752-y%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Experiences%20of%20stigma%20and%20HIV%20care%20engagement%20in%20the%20context%20of%20Treat%20All%20in%20Rwanda%3A%20a%20qualitative%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Ingabire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dana%22%2C%22lastName%22%3A%22Watnick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josephine%22%2C%22lastName%22%3A%22Gasana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francine%22%2C%22lastName%22%3A%22Umwiza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Athanase%22%2C%22lastName%22%3A%22Munyaneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gallican%22%2C%22lastName%22%3A%22Kubwimana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adebola%22%2C%22lastName%22%3A%22Adedimeji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ross%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20%27Treat%20All%27%20policies%20recommending%20immediate%20antiretroviral%20therapy%20%28ART%29%20soon%20after%20HIV%20diagnosis%20for%20all%20people%20living%20with%20HIV%20%28PLHIV%29%20are%20now%20ubiquitous%20in%20sub-Saharan%20Africa.%20While%20early%20ART%20initiation%20and%20retention%20is%20effective%20at%20curtailing%20disease%20progression%20and%20transmission%2C%20evidence%20suggests%20that%20stigma%20may%20act%20as%20a%20barrier%20to%20engagement%20in%20care.%20This%20study%20sought%20to%20understand%20the%20relationships%20between%20HIV%20stigma%20and%20engagement%20in%20care%20for%20PLHIV%20in%20Rwanda%20in%20the%20context%20of%20Treat%20All.%5CnMETHODS%3A%20Between%20September%202018%20and%20March%202019%2C%20we%20conducted%20semi-structured%2C%20qualitative%20interviews%20with%20adult%20PLHIV%20receiving%20care%20at%20two%20health%20centers%20in%20Kigali%2C%20Rwanda.%20We%20used%20a%20grounded%20theory%20approach%20to%20data%20analysis%20to%20develop%20conceptual%20framework%20describing%20how%20stigma%20influences%20HIV%20care%20engagement%20in%20the%20context%20of%20early%20Treat%20All%20policy%20implementation%20in%20Rwanda.%5CnRESULTS%3A%20Among%2037%20participants%2C%2027%20%2873%25%29%20were%20women%20and%20the%20median%20age%20was%2031%5Cu00a0years.%20Participants%20described%20how%20care%20engagement%20under%20Treat%20All%2C%20including%20taking%20medications%20and%20attending%20appointments%2C%20increased%20their%20visibility%20as%20PLHIV.%20This%20served%20to%20normalize%20HIV%20and%20use%20of%20ART%20but%20also%20led%20to%20high%20levels%20of%20anticipated%20stigma%20in%20the%20health%20center%20and%20community%20at%20early%20stages%20of%20treatment.%20Enacted%20stigma%20from%20family%20and%20community%20members%20and%20resultant%20internalized%20stigma%20acted%20as%20additional%20barriers%20to%20care%20engagement.%20Nonetheless%2C%20participants%20described%20how%20psychosocial%20support%20from%20care%20providers%20and%20family%20members%20helped%20them%20cope%20with%20stigma%20and%20promoted%20continued%20engagement%20in%20care.%5CnCONCLUSIONS%3A%20Treat%20All%20policy%20in%20Rwanda%20has%20heightened%20the%20visibility%20of%20HIV%20at%20the%20individual%20and%20social%20levels%2C%20which%20has%20influenced%20HIV%20stigma%2C%20normalization%2C%20psychosocial%20support%20and%20care%20engagement%20in%20complex%20ways.%20Leveraging%20the%20individual%20and%20community%20support%20described%20by%20PLHIV%20to%20deliver%20evidence-based%2C%20peer%20or%20provider-delivered%20stigma%20reduction%20interventions%20may%20aid%20in%20attaining%20Treat%20All%20goals.%22%2C%22date%22%3A%222023-09-19%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12889-023-16752-y%22%2C%22ISSN%22%3A%221471-2458%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222024-01-12T13%3A25%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22L9URNVGG%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Slogrove%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-15%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESlogrove%2C%20Amy%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBovu%2C%20Andisiwe%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3Ede%20Beer%2C%20Shani%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPhelanyane%2C%20Florence%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWilliams%2C%20Paige%20L.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Maternal%20and%20birth%20outcomes%20in%20pregnant%20people%20with%20and%20without%20HIV%20in%20the%20Western%20Cape%2C%20South%20Africa%3A%20population-based%20cohort%20study.%20%3Ci%3EAIDS%20%28London%2C%20England%29%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003728%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003728%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Maternal%20and%20birth%20outcomes%20in%20pregnant%20people%20with%20and%20without%20HIV%20in%20the%20Western%20Cape%2C%20South%20Africa%3A%20population-based%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20L.%22%2C%22lastName%22%3A%22Slogrove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andisiwe%22%2C%22lastName%22%3A%22Bovu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shani%22%2C%22lastName%22%3A%22de%20Beer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Phelanyane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paige%20L.%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexa%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Kalk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ushma%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerhard%22%2C%22lastName%22%3A%22Theron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elaine%20J.%22%2C%22lastName%22%3A%22Abrams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20F.%22%2C%22lastName%22%3A%22Cotton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Landon%22%2C%22lastName%22%3A%22Myer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Boulle%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20We%20evaluated%20associations%20of%20HIV%20and%20antiretroviral%20therapy%20%28ART%29%20with%20birth%20and%20maternal%20outcomes%20at%20a%20province-wide-level%20in%20the%20Western%20Cape%2C%20South%20Africa%2C%20in%20a%20recent%20cohort%20before%20dolutegravir-based%20first-line%20ART%20implementation.%5CnMETHODS%3A%20This%20retrospective%20cohort%20study%20included%20pregnant%20people%20delivering%20in%202018-2019%20with%20data%20in%20the%20Western%20Cape%20Provincial%20Health%20Data%20Centre%20which%20integrates%20individual-level%20data%20on%20all%20public%20sector%20patients%20from%20multiple%20electronic%20platforms%20using%20unique%20identifiers.%20Adverse%20birth%20outcomes%20%28stillbirth%2C%20low%20birth%20weight%20%28LBW%29%2C%20very%20LBW%20%28VLBW%29%29%20and%20maternal%20outcomes%20%28early%20and%20late%20pregnancy-related%20deaths%2C%20early%20and%20late%20hospitalizations%29%20were%20compared%20by%20HIV%5C%2FART%20status%20and%20adjusted%20prevalence%20ratios%20%28aPRs%29%20calculated%20using%20log-binomial%20regression.%5CnRESULTS%3A%20Overall%20171%2C960%20pregnant%20people%20and%20their%20singleton%20newborns%20were%20included%2C%2019%25%20%28N%5Cu200a%3D%5Cu200a32%2C015%29%20identified%20with%20HIV.%20Amongst%20pregnant%20people%20with%20HIV%20%28PPHIV%29%2C%2060%25%20%28N%5Cu200a%3D%5Cu200a19%2C157%29%20were%20on%20ART%20preconception%2C%2029%25%20%28N%5Cu200a%3D%5Cu200a9%2C276%29%20initiated%20ART%20during%20pregnancy%20and%2011%25%20%28N%5Cu200a%3D%5Cu200a3%2C582%29%20had%20no%20ART.%20Adjusted%20for%20maternal%20age%2C%20multiparity%2C%20hypertensive%20disorders%20and%20residential%20district%2C%20stillbirths%20were%20higher%20only%20for%20PPHIV%20not%20on%20ART%20%28aPR%201.31%20%5B95%25CI%201.04-1.66%5D%29%20compared%20to%20those%20without%20HIV.%20However%2C%20LBW%20and%20VLBW%20were%20higher%20among%20all%20PPHIV%2C%20with%20aPRs%20of%201.11-1.22%20for%20LBW%20and%201.14-1.54%20for%20VLBW.%20Pregnancy-initiated%20ART%20was%20associated%20with%20early%20pregnancy-related%20death%20%28aPR%203.21%3B%2095%25CI%201.55-6.65%29%2C%20and%20HIV%20with%20or%20without%20ART%20was%20associated%20with%20late%20pregnancy-related%20death%20%28aPRs%207.89-9.01%29.%5CnCONCLUSIONS%3A%20Even%20in%20the%20universal%20ART%20era%2C%20PPHIV%20experienced%20higher%20rates%20of%20LBW%20and%20VLBW%20newborns%2C%20and%20higher%20late%20pregnancy-related%20death%20regardless%20of%20ART%20status%20than%20pregnant%20people%20without%20HIV.%22%2C%22date%22%3A%222023-09-15%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003728%22%2C%22ISSN%22%3A%221473-5571%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-10-10T12%3A03%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22J88A92VI%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hansford%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHansford%2C%20Harrison%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECashin%2C%20Aidan%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJones%2C%20Matthew%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESwanson%2C%20Sonja%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EIslam%2C%20Nazrul%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Development%20of%20the%20TrAnsparent%20ReportinG%20of%20observational%20studies%20Emulating%20a%20Target%20trial%20%28TARGET%29%20guideline.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E13%3C%5C%2Fi%3E%20%289%29%2C%20S.%20e074626.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2023-074626%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2023-074626%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Development%20of%20the%20TrAnsparent%20ReportinG%20of%20observational%20studies%20Emulating%20a%20Target%20trial%20%28TARGET%29%20guideline%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harrison%20J.%22%2C%22lastName%22%3A%22Hansford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aidan%20G.%22%2C%22lastName%22%3A%22Cashin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20D.%22%2C%22lastName%22%3A%22Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonja%20A.%22%2C%22lastName%22%3A%22Swanson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nazrul%22%2C%22lastName%22%3A%22Islam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Issa%20J.%22%2C%22lastName%22%3A%22Dahabreh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbra%20A.%22%2C%22lastName%22%3A%22Dickerman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Garcia-Albeniz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20M.%22%2C%22lastName%22%3A%22Golub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Lodi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margarita%22%2C%22lastName%22%3A%22Moreno-Betancur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sallie-Anne%22%2C%22lastName%22%3A%22Pearson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastian%22%2C%22lastName%22%3A%22Schneeweiss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Sterne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melissa%20K.%22%2C%22lastName%22%3A%22Sharp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20A.%22%2C%22lastName%22%3A%22Stuart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%20A.%22%2C%22lastName%22%3A%22Hernan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hopin%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20H.%22%2C%22lastName%22%3A%22McAuley%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Observational%20studies%20are%20increasingly%20used%20to%20inform%20health%20decision-making%20when%20randomised%20trials%20are%20not%20feasible%2C%20ethical%20or%20timely.%20The%20target%20trial%20approach%20provides%20a%20framework%20to%20help%20minimise%20common%20biases%20in%20observational%20studies%20that%20aim%20to%20estimate%20the%20causal%20effect%20of%20interventions.%20Incomplete%20reporting%20of%20studies%20using%20the%20target%20trial%20framework%20limits%20the%20ability%20for%20clinicians%2C%20researchers%2C%20patients%20and%20other%20decision-makers%20to%20appraise%2C%20synthesise%20and%20interpret%20findings%20to%20inform%20clinical%20and%20public%20health%20practice%20and%20policy.%20This%20paper%20describes%20the%20methods%20that%20we%20will%20use%20to%20develop%20the%20TrAnsparent%20ReportinG%20of%20observational%20studies%20Emulating%20a%20Target%20trial%20%28TARGET%29%20reporting%20guideline.%5CnMETHODS%5C%2FDESIGN%3A%20The%20TARGET%20reporting%20guideline%20will%20be%20developed%20in%20five%20stages%20following%20recommended%20guidance.%20The%20first%20stage%20will%20identify%20target%20trial%20reporting%20practices%20by%20systematically%20reviewing%20published%20studies%20that%20explicitly%20emulated%20a%20target%20trial.%20The%20second%20stage%20will%20identify%20and%20refine%20items%20to%20be%20considered%20for%20inclusion%20in%20the%20TARGET%20guideline%20by%20consulting%20content%20experts%20using%20sequential%20online%20surveys.%20The%20third%20stage%20will%20prioritise%20and%20consolidate%20key%20items%20to%20be%20included%20in%20the%20TARGET%20guideline%20at%20an%20in-person%20consensus%20meeting%20of%20TARGET%20investigators.%20The%20fourth%20stage%20will%20produce%20and%20pilot-test%20both%20the%20TARGET%20guideline%20and%20explanation%20and%20elaboration%20document%20with%20relevant%20stakeholders.%20The%20fifth%20stage%20will%20disseminate%20the%20TARGET%20guideline%20and%20resources%20via%20journals%2C%20conferences%20and%20courses.%5CnETHICS%20AND%20DISSEMINATION%3A%20Ethical%20approval%20for%20the%20survey%20has%20been%20attained%20%28HC220536%29.%20The%20TARGET%20guideline%20will%20be%20disseminated%20widely%20in%20partnership%20with%20stakeholders%20to%20maximise%20adoption%20and%20improve%20reporting%20of%20these%20studies.%22%2C%22date%22%3A%222023-09-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2023-074626%22%2C%22ISSN%22%3A%222044-6055%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222024-03-18T11%3A17%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22LVFW4N2K%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Davy-Mendez%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-12%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavy-Mendez%2C%20Thibaut%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENapravnik%2C%20Sonia%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHogan%2C%20Brenna%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEron%2C%20Joseph%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGebo%2C%20Kelly%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Hospital%20Readmissions%20among%20Persons%20with%20HIV%20in%20the%20United%20States%20and%20Canada%2C%202005-2018%3A%20A%20Collaboration%20of%20Cohort%20Studies.%20%3Ci%3EThe%20Journal%20of%20Infectious%20Diseases%3C%5C%2Fi%3E%2C%20S.%20jiad396.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiad396%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiad396%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hospital%20Readmissions%20among%20Persons%20with%20HIV%20in%20the%20United%20States%20and%20Canada%2C%202005-2018%3A%20A%20Collaboration%20of%20Cohort%20Studies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaut%22%2C%22lastName%22%3A%22Davy-Mendez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonia%22%2C%22lastName%22%3A%22Napravnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenna%20C.%22%2C%22lastName%22%3A%22Hogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20J.%22%2C%22lastName%22%3A%22Eron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%20A.%22%2C%22lastName%22%3A%22Gebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20John%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maile%20Y.%22%2C%22lastName%22%3A%22Karris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20B.%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mari%20M.%22%2C%22lastName%22%3A%22Kitahata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heidi%20M.%22%2C%22lastName%22%3A%22Crane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ank%22%2C%22lastName%22%3A%22Nijhawan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathleen%20A.%22%2C%22lastName%22%3A%22McGinnis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20E.%22%2C%22lastName%22%3A%22Thorne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Viviane%20D.%22%2C%22lastName%22%3A%22Lima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20J.%22%2C%22lastName%22%3A%22Bosch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20A.%22%2C%22lastName%22%3A%22Colasanti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20S.%22%2C%22lastName%22%3A%22Rabkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raynell%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20A.%22%2C%22lastName%22%3A%22Berry%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Hospital%20readmission%20trends%20for%20persons%20with%20HIV%20%28PWH%29%20in%20North%20America%20in%20the%20context%20of%20policy%20changes%2C%20improved%20antiretroviral%20therapy%20%28ART%29%2C%20and%20aging%20are%20not%20well-known.%20We%20examined%20readmissions%202005-2018%20among%20adult%20PWH%20in%20NA-ACCORD.%5CnMETHODS%3A%20Linear%20risk%20regression%20estimated%20calendar%20trends%20in%2030-day%20readmissions%2C%20adjusted%20for%20demographics%2C%20CD4%20count%2C%20AIDS%20history%2C%20virologic%20suppression%20%28%3C400%20copies%5C%2FmL%29%2C%20and%20cohort.%5CnRESULTS%3A%20We%20examined%2020%2C189%20hospitalizations%20among%208%2C823%20PWH%20%2873%25%20cis-men%2C%2038%25%20White%2C%2038%25%20Black%29.%20PWH%20hospitalized%20in%202018%20vs.%202005%20had%20higher%20median%20age%20%2854%20vs.%2044%20years%29%2C%20CD4%20count%20%28469%20vs.%20274%20cells%5C%2F%5Cu03bcL%29%20and%20virologic%20suppression%20%2883%25%20vs.%2049%25%29.%20Unadjusted%2030-day%20readmissions%20decreased%20from%2020.1%25%20%2895%25%20CI%2017.9%25-22.3%25%29%20in%202005%20to%2016.3%25%20%2814.1%25-18.5%25%29%20in%202018.%20Absolute%20annual%20trends%20were%20-0.34%25%20%28-0.48%25%2C%20-0.19%25%29%20in%20unadjusted%20and%20-0.19%25%20%28-0.35%25%2C%20-0.02%25%29%20in%20adjusted%20analyses.%20By%20index%20hospitalization%20reason%2C%20there%20were%20significant%20adjusted%20decreases%20only%20for%20cardiovascular%20and%20psychiatric%20hospitalizations.%20Readmission%20reason%20was%20most%20frequently%20in%20the%20same%20diagnostic%20category%20as%20the%20index%20hospitalization.%5CnCONCLUSIONS%3A%20Readmissions%20decreased%20over%202005-2018%20but%20remained%20higher%20than%20the%20general%20population%27s.%20Significant%20decreases%20after%20adjusting%20for%20CD4%20count%20and%20virologic%20suppression%20suggest%20factors%20alongside%20improved%20ART%20contributed%20to%20lower%20readmissions.%20Efforts%20are%20needed%20to%20further%20prevent%20readmissions%20in%20PWH.%22%2C%22date%22%3A%222023-09-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Finfdis%5C%2Fjiad396%22%2C%22ISSN%22%3A%221537-6613%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-10-10T11%3A57%3A30Z%22%7D%7D%2C%7B%22key%22%3A%2297TK8ITG%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Olago%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-11%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOlago%2C%20Victor%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENimako%2C%20Gideon%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBartels%2C%20Lina%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBohlius%2C%20Julia%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDhokotera%2C%20Tafadzwa%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Cancer%20diagnostic%20service%20use%20in%20people%20with%20HIV%20in%20South%20Africa%3A%20a%20cross-sectional%20study.%20%3Ci%3EMedRxiv%3A%20The%20Preprint%20Server%20for%20Health%20Sciences%3C%5C%2Fi%3E%2C%20S.%202023.09.10.23295338.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2023.09.10.23295338%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2023.09.10.23295338%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cancer%20diagnostic%20service%20use%20in%20people%20with%20HIV%20in%20South%20Africa%3A%20a%20cross-sectional%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%22%2C%22lastName%22%3A%22Olago%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gideon%22%2C%22lastName%22%3A%22Nimako%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lina%22%2C%22lastName%22%3A%22Bartels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Bohlius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tafadzwa%22%2C%22lastName%22%3A%22Dhokotera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elvira%22%2C%22lastName%22%3A%22Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mazvita%22%2C%22lastName%22%3A%22Sengayi-Muchengeti%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20The%20objective%20of%20this%20study%20was%20to%20map%20place%20of%20cancer%20diagnosis%20in%20relation%20to%20Human%20Immunodeficiency%20Virus%20%28HIV%29%20care%20centre%20among%20people%20with%20HIV%20%28PWH%29%20within%20South%20Africa%20%28SA%29%20using%20national%20laboratory%20database.%5CnDESIGN%3A%20We%20linked%20HIV%20and%20cancer%20laboratory%20data%20from%202004-2014%20using%20supervised%20machine-learning%20algorithms.%20We%20performed%20a%20cross-sectional%20analysis%20comparing%20province%20where%20individuals%20accessed%20their%20HIV%20care%20versus%20where%20they%20had%20their%20cancer%20diagnosis.%5CnSETTING%3A%20We%20used%20laboratory%20test%20records%20related%20to%20HIV%20diagnostics%20and%20care%2C%20such%20as%20CD4%20cell%20counts%20and%20percentages%2C%20rapid%20tests%2C%20qualitative%20Polymerase%20Chain%20Reaction%20%28PCR%29%2C%20antibody%20and%20antigen%20tests%20for%20HIV%20data%20that%20was%20documented%20as%20HIV%20positive%20and%20laboratory%20diagnosed%20cancer%20records%20from%20SA.%5CnSTUDY%20POPULATION%3A%20Our%20study%20population%20consisted%20of%20HIV%20records%20from%20the%20National%20Health%20Laboratory%20Service%20%28NHLS%29%20that%20linked%20to%20cancer%20record%20at%20the%20National%20Cancer%20Registry%20%28NCR%29%20between%202004-2014.%5CnPRIMARY%20AND%20SECONDARY%20OUTCOMES%3A%20We%20linked%20HIV%20records%20from%20NHLS%20to%20cancer%20records%20at%20NCR%20in%20order%20to%20study%20the%20inherent%20characteristics%20of%20the%20population%20with%20both%20HIV%20and%20cancer.%5CnRESULTS%3A%20The%20study%20population%20was%2068%2C284%20individuals%20with%20cancer%20and%20documented%20HIV%20related%20laboratory%20test.%20The%20median%20age%20at%20cancer%20diagnosis%20was%2040%20%5BIQR%2C%2033-48%5D%20years%20for%20the%20study%20population%20with%20most%20cancers%20in%20PWH%20diagnosed%20in%20females%2070.9%25%20%5Bn%3D46%2C313%5D.%20Of%20all%20the%20PWH%20and%20cancer%2C%2025%25%20%28n%3D16%2C364%20p%20%3C%200.001%29%20sought%20treatment%20outside%20their%20province%20of%20residence%20with%2060.7%25%20%28n%3D10%2C235%29%20travelling%20to%20Gauteng.%20KZN%20had%2046.6%25%20%28n%3D4%2C107%29%20of%20its%20PWH%20getting%20cancer%20diagnosis%20in%20Gauteng.%20Western%20Cape%20had%2095%25%20%28n%3D6%2C200%29%20of%20PWH%20getting%20cancer%20diagnosis%20within%20the%20province.%5CnCONCLUSIONS%3A%20Our%20results%20showed%20health%20systems%20inequalities%20across%20provinces%20in%20South%20Africa%20with%20respect%20to%20cancer%20diagnosis.%20KZN%20for%20example%20had%20nearly%20half%20of%20the%20PWH%20getting%20cancer%20diagnosis%20outside%20the%20province%20while%20Western%20Cape%20is%20able%20to%20offer%20cancer%20diagnostic%20services%20to%20most%20of%20the%20PWH%20in%20the%20province.%20Gauteng%20is%20getting%20over%20burdened%20with%20referral%20for%20cancer%20diagnosis%20from%20other%20provinces.%20More%20effort%20is%20required%20to%20ensure%20equitable%20access%20to%20cancer%20diagnostic%20services%20within%20the%20country.%5CnARTICLE%20SUMMARY%3A%20Strengths%20and%20limitations%20of%20this%20study%3A%20We%20mapped%20the%20facilities%20of%20cancer%20diagnosis%20versus%20HIV%20care%20facilities%20for%20the%20PWH%20seeking%20cancer%20diagnosis%20in%20South%20Africa.We%20compared%20PWH%20who%20sought%20treatment%20in%20their%20province%20of%20residence%20versus%20those%20who%20sought%20treatment%20outside%20their%20province%20of%20residence.We%20used%20HIV%20care%20facility%27s%20addresses%20as%20a%20proxy%20for%20place%20of%20residence%20for%20PWH.We%20did%20not%20account%20for%20movement%20due%20to%20other%20reasons%20such%20as%20migration%20for%20better%20jobs%20and%20education.%22%2C%22date%22%3A%222023-09-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2023.09.10.23295338%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-10-10T12%3A04%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22DB4S28JM%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fuller%20et%20al.%22%2C%22parsedDate%22%3A%222023-09%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFuller%2C%20Gordon%20Ward%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHasan%2C%20Madina%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHodkinson%2C%20Peter%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMcAlpine%2C%20David%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGoodacre%2C%20Steve%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Training%20and%20testing%20of%20a%20gradient%20boosted%20machine%20learning%20model%20to%20predict%20adverse%20outcome%20in%20patients%20presenting%20to%20emergency%20departments%20with%20suspected%20covid-19%20infection%20in%20a%20middle-income%20setting.%20%3Ci%3EPLOS%20Digital%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E2%3C%5C%2Fi%3E%20%289%29%2C%20S.%20e0000309.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pdig.0000309%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pdig.0000309%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Training%20and%20testing%20of%20a%20gradient%20boosted%20machine%20learning%20model%20to%20predict%20adverse%20outcome%20in%20patients%20presenting%20to%20emergency%20departments%20with%20suspected%20covid-19%20infection%20in%20a%20middle-income%20setting%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gordon%20Ward%22%2C%22lastName%22%3A%22Fuller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Madina%22%2C%22lastName%22%3A%22Hasan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Hodkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22McAlpine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steve%22%2C%22lastName%22%3A%22Goodacre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20A.%22%2C%22lastName%22%3A%22Bath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Sbaffi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yasein%22%2C%22lastName%22%3A%22Omer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lee%22%2C%22lastName%22%3A%22Wallis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carl%22%2C%22lastName%22%3A%22Marincowitz%22%7D%5D%2C%22abstractNote%22%3A%22COVID-19%20infection%20rates%20remain%20high%20in%20South%20Africa.%20Clinical%20prediction%20models%20may%20be%20helpful%20for%20rapid%20triage%2C%20and%20supporting%20clinical%20decision%20making%2C%20for%20patients%20with%20suspected%20COVID-19%20infection.%20The%20Western%20Cape%2C%20South%20Africa%2C%20has%20integrated%20electronic%20health%20care%20data%20facilitating%20large-scale%20linked%20routine%20datasets.%20The%20aim%20of%20this%20study%20was%20to%20develop%20a%20machine%20learning%20model%20to%20predict%20adverse%20outcome%20in%20patients%20presenting%20with%20suspected%20COVID-19%20suitable%20for%20use%20in%20a%20middle-income%20setting.%20A%20retrospective%20cohort%20study%20was%20conducted%20using%20linked%2C%20routine%20data%2C%20from%20patients%20presenting%20with%20suspected%20COVID-19%20infection%20to%20public-sector%20emergency%20departments%20%28EDs%29%20in%20the%20Western%20Cape%2C%20South%20Africa%20between%2027th%20August%202020%20and%2031st%20October%202021.%20The%20primary%20outcome%20was%20death%20or%20critical%20care%20admission%20at%2030%20days.%20An%20XGBoost%20machine%20learning%20model%20was%20trained%20and%20internally%20tested%20using%20split-sample%20validation.%20External%20validation%20was%20performed%20in%203%20test%20cohorts%3A%20Western%20Cape%20patients%20presenting%20during%20the%20Omicron%20COVID-19%20wave%2C%20a%20UK%20cohort%20during%20the%20ancestral%20COVID-19%20wave%2C%20and%20a%20Sudanese%20cohort%20during%20ancestral%20and%20Eta%20waves.%20A%20total%20of%20282%2C051%20cases%20were%20included%20in%20a%20complete%20case%20training%20dataset.%20The%20prevalence%20of%2030-day%20adverse%20outcome%20was%204.0%25.%20The%20most%20important%20features%20for%20predicting%20adverse%20outcome%20were%20the%20requirement%20for%20supplemental%20oxygen%2C%20peripheral%20oxygen%20saturations%2C%20level%20of%20consciousness%20and%20age.%20Internal%20validation%20using%20split-sample%20test%20data%20revealed%20excellent%20discrimination%20%28C-statistic%200.91%2C%2095%25%20CI%200.90%20to%200.91%29%20and%20calibration%20%28CITL%20of%201.05%29.%20The%20model%20achieved%20C-statistics%20of%200.84%20%2895%25%20CI%200.84%20to%200.85%29%2C%200.72%20%2895%25%20CI%200.71%20to%200.73%29%2C%20and%200.62%2C%20%2895%25%20CI%200.59%20to%200.65%29%20in%20the%20Omicron%2C%20UK%2C%20and%20Sudanese%20test%20cohorts.%20Results%20were%20materially%20unchanged%20in%20sensitivity%20analyses%20examining%20missing%20data.%20An%20XGBoost%20machine%20learning%20model%20achieved%20good%20discrimination%20and%20calibration%20in%20prediction%20of%20adverse%20outcome%20in%20patients%20presenting%20with%20suspected%20COVID19%20to%20Western%20Cape%20EDs.%20Performance%20was%20reduced%20in%20temporal%20and%20geographical%20external%20validation.%22%2C%22date%22%3A%222023-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pdig.0000309%22%2C%22ISSN%22%3A%222767-3170%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-10-10T11%3A54%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22NSA73LXB%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nachega%20et%20al.%22%2C%22parsedDate%22%3A%222023-09%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENachega%2C%20Jean%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMusoke%2C%20Philippa%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKilmarx%2C%20Peter%20H.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGandhi%2C%20Monica%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGrinsztejn%2C%20Beatriz%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Global%20HIV%20control%3A%20is%20the%20glass%20half%20empty%20or%20half%20full%3F%20%3Ci%3EThe%20Lancet.%20HIV%3C%5C%2Fi%3E%2C%20%3Ci%3E10%3C%5C%2Fi%3E%20%289%29%2C%20S.%20e617%26%23x2013%3Be622.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2823%2900150-9%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2823%2900150-9%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Global%20HIV%20control%3A%20is%20the%20glass%20half%20empty%20or%20half%20full%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20B.%22%2C%22lastName%22%3A%22Nachega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippa%22%2C%22lastName%22%3A%22Musoke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20H.%22%2C%22lastName%22%3A%22Kilmarx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monica%22%2C%22lastName%22%3A%22Gandhi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anton%22%2C%22lastName%22%3A%22Pozniak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angeli%22%2C%22lastName%22%3A%22Rawat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lindsay%22%2C%22lastName%22%3A%22Wilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20J.%22%2C%22lastName%22%3A%22Mills%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederick%20L.%22%2C%22lastName%22%3A%22Altice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20W.%22%2C%22lastName%22%3A%22Mellors%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20C.%22%2C%22lastName%22%3A%22Quinn%22%7D%5D%2C%22abstractNote%22%3A%22The%20massive%20scale-up%20of%20HIV%20treatment%20and%20prevention%20over%20the%20past%20two%20decades%20has%20resulted%20in%20important%20reductions%20in%20new%20infections%20and%20mortality%20globally.%20Reduction%20in%20HIV%20incidence%2C%20however%2C%20has%20been%20unequal%2C%20with%20worsening%20epidemics%20in%20regions%20where%20the%20reach%20and%20scale%20of%20HIV%20control%20programmes%20have%20been%20insufficient%2C%20especially%20in%20eastern%20Europe%2C%20central%20Asia%2C%20the%20Middle%20East%2C%20north%20Africa%2C%20and%20Latin%20America%20where%20HIV%20epidemics%20are%20concentrated%20among%20key%20populations%2C%20including%20people%20who%20inject%20drugs%2C%20men%20who%20have%20sex%20with%20men%2C%20transgender%20people%2C%20and%20some%20minority%20racial%20and%20ethnic%20groups.%20The%20global%20state%20of%20the%20HIV%20pandemic%20highlights%20disparities%20in%20HIV%20control%20efforts%20and%20provides%20a%20roadmap%20for%20what%20should%20be%20done%2C%20including%20investment%20to%20better%20implement%20the%20effective%20HIV%20prevention%20and%20treatment%20tools%20that%20are%20available%2C%20but%20whose%20adoption%20and%20scale-up%20are%20not%20yet%20sufficient%20to%20get%20us%20close%20to%20an%20AIDS-free%20generation.%20To%20achieve%20the%20full%20potential%20of%20global%20HIV%20control%2C%20we%20call%20for%20urgent%2C%20evidence-informed%20implementation%20at%20scale%20of%20our%20existing%20and%20novel%20HIV%20prevention%20and%20treatment%20strategies%20in%20ways%20that%20are%20better%2C%20faster%2C%20more%20efficient%2C%20and%20cost-effective%2C%20especially%20in%20key%20populations%20and%20regions%20where%20the%20HIV%20pandemic%20continues%20to%20expand.%22%2C%22date%22%3A%222023-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS2352-3018%2823%2900150-9%22%2C%22ISSN%22%3A%222352-3018%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222023-10-10T11%3A50%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22W2HVK3BT%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bocage%20et%20al.%22%2C%22parsedDate%22%3A%222023-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBocage%2C%20A.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECoelho%2C%20L.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELake%2C%20J.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EClark%2C%20J.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETorres%2C%20T.%20S.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20The%20Impact%20of%20COVID-19%20on%20HIV%20Care%20in%20Rio%20de%20Janeiro%2C%20Brazil%202019-2021%3A%20Disparities%20by%20Age%20and%20Gender.%20%3Ci%3EAIDS%20Behav%3C%5C%2Fi%3E%2C%20%3Ci%3E27%3C%5C%2Fi%3E%20%288%29%2C%20S.%202629%26%23x2013%3B2641.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-023-03988-3%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-023-03988-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Impact%20of%20COVID-19%20on%20HIV%20Care%20in%20Rio%20de%20Janeiro%2C%20Brazil%202019-2021%3A%20Disparities%20by%20Age%20and%20Gender%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20E.%22%2C%22lastName%22%3A%22Bocage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20E.%22%2C%22lastName%22%3A%22Coelho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20E.%22%2C%22lastName%22%3A%22Lake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Clark%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20S.%22%2C%22lastName%22%3A%22Torres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20M.%22%2C%22lastName%22%3A%22Jalil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20W.%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20I.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%5D%2C%22abstractNote%22%3A%22We%20evaluated%20COVID-19%27s%20impact%20on%20HIV%20care%20indicators%20among%20INI%5C%2FFIOCRUZ%27s%20HIV%20Clinical%20Cohort%20in%20Rio%20de%20Janeiro%2C%20Brazil%3A%20%281%29%20Adequate%20care%20visits%3A%20two%20visits%20%3E%5C%2F%3D%2090%20days%20apart%3B%20%282%29%20Adequate%20viral%20load%20monitoring%3A%20%3E%5C%2F%3D%202%20viral%20load%20results%20%3E%5C%2F%3D%2090%20days%20apart%3B%20%283%29%20Consistent%20viral%20suppression%3A%20all%20viral%20loads%20%3C%2040%20copies%5C%2FmL%3B%20and%20%284%29%20ART%20medication%20possession%20ratio%20%28MPR%29%20%3E%5C%2F%3D%2095%25.%20Chi-square%20tests%20compared%20the%20fraction%20of%20participants%20meeting%20each%20indicator%20per%20period%3A%20pre-pandemic%20%283%5C%2F1%5C%2F2019-2%5C%2F29%5C%2F2020%29%20and%20post-pandemic%20%283%5C%2F1%5C%2F2020-2%5C%2F28%5C%2F2021%29.%20Logistic%20regression%20models%20were%20used%20to%20assess%20disparities%20in%20adequate%20care%20visits.%20Among%20906%20participants%2C%20care%20visits%20and%20viral%20load%20monitoring%20decreased%20pre-pandemic%20to%20post-pandemic%3A%2077.0-55.1%25%20and%2036.6-11.6%25%20%28both%20p%20%3C%200.001%29%2C%20respectively.%20The%20optimal%20MPR%20rate%20improved%20from%2025.5%20to%2040.0%25%20%28p%20%3C%200.001%29.%20Post-pandemic%20period%20%28aOR%200.33%2C%20CI%200.28-0.40%29%2C%20transgender%20women%20%28aOR%200.34%2C%20CI%200.22-0.53%29%2C%20and%20those%20aged%2018-24%20years%20%28aOR%200.67%2C%20CI%200.45-0.97%29%20had%20lower%20odds%20of%20adequate%20care%20visits.%20COVID-19%20disrupted%20care%20access%20disproportionately%20for%20transgender%20women%20and%20younger%20participants.%22%2C%22date%22%3A%22Aug%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10461-023-03988-3%22%2C%22ISSN%22%3A%221573-3254%20%28Electronic%29%201090-7165%20%28Print%29%201090-7165%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A49%3A28Z%22%7D%7D%2C%7B%22key%22%3A%222222KS83%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sudjaritruk%20et%20al.%22%2C%22parsedDate%22%3A%222023-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESudjaritruk%2C%20Tavitiya%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKanjanavanit%2C%20Suparat%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChaito%2C%20Tanachot%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESricharoen%2C%20Natthanidnan%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPrasarakee%2C%20Chanidapa%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20A%20Three-Year%20Follow-Up%20of%20Bone%20Density%20Among%20Thai%20Adolescents%20With%20Perinatally%20Acquired%20HIV%20After%20Completion%20of%20Vitamin%20D%20and%20Calcium%20Supplementation.%20%3Ci%3EThe%20Journal%20of%20Adolescent%20Health%3A%20Official%20Publication%20of%20the%20Society%20for%20Adolescent%20Medicine%3C%5C%2Fi%3E%2C%20%3Ci%3E73%3C%5C%2Fi%3E%20%282%29%2C%20S.%20262%26%23x2013%3B270.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jadohealth.2023.03.012%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jadohealth.2023.03.012%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20Three-Year%20Follow-Up%20of%20Bone%20Density%20Among%20Thai%20Adolescents%20With%20Perinatally%20Acquired%20HIV%20After%20Completion%20of%20Vitamin%20D%20and%20Calcium%20Supplementation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tavitiya%22%2C%22lastName%22%3A%22Sudjaritruk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suparat%22%2C%22lastName%22%3A%22Kanjanavanit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tanachot%22%2C%22lastName%22%3A%22Chaito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natthanidnan%22%2C%22lastName%22%3A%22Sricharoen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chanidapa%22%2C%22lastName%22%3A%22Prasarakee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saowalak%22%2C%22lastName%22%3A%22Sarachai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thanyawee%22%2C%22lastName%22%3A%22Puthanakit%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20To%20determine%20changes%20in%20bone%20mineral%20density%20%28BMD%29%20and%20bone%20metabolism-related%20biomarkers%20among%20Thai%20adolescents%20with%20perinatally%20acquired%20HIV%20infection%20%28PHIVA%29%20at%203%5Cu00a0years%20following%20completion%20of%20vitamin%20D%20and%20calcium%20%28VitD%5C%2FCal%29%20supplementation.%5CnMETHODS%3A%20An%20observational%20follow-up%20study%20was%20conducted%20among%20PHIVA%20who%20received%2048-week%20VitD%5C%2FCal%20supplementation%20%28either%20high-dose%20%5B3%2C200%20IU%5C%2F1%2C200%5Cu00a0mg%20daily%5D%20or%20standard-dose%20%5B400%20IU%5C%2F1%2C200%5Cu00a0mg%20daily%5D%29.%20Lumbar%20spine%20BMD%20%28LSBMD%29%20was%20assessed%20by%20dual-energy%20x-ray%20absorptiometry.%20Serum%2025-hydroxyvitamin%20D%2C%20intact%20parathyroid%20hormone%2C%20and%20bone%20turnover%20markers%20were%20measured.%20Changes%20in%20LSBMD%20z-scores%20and%20other%20bone%20parameters%20at%203%5Cu00a0years%20after%20stopping%20VitD%5C%2FCal%20supplementation%20compared%20with%20baseline%20or%20week%2048%20of%20supplementation%20were%20assessed%20among%20participants%20previously%20receiving%20high-dose%20and%20standard-dose%20VitD%5C%2FCal%20supplementation.%5CnRESULTS%3A%20Of%20114%20enrolled%20PHIVA%2C%2046%25%20and%2054%25%20had%20previously%20received%20high-dose%20and%20standard-dose%20VitD%5C%2FCal%20supplementation%2C%20respectively.%20The%20median%20age%20was%2020%5Cu00a0years%3B%2053%25%20were%20male.%20At%203%5Cu00a0years%20after%20completion%20of%20VitD%5C%2FCal%20supplementation%2C%20we%20observed%20a%20significant%20decline%20in%2025-hydroxyvitamin%20D%20and%20increase%20in%20intact%20parathyroid%20hormone%20but%20no%20significant%20rebounds%20of%20C-terminal%20telopeptides%20of%20collagen%20type%20I%20and%20procollagen%20type%20I%20amino-terminal%20propeptides%20and%20no%20significant%20changes%20in%20LSBMD%20z-scores%20among%20PHIVA%20in%20both%20treatment%20groups%2C%20compared%20with%20the%20measurements%20at%20week%2048%20of%20supplementation.%20Notably%2C%20LSBMD%20z-scores%20at%203%5Cu00a0years%20after%20stopping%20VitD%5C%2FCal%20supplements%20were%20not%20significantly%20altered%20from%20baseline%20evaluations%20in%20both%20PHIVA%20groups.%5CnDISCUSSION%3A%20Three%20years%20after%20completion%20of%20high-dose%20or%20standard-dose%20VitD%5C%2FCal%20supplementation%2C%20LSBMD%20z-scores%20of%20our%20Thai%20PHIVA%20were%20not%20significantly%20changed%20from%20baseline%20and%20week%2048%20of%20supplementation.%20VitD%5C%2FCal%20supplementation%20of%20PHIVA%20during%20periods%20of%20peak%20bone%20mass%20accrual%20may%20have%20sustained%20and%20long-term%20skeletal%20benefits.%22%2C%22date%22%3A%222023-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jadohealth.2023.03.012%22%2C%22ISSN%22%3A%221879-1972%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222024-01-12T13%3A26%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22K22SKTEE%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Parcesepe%20et%20al.%22%2C%22parsedDate%22%3A%222023-08%22%2C%22numChildren%22%3A10%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EParcesepe%2C%20Angela%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStockton%2C%20Melissa%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERemch%2C%20Molly%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWester%2C%20C.%20William%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBernard%2C%20Charlotte%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Availability%20of%20screening%20and%20treatment%20for%20common%20mental%20disorders%20in%20HIV%20clinic%20settings%3A%20data%20from%20the%20global%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Consortium%2C%202016-2017%20and%202020.%20%3Ci%3EJournal%20of%20the%20International%20AIDS%20Society%3C%5C%2Fi%3E%2C%20%3Ci%3E26%3C%5C%2Fi%3E%20%288%29%2C%20S.%20e26147.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26147%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26147%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Availability%20of%20screening%20and%20treatment%20for%20common%20mental%20disorders%20in%20HIV%20clinic%20settings%3A%20data%20from%20the%20global%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Consortium%2C%202016-2017%20and%202020%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%20M.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melissa%22%2C%22lastName%22%3A%22Stockton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Molly%22%2C%22lastName%22%3A%22Remch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rogers%22%2C%22lastName%22%3A%22Ajeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leslie%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edith%22%2C%22lastName%22%3A%22Kwobah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mpho%22%2C%22lastName%22%3A%22Tlali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Junko%22%2C%22lastName%22%3A%22Tanuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Nsonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aimee%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Lancaster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Common%20mental%20disorders%20%28CMDs%29%20are%20highly%20prevalent%20among%20people%20with%20HIV.%20Integrating%20mental%20healthcare%20into%20HIV%20care%20may%20improve%20mental%20health%20and%20HIV%20treatment%20outcomes.%20We%20describe%20the%20reported%20availability%20of%20screening%20and%20treatment%20for%20depression%2C%20anxiety%20and%20post-traumatic%20stress%20disorder%20%28PTSD%29%20at%20global%20HIV%20treatment%20centres%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Consortium%20in%202020%20and%20changes%20in%20availability%20at%20sites%20in%20low-%20or%20middle-income%20countries%20%28LMICs%29%20between%202016%5C%2F2017%20and%202020.%5CnMETHODS%3A%20In%202020%2C%20238%20sites%20contributing%20individual-level%20data%20to%20the%20IeDEA%20Consortium%20and%20in%202016%5C%2F2017%20a%20stratified%20random%20sample%20of%20IeDEA%20sites%20in%20LMICs%20were%20eligible%20to%20participate%20in%20site%20surveys%20on%20the%20availability%20of%20screening%20and%20treatment%20for%20CMDs.%20We%20assessed%20trends%20over%20time%20for%2068%20sites%20across%2027%20LMICs%20that%20participated%20in%20both%20surveys.%5CnRESULTS%3A%20Among%20the%20238%20sites%20eligible%20to%20participate%20in%20the%202020%20site%20survey%2C%20227%20%2895%25%29%20participated%2C%20and%20mental%20health%20screening%20and%20treatment%20data%20were%20available%20for%20223%20%2898%25%29%20sites%20across%2041%20countries.%20A%20total%20of%2095%20sites%20across%2029%20LMICs%20completed%20the%202016%5C%2F2017%20survey.%20In%202020%2C%2068%25%20of%20sites%20were%20in%20urban%20settings%2C%20and%2077%25%20were%20in%20LMICs.%20Overall%2C%2050%25%2C%2014%25%20and%2012%25%20of%20sites%20reported%20screening%20with%20a%20validated%20instrument%20for%20depression%2C%20anxiety%20and%20PTSD%2C%20respectively.%20Screening%20plus%20treatment%20in%20the%20form%20of%20counselling%20was%20available%20for%20depression%2C%20anxiety%20and%20PTSD%20at%2046%25%2C%2013%25%20and%2011%25%20of%20sites%2C%20respectively.%20Screening%20plus%20treatment%20in%20the%20form%20of%20medication%20was%20available%20for%20depression%2C%20anxiety%20and%20PTSD%20at%2036%25%2C%2011%25%20and%208%25%20of%20sites%2C%20respectively.%20Among%20sites%20that%20participated%20in%20both%20surveys%2C%20screening%20for%20depression%20was%20more%20commonly%20available%20in%202020%20than%202016%5C%2F2017%20%2875%25%20vs.%2059%25%2C%20respectively%2C%20p%20%3D%200.048%29.%5CnCONCLUSIONS%3A%20Reported%20availability%20of%20screening%20for%20depression%20increased%20among%20this%20group%20of%20IeDEA%20sites%20in%20LMICs%20between%202016%5C%2F2017%20and%202020.%20However%2C%20substantial%20gaps%20persist%20in%20the%20availability%20of%20mental%20healthcare%20at%20HIV%20treatment%20sites%20across%20global%20settings%2C%20particularly%20in%20resource-constrained%20settings.%20Implementation%20of%20sustainable%20strategies%20to%20integrate%20mental%20health%20services%20into%20HIV%20care%20is%20needed.%22%2C%22date%22%3A%222023-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26147%22%2C%22ISSN%22%3A%221758-2652%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222024-01-12T13%3A25%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22L8YKFKT6%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chiarappa%20et%20al.%22%2C%22parsedDate%22%3A%222023-08%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChiarappa%2C%20Joseph%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHoover%2C%20Donald%20R.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPedley%2C%20Alison%3C%5C%2Fspan%3E%20%282023%29.%20Economizing%20comparative%20Poisson%20clinical%20trials%20of%20multiple%20experimental%20treatments%20by%20testing%20against%20the%20same%20control.%20%3Ci%3EStatistical%20Methods%20in%20Medical%20Research%3C%5C%2Fi%3E%2C%20%3Ci%3E32%3C%5C%2Fi%3E%20%288%29%2C%20S.%201604%26%23x2013%3B1615.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F09622802231181235%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F09622802231181235%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Economizing%20comparative%20Poisson%20clinical%20trials%20of%20multiple%20experimental%20treatments%20by%20testing%20against%20the%20same%20control%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20A.%22%2C%22lastName%22%3A%22Chiarappa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Donald%20R.%22%2C%22lastName%22%3A%22Hoover%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alison%22%2C%22lastName%22%3A%22Pedley%22%7D%5D%2C%22abstractNote%22%3A%22Comparative%20Poisson%20trials%20of%20an%20experimental%20treatment%20versus%20a%20control%20typically%20condition%20on%20the%20total%20number%20of%20events%20that%20occur%20across%20both%20arms%20%28Design%20A%29.%20Inference%20is%20based%20on%20the%20binomial%20distribution.%20Recently%2C%20an%20approach%20termed%20Design%20C%20to%20compare%20K%20experimental%20treatments%20to%20the%20same%20control%20was%20introduced.%20Under%20Design%20C%20without%20curtailment%2C%20the%20trial%20continues%20until%20a%20prespecified%20number%20of%20events%20occur%20in%20the%20control%20arm%2C%20leading%20to%20inference%20based%20on%20the%20negative%20multinomial%20distribution.%20The%20question%20remains%20of%20how%20advantageous%20it%20is%20to%20conduct%20one%20Design%20C%20trial%20comparing%20K%20experimental%20treatment%20arms%20to%20the%20same%20control%20arm%20as%20opposed%20to%20conducting%20K%20separate%20Design%20A%20trials%20each%20comparing%20one%20experimental%20treatment%20arm%20to%20a%20different%20control%20arm.%20This%20paper%2C%20therefore%2C%20compares%20the%20expected%20number%20of%20subjects%20to%20enroll%20for%20the%20two%20designs%20under%20uncurtailed%20and%20curtailed%20settings.%20The%20designs%20are%20evaluated%20when%20the%20null%20hypothesis%20and%20various%20assumptions%20for%20the%20alternative%20hypothesis%20hold.%20We%20simulate%20a%20variety%20of%20combinations%20for%20the%20Type%201%20error%2C%20power%2C%20and%20ratio%20of%20the%20incidence%20rate%20of%20events%20in%20the%20experimental%20treatment%20to%20control%20arms.%20Design%20C%20frequently%20offers%20significant%20savings%20in%20terms%20of%20sample%20size%20relative%20to%20Design%20A.%22%2C%22date%22%3A%222023-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F09622802231181235%22%2C%22ISSN%22%3A%221477-0334%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222023-10-10T11%3A51%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22FKSXKEEB%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zhou%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-14%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZhou%2C%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBakoyannis%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZhang%2C%20Y.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EYiannoutsos%2C%20C.%20T.%3C%5C%2Fspan%3E%20%282023%29.%20Semiparametric%20marginal%20regression%20for%20clustered%20competing%20risks%20data%20with%20missing%20cause%20of%20failure.%20%3Ci%3EBiostatistics%3C%5C%2Fi%3E%2C%20%3Ci%3E24%3C%5C%2Fi%3E%20%283%29%2C%20S.%20795%26%23x2013%3B810.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbiostatistics%5C%2Fkxac012%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbiostatistics%5C%2Fkxac012%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Semiparametric%20marginal%20regression%20for%20clustered%20competing%20risks%20data%20with%20missing%20cause%20of%20failure%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Zhou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Bakoyannis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%5D%2C%22abstractNote%22%3A%22Clustered%20competing%20risks%20data%20are%20commonly%20encountered%20in%20multicenter%20studies.%20The%20analysis%20of%20such%20data%20is%20often%20complicated%20due%20to%20informative%20cluster%20size%20%28ICS%29%2C%20a%20situation%20where%20the%20outcomes%20under%20study%20are%20associated%20with%20the%20size%20of%20the%20cluster.%20In%20addition%2C%20the%20cause%20of%20failure%20is%20frequently%20incompletely%20observed%20in%20real-world%20settings.%20To%20the%20best%20of%20our%20knowledge%2C%20there%20is%20no%20methodology%20for%20population-averaged%20analysis%20with%20clustered%20competing%20risks%20data%20with%20an%20ICS%20and%20missing%20causes%20of%20failure.%20To%20address%20this%20problem%2C%20we%20consider%20the%20semiparametric%20marginal%20proportional%20cause-specific%20hazards%20model%20and%20propose%20a%20maximum%20partial%20pseudolikelihood%20estimator%20under%20a%20missing%20at%20random%20assumption.%20To%20make%20the%20latter%20assumption%20more%20plausible%20in%20practice%2C%20we%20allow%20for%20auxiliary%20variables%20that%20may%20be%20related%20to%20the%20probability%20of%20missingness.%20The%20proposed%20method%20does%20not%20impose%20assumptions%20regarding%20the%20within-cluster%20dependence%20and%20allows%20for%20ICS.%20The%20asymptotic%20properties%20of%20the%20proposed%20estimators%20for%20both%20regression%20coefficients%20and%20infinite-dimensional%20parameters%2C%20such%20as%20the%20marginal%20cumulative%20incidence%20functions%2C%20are%20rigorously%20established.%20Simulation%20studies%20show%20that%20the%20proposed%20method%20performs%20well%20and%20that%20methods%20that%20ignore%20the%20within-cluster%20dependence%20and%20the%20ICS%20lead%20to%20invalid%20inferences.%20The%20proposed%20method%20is%20applied%20to%20competing%20risks%20data%20from%20a%20large%20multicenter%20HIV%20study%20in%20sub-Saharan%20Africa%20where%20a%20significant%20portion%20of%20causes%20of%20failure%20is%20missing.%22%2C%22date%22%3A%22Jul%2014%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fbiostatistics%5C%2Fkxac012%22%2C%22ISSN%22%3A%221468-4357%20%28Electronic%29%201465-4644%20%28Print%29%201465-4644%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A27%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22GGX2LKGQ%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thomadakis%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EThomadakis%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EYiannoutsos%2C%20C.%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPantazis%2C%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDiero%2C%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMwangi%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20The%20Effect%20of%20HIV%20Treatment%20Interruption%20on%20Subsequent%20Immunological%20Response.%20%3Ci%3EAm%20J%20Epidemiol%3C%5C%2Fi%3E%2C%20%3Ci%3E192%3C%5C%2Fi%3E%20%287%29%2C%20S.%201181%26%23x2013%3B1191.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Faje%5C%2Fkwad076%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Faje%5C%2Fkwad076%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Effect%20of%20HIV%20Treatment%20Interruption%20on%20Subsequent%20Immunological%20Response%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Thomadakis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Pantazis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mwangi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20S.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Touloumi%22%7D%5D%2C%22abstractNote%22%3A%22Recovery%20of%20CD4-positive%20T%20lymphocyte%20count%20after%20initiation%20of%20antiretroviral%20therapy%20%28ART%29%20has%20been%20thoroughly%20examined%20among%20people%20with%20human%20immunodeficiency%20virus%20infection.%20However%2C%20immunological%20response%20after%20restart%20of%20ART%20following%20care%20interruption%20is%20less%20well%20studied.%20We%20compared%20CD4%20cell-count%20trends%20before%20disengagement%20from%20care%20and%20after%20ART%20reinitiation.%20Data%20were%20obtained%20from%20the%20East%20Africa%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Collaboration%20%282001-2011%3B%20n%20%3D%2062%2C534%29.%20CD4%20cell-count%20trends%20before%20disengagement%2C%20during%20disengagement%2C%20and%20after%20ART%20reinitiation%20were%20simultaneously%20estimated%20through%20a%20linear%20mixed%20model%20with%202%20subject-specific%20knots%20placed%20at%20the%20times%20of%20disengagement%20and%20treatment%20reinitiation.%20We%20also%20estimated%20CD4%20trends%20conditional%20on%20the%20baseline%20CD4%20value.%20A%20total%20of%2010%2C961%20patients%20returned%20to%20care%20after%20disengagement%20from%20care%2C%20with%20the%20median%20gap%20in%20care%20being%202.7%20%28interquartile%20range%2C%202.1-5.4%29%20months.%20Our%20model%20showed%20that%20CD4%20cell-count%20increases%20after%20ART%20reinitiation%20were%20much%20slower%20than%20those%20before%20disengagement.%20Assuming%20that%20disengagement%20from%20care%20occurred%2012%20months%20after%20ART%20initiation%20and%20a%203-month%20treatment%20gap%2C%20CD4%20counts%20measured%20at%203%20years%20since%20ART%20initiation%20would%20be%20lower%20by%2036.5%20cells%5C%2FmuL%20than%20those%20obtained%20under%20no%20disengagement.%20Given%20that%20poorer%20CD4%20restoration%20is%20associated%20with%20increased%20mortality%5C%2Fmorbidity%2C%20specific%20interventions%20targeted%20at%20better%20retention%20in%20care%20are%20urgently%20required.%22%2C%22date%22%3A%22Jul%207%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Faje%5C%2Fkwad076%22%2C%22ISSN%22%3A%221476-6256%20%28Electronic%29%200002-9262%20%28Print%29%200002-9262%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A30%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22QAUT66D2%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ingle%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EIngle%2C%20S.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMiro%2C%20J.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMay%2C%20M.%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECain%2C%20L.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESchwimmer%2C%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Early%20Antiretroviral%20Therapy%20Not%20Associated%20With%20Higher%20Cryptococcal%20Meningitis%20Mortality%20in%20People%20With%20Human%20Immunodeficiency%20Virus%20in%20High-Income%20Countries%3A%20An%20International%20Collaborative%20Cohort%20Study.%20%3Ci%3EClin%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E77%3C%5C%2Fi%3E%20%281%29%2C%20S.%2064%26%23x2013%3B73.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad122%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad122%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Early%20Antiretroviral%20Therapy%20Not%20Associated%20With%20Higher%20Cryptococcal%20Meningitis%20Mortality%20in%20People%20With%20Human%20Immunodeficiency%20Virus%20in%20High-Income%20Countries%3A%20An%20International%20Collaborative%20Cohort%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20M.%22%2C%22lastName%22%3A%22Ingle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Miro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20T.%22%2C%22lastName%22%3A%22May%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20E.%22%2C%22lastName%22%3A%22Cain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Schwimmer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Zangerle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Sambatakou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cazanave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Reiss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Brandes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20C.%22%2C%22lastName%22%3A%22Bucher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Sabin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Vidal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Obel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mocroft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Wittkop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22d%27Arminio%20Monforte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Torti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Mussini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Furrer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Konopnicki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Teira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20S.%22%2C%22lastName%22%3A%22Saag%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20M.%22%2C%22lastName%22%3A%22Crane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Jacobson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20C.%22%2C%22lastName%22%3A%22Mathews%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Geng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Eron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kroch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%20C.%22%2C%22lastName%22%3A%22Sterne%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Randomized%20controlled%20trials%20%28RCTs%29%20from%20low-%20and%20middle-income%20settings%20suggested%20that%20early%20initiation%20of%20antiretroviral%20therapy%20%28ART%29%20leads%20to%20higher%20mortality%20rates%20among%20people%20with%20HIV%20%28PWH%29%20who%20present%20with%20cryptococcal%20meningitis%20%28CM%29.%20There%20is%20limited%20information%20about%20the%20impact%20of%20ART%20timing%20on%20mortality%20rates%20in%20similar%20people%20in%20high-income%20settings.%20METHODS%3A%20Data%20on%20ART-naive%20PWH%20with%20CM%20diagnosed%20from%201994%20to%202012%20from%20Europe%5C%2FNorth%20America%20were%20pooled%20from%20the%20COHERE%2C%20NA-ACCORD%2C%20and%20CNICS%20HIV%20cohort%20collaborations.%20Follow-up%20was%20considered%20to%20span%20from%20the%20date%20of%20CM%20diagnosis%20to%20earliest%20of%20the%20following%3A%20death%2C%20last%20follow-up%2C%20or%206%20months.%20We%20used%20marginal%20structural%20models%20to%20mimic%20an%20RCT%20comparing%20the%20effects%20of%20early%20%28within%2014%20days%20of%20CM%29%20and%20late%20%2814-56%20days%20after%20CM%29%20ART%20on%20all-cause%20mortality%2C%20adjusting%20for%20potential%20confounders.%20RESULTS%3A%20Of%20190%20participants%20identified%2C%2033%20%2817%25%29%20died%20within%206%20months.%20At%20CM%20diagnosis%2C%20their%20median%20age%20%28interquartile%20range%29%20was%2038%20%2833-44%29%20years%3B%20the%20median%20CD4%2B%20T-cell%20count%2C%2019%5C%2FmuL%20%2810-56%5C%2FmuL%29%3B%20and%20median%20HIV%20viral%20load%2C%205.3%20%284.9-5.6%29%20log10%20copies%5C%2FmL.%20Most%20participants%20%28n%20%3D%20157%20%5B83%25%5D%29%20were%20male%2C%20and%20145%20%2876%25%29%20started%20ART.%20Mimicking%20an%20RCT%2C%20with%20190%20people%20in%20each%20group%2C%20there%20were%2013%20deaths%20among%20participants%20with%20an%20early%20ART%20regimen%20and%2020%20deaths%20among%20those%20with%20a%20late%20ART%20regimen.%20The%20crude%20and%20adjusted%20hazard%20ratios%20comparing%20late%20with%20early%20ART%20were%201.28%20%2895%25%20confidence%20interval%2C%20.64-2.56%29%20and%201.40%20%28.66-2.95%29%2C%20respectively.%20CONCLUSIONS%3A%20We%20found%20little%20evidence%20that%20early%20ART%20was%20associated%20with%20higher%20mortality%20rates%20among%20PWH%20presenting%20with%20CM%20in%20high-income%20settings%2C%20although%20confidence%20intervals%20were%20wide.%22%2C%22date%22%3A%22Jul%205%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciad122%22%2C%22ISSN%22%3A%221537-6591%20%28Electronic%29%201058-4838%20%28Print%29%201058-4838%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A43%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22QZJ4MTKF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Haas%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHaas%2C%20Andreas%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKunzekwenyika%2C%20Cordelia%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EManzero%2C%20Josphat%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHossmann%2C%20Stefanie%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELimacher%2C%20Andreas%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Effect%20of%20the%20Friendship%20Bench%20Intervention%20on%20Antiretroviral%20Therapy%20Outcomes%20and%20Mental%20Health%20Symptoms%20in%20Rural%20Zimbabwe%3A%20A%20Cluster%20Randomized%20Trial.%20%3Ci%3EJAMA%20Network%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E6%3C%5C%2Fi%3E%20%287%29%2C%20S.%20e2323205.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamanetworkopen.2023.23205%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamanetworkopen.2023.23205%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20the%20Friendship%20Bench%20Intervention%20on%20Antiretroviral%20Therapy%20Outcomes%20and%20Mental%20Health%20Symptoms%20in%20Rural%20Zimbabwe%3A%20A%20Cluster%20Randomized%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cordelia%22%2C%22lastName%22%3A%22Kunzekwenyika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josphat%22%2C%22lastName%22%3A%22Manzero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefanie%22%2C%22lastName%22%3A%22Hossmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%22%2C%22lastName%22%3A%22Limacher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janneke%20H.%22%2C%22lastName%22%3A%22van%20Dijk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%22%2C%22lastName%22%3A%22Manhibi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Per%22%2C%22lastName%22%3A%22von%20Groote%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20A.%22%2C%22lastName%22%3A%22Hobbins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruth%22%2C%22lastName%22%3A%22Verhey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Friendship%20Bench%20ART%20trial%20group%22%7D%5D%2C%22abstractNote%22%3A%22IMPORTANCE%3A%20Common%20mental%20disorders%20%28CMD%29%2C%20which%20include%20depression%20and%20anxiety%2C%20are%20prevalent%20among%20people%20living%20with%20HIV%20and%20are%20associated%20with%20suboptimal%20antiretroviral%20therapy%20%28ART%29%20adherence.%5CnOBJECTIVE%3A%20To%20assess%20the%20effect%20of%20a%20lay%20health%20worker-led%20psychological%20intervention%20on%20ART%20adherence%2C%20virologic%20suppression%2C%20and%20mental%20health%20symptoms.%5CnDESIGN%2C%20SETTING%2C%20AND%20PARTICIPANTS%3A%20Open-label%20pragmatic%20cluster%20trial%20with%201%3A1%20block%20randomization%20of%2016%20health%20facilities%20in%20rural%20Bikita%2C%20Zimbabwe.%20Recruitment%20occurred%20from%20October%202018%20to%20December%202019%2C%20and%20participants%20were%20followed%20up%20for%2012%20months%2C%20ending%20in%20December%202020.%20Participants%20were%20adults%20aged%2018%20years%20and%20older%2C%20who%20spoke%20English%20or%20Shona%2C%20screened%20positive%20for%20CMD%20%28Shona%20Symptoms%20Questionnaire%20%5BSSQ%5D-14%20score%20%5Cu22659%29%2C%20received%20first-line%20ART%20for%206%20or%20more%20months%2C%20had%20no%20World%20Health%20Organization%20stage%204%20disease%2C%20no%20psychosis%2C%20were%20not%20pregnant%2C%20and%20provided%20informed%20consent.%20Data%20were%20analyzed%20from%20March%202021%20to%20February%202022.%5CnINTERVENTION%3A%20The%20Friendship%20Bench%2C%20consisting%20of%206%20lay%20health%20worker-led%20weekly%20problem-solving%20therapy%20sessions%20and%20optional%20peer-led%20group%20support.%5CnMAIN%20OUTCOMES%20AND%20MEASURES%3A%20The%20primary%20outcome%20was%20mean%20adherence%20during%202%20to%206%20months%20of%20follow-up%2C%20and%20the%20secondary%20outcomes%20were%20mean%20adherence%20during%201%20to%2012%20months%20of%20follow-up%2C%20change%20in%20SSQ-14%20and%20Patient%20Health%20Questionnaire%20%28PHQ-9%29%20scores%20%283%2C%206%2C%209%2C%20and%2012%20months%29%2C%20and%20viral%20load%20suppression%20%286%20and%2012%20months%29.%5CnRESULTS%3A%20A%20total%20of%20516%20participants%20were%20recruited%20%28244%20in%20Friendship%20Bench%20and%20272%20in%20enhanced%20standard%20care%20facilities%29%3B%20438%20%2884.9%25%29%20were%20female%20and%20the%20mean%20%28SD%29%20age%20was%2045.6%20%2810.9%29%20years.%20Mean%20%28SD%29%20adherence%20between%202%20to%206%20months%20was%2089.9%25%20%2818.4%25%29%20in%20the%20Friendship%20Bench%20group%20and%2087.2%25%20%2820.1%25%29%20in%20the%20control%20group.%20The%20intervention%20had%20no%20statistically%20significant%20effect%20on%20adherence%20between%202%20to%206%20months%20%28unadjusted%20mean%20difference%2C%201.93%20percentage%20points%3B%2095%25%20CI%2C%20-1.20%20to%205.06%20percentage%20points%3B%20P%5Cu2009%3D%5Cu2009.23%29%2C%20between%20months%201%20to%2012%20%28mean%20difference%200.79%20percentage%20points%3B%2095%25%20CI%2C%20-2.14%20to%203.71%20percentage%20points%3B%20P%5Cu2009%3D%5Cu2009.60%29%2C%20or%20viral%20suppression.%20Declines%20in%20SSQ-14%20scores%20from%20baseline%20to%203%20months%20%28difference%2C%20-1.65%3B%2095%25%20CI%2C%20-3.07%20to%20-0.24%29%2C%206%20months%20%28difference%2C%20-1.57%3B%2095%25%20CI%2C%20-2.98%20to%20-0.15%29%2C%20and%209%20months%20%28difference%2C%20-1.63%3B%2095%25%20CI%2C%20-3.05%20to%20-0.22%29%20were%20greater%20in%20the%20Friendship%20Bench%20than%20the%20standard%20care%20group%20%28P%5Cu2009%3C%5Cu2009.05%29.%20There%20were%20no%20differences%20in%20the%20decline%20in%20the%20SSQ-14%20scores%20from%20baseline%20to%2012%20months%20and%20in%20declines%20in%20PHQ-9%20scores%20from%20baseline%20to%203%2C%206%2C%209%2C%20and%2012%20months.%5CnCONCLUSIONS%20AND%20RELEVANCE%3A%20In%20this%20randomized%20trial%20of%20HIV-positive%20participants%20with%20CMD%2C%20the%20Friendship%20Bench%20intervention%20had%20no%20effect%20on%20adherence%20and%20viral%20suppression%2C%20possibly%20due%20to%20the%20absence%20of%20skill-based%20adherence%20training%20and%20a%20ceiling%20effect.%5CnTRIAL%20REGISTRATION%3A%20ClinicalTrials.gov%20Identifier%3A%20NCT03704805.%22%2C%22date%22%3A%222023-07-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1001%5C%2Fjamanetworkopen.2023.23205%22%2C%22ISSN%22%3A%222574-3805%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222024-01-24T16%3A08%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22RS75ZUAW%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marincowitz%20et%20al.%22%2C%22parsedDate%22%3A%222023-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMarincowitz%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESbaffi%2C%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHasan%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHodkinson%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMcAlpine%2C%20D.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20External%20validation%20of%20triage%20tools%20for%20adults%20with%20suspected%20COVID-19%20in%20a%20middle-income%20setting%3A%20an%20observational%20cohort%20study.%20%3Ci%3EEmerg%20Med%20J%3C%5C%2Fi%3E%2C%20%3Ci%3E40%3C%5C%2Fi%3E%20%287%29%2C%20S.%20509%26%23x2013%3B517.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Femermed-2022-212827%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Femermed-2022-212827%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22External%20validation%20of%20triage%20tools%20for%20adults%20with%20suspected%20COVID-19%20in%20a%20middle-income%20setting%3A%20an%20observational%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Marincowitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Sbaffi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Hasan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Hodkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22McAlpine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Fuller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Goodacre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20A.%22%2C%22lastName%22%3A%22Bath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Omer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Wallis%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Tools%20proposed%20to%20triage%20ED%20acuity%20in%20suspected%20COVID-19%20were%20derived%20and%20validated%20in%20higher%20income%20settings%20during%20early%20waves%20of%20the%20pandemic.%20We%20estimated%20the%20accuracy%20of%20seven%20risk-stratification%20tools%20recommended%20to%20predict%20severe%20illness%20in%20the%20Western%20Cape%2C%20South%20Africa.%20METHODS%3A%20An%20observational%20cohort%20study%20using%20routinely%20collected%20data%20from%20EDs%20across%20the%20Western%20Cape%2C%20from%2027%20August%202020%20to%2011%20March%202022%2C%20was%20conducted%20to%20assess%20the%20performance%20of%20the%20PRIEST%20%28Pandemic%20Respiratory%20Infection%20Emergency%20System%20Triage%29%20tool%2C%20NEWS2%20%28National%20Early%20Warning%20Score%2C%20version%202%29%2C%20TEWS%20%28Triage%20Early%20Warning%20Score%29%2C%20the%20WHO%20algorithm%2C%20CRB-65%2C%20Quick%20COVID-19%20Severity%20Index%20and%20PMEWS%20%28Pandemic%20Medical%20Early%20Warning%20Score%29%20in%20suspected%20COVID-19.%20The%20primary%20outcome%20was%20intubation%20or%20non-invasive%20ventilation%2C%20death%20or%20intensive%20care%20unit%20admission%20at%2030%20days.%20RESULTS%3A%20Of%20the%20446%20084%20patients%2C%2015%20397%20%283.45%25%2C%2095%25%20CI%2034%25%20to%2035.1%25%29%20experienced%20the%20primary%20outcome.%20Clinical%20decision-making%20for%20inpatient%20admission%20achieved%20a%20sensitivity%20of%200.77%20%2895%25%20CI%200.76%20to%200.78%29%2C%20specificity%20of%200.88%20%2895%25%20CI%200.87%20to%200.88%29%20and%20the%20negative%20predictive%20value%20%28NPV%29%20of%200.99%20%2895%25%20CI%200.99%20to%200.99%29.%20NEWS2%2C%20PMEWS%20and%20PRIEST%20scores%20achieved%20good%20estimated%20discrimination%20%28C-statistic%200.79%20to%200.82%29%20and%20identified%20patients%20at%20risk%20of%20adverse%20outcomes%20at%20recommended%20cut-offs%20with%20moderate%20sensitivity%20%28%3E0.8%29%20and%20specificity%20ranging%20from%200.41%20to%200.64.%20Use%20of%20the%20tools%20at%20recommended%20thresholds%20would%20have%20more%20than%20doubled%20admissions%2C%20with%20only%20a%200.01%25%20reduction%20in%20false%20negative%20triage.%20CONCLUSION%3A%20No%20risk%20score%20outperformed%20existing%20clinical%20decision-making%20in%20determining%20the%20need%20for%20inpatient%20admission%20based%20on%20prediction%20of%20the%20primary%20outcome%20in%20this%20setting.%20Use%20of%20the%20PRIEST%20score%20at%20a%20threshold%20of%20one%20point%20higher%20than%20the%20previously%20recommended%20best%20approximated%20existing%20clinical%20accuracy.%22%2C%22date%22%3A%22Jul%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Femermed-2022-212827%22%2C%22ISSN%22%3A%221472-0213%20%28Electronic%29%201472-0205%20%28Print%29%201472-0205%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A45%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22RHAAX2AX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Person%20et%20al.%22%2C%22parsedDate%22%3A%222023-06-16%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPerson%2C%20Anna%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECrabtree-Ramirez%2C%20Brenda%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKim%2C%20Ahra%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVeloso%2C%20Valdil%26%23xE9%3Ba%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMaruri%2C%20Fernanda%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Cryptococcal%20Meningitis%20and%20Clinical%20Outcomes%20in%20Persons%20With%20Human%20Immunodeficiency%20Virus%3A%20A%20Global%20View.%20%3Ci%3EClinical%20Infectious%20Diseases%3A%20An%20Official%20Publication%20of%20the%20Infectious%20Diseases%20Society%20of%20America%3C%5C%2Fi%3E%2C%20%3Ci%3E76%3C%5C%2Fi%3E%20%2812%29%2C%20S.%202116%26%23x2013%3B2125.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad076%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad076%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cryptococcal%20Meningitis%20and%20Clinical%20Outcomes%20in%20Persons%20With%20Human%20Immunodeficiency%20Virus%3A%20A%20Global%20View%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20K.%22%2C%22lastName%22%3A%22Person%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahra%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdil%5Cu00e9a%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22John%20Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darma%22%2C%22lastName%22%3A%22Imran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kinh%22%2C%22lastName%22%3A%22Van%20Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Nalitya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Winnie%22%2C%22lastName%22%3A%22Muyindike%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Cryptococcal%20meningitis%20%28CM%29%20is%20a%20major%20cause%20of%20morbidity%20and%20mortality%20in%20persons%20with%20human%20immunodeficiency%20virus%20%28HIV%3B%20PWH%29.%20Little%20is%20known%20about%20CM%20outcomes%20and%20availability%20of%20diagnostic%20and%20treatment%20modalities%20globally.%5CnMETHODS%3A%20In%20this%20retrospective%20cohort%20study%2C%20we%20investigated%20CM%20incidence%20and%20all-cause%20mortality%20in%20PWH%20in%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20cohort%20from%201996%20to%202017.%20We%20estimated%20incidence%20using%20quasi-Poisson%20models%20adjusted%20for%20sex%2C%20age%2C%20calendar%20year%2C%20CD4%20cell%20count%20%28CD4%29%2C%20and%20antiretroviral%20therapy%20%28ART%29%20status.%20Mortality%20after%20CM%20diagnosis%20was%20examined%20using%20multivariable%20Cox%20models.%20A%20site%20survey%20from%202017%20assessed%20availability%20of%20CM%20diagnostic%20and%20treatment%20modalities.%5CnRESULTS%3A%20Among%20518%20852%20PWH%2C%20there%20were%203857%20cases%20of%20CM%20with%20an%20estimated%20incidence%20of%201.54%20per%201000%20person-years.%20Mortality%20over%20a%20median%20of%202.6%20years%20of%20post-CM%20diagnosis%20follow-up%20was%2031.6%25%2C%20with%2029%25%20lost%20to%20follow-up.%20In%20total%2C%202478%20%2864%25%29%20were%20diagnosed%20with%20CM%20after%20ART%20start%20with%20a%20median%20of%20253%20days%20from%20ART%20start%20to%20CM%20diagnosis.%20Older%20age%20%28hazard%20%5BHR%5D%2C%201.31%20for%2050%20vs%2035%20years%29%2C%20lower%20CD4%20%28HR%2C%201.15%20for%20200%20vs%20350%20cells%5C%2Fmm3%29%2C%20and%20earlier%20year%20of%20CM%20diagnosis%20%28HR%2C%200.51%20for%202015%20vs%202000%29%20were%20associated%20with%20higher%20mortality.%20Of%2089%20sites%2C%2034%25%20reported%20access%20to%20amphotericin%20B%3B%2012%25%20had%20access%20to%20flucytosine.%5CnCONCLUSIONS%3A%20Mortality%20after%20CM%20diagnosis%20was%20high.%20A%20substantial%20portion%20of%20CM%20cases%20occurred%20after%20ART%20start%2C%20though%20incidence%20and%20mortality%20may%20be%20higher%20than%20reported%20due%20to%20ascertainment%20bias.%20Many%20sites%20lacked%20access%20to%20recommended%20CM%20treatment.%22%2C%22date%22%3A%222023-06-16%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciad076%22%2C%22ISSN%22%3A%221537-6591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22D9WC3N3V%22%2C%228IRGNQWZ%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222024-01-12T13%3A25%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22A3X487HE%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kubjane%20et%20al.%22%2C%22parsedDate%22%3A%222023-06-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKubjane%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECornell%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOsman%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBoulle%2C%20A.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJohnson%2C%20L.%20F.%3C%5C%2Fspan%3E%20%282023%29.%20Drivers%20of%20sex%20differences%20in%20the%20South%20African%20adult%20tuberculosis%20incidence%20and%20mortality%20trends%2C%201990-2019.%20%3Ci%3ESci%20Rep%3C%5C%2Fi%3E%2C%20%3Ci%3E13%3C%5C%2Fi%3E%20%281%29%2C%20S.%209487.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-023-36432-6%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-023-36432-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Drivers%20of%20sex%20differences%20in%20the%20South%20African%20adult%20tuberculosis%20incidence%20and%20mortality%20trends%2C%201990-2019%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kubjane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Osman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%5D%2C%22abstractNote%22%3A%22Males%20have%20higher%20tuberculosis%20incidence%20and%20mortality%20rates%20than%20females.%20This%20study%20aimed%20to%20assess%20how%20sex%20differences%20in%20tuberculosis%20incidence%20and%20mortality%20could%20be%20explained%20by%20sex%20differences%20in%20HIV%2C%20antiretroviral%20treatment%20%28ART%29%20uptake%2C%20smoking%2C%20alcohol%20abuse%2C%20undernutrition%2C%20diabetes%2C%20social%20contact%20rates%2C%20health-seeking%20patterns%2C%20and%20treatment%20discontinuation.%20We%20developed%20an%20age-sex-stratified%20dynamic%20tuberculosis%20transmission%20model%20and%20calibrated%20it%20to%20South%20African%20data.%20We%20estimated%20male-to-female%20%28M%3AF%29%20tuberculosis%20incidence%20and%20mortality%20ratios%2C%20the%20effect%20of%20the%20abovementioned%20factors%20on%20the%20M%3AF%20ratios%20and%20PAFs%20for%20the%20tuberculosis%20risk%20factors.%20Over%20the%20period%201990-2019%2C%20the%20M%3AF%20ratios%20for%20tuberculosis%20incidence%20and%20mortality%20rates%20persisted%20above%201.0%2C%20and%20the%20figures%20reached%201.70%20and%201.65%2C%20respectively%2C%20by%20the%20end%20of%202019.%20In%202019%2C%20HIV%20contributed%20greater%20increases%20in%20tuberculosis%20incidence%20among%20females%20than%20males%20%2854.5%25%20vs.%2045.6%25%29%3B%20however%2C%20females%20experienced%20more%20reductions%20due%20to%20ART%20than%20males%20%2838.3%25%20vs.%2017.5%25%29.%20PAFs%20for%20tuberculosis%20incidence%20due%20to%20alcohol%20abuse%2C%20smoking%2C%20and%20undernutrition%2C%20in%20men%20were%2051.4%25%2C%2029.5%25%2C%20and%2016.1%25%2C%20respectively%2C%20higher%20than%20females%20%2830.1%25%2C%2015.4%25%2C%20and%2010.7%25%2C%20respectively%29%3B%20the%20PAF%20due%20to%20diabetes%20was%20higher%20in%20females%20than%20males%20%2822.9%25%20vs.%2017.5%25%29.%20Lower%20health-seeking%20rates%20in%20males%20accounted%20for%20a%207%25%20higher%20mortality%20rate%20in%20men.%20The%20higher%20burden%20of%20tuberculosis%20in%20men%20highlights%20the%20need%20to%20improve%20men%27s%20access%20to%20routine%20screening%20and%20ensure%20earlier%20diagnosis.%20Sustained%20efforts%20in%20providing%20ART%20remain%20critical%20in%20reducing%20HIV-associated%20tuberculosis.%20Additional%20interventions%20to%20reduce%20alcohol%20abuse%20and%20tobacco%20smoking%20are%20also%20needed.%22%2C%22date%22%3A%22Jun%2010%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-023-36432-6%22%2C%22ISSN%22%3A%222045-2322%20%28Electronic%29%202045-2322%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A42%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22ZHPVL3IM%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kassanjee%20et%20al.%22%2C%22parsedDate%22%3A%222023-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKassanjee%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavies%2C%20M.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENgwenya%2C%20O.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOsei-Yeboah%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJacobs%2C%20T.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20COVID-19%20among%20adults%20living%20with%20HIV%3A%20correlates%20of%20mortality%20among%20public%20sector%20healthcare%20users%20in%20Western%20Cape%2C%20South%20Africa.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E26%3C%5C%2Fi%3E%20%286%29%2C%20S.%20e26104.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26104%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26104%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22COVID-19%20among%20adults%20living%20with%20HIV%3A%20correlates%20of%20mortality%20among%20public%20sector%20healthcare%20users%20in%20Western%20Cape%2C%20South%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Ngwenya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Osei-Yeboah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Jacobs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Morden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Timmerman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Britz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mendelson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Taljaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Riou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Tiffin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Zinyakatira%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20While%20a%20large%20proportion%20of%20people%20with%20HIV%20%28PWH%29%20have%20experienced%20SARS-CoV-2%20infections%2C%20there%20is%20uncertainty%20about%20the%20role%20of%20HIV%20disease%20severity%20on%20COVID-19%20outcomes%2C%20especially%20in%20lower-income%20settings.%20We%20studied%20the%20association%20of%20mortality%20with%20characteristics%20of%20HIV%20severity%20and%20management%2C%20and%20vaccination%2C%20among%20adult%20PWH.%20METHODS%3A%20We%20analysed%20observational%20cohort%20data%20on%20all%20PWH%20aged%20%3E%5C%2F%3D15%20years%20experiencing%20a%20diagnosed%20SARS-CoV-2%20infection%20%28until%20March%202022%29%2C%20who%20accessed%20public%20sector%20healthcare%20in%20the%20Western%20Cape%20province%20of%20South%20Africa.%20Logistic%20regression%20was%20used%20to%20study%20the%20association%20of%20mortality%20with%20evidence%20of%20antiretroviral%20therapy%20%28ART%29%20collection%2C%20time%20since%20first%20HIV%20evidence%2C%20CD4%20cell%20count%2C%20viral%20load%20%28among%20those%20with%20evidence%20of%20ART%20collection%29%20and%20COVID-19%20vaccination%2C%20adjusting%20for%20demographic%20characteristics%2C%20comorbidities%2C%20admission%20pressure%2C%20location%20and%20time%20period.%20RESULTS%3A%20Mortality%20occurred%20in%205.7%25%20%2895%25%20CI%3A%205.3%2C6.0%29%20of%2017%2C831%20first-diagnosed%20infections.%20Higher%20mortality%20was%20associated%20with%20lower%20recent%20CD4%2C%20no%20evidence%20of%20ART%20collection%2C%20high%20or%20unknown%20recent%20viral%20load%20and%20recent%20first%20HIV%20evidence%2C%20differentially%20by%20age.%20Vaccination%20was%20protective.%20The%20burden%20of%20comorbidities%20was%20high%2C%20and%20tuberculosis%20%28especially%20more%20recent%20episodes%20of%20tuberculosis%29%2C%20chronic%20kidney%20disease%2C%20diabetes%20and%20hypertension%20were%20associated%20with%20higher%20mortality%2C%20more%20strongly%20in%20younger%20adults.%20CONCLUSIONS%3A%20Mortality%20was%20strongly%20associated%20with%20suboptimal%20HIV%20control%2C%20and%20the%20prevalence%20of%20these%20risk%20factors%20increased%20in%20later%20COVID-19%20waves.%20It%20remains%20a%20public%20health%20priority%20to%20ensure%20PWH%20are%20on%20suppressive%20ART%20and%20vaccinated%2C%20and%20manage%20any%20disruptions%20in%20care%20that%20occurred%20during%20the%20pandemic.%20The%20diagnosis%20and%20management%20of%20comorbidities%2C%20including%20for%20tuberculosis%2C%20should%20be%20optimized.%22%2C%22date%22%3A%22Jun%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26104%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A40%3A36Z%22%7D%7D%2C%7B%22key%22%3A%227SE7PYQH%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lea%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-24%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELea%2C%20A.%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELeyden%2C%20W.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESofrygin%2C%20O.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMarafino%2C%20B.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESkarbinski%2C%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Human%20Immunodeficiency%20Virus%20Status%2C%20Tenofovir%20Exposure%2C%20and%20the%20Risk%20of%20Poor%20Coronavirus%20Disease%2019%20Outcomes%3A%20Real-World%20Analysis%20From%206%20United%20States%20Cohorts%20Before%20Vaccine%20Rollout.%20%3Ci%3EClin%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E76%3C%5C%2Fi%3E%20%2810%29%2C%20S.%201727%26%23x2013%3B1734.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad084%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad084%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Human%20Immunodeficiency%20Virus%20Status%2C%20Tenofovir%20Exposure%2C%20and%20the%20Risk%20of%20Poor%20Coronavirus%20Disease%2019%20Outcomes%3A%20Real-World%20Analysis%20From%206%20United%20States%20Cohorts%20Before%20Vaccine%20Rollout%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20N.%22%2C%22lastName%22%3A%22Lea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20A.%22%2C%22lastName%22%3A%22Leyden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Sofrygin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20J.%22%2C%22lastName%22%3A%22Marafino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Skarbinski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Napravnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Agil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Augenbraun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Benning%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Jefferson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20C.%22%2C%22lastName%22%3A%22Marconi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20S.%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20S.%22%2C%22lastName%22%3A%22Gordon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Bastarache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Gangireddy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20B.%22%2C%22lastName%22%3A%22Coburn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22Gebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20People%20with%20human%20immunodeficiency%20virus%20%28HIV%29%20%28PWH%29%20may%20be%20at%20increased%20risk%20for%20severe%20coronavirus%20disease%202019%20%28COVID-19%29%20outcomes.%20We%20examined%20HIV%20status%20and%20COVID-19%20severity%2C%20and%20whether%20tenofovir%2C%20used%20by%20PWH%20for%20HIV%20treatment%20and%20people%20without%20HIV%20%28PWoH%29%20for%20HIV%20prevention%2C%20was%20associated%20with%20protection.%20METHODS%3A%20Within%206%20cohorts%20of%20PWH%20and%20PWoH%20in%20the%20United%20States%2C%20we%20compared%20the%2090-day%20risk%20of%20any%20hospitalization%2C%20COVID-19%20hospitalization%2C%20and%20mechanical%20ventilation%20or%20death%20by%20HIV%20status%20and%20by%20prior%20exposure%20to%20tenofovir%2C%20among%20those%20with%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection%20between%201%20March%20and%2030%20November%202020.%20Adjusted%20risk%20ratios%20%28aRRs%29%20were%20estimated%20by%20targeted%20maximum%20likelihood%20estimation%2C%20with%20adjustment%20for%20demographics%2C%20cohort%2C%20smoking%2C%20body%20mass%20index%2C%20Charlson%20comorbidity%20index%2C%20calendar%20period%20of%20first%20infection%2C%20and%20CD4%20cell%20counts%20and%20HIV%20RNA%20levels%20%28in%20PWH%20only%29.%20RESULTS%3A%20Among%20PWH%20%28n%20%3D%201785%29%2C%2015%25%20were%20hospitalized%20for%20COVID-19%20and%205%25%20received%20mechanical%20ventilation%20or%20died%2C%20compared%20with%206%25%20and%202%25%2C%20respectively%2C%20for%20PWoH%20%28n%20%3D%20189%20351%29.%20Outcome%20prevalence%20was%20lower%20for%20PWH%20and%20PWoH%20with%20prior%20tenofovir%20use.%20In%20adjusted%20analyses%2C%20PWH%20were%20at%20increased%20risk%20compared%20with%20PWoH%20for%20any%20hospitalization%20%28aRR%2C%201.31%20%5B95%25%20confidence%20interval%2C%201.20-1.44%5D%29%2C%20COVID-19%20hospitalizations%20%281.29%20%5B1.15-1.45%5D%29%2C%20and%20mechanical%20ventilation%20or%20death%20%281.51%20%5B1.19-1.92%5D%29.%20Prior%20tenofovir%20use%20was%20associated%20with%20reduced%20hospitalizations%20among%20PWH%20%28aRR%2C%200.85%20%5B95%25%20confidence%20interval%2C%20.73-.99%5D%29%20and%20PWoH%20%280.71%20%5B.62-.81%5D%29.%20CONCLUSIONS%3A%20Before%20COVID-19%20vaccine%20availability%2C%20PWH%20were%20at%20greater%20risk%20for%20severe%20outcomes%20than%20PWoH.%20Tenofovir%20was%20associated%20with%20a%20significant%20reduction%20in%20clinical%20events%20for%20both%20PWH%20and%20PWoH.%22%2C%22date%22%3A%22May%2024%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciad084%22%2C%22ISSN%22%3A%221537-6591%20%28Electronic%29%201058-4838%20%28Print%29%201058-4838%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A47%3A44Z%22%7D%7D%2C%7B%22key%22%3A%225NYZBK8G%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Queiroz%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EQueiroz%2C%20Artur%20T.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVinhaes%2C%20Caian%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFukutani%2C%20Eduardo%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGupte%2C%20Akshay%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKumar%2C%20Nathella%20Pavan%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20A%20multi-center%2C%20prospective%20cohort%20study%20of%20whole%20blood%20gene%20expression%20in%20the%20tuberculosis-diabetes%20interaction.%20%3Ci%3EScientific%20Reports%3C%5C%2Fi%3E%2C%20%3Ci%3E13%3C%5C%2Fi%3E%20%281%29%2C%20S.%207769.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-023-34847-9%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-023-34847-9%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20multi-center%2C%20prospective%20cohort%20study%20of%20whole%20blood%20gene%20expression%20in%20the%20tuberculosis-diabetes%20interaction%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20R.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akshay%20N.%22%2C%22lastName%22%3A%22Gupte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathella%20Pavan%22%2C%22lastName%22%3A%22Kumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyoshi%20F.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subash%22%2C%22lastName%22%3A%22Babu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjay%22%2C%22lastName%22%3A%22Gaikwad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rajesh%22%2C%22lastName%22%3A%22Karyakarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vidya%22%2C%22lastName%22%3A%22Mave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mandar%22%2C%22lastName%22%3A%22Paradhkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vijay%22%2C%22lastName%22%3A%22Viswanathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amita%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hardy%22%2C%22lastName%22%3A%22Kornfeld%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT%20Brazil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT%20India%20Consortia%22%7D%5D%2C%22abstractNote%22%3A%22Diabetes%20mellitus%20%28DM%29%20increases%20tuberculosis%20%28TB%29%20severity.%20We%20compared%20blood%20gene%20expression%20in%20adults%20with%20pulmonary%20TB%2C%20with%20or%20without%20diabetes%20mellitus%20%28DM%29%20from%20sites%20in%20Brazil%20and%20India.%20RNA%20sequencing%20%28RNAseq%29%20performed%20at%20baseline%20and%20during%20TB%20treatment.%20Publicly%20available%20baseline%20RNAseq%20data%20from%20South%20Africa%20and%20Romania%20reported%20by%20the%20TANDEM%20Consortium%20were%20also%20analyzed.%20Across%20the%20sites%2C%20differentially%20expressed%20genes%20varied%20for%20each%20condition%20%28DM%2C%20TB%2C%20and%20TBDM%29%20and%20no%20pattern%20classified%20any%20one%20group%20across%20all%20sites.%20A%20concise%20signature%20of%20TB%20disease%20was%20identified%20but%20this%20was%20expressed%20equally%20in%20TB%20and%20TBDM.%20Pathway%20enrichment%20analysis%20failed%20to%20distinguish%20TB%20from%20TBDM%2C%20although%20there%20was%20a%20trend%20for%20greater%20neutrophil%20and%20innate%20immune%20pathway%20activation%20in%20TBDM%20participants.%20Pathways%20associated%20with%20insulin%20resistance%2C%20metabolic%20dysfunction%2C%20diabetic%20complications%2C%20and%20chromosomal%20instability%20were%20positively%20correlated%20with%20glycohemoglobin.%20The%20immune%20response%20to%20pulmonary%20TB%20as%20reflected%20by%20whole%20blood%20gene%20expression%20is%20substantially%20similar%20with%20or%20without%20comorbid%20DM.%20Gene%20expression%20pathways%20associated%20with%20the%20microvascular%20and%20macrovascular%20complications%20of%20DM%20are%20upregulated%20during%20TB%2C%20supporting%20a%20syndemic%20interaction%20between%20these%20coprevalent%20diseases.%22%2C%22date%22%3A%222023-05-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-023-34847-9%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222024-01-12T13%3A25%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22TTF9I5PE%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Banholzer%20et%20al.%22%2C%22parsedDate%22%3A%222023-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBanholzer%2C%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZurcher%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJent%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBittel%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFurrer%2C%20L.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20SARS-CoV-2%20transmission%20with%20and%20without%20mask%20wearing%20or%20air%20cleaners%20in%20schools%20in%20Switzerland%3A%20A%20modeling%20study%20of%20epidemiological%2C%20environmental%2C%20and%20molecular%20data.%20%3Ci%3EPLoS%20Med%3C%5C%2Fi%3E%2C%20%3Ci%3E20%3C%5C%2Fi%3E%20%285%29%2C%20S.%20e1004226.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004226%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004226%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22SARS-CoV-2%20transmission%20with%20and%20without%20mask%20wearing%20or%20air%20cleaners%20in%20schools%20in%20Switzerland%3A%20A%20modeling%20study%20of%20epidemiological%2C%20environmental%2C%20and%20molecular%20data%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Banholzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Zurcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Jent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Bittel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Furrer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Hascher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fenner%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Growing%20evidence%20suggests%20an%20important%20contribution%20of%20airborne%20transmission%20to%20the%20overall%20spread%20of%20Severe%20Acute%20Respiratory%20Syndrome%20Coronavirus%202%20%28SARS-CoV-2%29%2C%20in%20particular%20via%20smaller%20particles%20called%20aerosols.%20However%2C%20the%20contribution%20of%20school%20children%20to%20SARS-CoV-2%20transmission%20remains%20uncertain.%20The%20aim%20of%20this%20study%20was%20to%20assess%20transmission%20of%20airborne%20respiratory%20infections%20and%20the%20association%20with%20infection%20control%20measures%20in%20schools%20using%20a%20multiple-measurement%20approach.%20METHODS%20AND%20FINDINGS%3A%20We%20collected%20epidemiological%20%28cases%20of%20Coronavirus%20Disease%202019%20%28COVID-19%29%29%2C%20environmental%20%28CO2%2C%20aerosol%20and%20particle%20concentrations%29%2C%20and%20molecular%20data%20%28bioaerosol%20and%20saliva%20samples%29%20over%207%20weeks%20from%20January%20to%20March%202022%20%28Omicron%20wave%29%20in%202%20secondary%20schools%20%28n%20%3D%2090%2C%20average%2018%20students%5C%2Fclassroom%29%20in%20Switzerland.%20We%20analyzed%20changes%20in%20environmental%20and%20molecular%20characteristics%20between%20different%20study%20conditions%20%28no%20intervention%2C%20mask%20wearing%2C%20air%20cleaners%29.%20Analyses%20of%20environmental%20changes%20were%20adjusted%20for%20different%20ventilation%2C%20the%20number%20of%20students%20in%20class%2C%20school%20and%20weekday%20effects.%20We%20modeled%20disease%20transmission%20using%20a%20semi-mechanistic%20Bayesian%20hierarchical%20model%2C%20adjusting%20for%20absent%20students%20and%20community%20transmission.%20Molecular%20analysis%20of%20saliva%20%2821%5C%2F262%20positive%29%20and%20airborne%20samples%20%2810%5C%2F130%29%20detected%20SARS-CoV-2%20throughout%20the%20study%20%28weekly%20average%20viral%20concentration%200.6%20copies%5C%2FL%29%20and%20occasionally%20other%20respiratory%20viruses.%20Overall%20daily%20average%20CO2%20levels%20were%201%2C064%20%2B%5C%2F-%20232%20ppm%20%28%2B%5C%2F-%20standard%20deviation%29.%20Daily%20average%20aerosol%20number%20concentrations%20without%20interventions%20were%20177%20%2B%5C%2F-%20109%201%5C%2Fcm3%20and%20decreased%20by%2069%25%20%2895%25%20CrI%2042%25%20to%2086%25%29%20with%20mask%20mandates%20and%2039%25%20%2895%25%20CrI%204%25%20to%2069%25%29%20with%20air%20cleaners.%20Compared%20to%20no%20intervention%2C%20the%20transmission%20risk%20was%20lower%20with%20mask%20mandates%20%28adjusted%20odds%20ratio%200.19%2C%2095%25%20CrI%200.09%20to%200.38%29%20and%20comparable%20with%20air%20cleaners%20%281.00%2C%2095%25%20CrI%200.15%20to%206.51%29.%20Study%20limitations%20include%20possible%20confounding%20by%20period%20as%20the%20number%20of%20susceptible%20students%20declined%20over%20time.%20Furthermore%2C%20airborne%20detection%20of%20pathogens%20document%20exposure%20but%20not%20necessarily%20transmission.%20CONCLUSIONS%3A%20Molecular%20detection%20of%20airborne%20and%20human%20SARS-CoV-2%20indicated%20sustained%20transmission%20in%20schools.%20Mask%20mandates%20were%20associated%20with%20greater%20reductions%20in%20aerosol%20concentrations%20than%20air%20cleaners%20and%20with%20lower%20transmission.%20Our%20multiple-measurement%20approach%20could%20be%20used%20to%20continuously%20monitor%20transmission%20risk%20of%20respiratory%20infections%20and%20the%20effectiveness%20of%20infection%20control%20measures%20in%20schools%20and%20other%20congregate%20settings.%22%2C%22date%22%3A%22May%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pmed.1004226%22%2C%22ISSN%22%3A%221549-1676%20%28Electronic%29%201549-1277%20%28Print%29%201549-1277%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A35%3A48Z%22%7D%7D%2C%7B%22key%22%3A%224I6XHRSC%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nachega%20et%20al.%22%2C%22parsedDate%22%3A%222023-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENachega%2C%20J.%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENsanzimana%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERawat%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWilson%2C%20L.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERosenthal%2C%20P.%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Advancing%20detection%20and%20response%20capacities%20for%20emerging%20and%20re-emerging%20pathogens%20in%20Africa.%20%3Ci%3ELancet%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E23%3C%5C%2Fi%3E%20%285%29%2C%20S.%20e185%26%23x2013%3Be189.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2822%2900723-X%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2822%2900723-X%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Advancing%20detection%20and%20response%20capacities%20for%20emerging%20and%20re-emerging%20pathogens%20in%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20B.%22%2C%22lastName%22%3A%22Nachega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Nsanzimana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Rawat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Wilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20J.%22%2C%22lastName%22%3A%22Rosenthal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Siedner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20K.%22%2C%22lastName%22%3A%22Varma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20H.%22%2C%22lastName%22%3A%22Kilmarx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Mutesa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Tanner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Binagwaho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Forrest%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Mbala-Kingebeni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Muyembe-Tamfum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Ntoumi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Zumla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22de%20Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20J.%22%2C%22lastName%22%3A%22Mills%22%7D%5D%2C%22abstractNote%22%3A%22Recurrent%20disease%20outbreaks%20caused%20by%20a%20range%20of%20emerging%20and%20resurging%20pathogens%20over%20the%20past%20decade%20reveal%20major%20gaps%20in%20public%20health%20preparedness%2C%20detection%2C%20and%20response%20systems%20in%20Africa.%20Underlying%20causes%20of%20recurrent%20disease%20outbreaks%20include%20inadequacies%20in%20the%20detection%20of%20new%20infectious%20disease%20outbreaks%20in%20the%20community%2C%20in%20rapid%20pathogen%20identification%2C%20and%20in%20proactive%20surveillance%20systems.%20In%20sub-Saharan%20Africa%2C%20where%2070%25%20of%20zoonotic%20outbreaks%20occur%2C%20there%20remains%20the%20perennial%20risk%20of%20outbreaks%20of%20new%20or%20re-emerging%20pathogens%20for%20which%20no%20vaccines%20or%20treatments%20are%20available.%20As%20the%20Ebola%20virus%20disease%2C%20COVID-19%2C%20and%20mpox%20%28formerly%20known%20as%20monkeypox%29%20outbreaks%20highlight%2C%20a%20major%20paradigm%20shift%20is%20required%20to%20establish%20an%20effective%20infrastructure%20and%20common%20frameworks%20for%20preparedness%20and%20to%20prompt%20national%20and%20regional%20public%20health%20responses%20to%20mitigate%20the%20effects%20of%20future%20pandemics%20in%20Africa.%22%2C%22date%22%3A%22May%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS1473-3099%2822%2900723-X%22%2C%22ISSN%22%3A%221474-4457%20%28Electronic%29%201473-3099%20%28Print%29%201473-3099%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A14%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22DBNA47PF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Murenzi%20et%20al.%22%2C%22parsedDate%22%3A%222023-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMurenzi%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKim%2C%20H.%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShi%2C%20Q.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMuhoza%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMunyaneza%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Association%20Between%20Time%20to%20Antiretroviral%20Therapy%20and%20Loss%20to%20Care%20Among%20Newly%20Diagnosed%20Rwandan%20People%20Living%20with%20Human%20Immunodeficiency%20Virus.%20%3Ci%3EAIDS%20Res%20Hum%20Retroviruses%3C%5C%2Fi%3E%2C%20%3Ci%3E39%3C%5C%2Fi%3E%20%285%29%2C%20S.%20253%26%23x2013%3B261.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2FAID.2022.0023%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2FAID.2022.0023%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20Between%20Time%20to%20Antiretroviral%20Therapy%20and%20Loss%20to%20Care%20Among%20Newly%20Diagnosed%20Rwandan%20People%20Living%20with%20Human%20Immunodeficiency%20Virus%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20Y.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Q.%22%2C%22lastName%22%3A%22Shi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Muhoza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Munyaneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Kubwimana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Remera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Nsanzimana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ross%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20improved%20clinical%20outcomes%20of%20initiating%20antiretroviral%20therapy%20%28ART%29%20soon%20after%20diagnosis%2C%20conflicting%20evidence%20exists%20regarding%20the%20impact%20of%20same-day%20ART%20initiation%20on%20subsequent%20clinical%20outcomes.%20We%20aimed%20to%20characterize%20the%20associations%20of%20time%20to%20ART%20initiation%20with%20loss%20to%20care%20and%20viral%20suppression%20in%20a%20cohort%20of%20newly%20diagnosed%20people%20living%20with%20HIV%20%28PLHIV%29%20entering%20care%20after%20Rwanda%20implemented%20a%20national%20%5C%22Treat%20All%5C%22%20policy.%20We%20conducted%20a%20secondary%20analysis%20of%20routinely%20collected%20data%20of%20adult%20PLHIV%20enrolling%20in%20HIV%20care%20at%2010%20health%20facilities%20in%20Kigali%2C%20Rwanda.%20Time%20from%20enrollment%20to%20ART%20initiation%20was%20categorized%20as%20same%20day%2C%201-7%20days%2C%20or%20%3E7%20days.%20We%20examined%20associations%20between%20time%20to%20ART%20and%20loss%20to%20care%20%28%3E120%20days%20since%20last%20health%20facility%20visit%29%20using%20Cox%20proportional%20hazards%20models%2C%20and%20between%20time%20to%20ART%20and%20viral%20suppression%20using%20logistic%20regression.%20Of%202%2C524%20patients%20included%20in%20this%20analysis%2C%201%2C452%20%2857.5%25%29%20were%20women%20and%20the%20median%20age%20was%2032%20%28interquartile%20range%3A%2026-39%29.%20Loss%20to%20care%20was%20more%20frequent%20among%20patients%20who%20initiated%20ART%20on%20the%20same%20day%20%2815.9%25%29%2C%20compared%20with%20those%20initiating%20ART%201-7%20days%20%2812.3%25%29%20or%20%3E7%20days%20%2810.1%25%29%2C%20p%20%3C%20.001.%20In%20multivariable%20analyses%2C%20same-day%20ART%20initiation%20was%20associated%20with%20a%20greater%20hazard%20of%20loss%20to%20care%20compared%20with%20initiating%20%3E7%20days%20after%20enrollment%20%28adjusted%20hazard%20ratio%201.39%2C%2095%25%20confidence%20interval%3A%201.04-1.85%29.%20A%20total%20of%201%2C698%20%2867.3%25%29%20had%20available%20data%20on%20viral%20load%20measured%20within%20455%20days%20after%20enrollment.%20Of%20these%2C%201%2C476%20%2887%25%29%20were%20virally%20suppressed.%20A%20higher%20proportion%20of%20patients%20initiating%20ART%20on%20the%20same%20day%20were%20virally%20suppressed%20%2889%25%29%20compared%20with%20those%20initiating%201-7%20days%20%2884%25%29%20or%20%3E7%20days%20%2888%25%29%20after%20enrollment.%20This%20association%20was%20not%20statistically%20significant.%20Our%20findings%20suggest%20that%20ensuring%20adequate%2C%20early%20support%20for%20PLHIV%20initiating%20ART%20rapidly%20may%20be%20important%20to%20improve%20retention%20in%20care%20for%20newly%20diagnosed%20PLHIV%20in%20the%20era%20of%20Treat%20All.%22%2C%22date%22%3A%22May%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1089%5C%2FAID.2022.0023%22%2C%22ISSN%22%3A%221931-8405%20%28Electronic%29%200889-2229%20%28Print%29%200889-2229%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A16%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22UHLSUZVX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Admase%20et%20al.%22%2C%22parsedDate%22%3A%222023-04-17%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAdmase%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJoshi%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBorse%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDeshpande%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKulkarni%2C%20V.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Challenges%20with%20the%20use%20of%20Xpert%20HPV%20as%20a%20screening%20tool%20for%20oral%20HPV%20among%20people%20living%20with%20HIV%20%28PLHIV%29%3A%20experiences%20from%20Pune%2C%20India.%20%3Ci%3EBMC%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E23%3C%5C%2Fi%3E%20%281%29%2C%20S.%20233.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-023-08210-2%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-023-08210-2%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Challenges%20with%20the%20use%20of%20Xpert%20HPV%20as%20a%20screening%20tool%20for%20oral%20HPV%20among%20people%20living%20with%20HIV%20%28PLHIV%29%3A%20experiences%20from%20Pune%2C%20India%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Admase%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Joshi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Borse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Deshpande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Kulkarni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Thakur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Chavan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Nimkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Mave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Marbaniang%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20People%20living%20with%20HIV%20%28PLHIV%29%20are%20at%20higher%20risk%20for%20human%20papillomavirus%20%28HPV%29-related%20oropharyngeal%20cancers%20compared%20to%20the%20general%20population.%20Xpert%20HPV%20test%20is%20a%20polymerase%20chain%20reaction%20%28PCR%29%20assay%20capable%20of%20rapid%20HPV%20detection.%20Performing%20the%20assay%20requires%20minimal%20intervention%20by%20laboratory%20personnel.%20Its%20use%20could%20improve%20oropharyngeal%20cancer%20screening%20among%20PLHIV%20living%20in%20low-and%20middle-income%20countries%20%28LMICs%29%20with%20limited%20diagnostic%20capacities.%20However%2C%20Xpert%20HPV%20performance%20for%20oral%20samples%20has%20not%20been%20evaluated.%20Here%2C%20we%20describe%20our%20experience%20with%20Xpert%20HPV%20and%20compare%20its%20results%20with%20traditional%20PCR%2C%20for%20oral%20samples.%20METHODS%3A%20Oral%20samples%20from%20429%20PLHIV%20receiving%20care%20at%20a%20tertiary%20care%20hospital%20affiliated%20antiretroviral%20therapy%20center%20in%20Pune%2C%20India%20were%20used.%20Samples%20were%20collected%20either%20after%20a%2030s%20oral%20rinse%20and%20gargle%20%28n%20%3D%20335%29%20or%20in%20combination%20with%20cytobrush%20scraping%20of%20the%20oral%20mucosa%20%28n%20%3D%2091%29.%20Unsuccessful%20tests%20were%20those%20that%20generated%20an%20invalid%20or%20error%20result%20on%20Xpert%20HPV.%20Successful%20tests%20were%20those%20that%20generated%20a%20positive%20or%20negative%20result.%20Kappa%20statistic%20was%20used%20to%20compare%20concordance%20between%20Xpert%20HPV%20and%20traditional%20real-time%20PCR%20results.%20RESULTS%3A%20There%20were%2029.8%25%20%28n%20%3D%20127%29%20unsuccessful%20tests%2C%20of%20which%2078.7%25%20%28n%20%3D%20100%29%20were%20invalid%20and%2021.3%25%20%28n%20%3D%2027%29%20were%20error%20results.%20Adding%20cytobrush%20scraping%20to%20oral%20rinse%20as%20a%20collection%20procedure%20did%20not%20significantly%20reduce%20the%20proportion%20of%20unsuccessful%20tests%20%28p%20%3D%200.9%29.%20For%20successful%20tests%2C%20HPV%20positivity%20on%20Xpert%20was%200.3%25%20%28n%20%3D%201%5C%2F299%29.%20Kappa%20statistic%20was%200.11%2C%20indicating%20poor%20agreement%20between%20Xpert%20HPV%20and%20traditional%20PCR%20results.%20CONCLUSIONS%3A%20Presently%2C%20Xpert%20HPV%20appears%20to%20have%20limited%20use%20for%20oral%20HPV%20detection%20among%20PLHIV%20using%20oral%20samples.%20More%20research%20to%20improve%20the%20diagnostic%20capabilities%20of%20Xpert%20HPV%20for%20oral%20samples%20among%20PLHIV%20is%20needed.%22%2C%22date%22%3A%22Apr%2017%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12879-023-08210-2%22%2C%22ISSN%22%3A%221471-2334%20%28Electronic%29%201471-2334%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A38%3A37Z%22%7D%7D%5D%7D
Banholzer, Nicolas; Jent, Philipp; Bittel, Pascal; Zürcher, Kathrin; Furrer, Lavinia et al. (2023). Air cleaners and respiratory infections in schools: A modeling study using epidemiological, environmental, and molecular data. MedRxiv: The Preprint Server for Health Sciences, S. 2023.12.29.23300635. http://doi.org/10.1101/2023.12.29.23300635.
Trickey, Adam; Johnson, Leigh F.; Fung, Fai; Bonifacio, Rogerio; Iwuji, Collins et al. (2023). Associations of inter-annual rainfall decreases with subsequent HIV outcomes for persons with HIV on antiretroviral therapy in Southern Africa: a collaborative analysis of cohort studies. BMC Infectious Diseases, 23 (1), S. 889. http://doi.org/10.1186/s12879-023-08902-9.
Hill, Sarah E.; Zhang, Chenshu; Remera, Eric; Ingabire, Charles; Umwiza, Francine et al. (2023). Association Between Clinical Encounter Frequency and HIV-Related Stigma Among Newly-Diagnosed People Living with HIV in Rwanda. AIDS and Behavior. http://doi.org/10.1007/s10461-023-04226-6.
Skrivankova, Veronika W.; Hossmann, Stefanie; Cornell, Morna; Ballif, Marie; Dupont, Carole et al. (2023). Authorship inequalities in global health research: the IeDEA Southern Africa collaboration. BMJ Global Health, 8 (12), S. e013316. http://doi.org/10.1136/bmjgh-2023-013316.
Chammartin, Frédérique; Mocroft, Amanda; Egle, Alexander; Zangerle, Robert; Smith, Colette et al. (2023). Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral Treated People With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, S. ciad671. http://doi.org/10.1093/cid/ciad671.
Rodrigues, Moreno M. S.; Barreto-Duarte, Beatriz; Vinhaes, Caian L.; Araújo-Pereira, Mariana; Fukutani, Eduardo R. et al. (2023). Machine learning algorithms using national registry data to predict loss to follow- up during tuberculosis treatment. Research Square, S. rs.3.rs-3706875. http://doi.org/10.21203/rs.3.rs-3706875/v1.
Grinsztejn, Eduarda; Cardoso, Sandra Wagner; Velasque, Luciane; Hoagland, Brenda; Dos Santos, Desiree Gomes et al. (2023). Impact of Latent M. tuberculosis Infection Treatment on Time to CD4/CD8 Recovery in Acute, Recent, and Chronic HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 94 (4), S. 355–363. http://doi.org/10.1097/QAI.0000000000003284.
DeLong, Stephanie M.; Xu, Yizhen; Genberg, Becky L.; Nyambura, Monicah; Goodrich, Suzanne et al. (2023). Population-Based Estimates and Predictors of Child and Adolescent Linkage to HIV Care or Death in Western Kenya. Journal of Acquired Immune Deficiency Syndromes (1999), 94 (4), S. 281–289. http://doi.org/10.1097/QAI.0000000000003288.
Bourgi, Kassem; Ofner, Susan; Musick, Beverly; Wools-Kaloustian, Kara; Humphrey, John M. et al. (2023). Preswitch Regimens Influence the Rate of Weight Gain After Switch to Tenofovir Disoproxil Fumarate, Lamivudine, and Dolutegravir (TLD): Study From an East African Cohort. Open Forum Infectious Diseases, 10 (12), S. ofad581. http://doi.org/10.1093/ofid/ofad581.
Meireles, Glaucia; Nobre, Aline A.; Cardoso, Sandra W.; Velasque, Luciane; Veloso, Valdilea G. et al. (2023). Real-world effectiveness of WHO recommended first-line antiretroviral therapies: a cohort study from a middle-income country. AIDS Care, 35 (12), S. 1891–1903. http://doi.org/10.1080/09540121.2023.2190954.
Sornillo, Johanna Beulah; Ditangco, Rossana; Lumbiganon, Pagakrong; Vu, Thien An; Le, Oanh Ngoc et al. (2023). Disclosure of HIV status and associated clinical outcomes of children and adolescents living with HIV in Asia. AIDS Care, 35 (12), S. 1928–1937. http://doi.org/10.1080/09540121.2023.2176424.
Morgan, Camille E.; Ngimbi, Patrick; Boisson-Walsh, Alix Jn; Ntambua, Sarah; Matondo, Jolie et al. (2023). Hepatitis B virus prevalence and transmission in the households of pregnant women in Kinshasa, Democratic Republic of Congo. MedRxiv: The Preprint Server for Health Sciences, S. 2023.11.27.23298863. http://doi.org/10.1101/2023.11.27.23298863.
Amorim, Gustavo; Tao, Ran; Lotspeich, Sarah; Shaw, Pamela A.; Lumley, Thomas et al. (2023). Three-phase generalized raking and multiple imputation estimators to address error-prone data. Statistics in Medicine. http://doi.org/10.1002/sim.9967.
Boni, Simon P.; Tenet, Vanessa; Horo, Apollinaire; Heideman, Daniëlle A. M.; Bleeker, Maaike C. G. et al. (2023). High-risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Côte d’Ivoire, 2018 to 2020. International Journal of Cancer. http://doi.org/10.1002/ijc.34774.
Muula, Guy K.; Bosomprah, Samuel; Sinkala, Edford; Nsokolo, Bright; Musonda, Taonga et al. (2023). Hepatitis B viral replication markers and hepatic fibrosis in untreated chronic hepatitis B virus infection with and without HIV coinfection in Zambia. AIDS (London, England), 37 (13), S. 2015–2020. http://doi.org/10.1097/QAD.0000000000003659.
Ruffieux, Yann; Wettstein, Anja; Maartens, Gary; Folb, Naomi; Mesa-Vieira, Cristina et al. (2023). Life years lost associated with mental illness: A cohort study of beneficiaries of a South African medical insurance scheme. Journal of Affective Disorders, 340, S. 204–212. http://doi.org/10.1016/j.jad.2023.08.013.
Loosli, Tom; Hossmann, Stefanie; Ingle, Suzanne M.; Okhai, Hajra; Kusejko, Katharina et al. (2023). HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. The Lancet. HIV, 10 (11), S. e733–e741. http://doi.org/10.1016/S2352-3018(23)00228-X.
Boni, Simon P.; Horo, Apollinaire; Didi-Kouko-Coulibaly, Judith; Tanon, Aristophane; Tchounga, Boris K. et al. (2023). Impact of HIV infection on access to cancer care and survival among women with invasive cervical cancer in Côte d’Ivoire: A prospective cohort study. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics, 163 (2), S. 392–401. http://doi.org/10.1002/ijgo.14925.
Lesko, Catherine R.; Falade-Nwulia, Oluwaseun O.; Pytell, Jarratt D.; Hutton, Heidi E.; Fojo, Anthony T. et al. (2023). Joint effects of substance use disorders and recent substance use on HIV viral non-suppression among people engaged in HIV care in an urban clinic, 2014-2019. Addiction (Abingdon, England), 118 (11), S. 2193–2202. http://doi.org/10.1111/add.16301.
Zotova, Natalia; Munyaneza, Athanase; Murenzi, Gad; Kubwimana, Gallican; Adedimeji, Adebola et al. (2023). Low birth weight among infants and pregnancy outcomes among women living with HIV and HIV-negative women in Rwanda. Research Square, S. rs.3.rs-3467879. http://doi.org/10.21203/rs.3.rs-3467879/v1.
Metekoua, Carole; Ruffieux, Yann; Olago, Victor; Dhokotera, Tafadzwa; Egger, Matthias et al. (2023). Decreasing incidence of conjunctival squamous cell carcinoma in people with HIV in South Africa. Journal of the National Cancer Institute, 115 (10), S. 1213–1219. http://doi.org/10.1093/jnci/djad119.
Rudolph, Jacqueline E.; Calkins, Keri; Xu, Xiaoqiang; Wentz, Eryka; Pirsl, Filip et al. (2023). Comparing cancer incidence in an observational cohort of Medicaid beneficiaries with and without HIV, 2001-2015. Journal of Acquired Immune Deficiency Syndromes (1999). http://doi.org/10.1097/QAI.0000000000003318.
Dantuluri, Meghana L.; Rubin, Leah H.; Manabe, Yukari C.; Moore, Richard D. & Althoff, Keri N. (2023). Selection of cognitive impairment screening tools for longitudinal implementation in an HIV clinical care setting. AIDS Care, 35 (10), S. 1619–1627. http://doi.org/10.1080/09540121.2023.2165614.
Eden, Svetlana K.; Li, Chun & Shepherd, Bryan E. (2023). Spearman-like correlation measure adjusting for covariates in bivariate survival data. Biometrical Journal. Biometrische Zeitschrift, S. e2200137. http://doi.org/10.1002/bimj.202200137.
Kasaie, Parastu; Stewart, Cameron; Humes, Elizabeth; Gerace, Lucas; Hyle, Emily P. et al. (2023). Impact of subgroup-specific heterogeneities and dynamic changes in mortality rates on forecasted population size, deaths, and age distribution of persons receiving antiretroviral treatment in the United States: a computer simulation study. Annals of Epidemiology, S. S1047- 2797(23)00171- 0. http://doi.org/10.1016/j.annepidem.2023.09.005.
Ingabire, Charles; Watnick, Dana; Gasana, Josephine; Umwiza, Francine; Munyaneza, Athanase et al. (2023). Experiences of stigma and HIV care engagement in the context of Treat All in Rwanda: a qualitative study. BMC Public Health, 23 (1), S. 1817. http://doi.org/10.1186/s12889-023-16752-y.
Slogrove, Amy L.; Bovu, Andisiwe; de Beer, Shani; Phelanyane, Florence; Williams, Paige L. et al. (2023). Maternal and birth outcomes in pregnant people with and without HIV in the Western Cape, South Africa: population-based cohort study. AIDS (London, England). http://doi.org/10.1097/QAD.0000000000003728.
Hansford, Harrison J.; Cashin, Aidan G.; Jones, Matthew D.; Swanson, Sonja A.; Islam, Nazrul et al. (2023). Development of the TrAnsparent ReportinG of observational studies Emulating a Target trial (TARGET) guideline. BMJ Open, 13 (9), S. e074626. http://doi.org/10.1136/bmjopen-2023-074626.
Davy-Mendez, Thibaut; Napravnik, Sonia; Hogan, Brenna C.; Eron, Joseph J.; Gebo, Kelly A. et al. (2023). Hospital Readmissions among Persons with HIV in the United States and Canada, 2005-2018: A Collaboration of Cohort Studies. The Journal of Infectious Diseases, S. jiad396. http://doi.org/10.1093/infdis/jiad396.
Olago, Victor; Nimako, Gideon; Bartels, Lina; Bohlius, Julia; Dhokotera, Tafadzwa et al. (2023). Cancer diagnostic service use in people with HIV in South Africa: a cross-sectional study. MedRxiv: The Preprint Server for Health Sciences, S. 2023.09.10.23295338. http://doi.org/10.1101/2023.09.10.23295338.
Fuller, Gordon Ward; Hasan, Madina; Hodkinson, Peter; McAlpine, David; Goodacre, Steve et al. (2023). Training and testing of a gradient boosted machine learning model to predict adverse outcome in patients presenting to emergency departments with suspected covid-19 infection in a middle-income setting. PLOS Digital Health, 2 (9), S. e0000309. http://doi.org/10.1371/journal.pdig.0000309.
Nachega, Jean B.; Musoke, Philippa; Kilmarx, Peter H.; Gandhi, Monica; Grinsztejn, Beatriz et al. (2023). Global HIV control: is the glass half empty or half full? The Lancet. HIV, 10 (9), S. e617–e622. http://doi.org/10.1016/S2352-3018(23)00150-9.
Bocage, A. E.; Coelho, L. E.; Lake, J. E.; Clark, J. L.; Torres, T. S. et al. (2023). The Impact of COVID-19 on HIV Care in Rio de Janeiro, Brazil 2019-2021: Disparities by Age and Gender. AIDS Behav, 27 (8), S. 2629–2641. http://doi.org/10.1007/s10461-023-03988-3.
Sudjaritruk, Tavitiya; Kanjanavanit, Suparat; Chaito, Tanachot; Sricharoen, Natthanidnan; Prasarakee, Chanidapa et al. (2023). A Three-Year Follow-Up of Bone Density Among Thai Adolescents With Perinatally Acquired HIV After Completion of Vitamin D and Calcium Supplementation. The Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine, 73 (2), S. 262–270. http://doi.org/10.1016/j.jadohealth.2023.03.012.
Parcesepe, Angela M.; Stockton, Melissa; Remch, Molly; Wester, C. William; Bernard, Charlotte et al. (2023). Availability of screening and treatment for common mental disorders in HIV clinic settings: data from the global International epidemiology Databases to Evaluate AIDS (IeDEA) Consortium, 2016-2017 and 2020. Journal of the International AIDS Society, 26 (8), S. e26147. http://doi.org/10.1002/jia2.26147.
Chiarappa, Joseph A.; Hoover, Donald R. & Pedley, Alison (2023). Economizing comparative Poisson clinical trials of multiple experimental treatments by testing against the same control. Statistical Methods in Medical Research, 32 (8), S. 1604–1615. http://doi.org/10.1177/09622802231181235.
Zhou, W.; Bakoyannis, G.; Zhang, Y. & Yiannoutsos, C. T. (2023). Semiparametric marginal regression for clustered competing risks data with missing cause of failure. Biostatistics, 24 (3), S. 795–810. http://doi.org/10.1093/biostatistics/kxac012.
Thomadakis, C.; Yiannoutsos, C. T.; Pantazis, N.; Diero, L.; Mwangi, A. et al. (2023). The Effect of HIV Treatment Interruption on Subsequent Immunological Response. Am J Epidemiol, 192 (7), S. 1181–1191. http://doi.org/10.1093/aje/kwad076.
Ingle, S. M.; Miro, J. M.; May, M. T.; Cain, L. E.; Schwimmer, C. et al. (2023). Early Antiretroviral Therapy Not Associated With Higher Cryptococcal Meningitis Mortality in People With Human Immunodeficiency Virus in High-Income Countries: An International Collaborative Cohort Study. Clin Infect Dis, 77 (1), S. 64–73. http://doi.org/10.1093/cid/ciad122.
Haas, Andreas D.; Kunzekwenyika, Cordelia; Manzero, Josphat; Hossmann, Stefanie; Limacher, Andreas et al. (2023). Effect of the Friendship Bench Intervention on Antiretroviral Therapy Outcomes and Mental Health Symptoms in Rural Zimbabwe: A Cluster Randomized Trial. JAMA Network Open, 6 (7), S. e2323205. http://doi.org/10.1001/jamanetworkopen.2023.23205.
Marincowitz, C.; Sbaffi, L.; Hasan, M.; Hodkinson, P.; McAlpine, D. et al. (2023). External validation of triage tools for adults with suspected COVID-19 in a middle-income setting: an observational cohort study. Emerg Med J, 40 (7), S. 509–517. http://doi.org/10.1136/emermed-2022-212827.
Person, Anna K.; Crabtree-Ramirez, Brenda; Kim, Ahra; Veloso, Valdiléa; Maruri, Fernanda et al. (2023). Cryptococcal Meningitis and Clinical Outcomes in Persons With Human Immunodeficiency Virus: A Global View. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 76 (12), S. 2116–2125. http://doi.org/10.1093/cid/ciad076.
Kubjane, M.; Cornell, M.; Osman, M.; Boulle, A. & Johnson, L. F. (2023). Drivers of sex differences in the South African adult tuberculosis incidence and mortality trends, 1990-2019. Sci Rep, 13 (1), S. 9487. http://doi.org/10.1038/s41598-023-36432-6.
Kassanjee, R.; Davies, M. A.; Ngwenya, O.; Osei-Yeboah, R.; Jacobs, T. et al. (2023). COVID-19 among adults living with HIV: correlates of mortality among public sector healthcare users in Western Cape, South Africa. J Int AIDS Soc, 26 (6), S. e26104. http://doi.org/10.1002/jia2.26104.
Lea, A. N.; Leyden, W. A.; Sofrygin, O.; Marafino, B. J.; Skarbinski, J. et al. (2023). Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout. Clin Infect Dis, 76 (10), S. 1727–1734. http://doi.org/10.1093/cid/ciad084.
Queiroz, Artur T. L.; Vinhaes, Caian L.; Fukutani, Eduardo R.; Gupte, Akshay N.; Kumar, Nathella Pavan et al. (2023). A multi-center, prospective cohort study of whole blood gene expression in the tuberculosis-diabetes interaction. Scientific Reports, 13 (1), S. 7769. http://doi.org/10.1038/s41598-023-34847-9.
Banholzer, N.; Zurcher, K.; Jent, P.; Bittel, P.; Furrer, L. et al. (2023). SARS-CoV-2 transmission with and without mask wearing or air cleaners in schools in Switzerland: A modeling study of epidemiological, environmental, and molecular data. PLoS Med, 20 (5), S. e1004226. http://doi.org/10.1371/journal.pmed.1004226.
Nachega, J. B.; Nsanzimana, S.; Rawat, A.; Wilson, L. A.; Rosenthal, P. J. et al. (2023). Advancing detection and response capacities for emerging and re-emerging pathogens in Africa. Lancet Infect Dis, 23 (5), S. e185–e189. http://doi.org/10.1016/S1473-3099(22)00723-X.
Murenzi, G.; Kim, H. Y.; Shi, Q.; Muhoza, B.; Munyaneza, A. et al. (2023). Association Between Time to Antiretroviral Therapy and Loss to Care Among Newly Diagnosed Rwandan People Living with Human Immunodeficiency Virus. AIDS Res Hum Retroviruses, 39 (5), S. 253–261. http://doi.org/10.1089/AID.2022.0023.
Admase, A.; Joshi, S.; Borse, R.; Deshpande, P.; Kulkarni, V. et al. (2023). Challenges with the use of Xpert HPV as a screening tool for oral HPV among people living with HIV (PLHIV): experiences from Pune, India. BMC Infect Dis, 23 (1), S. 233. http://doi.org/10.1186/s12879-023-08210-2.
2022
2775998
GXCKG69T
2022
1
padagogische-hochschule-bern-institut-vorschulstufe-und-primarstufe
50
date
desc
1194
https://www.iedea.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A50%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%2298CREFCG%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Salvi%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-17%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESalvi%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERaichur%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKadam%2C%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESangle%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGupte%2C%20N.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Virological%20failure%20among%20people%20living%20with%20HIV%20receiving%20second-line%20antiretroviral%20therapy%20in%20Pune%2C%20India.%20%3Ci%3EBMC%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E22%3C%5C%2Fi%3E%20%281%29%2C%20S.%20951.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-022-07894-2%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-022-07894-2%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Virological%20failure%20among%20people%20living%20with%20HIV%20receiving%20second-line%20antiretroviral%20therapy%20in%20Pune%2C%20India%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Salvi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Raichur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Kadam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Sangle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Gupte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Nevrekar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Patil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Chavan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Nimkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Marbaniang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Mave%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20number%20of%20people%20receiving%20second-line%20antiretroviral%20therapy%20%28ART%29%20has%20increased%20as%20global%20access%20to%20ART%20has%20expanded.%20Data%20on%20the%20burden%20and%20factors%20associated%20with%20second-line%20ART%20virologic%20failure%20%28VF%29%20from%20India%20remain%20limited.%20METHODS%3A%20We%20conducted%20cross-sectional%20viral%20load%20%28VL%29%20testing%20among%20adults%20%28%3E%5C%2F%3D%2018%20years%29%20who%20were%20registered%20at%20a%20publicly%20funded%20ART%20center%20in%20western%20India%20between%202014%20and%202015%20and%20had%20received%20second-line%20ART%20for%20at%20least%206%20months.%20Sociodemographic%20and%20clinical%20characteristics%20were%20abstracted%20from%20routinely%20collected%20programmatic%20data.%20Logistic%20regression%20evaluated%20factors%20associated%20with%20VF%20%28defined%20as%20VL%20%3E%201000%20copies%5C%2FmL%29.%20RESULTS%3A%20Among%20400%20participants%2C%20median%20age%20was%2040%20years%20%28IQR%2034-44%29%2C%2071%25%20%28285%5C%2F400%29%20were%20male%2C%20and%2015%25%20%2859%5C%2F400%29%20had%20VF.%20Relative%20to%20participants%20without%20VF%2C%20those%20with%20VF%20had%20lower%20median%20CD4%20counts%20%28230%20vs%20406%20cells%5C%2Fmm%283%29%2C%20p%20%3C%200.0001%29%2C%20lower%20weight%20at%20first-line%20failure%20%2849%20vs%2052%20kg%2C%20p%20%3D%200.003%29%2C%20were%20more%20likely%20to%20have%20an%20opportunistic%20infection%20%2817%25%20vs%203%25%2C%20p%20%3C%200.0001%29%20and%20less%20likely%20to%20have%20optimal%20ART%20adherence%20%2871%25%20vs%2087%25%2C%20p%20%3D%200.005%29.%20In%20multivariable%20analysis%2C%20VF%20was%20associated%20with%20opportunistic%20infection%20%28aOR%2C%204.84%3B%2095%25%20CI%2C%201.77-13.24%29%2C%20lower%20CD4%20count%20%28aOR%204.15%3B%2095%25%20CI%2C%201.98-8.71%29%20and%20lower%20weight%20at%20first-line%20failure%20%28aOR%2C%202.67%3B%2095%25%20CI%2C%201.33-5.34%29.%20CONCLUSIONS%3A%20We%20found%20second-line%20VF%20in%20about%20a%20sixth%20of%20participants%20in%20our%20setting%2C%20which%20was%20associated%20with%20nearly%20fivefold%20increased%20odds%20in%20the%20context%20of%20opportunistic%20infection.%20Weight%20could%20be%20a%20useful%20clinical%20indicator%20for%20second-line%20VF.%22%2C%22date%22%3A%22Dec%2017%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12879-022-07894-2%22%2C%22ISSN%22%3A%221471-2334%20%28Electronic%29%201471-2334%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A33%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22ER3TKIH8%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bourgi%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-15%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBourgi%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOfner%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMusick%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGriffith%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDiero%2C%20L.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Weight%20Gain%20Among%20Treatment-Naive%20Persons%20With%20HIV%20Receiving%20Dolutegravir%20in%20Kenya.%20%3Ci%3EJ%20Acquir%20Immune%20Defic%20Syndr%3C%5C%2Fi%3E%2C%20%3Ci%3E91%3C%5C%2Fi%3E%20%285%29%2C%20S.%20490%26%23x2013%3B496.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003087%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003087%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Weight%20Gain%20Among%20Treatment-Naive%20Persons%20With%20HIV%20Receiving%20Dolutegravir%20in%20Kenya%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Bourgi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Ofner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Griffith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20K.%22%2C%22lastName%22%3A%22Gupta%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Several%20recent%20studies%20have%20linked%20integrase%20strand%20transfer%20inhibitors%20%28INSTI%29%20with%20increased%20weight%20gain.%20SETTING%3A%20The%20effects%20of%20sex%20on%20weight%20gain%20with%20dolutegravir%20%28DTG%29-based%20antiretroviral%20therapy%20%28ART%29%20among%20treatment-naive%20participants%20in%20a%20lower-income%2C%20sub-Saharan%20population%20with%20high%20rates%20of%20pre-ART%20underweight%20and%20tuberculosis%20%28TB%29%20coinfection%20are%20unknown.%20METHODS%3A%20Our%20analysis%20included%20treatment-naive%20participants%20in%20Kenya%20and%20starting%20their%20first%20treatment%20regimen%20between%20January%201%2C%202015%2C%20and%20September%2030%2C%202018.%20Participants%20were%20grouped%20into%202%20cohorts%20based%20on%20the%20initial%20treatment%20regimen%20%5BDTG%20vs.%20nonnucleoside%20reverse%20transcriptase%20inhibitors%20%28NNRTI%29%5D.%20We%20modelled%20weight%20changes%20over%20time%20using%20a%20multivariable%20nonlinear%20mixed-effect%20model%2C%20with%20participant%20as%20a%20random%20effect.%20Logistic%20regression%20models%20were%20constructed%20to%20evaluate%20the%20association%20between%20different%20variables%20with%20extreme%20increase%20in%20body%20mass%20index%20%28%3E%5C%2F%3D10%25%20increase%29.%20RESULTS%3A%20Seventeen%20thousand%20forty-four%20participants%20met%20our%20inclusion%20criteria.%20Sixty-two%20percent%20of%20participants%20were%20women%2C%206%25%20were%20receiving%20active%20TB%20therapy%2C%20and%2097%25%20were%20on%20NNRTI-based%20regimens.%20Participants%20starting%20DTG-based%20regimens%20were%20more%20likely%20to%20gain%20weight%20when%20compared%20with%20participants%20starting%20NNRTI-based%20regimens.%20Female%20participants%20starting%20DTG-based%20regimens%20experienced%20the%20highest%20weight%20gain%20compared%20with%20other%20participants%20%28mean%20gain%20of%206.1%20kgs%20at%2018%20months%29.%20Female%20participants%20receiving%20DTG-based%20regimens%2C%20along%20with%20participants%20with%20lower%20CD4%20cell%20counts%2C%20underweight%20at%20baseline%2C%20and%20those%20receiving%20active%20TB%20therapy%20were%20also%20at%20higher%20risk%20for%20extreme%20body%20mass%20index%20increase.%20CONCLUSIONS%3A%20Our%20study%20in%20a%20lower-income%20sub-Saharan%20African%20population%20confirms%20higher%20weight%20gain%20with%20DTG-based%20regimens%20compared%20with%20traditional%20ART%20for%20treatment-naive%20patients.%22%2C%22date%22%3A%22Dec%2015%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003087%22%2C%22ISSN%22%3A%221944-7884%20%28Electronic%29%201525-4135%20%28Print%29%201525-4135%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A34%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22TE2K37AV%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lesko%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELesko%2C%20C.%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKeruly%2C%20J.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMoore%2C%20R.%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShen%2C%20N.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPytell%2C%20J.%20D.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20COVID-19%20and%20the%20HIV%20continuum%20in%20people%20living%20with%20HIV%20enrolled%20in%20Collaborating%20Consortium%20of%20Cohorts%20Producing%20NIDA%20Opportunities%20%28C3PNO%29%20cohorts.%20%3Ci%3EDrug%20Alcohol%20Depend%3C%5C%2Fi%3E%2C%20%3Ci%3E241%3C%5C%2Fi%3E%2C%20S.%20109355.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.drugalcdep.2022.109355%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.drugalcdep.2022.109355%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22COVID-19%20and%20the%20HIV%20continuum%20in%20people%20living%20with%20HIV%20enrolled%20in%20Collaborating%20Consortium%20of%20Cohorts%20Producing%20NIDA%20Opportunities%20%28C3PNO%29%20cohorts%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20R.%22%2C%22lastName%22%3A%22Lesko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20C.%22%2C%22lastName%22%3A%22Keruly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20M.%22%2C%22lastName%22%3A%22Shen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20D.%22%2C%22lastName%22%3A%22Pytell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Lau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20T.%22%2C%22lastName%22%3A%22Fojo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20H.%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kipke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20K.%22%2C%22lastName%22%3A%22Baum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Shoptaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20M.%22%2C%22lastName%22%3A%22Gorbach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Mustanski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Javanbakht%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Siminski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Chander%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20COVID-19%20pandemic%20disrupted%20the%20normal%20delivery%20of%20HIV%20care%2C%20altered%20social%20support%20networks%2C%20and%20caused%20economic%20insecurity.%20People%20with%20HIV%20%28PWH%29%20are%20vulnerable%20to%20such%20disruptions%2C%20particularly%20if%20they%20have%20a%20history%20of%20substance%20use.%20We%20describe%20engagement%20in%20care%20and%20adherence%20to%20antiretroviral%20therapy%20%28ART%29%20for%20PWH%20during%20the%20pandemic.%20METHODS%3A%20From%20May%202020%20to%20February%202021%2C%20773%20PWH%20enrolled%20in%206%20existing%20cohorts%20completed%201495%20surveys%20about%20substance%20use%20and%20engagement%20in%20HIV%20care%20during%20the%20COVID-19%20pandemic.%20We%20described%20the%20prevalence%20and%20correlates%20of%20having%20missed%20a%20visit%20with%20an%20HIV%20provider%20in%20the%20past%20month%20and%20having%20missed%20a%20dose%20of%20ART%20in%20the%20past%20week.%20RESULTS%3A%20Thirteen%20percent%20of%20people%20missed%20an%20HIV%20visit%20in%20the%20past%20month.%20Missing%20a%20visit%20was%20associated%20with%20unstable%20housing%2C%20food%20insecurity%2C%20anxiety%2C%20low%20resiliency%2C%20disruptions%20to%20mental%20health%20care%2C%20and%20substance%20use%20including%20cigarette%20smoking%2C%20hazardous%20alcohol%20use%2C%20cocaine%2C%20and%20cannabis%20use.%20Nineteen%20percent%20of%20people%20reported%20missing%20at%20least%20one%20dose%20of%20ART%20in%20the%20week%20prior%20to%20their%20survey.%20Missing%20a%20dose%20of%20ART%20was%20associated%20with%20being%20a%20man%2C%20low%20resiliency%2C%20disruptions%20to%20mental%20health%20care%2C%20cigarette%20smoking%2C%20hazardous%20alcohol%20use%2C%20cocaine%2C%20and%20cannabis%20use%2C%20and%20experiencing%20disruptions%20to%20substance%20use%20treatment.%20CONCLUSIONS%3A%20Social%20determinants%20of%20health%2C%20substance%20use%2C%20and%20disruptions%20to%20mental%20health%20and%20substance%20use%20treatment%20were%20associated%20with%20poorer%20engagement%20in%20HIV%20care.%20Close%20attention%20to%20continuity%20of%20care%20during%20times%20of%20social%20disruption%20is%20especially%20critical%20for%20PWH.%22%2C%22date%22%3A%22Dec%201%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.drugalcdep.2022.109355%22%2C%22ISSN%22%3A%221879-0046%20%28Electronic%29%200376-8716%20%28Print%29%200376-8716%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A40%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22LHALPPPF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22McCann%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMcCann%2C%20N.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStanic%2C%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPenazzato%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFlanagan%2C%20C.%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAbrams%2C%20E.%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Prevalence%20of%20undiagnosed%20HIV%20among%20children%20in%20South%20Africa%2C%20Cote%20d%26%23x2019%3BIvoire%20and%20Zimbabwe%3A%20a%20model-based%20analysis%20to%20inform%20paediatric%20HIV%20screening%20programmes.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%2812%29%2C%20S.%20e26045.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26045%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26045%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prevalence%20of%20undiagnosed%20HIV%20among%20children%20in%20South%20Africa%2C%20Cote%20d%27Ivoire%20and%20Zimbabwe%3A%20a%20model-based%20analysis%20to%20inform%20paediatric%20HIV%20screening%20programmes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20C.%22%2C%22lastName%22%3A%22McCann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Stanic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Penazzato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20F.%22%2C%22lastName%22%3A%22Flanagan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20J.%22%2C%22lastName%22%3A%22Abrams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20M.%22%2C%22lastName%22%3A%22Dugdale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Neilan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22Freedberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Fassinou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Doherty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Essajee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mushavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20I.%22%2C%22lastName%22%3A%22Soeteman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Ciaranello%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20To%20improve%20the%20diagnosis%20and%20survival%20of%20children%20living%20with%20HIV%20%28CLWH%29%2C%20the%20World%20Health%20Organization%20recommends%20testing%20approaches%20beyond%20traditional%20infant%20HIV%20testing%20programmes.%20Information%20about%20undiagnosed%20HIV%20prevalence%20among%20children%20of%20varying%20ages%20in%20the%20general%20population%20is%20needed%20to%20guide%20innovative%20national%5C%2Fsubnational%20case-finding%20and%20testing%20approaches.%20METHODS%3A%20We%20used%20the%20Cost-Effectiveness%20of%20Preventing%20AIDS%20Complications%20%28CEPAC%29-Pediatric%20model%20to%20estimate%20the%20prevalence%20of%20undiagnosed%20HIV%20in%202-%2C%205-%20and%2010-year-old%20children%20in%20South%20Africa%2C%20Cote%20d%27Ivoire%20and%20Zimbabwe%20in%202018.%20We%20simulated%20cohorts%20of%20children%20born%20in%202008%20%2810-year-olds%29%2C%202013%20%285-year-olds%29%20and%202016%20%282-year-olds%29.%20Country-%5C%2Fyear-specific%20inputs%20for%20pregnant%5C%2Fbreastfeeding%20women%20included%3A%20HIV%20prevalence%20%284.2-32.3%25%29%2C%20HIV%20incidence%20%280.03-0.24%25%5C%2Fmonth%29%2C%20knowledge%20of%20HIV%20status%20%2827-89%25%29%20and%20antiretroviral%20drug%20coverage%20%2836-95%25%29.%20Paediatric%20inputs%20included%20early%20infant%20testing%20coverage%20%286-95%25%29%20and%20breastfeeding%20duration%20%280-20%20months%29.%20We%20projected%20the%20proportion%20of%20surviving%20CLWH%20in%20whom%20HIV%20remained%20undiagnosed%20and%20the%20undiagnosed%20HIV%20prevalence%20among%20surviving%20children%20of%20each%20age%20in%20the%20general%20population.%20For%20children%20born%20in%202016%2C%20we%20projected%20survival%20and%20diagnosis%20of%20all%20CLWH%20through%202026.%20We%20conducted%20sensitivity%20analyses%20on%20model%20parameters.%20RESULTS%3A%20In%202018%2C%20the%20projected%20proportion%20of%20surviving%20CLWH%20whose%20HIV%20remained%20undiagnosed%20in%20South%20Africa%5C%2FCote%20d%27Ivoire%5C%2FZimbabwe%20was%2044.2%25%5C%2F55.8%25%5C%2F52.9%25%20among%202-year-old%20CLWH%3B%2029.0%25%5C%2F37.8%25%5C%2F33.2%25%20among%205-year-old%20CLWH%3B%20and%2018.3%25%5C%2F25.4%25%5C%2F23.1%25%20among%2010-year-old%20CLWH.%20Projected%20general%20population%20undiagnosed%20HIV%20prevalence%20in%20South%20Africa%5C%2FCote%20d%27Ivoire%5C%2FZimbabwe%20was%200.44%25%5C%2F0.32%25%5C%2F0.68%25%20among%202-year-olds%3B%200.25%25%5C%2F0.17%25%5C%2F0.41%25%20among%205-year-olds%3B%20and%200.24%25%5C%2F0.14%25%5C%2F0.38%25%20among%2010-year-olds.%20Among%20all%20CLWH%20born%20in%202016%2C%2050-54%25%20were%20projected%20to%20die%20without%20HIV%20diagnosis%20%28and%20subsequently%20without%20treatment%29%20within%2010%20years%20after%20birth%3B%2080-85%25%20of%20these%20deaths%20occurred%20in%20the%20first%202%20years.%20CONCLUSIONS%3A%20Projected%20population-level%20undiagnosed%20HIV%20prevalence%20is%20low%20and%20sharply%20decreases%20after%20age%202%2C%20with%20more%20CLWH%20dying%20than%20being%20diagnosed.%20Despite%20low%20undiagnosed%20prevalence%20in%20the%20general%20population%20of%20older%20children%2C%20we%20project%20that%20a%20large%20proportion%20of%20CLWH%20remain%20undiagnosed%2C%20suggesting%20that%20innovative%20strategies%20targeting%20untested%20children%20of%20all%20ages%20outside%20of%20health%20facility%20settings%20should%20be%20prioritized.%20Programmes%20could%20consider%20routine%20testing%20of%20the%20general%20population%20of%20children%20below%202%20in%20all%20settings%20and%20children%20of%20all%20ages%20in%20high-prevalence%20settings.%22%2C%22date%22%3A%22Dec%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26045%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A24%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22P6SLCVLG%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chihota%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChihota%2C%20B.%20V.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMandiriri%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShamu%2C%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMuula%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENyamutowa%2C%20H.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Metabolic%20syndrome%20among%20treatment-naive%20people%20living%20with%20and%20without%20HIV%20in%20Zambia%20and%20Zimbabwe%3A%20a%20cross-sectional%20analysis.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%2812%29%2C%20S.%20e26047.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26047%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26047%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Metabolic%20syndrome%20among%20treatment-naive%20people%20living%20with%20and%20without%20HIV%20in%20Zambia%20and%20Zimbabwe%3A%20a%20cross-sectional%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20V.%22%2C%22lastName%22%3A%22Chihota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mandiriri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Shamu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Muula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Nyamutowa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Taderera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Mwamba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Chilengi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bolton-Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bosomprah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20Southern%20Africa%22%2C%22lastName%22%3A%22for%20Ie%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Chronic%20viral%20replication%20has%20been%20linked%20to%20an%20increased%20risk%20of%20cardiovascular%20and%20metabolic%20diseases%20in%20people%20living%20with%20HIV%20%28PLWH%29%2C%20but%20few%20studies%20have%20evaluated%20this%20association%20in%20Southern%20Africa.%20We%20explored%20the%20determinants%20of%20metabolic%20syndrome%20%28MetS%29%20among%20treatment-naive%20adults%20living%20with%20and%20without%20HIV%20in%20Southern%20Africa.%20METHODS%3A%20Treatment-naive%20PLWH%20and%20people%20living%20without%20HIV%20%28PLWOH%29%20%3E%5C%2F%3D30%20years%20were%20consecutively%20enrolled%20from%20primary%20care%20clinics%20in%20Zambia%20and%20Zimbabwe.%20PLWOH%20were%20seronegative%20partners%20or%20persons%20presenting%20for%20HIV%20testing.%20We%20defined%20MetS%20as%20the%20presence%20of%20central%20obesity%20plus%20any%20two%20of%20the%20following%3A%20raised%20blood%20pressure%2C%20impaired%20fasting%20glucose%2C%20reduced%20high-density%20lipoprotein%20cholesterol%20and%20raised%20triglycerides%2C%20as%20defined%20by%20the%20International%20Diabetes%20Federation.%20We%20used%20logistic%20regression%20to%20determine%20factors%20associated%20with%20MetS.%20RESULTS%3A%20Between%20August%202019%20and%20March%202022%2C%20we%20screened%201285%20adults%20and%20enrolled%20420%20%2847%25%29%20PLWH%20and%20481%20%2853%25%29%20PLWOH.%20The%20median%20age%20was%20similar%20between%20PLWH%20and%20PLWOH%20%2840%20vs.%2038%20years%2C%20p%20%3C%200.24%29.%20In%20PLWH%2C%20the%20median%20CD4%28%2B%29%20count%20was%20228%20cells%5C%2Fmm%283%29%20%28IQR%20108-412%29%20and%20the%20viral%20load%20was%2024%2C114%20copies%5C%2Fml%20%28IQR%20277-214%2C271%29.%20Central%20obesity%20was%20present%20in%20365%5C%2F523%20%2870%25%29%20females%20and%2057%5C%2F378%20males%20%2815%25%29.%20MetS%20was%20diagnosed%20in%20172%5C%2F901%20%2819%25%2C%2095%25%20confidence%20interval%20%5BCI%5D%2017-22%25%29%2C%20and%20prevalence%20was%20higher%20among%20females%20than%20males%20%2827%25%20vs.%209%25%29.%20In%20multivariable%20analyses%2C%20HIV%20status%20was%20not%20associated%20with%20MetS%20%28adjusted%20odds%20ratio%20%5BaOR%5D%201.05%2C%2095%25%20CI%200.74-1.51%29.%20Risk%20factors%20for%20MetS%20included%20age%20older%20than%2050%20years%20%28aOR%202.31%2C%2095%25%20CI%201.49-3.59%29%2C%20female%20sex%20%28aOR%203.47%2C%2095%25%20CI%202.15-5.60%29%2C%20highest%20income%20%28aOR%202.19%2C%2095%25%20CI%201.39-3.44%29%20and%20less%20than%20World%20Health%20Organization%20recommended%20weekly%20physical%20activity%20%28aOR%203.35%2C%2095%25%20CI%201.41-7.96%29.%20CONCLUSIONS%3A%20We%20report%20a%20high%20prevalence%20of%20MetS%20and%20central%20obesity%20among%20females%20in%20urban%20Zambia%20and%20Zimbabwe.%20Lifestyle%20factors%20and%20older%20age%20appear%20to%20be%20the%20strongest%20predictors%20of%20MetS%20in%20our%20population%2C%20with%20no%20evident%20difference%20in%20MetS%20prevalence%20between%20treatment-naive%20PLWH%20and%20PLWOH.%22%2C%22date%22%3A%22Dec%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26047%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A34%3A26Z%22%7D%7D%2C%7B%22key%22%3A%224QMJKWAF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brazier%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A16%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrazier%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAjeh%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMaruri%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMusick%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFreeman%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Service%20delivery%20challenges%20in%20HIV%20care%20during%20the%20first%20year%20of%20the%20COVID-19%20pandemic%3A%20results%20from%20a%20site%20assessment%20survey%20across%20the%20global%20IeDEA%20consortium.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%2812%29%2C%20S.%20e26036.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26036%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26036%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Service%20delivery%20challenges%20in%20HIV%20care%20during%20the%20first%20year%20of%20the%20COVID-19%20pandemic%3A%20results%20from%20a%20site%20assessment%20survey%20across%20the%20global%20IeDEA%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ajeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20W.%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Shamu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Crabtree%20Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22d%27Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Tanser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%22%2C%22lastName%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Interruptions%20in%20treatment%20pose%20risks%20for%20people%20with%20HIV%20%28PWH%29%20and%20threaten%20progress%20in%20ending%20the%20HIV%20epidemic%3B%20however%2C%20the%20COVID-19%20pandemic%27s%20impact%20on%20HIV%20service%20delivery%20across%20diverse%20settings%20is%20not%20broadly%20documented.%20METHODS%3A%20From%20September%202020%20to%20March%202021%2C%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20research%20consortium%20surveyed%20238%20HIV%20care%20sites%20across%20seven%20geographic%20regions%20to%20document%20constraints%20in%20HIV%20service%20delivery%20during%20the%20first%20year%20of%20the%20pandemic%20and%20strategies%20for%20ensuring%20care%20continuity%20for%20PWH.%20Descriptive%20statistics%20were%20stratified%20by%20national%20HIV%20prevalence%20%28%3C1%25%2C%201-4.9%25%20and%20%3E%5C%2F%3D5%25%29%20and%20country%20income%20levels.%20RESULTS%3A%20Questions%20about%20pandemic-related%20consequences%20for%20HIV%20care%20were%20completed%20by%20225%20%2895%25%29%20sites%20in%2042%20countries%20with%20low%20%28n%20%3D%2082%29%2C%20medium%20%28n%20%3D%2086%29%20and%20high%20%28n%20%3D%2057%29%20HIV%20prevalence%2C%20including%20low-%20%28n%20%3D%2057%29%2C%20lower-middle%20%28n%20%3D%2079%29%2C%20upper-middle%20%28n%20%3D%2039%29%20and%20high-%20%28n%20%3D%2050%29%20income%20countries.%20Most%20sites%20reported%20being%20subject%20to%20pandemic-related%20restrictions%20on%20travel%2C%20service%20provision%20or%20other%20operations%20%2875%25%29%2C%20and%20experiencing%20negative%20impacts%20%2876%25%29%20on%20clinic%20operations%2C%20including%20decreased%20hours%5C%2Fdays%2C%20reduced%20provider%20availability%2C%20clinic%20reconfiguration%20for%20COVID-19%20services%2C%20record-keeping%20interruptions%20and%20suspension%20of%20partner%20support.%20Almost%20all%20sites%20in%20low-prevalence%20and%20high-income%20countries%20reported%20increased%20use%20of%20telemedicine%20%2885%25%20and%20100%25%2C%20respectively%29%2C%20compared%20with%20less%20than%20half%20of%20sites%20in%20high-prevalence%20and%20lower-income%20settings.%20Few%20sites%20in%20high-prevalence%20settings%20%282%25%29%20reported%20suspending%20antiretroviral%20therapy%20%28ART%29%20clinic%20services%2C%20and%20many%20reported%20adopting%20mitigation%20strategies%20to%20support%20adherence%2C%20including%20multi-month%20dispensing%20of%20ART%20%2895%25%29%20and%20designating%20community%20ART%20pick-up%20points%20%2844%25%29.%20While%20few%20sites%20%285%25%29%20reported%20stockouts%20of%20first-line%20ART%20regimens%2C%2010-11%25%20reported%20stockouts%20of%20second-%20and%20third-line%20regimens%2C%20respectively%2C%20primarily%20in%20high-prevalence%20and%20lower-income%20settings.%20Interruptions%20in%20HIV%20viral%20load%20%28VL%29%20testing%20included%20suspension%20of%20testing%20%2822%25%29%2C%20longer%20turnaround%20times%20%2841%25%29%20and%20supply%5C%2Freagent%20stockouts%20%2822%25%29%2C%20but%20did%20not%20differ%20across%20settings.%20CONCLUSIONS%3A%20While%20many%20sites%20in%20high%20HIV%20prevalence%20settings%20and%20lower-income%20countries%20reported%20introducing%20or%20expanding%20measures%20to%20support%20treatment%20adherence%20and%20continuity%20of%20care%2C%20the%20COVID-19%20pandemic%20resulted%20in%20disruptions%20to%20VL%20testing%20and%20ART%20supply%20chains%20that%20may%20negatively%20affect%20the%20quality%20of%20HIV%20care%20in%20these%20settings.%22%2C%22date%22%3A%22Dec%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26036%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A27%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22UUQZLRB7%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jiamsakul%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJiamsakul%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGani%2C%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAvihingsanon%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAzwa%2C%20I.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChaiwarith%2C%20R.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Brief%20Report%3A%20Mortality%20After%20Loss%20to%20Follow-Up-A%20Linkage%20Study%20of%20People%20Living%20With%20HIV%20in%20Thailand%20and%20Malaysia.%20%3Ci%3EJ%20Acquir%20Immune%20Defic%20Syndr%3C%5C%2Fi%3E%2C%20%3Ci%3E91%3C%5C%2Fi%3E%20%283%29%2C%20S.%20290%26%23x2013%3B295.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003067%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003067%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Brief%20Report%3A%20Mortality%20After%20Loss%20to%20Follow-Up-A%20Linkage%20Study%20of%20People%20Living%20With%20HIV%20in%20Thailand%20and%20Malaysia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Gani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Azwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Chaiwarith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khusuwan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Law%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kiertiburanakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20Asia-Pacific%22%2C%22lastName%22%3A%22Ie%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Linkage%20studies%20have%20reported%20high%20rates%20of%20previously%20unascertained%20mortality%20among%20people%20living%20with%20HIV%20%28PLHIV%29%20who%20have%20been%20lost%20to%20follow-up%20%28LTFU%29.%20We%20assessed%20survival%20outcomes%20among%20PLHIV%20who%20were%20LTFU%20in%20Thailand%20and%20Malaysia%2C%20through%20linkages%20to%20a%20national%20death%20registry%20or%20HIV%20database.%20METHODS%3A%20Data%20linkages%20with%20the%20national%20death%20registry%20or%20national%20HIV%20database%20were%20conducted%20in%202020%20on%20all%20PLHIV%20who%20met%20LTFU%20criteria%20while%20enrolled%20in%20care%20at%20participating%20HIV%20clinical%20sites.%20LTFU%20was%20defined%20as%20having%20no%20documented%20clinical%20contact%20in%20the%20previous%20year%2C%20excluding%20transfers%20and%20deaths.%20Survival%20time%20was%20analyzed%20using%20the%20Cox%20regression%2C%20stratified%20by%20site.%20RESULTS%3A%20Data%20linkages%20were%20performed%20for%20489%20PLHIV%20who%20had%20been%20LTFU%20at%20sites%20in%20Malaysia%20%28n%20%3D%202%29%20and%20Thailand%20%28n%20%3D%204%29.%20There%20were%20151%20%2831%25%29%20deaths%20after%20being%20LTFU%3B%20the%20mortality%20rate%20was%204.89%20per%20100%20person-years.%20Risk%20factors%20for%20mortality%20after%20being%20LTFU%20were%20older%20age%20%5B41-50%20years%3A%20hazard%20ratio%20%28HR%29%20%3D%201.99%2C%2095%25%20confidence%20interval%20%28CI%29%3A%201.08%20to%203.68%3B%20and%20older%20than%2050%20years%3A%20HR%20%3D%204.93%2C%2095%25%20CI%3A%202.63%20to%209.22%3B%20vs.%20age%2030%20years%20or%20younger%5D%3B%20receiving%20NRTI%20%2B%20PI%20%28HR%20%3D%201.87%2C%2095%25%20CI%3A%201.22%20to%202.85%20vs.%20NRTI%20%2B%20NNRTI%29%3B%20positive%20hepatitis%20C%20antibody%20%28HR%20%3D%202.25%2C%2095%25%20CI%3A%201.40%20to%203.62%29%3B%20and%20having%20previous%20AIDS%20illness%20%28HR%20%3D%201.45%2C%2095%25%20CI%3A%201.03%20to%202.05%29.%20An%20improved%20survival%20was%20seen%20with%20a%20higher%20CD4%20count%20%28CD4%20351-500%20cells%5C%2FmicroL%3A%20HR%20%3D%200.40%2C%2095%25CI%3A%200.21-0.76%3B%20and%20CD4%20%26gt%3B500%20cells%5C%2FmicroL%3A%20HR%20%3D%200.43%2C%2095%25CI%3A%200.25-0.75%3B%20vs.%20CD4%20%3C%5C%2F%3D200%20cells%5C%2FmicroL%29.%20CONCLUSIONS%3A%20Almost%20one-third%20of%20PLHIV%20who%20were%20LTFU%20in%20this%20cohort%20had%20died%20while%20out%20of%20care%2C%20emphasizing%20the%20importance%20of%20efforts%20to%20reengage%20PLHIV%20after%20they%20have%20been%20LTFU%20and%20ensure%20they%20have%20access%20to%20ongoing%20ART.%22%2C%22date%22%3A%22Nov%201%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003067%22%2C%22ISSN%22%3A%221944-7884%20%28Electronic%29%201525-4135%20%28Print%29%201525-4135%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A37%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22HRKURFRR%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rupasinghe%20et%20al.%22%2C%22parsedDate%22%3A%222022-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERupasinghe%2C%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChoi%2C%20J.%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EYunihastuti%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKiertiburanakul%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERoss%2C%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Factors%20associated%20with%20high%20alanine%20aminotransferase%20%28ALT%29%20and%20cirrhosis%20in%20people%20living%20with%20HIV%20on%20combination%20antiretroviral%20treatment%20%28cART%29%20in%20the%20Asia-Pacific.%20%3Ci%3EJ%20Med%20Virol%3C%5C%2Fi%3E%2C%20%3Ci%3E94%3C%5C%2Fi%3E%20%2811%29%2C%20S.%205451%26%23x2013%3B5464.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjmv.28019%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjmv.28019%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Factors%20associated%20with%20high%20alanine%20aminotransferase%20%28ALT%29%20and%20cirrhosis%20in%20people%20living%20with%20HIV%20on%20combination%20antiretroviral%20treatment%20%28cART%29%20in%20the%20Asia-Pacific%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Rupasinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Y.%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Yunihastuti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kiertiburanakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20S.%22%2C%22lastName%22%3A%22Ly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Chaiwarith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20J.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kamarulzaman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khusuwan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Van%20Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20P.%22%2C%22lastName%22%3A%22Merati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Sangle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Oon%20Tek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Tanuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ditangco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20L.%20H.%22%2C%22lastName%22%3A%22Sim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Pujari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22Treat%20Asia%20HIV%20Observational%20Database%20of%20IeDEA%20Asia-Pacific%22%7D%5D%2C%22abstractNote%22%3A%22Liver%20disease%20is%20a%20growing%20burden%20among%20people%20living%20with%20HIV%20%28PLHIV%29%20in%20resource-limited%20settings.%20As%20an%20indicator%20of%20liver%20disease%2C%20risk%20factors%20of%20high%20alanine%20aminotransferase%20%28ALT%29%20and%20cirrhosis%20were%20assessed%20among%20PLHIV%20in%20the%20TREAT%20Asia%20HIV%20Observational%20Database%20%28TAHOD%29.%20Patients%20on%20combination%20antiretroviral%20therapy%20%28cART%29%20with%20a%20pre-cART%20ALT%20measurement%20and%20at%20least%20one%20follow-up%20ALT%20measurement%20were%20included.%20Factors%20associated%20with%20high%20ALT%20%28ALT%20levels%20%3E%205%20times%20its%20upper%20limit%20of%20normal%29%20were%20analyzed%20using%20repeated%20measure%20logistic%20regression%20over%20a%2010-year%20follow-up%20period.%20Liver%20cirrhosis%20was%20defined%20as%20having%20an%20AST%20to%20Platelet%20Ratio%20Index%20score%20%3E%201.5%2C%20fibrosis-4%20score%20%3E%203.25%2C%20or%20a%20clinical%20diagnosis%20of%20cirrhosis.%20Cox%20regression%20analysis%20stratified%20by%20site%20was%20used%20to%20analyze%20factors%20associated%20with%20cirrhosis%20among%20those%20in%20follow-up%20after%202015.%20Of%205182%20patients%2C%20101%20patients%20%281.9%25%29%20had%20high%20ALT%20levels%20with%20hepatitis%20C%20virus%20%28HCV%29%20antibody%20positive%20%28odds%20ratio%20%5BOR%5D%3A%204.98%2C%2095%25%20confidence%20interval%20%5BCI%5D%3A%202.82-8.77%2C%20p%20%3C%200.001%29%20and%20ever%20high%20alcohol%20consumption%20%28OR%3A%202.33%2C%2095%25%20CI%3A%201.00-5.46%2C%20p%20%3D%200.050%29%20as%20likely%20factors.%20Among%206318%20PLHIV%20in%20the%20liver%20cirrhosis%20analysis%2C%20151%20%282%25%29%20developed%20cirrhosis%20%28incidence%20rate%20%3D%200.82%20per%20100%20person-years%29.%20Those%20HCV-antibody%20positive%20%28hazard%20ratio%20%5BHR%5D%3A%205.54%2C%2095%25%20CI%3A%203.75-8.18%2C%20p%20%3C%200.001%29%20and%20had%20high%20alcohol%20consumption%20%28HR%3A%202.06%2C%2095%25%20CI%3A%201.23-3.45%2C%20p%20%3D%200.006%29%20were%20associated%20with%20liver%20cirrhosis.%20HCV-antibody%20positive%20and%20high%20alcohol%20consumption%20are%20factors%20associated%20with%20high%20ALT.%20With%20raised%20ALT%20levels%20as%20a%20known%20factor%20associated%20with%20liver%20cirrhosis%2C%20greater%20efforts%20are%20required%20in%20managing%20ALT%20levels%20and%20reducing%20the%20risk%20of%20developing%20liver%20cirrhosis%20among%20those%20positive%20for%20HCV-antibody%20and%20those%20who%20consume%20alcohol.%22%2C%22date%22%3A%22Nov%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjmv.28019%22%2C%22ISSN%22%3A%221096-9071%20%28Electronic%29%200146-6615%20%28Print%29%200146-6615%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A45%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22TLX7GHP2%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sobral%20et%20al.%22%2C%22parsedDate%22%3A%222022-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESobral%2C%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EArriaga%2C%20M.%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESouza%2C%20A.%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAraujo-Pereira%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBarreto-Duarte%2C%20B.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Determinants%20of%20losses%20in%20the%20tuberculosis%20infection%20cascade%20of%20care%20among%20children%20and%20adolescent%20contacts%20of%20pulmonary%20tuberculosis%20cases%3A%20A%20Brazilian%20multi-centre%20longitudinal%20study.%20%3Ci%3ELancet%20Reg%20Health%20Am%3C%5C%2Fi%3E%2C%20%3Ci%3E15%3C%5C%2Fi%3E%2C%20S.%20100358.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2022.100358%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2022.100358%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Determinants%20of%20losses%20in%20the%20tuberculosis%20infection%20cascade%20of%20care%20among%20children%20and%20adolescent%20contacts%20of%20pulmonary%20tuberculosis%20cases%3A%20A%20Brazilian%20multi-centre%20longitudinal%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Sobral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20B.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Araujo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Sales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Benjamin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20G.%22%2C%22lastName%22%3A%22de%20Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Spener-Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Cavalcante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Silva%20J.%20R.%22%2C%22lastName%22%3A%22Lapa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Approximately%2010%25%20of%20the%20global%20tuberculosis%20%28TB%29%20burden%20is%20in%20children.%20Identification%2C%20diagnosis%2C%20and%20early%20treatment%20of%20Mycobacterium%20tuberculosis%20infection%20%28TBI%29%20is%20critical%20to%20prevent%20progression%20to%20TB%20in%20children.%20The%20risk%20of%20TB%2C%20including%20severe%20disease%2C%20is%20highest%20in%20children%20%3C5%20years%20old.%20We%20evaluated%20the%20cascade%20of%20TBI%20care%20among%20child%20and%20adolescent%20TB%20contacts%20to%20identify%20factors%20associated%20with%20losses%20in%20the%20cascade.%20METHODS%3A%20Close%20contacts%20%3C%5C%2F%3D%2018%20years%20old%20of%20pulmonary%20TB%20patients%20enrolled%20between%202015%20and%202019%20in%20a%20multi-centre%20Brazilian%20cohort%20were%20followed%20for%20up%20to%2024%20months%20and%20classified%20according%20to%20age%20groups%3A%20%3C5%20years%2C%205-9%20years%2C%2010-14%20years%20and%2015-18%20years.%20Data%20on%20clinical%20investigation%2C%20radiographic%20examination%2C%20IGRA%20testing%20at%20baseline%20and%206%20months%2C%20initiation%20and%20completion%20of%20TB%20preventive%20treatment%20%28TPT%29%20were%20collected.%20Multivariable%20regression%20analyses%20identified%20factors%20associated%20with%20TBI%20and%20losses%20in%20the%20cascade%20of%20care%20in%20children%20and%20adolescents.%20FINDINGS%3A%20Among%201795%20TB%20contacts%20initially%20identified%2C%20530%20%2829.5%25%29%20were%20%3C%5C%2F%3D18%20years%20old.%20Losses%20for%20all%20steps%20in%20the%20cascade%20were%20especially%20high%20in%20children%20%3C5%20years%20old%20%2888%25%29%20because%20at%20this%20age%20all%20contacts%20are%20recommended%20to%20initiate%20TPT.%20As%20a%20proportion%20of%20all%20children%2C%20completion%20of%20TPT%20was%20low%20%28between%2010%25%20and%2013%25%29%20in%20all%20age-groups.%20Furthermore%2C%20multivariable%20regression%20revealed%20that%20younger%20age%20of%20contacts%20and%20TB%20index%20cases%20who%20were%20female%2C%20had%20pulmonary%20cavities%2C%20and%20persistent%20cough%20were%20independently%20associated%20with%20losses%20in%20the%20cascade%20of%20care%20among%20persons%20%3C%5C%2F%3D18%20years%20old.%20INTERPRETATION%3A%20Losses%20in%20the%20TBI%20cascade%20were%20the%20highest%20among%20children%20%3C5%20years%2C%20which%20was%20the%20group%20at%20highest%20risk%20for%20TB%20among%20the%20four%20age%20groups.%20The%20findings%20highlight%20the%20need%20to%20improve%20screening%2C%20initiation%2C%20and%20completion%20of%20TPT%20of%20young%20children%20who%20are%20close%20contacts%20of%20people%20with%20TB%20in%20Brazil.%20FUNDING%3A%20National%20Institutes%20of%20Allergy%20and%20Infectious%20Diseases.%22%2C%22date%22%3A%22Nov%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lana.2022.100358%22%2C%22ISSN%22%3A%222667-193X%20%28Electronic%29%202667-193X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A41%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22LC8RM56M%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bartelt%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-26%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBartelt%2C%20L.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMarkmann%2C%20A.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENelson%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKeys%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERoot%2C%20H.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Outcomes%20of%20Convalescent%20Plasma%20with%20Defined%20High%20versus%20Lower%20Neutralizing%20Antibody%20Titers%20against%20SARS-CoV-2%20among%20Hospitalized%20Patients%3A%20CoronaVirus%20Inactivating%20Plasma%20%28CoVIP%29%20Study.%20%3Ci%3EMBio%3C%5C%2Fi%3E%2C%20%3Ci%3E13%3C%5C%2Fi%3E%20%285%29%2C%20S.%20e0175122.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2Fmbio.01751-22%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2Fmbio.01751-22%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcomes%20of%20Convalescent%20Plasma%20with%20Defined%20High%20versus%20Lower%20Neutralizing%20Antibody%20Titers%20against%20SARS-CoV-2%20among%20Hospitalized%20Patients%3A%20CoronaVirus%20Inactivating%20Plasma%20%28CoVIP%29%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Bartelt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20J.%22%2C%22lastName%22%3A%22Markmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Nelson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Keys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Root%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20I.%22%2C%22lastName%22%3A%22Henderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Kuruc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Baker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20R.%22%2C%22lastName%22%3A%22Bhowmik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20J.%22%2C%22lastName%22%3A%22Hou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Premkumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cornaby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Schmitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Weiss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Baric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22de%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lachiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Napravnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22van%20Duin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20M.%22%2C%22lastName%22%3A%22Margolis%22%7D%5D%2C%22abstractNote%22%3A%22COVID-19%20convalescent%20plasma%20%28CCP%29%20was%20an%20early%20and%20widely%20adopted%20putative%20therapy%20for%20severe%20COVID-19.%20Results%20from%20randomized%20control%20trials%20and%20observational%20studies%20have%20failed%20to%20demonstrate%20a%20clear%20therapeutic%20role%20for%20CCP%20for%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20%28SARS-CoV-2%29%20infection.%20Underlying%20these%20inconclusive%20findings%20is%20a%20broad%20heterogeneity%20in%20the%20concentrations%20of%20neutralizing%20antibodies%20%28nAbs%29%20between%20different%20CCP%20donors.%20We%20conducted%20this%20study%20to%20evaluate%20the%20effectiveness%20and%20safety%20of%20nAb%20titer-defined%20CCP%20in%20adults%20admitted%20to%20an%20academic%20referral%20hospital.%20Patients%20positive%20by%20a%20SARS-CoV-2%20nucleic%20acid%20amplification%20test%20and%20with%20symptoms%20for%20%3C10%20days%20were%20eligible.%20Participants%20received%20either%20CCP%20with%20nAb%20titers%20of%20%3E1%3A640%20%28high-titer%20group%29%20or%20%3E%5C%2F%3D1%3A160%20to%201%3A640%20%28standard-titer%20group%29%20in%20addition%20to%20standard%20of%20care%20treatments.%20The%20primary%20clinical%20outcome%20was%20time%20to%20hospital%20discharge%2C%20with%20mortality%20and%20respiratory%20support%20evaluated%20as%20secondary%20outcomes.%20Adverse%20events%20were%20contrasted%20by%20CCP%20titer.%20Between%2028%20August%20and%204%20December%202020%2C%20316%20participants%20were%20screened%2C%20and%2055%20received%20CCP%2C%20with%2014%20and%2041%20receiving%20high-%20versus%20standard-titer%20CCP%2C%20respectively.%20Time%20to%20hospital%20discharge%20was%20shorter%20among%20participants%20receiving%20high-%20versus%20standard-titer%20CCP%2C%20accounting%20for%20death%20as%20a%20competing%20event%20%28hazard%20ratio%2C%201.94%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%201.05%20to%203.58%3B%20Gray%27s%20P%20%3D%200.02%29.%20Severe%20adverse%20events%20%28SAEs%29%20%28%3E%5C%2F%3Dgrade%203%29%20occurred%20in%204%20%2829%25%29%20and%2023%20%2856%25%29%20of%20participants%20receiving%20the%20high%20versus%20standard%20titer%2C%20respectively%2C%20by%20day%2028%20%28risk%20ratio%2C%200.51%3B%2095%25%20CI%2C%200.21%20to%201.22%3B%20Fisher%27s%20P%20%3D%200.12%29.%20There%20were%20no%20observed%20treatment-related%20AEs.%20%28This%20study%20has%20been%20registered%20at%20ClinicalTrials.gov%20under%20registration%20no.%20NCT04524507%29.%20IMPORTANCE%20In%20this%20study%2C%20in%20a%20high-risk%20population%20of%20patients%20admitted%20for%20COVID-19%2C%20we%20found%20an%20earlier%20time%20to%20hospital%20discharge%20among%20participants%20receiving%20CCP%20with%20nAb%20titers%20of%20%3E1%3A640%20compared%20with%20participants%20receiving%20CCP%20with%20a%20lower%20nAb%20titer%20and%20no%20CCP-related%20AEs.%20The%20significance%20of%20our%20research%20is%20in%20identifying%20a%20dose%20response%20of%20CCP%20and%20clinical%20outcomes%20based%20on%20nAb%20titer.%20Although%20limited%20by%20a%20small%20study%20size%2C%20these%20findings%20support%20further%20study%20of%20high-nAb-titer%20CCP%20defined%20as%20%3E1%3A640%20in%20the%20treatment%20of%20COVID-19.%22%2C%22date%22%3A%22Oct%2026%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1128%5C%2Fmbio.01751-22%22%2C%22ISSN%22%3A%222150-7511%20%28Electronic%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A26%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22VIS9ZD6Y%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Horberg%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHorberg%2C%20M.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWatson%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBhatia%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJefferson%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECerta%2C%20J.%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Post-acute%20sequelae%20of%20SARS-CoV-2%20with%20clinical%20condition%20definitions%20and%20comparison%20in%20a%20matched%20cohort.%20%3Ci%3ENat%20Commun%3C%5C%2Fi%3E%2C%20%3Ci%3E13%3C%5C%2Fi%3E%20%281%29%2C%20S.%205822.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41467-022-33573-6%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41467-022-33573-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Post-acute%20sequelae%20of%20SARS-CoV-2%20with%20clinical%20condition%20definitions%20and%20comparison%20in%20a%20matched%20cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Watson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bhatia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Jefferson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Certa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fathi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Moore%22%7D%5D%2C%22abstractNote%22%3A%22Disease%20characterization%20of%20Post-Acute%20Sequelae%20of%20SARS-CoV-2%20%28PASC%29%20does%20not%20account%20for%20pre-existing%20conditions%20and%20time%20course%20of%20incidence.%20We%20utilized%20longitudinal%20data%20and%20matching%20to%20a%20COVID%20PCR-negative%20population%20to%20discriminate%20PASC%20conditions%20over%20time%20within%20our%20patient%20population%20during%202020.%20Clinical%20Classification%20Software%20was%20used%20to%20identify%20PASC%20condition%20groupings.%20Conditions%20were%20specified%20acute%20and%20persistent%20%28occurring%200-30%20days%20post%20COVID%20PCR%20and%20persisted%2030-120%20days%20post-test%29%20or%20late%20%28occurring%20initially%2030-120%20days%20post-test%29.%20We%20matched%203%3A1%20COVID%20PCR-negative%20COVIDPCR-positive%20by%20age%2C%20sex%2C%20testing%20month%20and%20service%20area%2C%20controlling%20for%20pre-existing%20conditions%20up%20to%20four%20years%20prior%3B%2028%2C118%20PCR-positive%20to%2070%2C293%20PCR-negative%20patients%20resulted.%20We%20estimated%20PASC%20risk%20from%20the%20matched%20cohort.%20Risk%20of%20any%20PASC%20condition%20was%2012%25%20greater%20for%20PCR-positive%20patients%20in%20the%20late%20period%20with%20a%20significantly%20higher%20risk%20of%20anosmia%2C%20cardiac%20dysrhythmia%2C%20diabetes%2C%20genitourinary%20disorders%2C%20malaise%2C%20and%20nonspecific%20chest%20pain.%20Our%20findings%20contribute%20to%20a%20more%20refined%20PASC%20definition%20which%20can%20enhance%20clinical%20care.%22%2C%22date%22%3A%22Oct%2012%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41467-022-33573-6%22%2C%22ISSN%22%3A%222041-1723%20%28Electronic%29%202041-1723%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A23%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22HLEGYTCW%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kalua%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKalua%2C%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEgger%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJahn%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChimpandule%2C%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKolola%2C%20R.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20HIV%20suppression%20was%20maintained%20during%20the%20COVID-19%20pandemic%20in%20Malawi%3A%20a%20program-level%20cohort%20study.%20%3Ci%3EJ%20Clin%20Epidemiol%3C%5C%2Fi%3E%2C%20%3Ci%3E150%3C%5C%2Fi%3E%2C%20S.%20116%26%23x2013%3B125.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jclinepi.2022.06.019%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jclinepi.2022.06.019%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV%20suppression%20was%20maintained%20during%20the%20COVID-19%20pandemic%20in%20Malawi%3A%20a%20program-level%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Kalua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Chimpandule%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Kolola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Anderegg%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Measures%20introduced%20to%20reduce%20the%20spread%20of%20SARS-CoV-2%20by%20the%20Malawi%20government%20and%20the%20national%20HIV%20care%20program%20might%20have%20compromised%20treatment%20outcomes%20of%20patients%20living%20with%20HIV%20on%20antiretroviral%20therapy%20%28ART%29.%20We%20studied%20viral%20load%20%28VL%29%20outcomes%20before%20and%20during%20the%20COVID-19%20epidemic%20in%20Malawi.%20METHODS%3A%20In%20this%20population-based%20cohort%20study%2C%20we%20included%20all%20routine%20VL%20measurements%20collected%20from%20July%202019%20to%20December%202020%20in%20about%20650%20ART%20clinics%20in%20Malawi.%20We%20examined%20differences%20between%20pandemic%20periods%20%28before%5C%2Fduring%20COVID-19%29%20for%20i%29%20VL%20monitoring%2C%20and%20ii%29%20VL%20suppression%20%28VLS%3A%20%3C1%2C000%20copies%5C%2Fml%29.%20For%20i%29%20we%20studied%20the%20number%20of%20VL%20measurements%20over%20time%20and%20assessed%20predictors%20of%20missed%20measurements%20before%20and%20during%20COVID-19%20in%20logistic%20regression%20models.%20For%20ii%29%20we%20estimated%20the%20odds%20of%20VLS%20before%20and%20during%20the%20COVID-19%20epidemic%20stratified%20by%20treatment%20regimen%20using%20generalized%20estimation%20equations%20adjusted%20for%20age%2C%20sex%2C%20time%20on%20ART%2C%20and%20type%20of%20biological%20sample.%20We%20imputed%20missing%20treatment%20regimens%20by%20population-calibrated%20multiple%20imputation.%20RESULTS%3A%20We%20included%20607%2C894%20routine%20VL%20samples%20from%20556%2C281%20patients.%20VL%20testing%20declined%20during%20COVID-19%20%28243%2C729%3B%2040%25%29%20compared%20to%20before%20COVID-19%20%28365%2C265%3B%2060%25%29%2C%20but%20predictors%20of%20missing%20tests%20were%20similar%20in%20the%20two%20periods.%20VLS%20rates%20increased%20slightly%20from%2093%25%20before%20to%2094%25%20during%20COVID-19.%20Compared%20to%20before%20COVID-19%2C%20the%20odds%20of%20VLS%20increased%20during%20COVID-19%20for%20patients%20on%20protease%20inhibitor-based%20%28PI%29%20regimens%20%28adjusted%20odds%20ratio%20%5BaOR%5D%201.22%2C%2095%25%20CI%3A%200.99-1.49%29%20and%20for%20patients%20on%20integrase%20strand%20transfer%20inhibitor-based%20%28INSTI%29%20regimens%20%28aOR%201.10%2C%2095%25%20CI%3A%201.03-1.17%29.%20There%20was%20no%20difference%20in%20VLS%20between%20the%20two%20periods%20among%20patients%20on%20nonnucleoside%20reverse%20transcriptase%20inhibitor-based%20%28NNRTI%29%20regimens.%20VLS%20varied%20by%20age%2C%20sex%2C%20regimen%2C%20and%20duration%20on%20ART%2C%20ranging%20from%2045.1%25%20%2895%25%20CI%2040.3-50.0%25%29%20to%2097.2%25%20%2895%25%20CI%2096.9-97.4%25%29.%20CONCLUSION%3A%20There%20was%20a%20significant%20decline%20in%20VL%20monitoring%20during%20COVID-19%2C%20but%20we%20did%20not%20find%20clear%20evidence%20that%20the%20pandemic%20reduced%20VL%20suppression%20rates.%20Routine%20scheduled%20VL%20monitoring%2C%20targeted%20adherence%20support%2C%20and%20timely%20regimen%20switches%20for%20patients%20with%20treatment%20failure%20remain%20critical%20to%20improving%20VLS.%22%2C%22date%22%3A%22Oct%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jclinepi.2022.06.019%22%2C%22ISSN%22%3A%221878-5921%20%28Electronic%29%200895-4356%20%28Print%29%200895-4356%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A20%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22AWBVNXEF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marti%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A8%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMarti%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZurcher%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEnane%2C%20L.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDiero%2C%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMarcy%2C%20O.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Impact%20of%20the%20COVID-19%20pandemic%20on%20TB%20services%20at%20ART%20programmes%20in%20low-%20and%20middle-income%20countries%3A%20a%20multi-cohort%20survey.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%2810%29%2C%20S.%20e26018.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26018%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26018%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20the%20COVID-19%20pandemic%20on%20TB%20services%20at%20ART%20programmes%20in%20low-%20and%20middle-income%20countries%3A%20a%20multi-cohort%20survey%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Marti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Zurcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Marcy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khusuwan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Yunihastuti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Reubenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20S.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20global%20consortium%22%2C%22lastName%22%3A%22Ie%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20COVID-19%20stretched%20healthcare%20systems%20to%20their%20limits%2C%20particularly%20in%20settings%20with%20a%20pre-existing%20high%20burden%20of%20infectious%20diseases%2C%20including%20HIV%20and%20tuberculosis%20%28TB%29.%20We%20studied%20the%20impact%20of%20COVID-19%20on%20TB%20services%20at%20antiretroviral%20therapy%20%28ART%29%20clinics%20in%20low-%20and%20middle-income%20countries.%20METHODS%3A%20We%20surveyed%20ART%20clinics%20providing%20TB%20services%20in%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%20in%20Africa%20and%20the%20Asia-Pacific%20until%20July%202021%20%28TB%20diagnoses%20until%20the%20end%20of%202021%29.%20We%20collected%20site-level%20data%20using%20standardized%20questionnaires.%20RESULTS%3A%20Of%2046%20participating%20ART%20clinics%2C%2032%20%2870%25%29%20were%20in%20Africa%20and%2014%20%2830%25%29%20in%20the%20Asia-Pacific%3B%2052%25%20provided%20tertiary%20care.%20Most%20clinics%20%2885%25%29%20reported%20disrupted%20routine%20HIV%20care%20services%20during%20the%20pandemic%2C%20both%20in%20Africa%20%2884%25%29%20and%20the%20Asia-Pacific%20%2886%25%29.%20The%20most%20frequently%20reported%20impacts%20were%20on%20staff%20%2852%25%29%20and%20resource%20shortages%20%2837%25%3B%20protective%20clothing%2C%20face%20masks%20and%20disinfectants%29.%20Restrictions%20in%20TB%20health%20services%20were%20observed%20in%2012%20clinics%20%2826%25%29%2C%20mainly%20reduced%20access%20to%20TB%20diagnosis%20and%20postponed%20follow-up%20visits%20%286%5C%2F12%2C%2050%25%20each%29%2C%20and%20restrictions%20in%20TB%20laboratory%20services%20%2822%25%29.%20Restrictions%20of%20TB%20services%20were%20addressed%20by%20dispensing%20TB%20drugs%20for%20longer%20periods%20than%20usual%20%287%5C%2F12%2C%2058%25%29%2C%20providing%20telehealth%20services%20%283%5C%2F12%2C%2025%25%29%20and%20with%20changes%20in%20directly%20observed%20therapy%20%28DOT%29%20%28e.g.%20virtual%20DOT%2C%203%5C%2F12%29.%20The%20number%20of%20TB%20diagnoses%20at%20participating%20clinics%20decreased%20by%2021%25%20in%202020%20compared%20to%202019%3B%20the%20decline%20was%20more%20pronounced%20in%20tertiary%20than%20primary%5C%2Fsecondary%20clinics%20%2824%25%20vs.%2012%25%29%20and%20in%20sites%20from%20the%20Asia-Pacific%20compared%20to%20Africa%20%2846%25%20vs.%2014%25%29.%20In%202021%2C%20TB%20diagnoses%20continued%20to%20decline%20in%20Africa%20%28-8%25%29%20but%20not%20in%20the%20Asia-Pacific%20%28%2B62%25%29%20compared%20to%202020.%20During%20the%20pandemic%2C%20new%20infection%20control%20measures%20were%20introduced%20or%20intensified%20at%20the%20clinics%2C%20including%20wearing%20face%20masks%2C%20hand%20sanitation%20and%20patient%20triage.%20CONCLUSIONS%3A%20The%20COVID-19%20pandemic%20led%20to%20staff%20shortages%2C%20reduced%20access%20to%20TB%20care%20and%20delays%20in%20follow-up%20visits%20for%20people%20with%20TB%20across%20IeDEA%20sites%20in%20Africa%20and%20the%20Asia-Pacific.%20Increased%20efforts%20are%20needed%20to%20restore%20and%20secure%20ongoing%20access%20to%20essential%20TB%20services%20in%20these%20contexts.%22%2C%22date%22%3A%22Oct%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26018%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A21%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22R8NTX9IG%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stalter%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStalter%2C%20R.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAmorim%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMocello%2C%20A.%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJakait%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShepherd%2C%20B.%20E.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Contraceptive%20implant%20use%20duration%20is%20not%20associated%20with%20breakthrough%20pregnancy%20among%20women%20living%20with%20HIV%20and%20using%20efavirenz%3A%20a%20retrospective%2C%20longitudinal%20analysis.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%289%29%2C%20S.%20e26001.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26001%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26001%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Contraceptive%20implant%20use%20duration%20is%20not%20associated%20with%20breakthrough%20pregnancy%20among%20women%20living%20with%20HIV%20and%20using%20efavirenz%3A%20a%20retrospective%2C%20longitudinal%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20M.%22%2C%22lastName%22%3A%22Stalter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20R.%22%2C%22lastName%22%3A%22Mocello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Jakait%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20A.%22%2C%22lastName%22%3A%22Bukusi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20R.%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20C.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Group%22%2C%22lastName%22%3A%22Implant%5C%2FEfavirenz%20Study%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20regional%20consortium%22%2C%22lastName%22%3A%22the%20East%20Africa%20Ie%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Contraceptive%20implants%20containing%20etonogestrel%20and%20levonorgestrel%20have%20emerged%20as%20popular%20contraceptive%20options%20among%20women%20in%20areas%20of%20high%20HIV%20burden%20in%20sub-Saharan%20Africa.%20However%2C%20recent%20pharmacokinetic%20data%20have%20shown%20drug-drug%20interactions%20between%20implants%20and%20efavirenz-containing%20antiretroviral%20therapy%20%28ART%29%2C%20reducing%20the%20effectiveness%20of%20the%20implants.%20Here%2C%20we%20evaluated%20pregnancy%20incidence%20in%206-month%20intervals%20following%20implant%20initiation%20among%20women%20using%20efavirenz%20and%20contraceptive%20implants%20to%20assess%20whether%20the%20risk%20of%20breakthrough%20pregnancy%20is%20higher%20after%20specific%20periods%20of%20implant%20use.%20METHODS%3A%20We%20used%20data%20from%20a%20retrospective%20longitudinal%20analysis%20of%20women%20living%20with%20HIV%20ages%2018-45%20years%20in%20western%20Kenya%20who%20attended%20HIV-care%20facilities%20between%202011%20and%202015.%20We%20used%20Cox%20proportional%20hazard%20models%20to%20compute%20hazard%20ratios%20%28HRs%29%20for%20breakthrough%20pregnancy%20by%20implant%20type%20and%20ART%20regimen.%20Depending%20on%20the%20model%2C%20we%20adjusted%20for%20socio-demographic%20and%20clinical%20factors%2C%20programme%2C%20site%20and%20interaction%20between%20calendar%20time%20and%20ART%20regimen.%20We%20utilized%20inverse%20probability%20weights%20%28IPWs%29%20to%20account%20for%20three%20sampling%20phases%20%28electronic%20medical%20record%20%5BEMR%5D%2C%20chart%20review%20and%20phone%20interview%29%20and%20calculated%20overall%20parameter%20estimates.%20RESULTS%3A%20Women%20contributed%2014%2C768%20woman-years%20from%20the%20largest%20sampling%20phase%20%28EMR%29.%20The%20median%20age%20was%2031%20years.%20Women%20used%20etonogestrel%20implants%20for%2026-69%25%20of%20the%20time%20and%20levonorgestrel%20implants%20for%207-31%25%20of%20the%20time%2C%20depending%20on%20the%20sampling%20phase.%20Women%20used%20efavirenz%2C%20nevirapine%20or%20no%20ART%20for%2027-33%25%2C%2040-46%25%20and%2015-26%25%20of%20follow-ups%2C%20respectively.%20When%20combining%20sampling%20phases%2C%20there%20was%20little%20evidence%20to%20suggest%20that%20the%20relative%20hazard%20of%20pregnancy%20among%20efavirenz-containing%20ART%20users%20relative%20to%20nevirapine-containing%20ART%20changed%20with%20length%20of%20time%20on%20implants%3A%20IPW-adjusted%20HR%20of%203.1%20%28CI%3A%20%5B1.5%3B%206.4%5D%29%20at%2012%20months%2C%203.4%20%28CI%3A%20%5B1.8%3B%206.3%5D%29%20at%2024%20months%2C%203.8%20%28CI%3A%20%5B1.9%3B%207.7%5D%29%20at%2036%20months%20and%204.2%20%28CI%3A%20%5B1.6%3B%2011.1%5D%29%20at%2048%20months%20%28interaction%20p-value%20%3D%200.88%29.%20Similarly%2C%20no%20significant%20change%20in%20HRs%20over%20time%20was%20found%20when%20comparing%20women%20not%20using%20ART%20to%20nevirapine-containing%20ART%20users%20%28interaction%20p-value%20%3D%200.49%29.%20CONCLUSIONS%3A%20We%20did%20not%20find%20evidence%20to%20suggest%20implants%20being%20more%20fallible%20from%20drug-drug%20interactions%20with%20efavirenz%20at%20later%20time%20intervals%20of%20implant%20use.%20Thus%2C%20we%20would%20not%20recommend%20shortening%20the%20duration%20of%20implant%20use%20or%20replacing%20implants%20sooner%20when%20concomitantly%20used%20with%20efavirenz.%22%2C%22date%22%3A%22Sep%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26001%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A40%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22YNT7B8LY%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wada%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A12%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWada%2C%20P.%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKim%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJayathilake%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDuda%2C%20S.%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAbo%2C%20Y.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Site-Level%20Comprehensiveness%20of%20Care%20Is%20Associated%20with%20Individual%20Clinical%20Retention%20Among%20Adults%20Living%20with%20HIV%20in%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%2C%20a%20Global%20HIV%20Cohort%20Collaboration%2C%202000-2016.%20%3Ci%3EAIDS%20Patient%20Care%20STDS%3C%5C%2Fi%3E%2C%20%3Ci%3E36%3C%5C%2Fi%3E%20%289%29%2C%20S.%20343%26%23x2013%3B355.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fapc.2022.0042%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fapc.2022.0042%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Site-Level%20Comprehensiveness%20of%20Care%20Is%20Associated%20with%20Individual%20Clinical%20Retention%20Among%20Adults%20Living%20with%20HIV%20in%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%2C%20a%20Global%20HIV%20Cohort%20Collaboration%2C%202000-2016%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Y.%22%2C%22lastName%22%3A%22Wada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Jayathilake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Abo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20J.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%5D%2C%22abstractNote%22%3A%22Retention%20in%20care%20%28RIC%29%20reduces%20HIV%20transmission%20and%20associated%20morbidity%20and%20mortality.%20We%20examined%20whether%20delivery%20of%20comprehensive%20services%20influenced%20individual%20RIC%20within%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20network.%20We%20collected%20site%20data%20through%20IeDEA%20assessments%201.0%20%282000-2009%29%20and%202.0%20%282010-2016%29.%20Each%20site%20received%20a%20comprehensiveness%20score%20for%20service%20availability%20%281%20%3D%20present%2C%200%20%3D%20absent%29%2C%20with%20tallies%20ranging%20from%200%20to%207.%20We%20obtained%20individual-level%20cohort%20data%20for%20adults%20with%20at%20least%20one%20visit%20from%202000%20to%202016%20at%20sites%20responding%20to%20either%20assessment.%20Person-time%20was%20recorded%20annually%2C%20with%20RIC%20defined%20as%20completing%20two%20visits%20at%20least%2090%20days%20apart%20in%20each%20calendar%20year.%20Multivariable%20modified%20Poisson%20regression%20clustered%20by%20site%20yielded%20risk%20ratios%20and%20predicted%20probabilities%20for%20individual%20RIC%20by%20comprehensiveness.%20Among%20347%2C060%20individuals%20in%20care%20at%20122%20sites%20with%201%2C619%2C558%20person-years%20of%20follow-up%2C%2069.8%25%20of%20person-time%20was%20retained%20in%20care%2C%20varying%20by%20region%20from%2053.8%25%20%28Asia-Pacific%29%20to%2082.7%25%20%28East%20Africa%29%3B%20RIC%20improved%20by%20about%202%25%20per%20year%20from%202000%20to%202016%20%28p%20%3D%200.012%29.%20Every%20site%20provided%20CD4%28%2B%29%20count%20testing%2C%20and%20%3E90%25%20of%20individuals%20received%20care%20at%20sites%20that%20provided%20combination%20antiretroviral%20therapy%20adherence%20measures%2C%20prevention%20of%20mother-to-child%20transmission%2C%20tuberculosis%20screening%2C%20HIV-related%20prevention%2C%20and%20community%20tracing%20services.%20In%20adjusted%20models%2C%20individuals%20at%20sites%20with%20more%20comprehensive%20services%20had%20higher%20probabilities%20of%20RIC%20%280.71%2C%200.74%2C%20and%200.83%20for%20scores%205%2C%206%2C%20and%207%2C%20respectively%3B%20p%20%3D%200.019%29.%20Within%20IeDEA%2C%20greater%20site-level%20comprehensiveness%20of%20services%20was%20associated%20with%20improved%20individual%20RIC.%20Much%20work%20remains%20in%20exploring%20this%20relationship%2C%20which%20may%20inform%20HIV%20clinical%20practice%20and%20health%20systems%20planning.%22%2C%22date%22%3A%22Sep%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1089%5C%2Fapc.2022.0042%22%2C%22ISSN%22%3A%221557-7449%20%28Electronic%29%201087-2914%20%28Print%29%201087-2914%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22ZBJI578D%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A28%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22EQJ3YSKM%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Murenzi%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-25%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMurenzi%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShumbusho%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHansen%2C%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMunyaneza%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGage%2C%20J.%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Long-term%20human%20papillomavirus%20vaccination%20effectiveness%20and%20immunity%20in%20Rwandan%20women%20living%20with%20and%20without%20HIV%3A%20a%20study%20protocol.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E12%3C%5C%2Fi%3E%20%288%29%2C%20S.%20e061650.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2022-061650%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2022-061650%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20human%20papillomavirus%20vaccination%20effectiveness%20and%20immunity%20in%20Rwandan%20women%20living%20with%20and%20without%20HIV%3A%20a%20study%20protocol%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Shumbusho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Hansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Munyaneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20C.%22%2C%22lastName%22%3A%22Gage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Muhoza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Kanyabwisha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Pierz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Tuyisenge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20E.%22%2C%22lastName%22%3A%22Castle%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Prophylactic%20human%20papillomavirus%20%28HPV%29%20vaccines%20have%20been%20shown%20to%20be%20highly%20effective%20in%20protecting%20women%20against%20cervical%20infections%2C%20high-grade%20abnormalities%20and%20cancer%20caused%20by%20the%20targeted%20HPV%20types.%20However%2C%20the%20evidence%20for%20their%20effectiveness%20in%20women%20living%20with%20HIV%20%28WLWH%29%20is%20less%20clear.%20METHODS%3A%20WLWH%20and%20HIV-negative%20women%20who%20likely%20did%20%28birth%20cohorts%201996%20and%20later%29%20and%20WLWH%20and%20HIV%28-%29%20negative%20who%20likely%20did%20not%20%28birth%20cohorts%20before%201996%29%20receive%20HPV%20vaccination%20%28n%3D3028%3B%20757%20participants%20for%20each%20of%20the%20four%20groups%29.%20Between%20groups%2C%20we%20will%20compare%20cervicovaginal%2C%20anal%20and%20oral%20prevalent%20and%206-12%20month%20persistent%20HPV6%5C%2F11%5C%2F16%5C%2F18%20infections%20as%20measured%20using%20a%20modified%20AmpFire%20HPV%20genotyping%20assay%20that%20tests%20for%2015%20high-risk%20or%20intermediate-risk%20HPV%20genotypes%2C%20HPV6%20and%20HPV11.%20We%20will%20also%20compare%20the%20HPV%20immune%20response%20in%20HPV-vaccinated%20WLWH%20to%20HPV-vaccinated%20HIV-negative%20women%20using%20an%20anti-HPV16%20and%20anti-HPV18%20ELISA.%20Vaccination%20status%20will%20be%20confirmed%20through%20national%20vaccination%20records.%20ANALYSIS%3A%20We%20will%20calculate%20point%20prevalence%20and%20prevalence%20of%206-12%20month%20persisting%20infections%20by%20individual%20HPV-type%20specific%20infections%20and%20groups%20of%20infections%20for%20each%20anatomic%20site%20and%20for%20each%20group%20of%20women.%20Results%20will%20be%20stratified%20by%20age%20at%20vaccination%2C%20age%20at%20enrolment%20and%20the%20number%20of%20doses%20%283%20vs%202%29%20as%20well%20as%20other%20factors%20possibly%20associated%20with%20HPV%20prevalence.%20Differences%20in%20endpoints%20between%20groups%2C%20overall%20and%20between%20subgroups%2C%20will%20be%20tested%20for%20statistical%20significance%20%28p%3C0.05%29%20using%20Fisher%27s%20exact%20or%20Pearson%20chi%282%29%20test.%20Differences%20in%20geometric%20mean%20titres%20and%20seropositivity%20will%20be%20tested%20for%20statistical%20significance%20using%20the%20Mann-Whitney%20and%20Fisher%27s%20exact%20tests%2C%20respectively.%20ETHICS%20AND%20DISSEMINATION%3A%20The%20study%20was%20approved%20by%20the%20Albert%20Einstein%20College%20of%20Medicine%20Institutional%20Review%20Board%20and%20the%20Rwanda%20National%20Ethics%20Committee.%20Results%20will%20be%20disseminated%20through%20publication%20in%20peer-reviewed%20journals.%22%2C%22date%22%3A%22Aug%2025%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2022-061650%22%2C%22ISSN%22%3A%222044-6055%20%28Electronic%29%202044-6055%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A37%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22T3VRSJI7%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Asangbeh-Kerman%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAsangbeh-Kerman%2C%20S.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavidovic%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETaghavi%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKachingwe%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERammipi%2C%20K.%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Cervical%20cancer%20prevention%20in%20countries%20with%20the%20highest%20HIV%20prevalence%3A%20a%20review%20of%20policies.%20%3Ci%3EBMC%20Public%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E22%3C%5C%2Fi%3E%20%281%29%2C%20S.%201530.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-022-13827-0%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-022-13827-0%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cervical%20cancer%20prevention%20in%20countries%20with%20the%20highest%20HIV%20prevalence%3A%20a%20review%20of%20policies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20L.%22%2C%22lastName%22%3A%22Asangbeh-Kerman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Davidovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Taghavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Kachingwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20M.%22%2C%22lastName%22%3A%22Rammipi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Muzingwani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Pascoe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Jousse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mulongo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mwanahamuntu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Tapela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Akintade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Basu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X.%22%2C%22lastName%22%3A%22Dlamini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Bohlius%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Cervical%20cancer%20%28CC%29%20is%20the%20leading%20cause%20of%20cancer-related%20death%20among%20women%20in%20sub-Saharan%20Africa.%20It%20occurs%20most%20frequently%20in%20women%20living%20with%20HIV%20%28WLHIV%29%20and%20is%20classified%20as%20an%20AIDS-defining%20illness.%20Recent%20World%20Health%20Organisation%20%28WHO%29%20recommendations%20provide%20guidance%20for%20CC%20prevention%20policies%2C%20with%20specifications%20for%20WLHIV.%20We%20systematically%20reviewed%20policies%20for%20CC%20prevention%20and%20control%20in%20sub-Saharan%20countries%20with%20the%20highest%20HIV%20prevalence.%20METHODS%3A%20We%20included%20countries%20with%20an%20HIV%20prevalence%20%3E%5C%2F%3D%2010%25%20in%202018%20and%20policies%20published%20between%20January%201%28st%29%202010%20and%20March%2031%28st%29%202022.%20We%20searched%20Medline%20via%20PubMed%2C%20the%20international%20cancer%20control%20partnership%20website%20and%20national%20governmental%20websites%20of%20included%20countries%20for%20relevant%20policy%20documents.%20The%20online%20document%20search%20was%20supplemented%20with%20expert%20consultation%20for%20each%20included%20country.%20We%20synthesised%20aspects%20defined%20in%20policies%20for%20HPV%20vaccination%2C%20sex%20education%2C%20condom%20use%2C%20tobacco%20control%2C%20male%20circumcision%2Ccervical%20screening%2C%20diagnosis%20and%20treatment%20of%20cervical%20pre-cancerous%20lesions%20and%20cancer%2C%20monitoring%20mechanisms%20and%20cost%20of%20services%20to%20women%20while%20highlighting%20specificities%20for%20WLHIV.%20RESULTS%3A%20We%20reviewed%2033%20policy%20documents%20from%20nine%20countries.%20All%20included%20countries%20had%20policies%20on%20CC%20prevention%20and%20control%20either%20as%20a%20standalone%20policy%20%2877.8%25%29%2C%20or%20as%20part%20of%20a%20cancer%20or%20non-communicable%20diseases%20policy%20%2822.2%25%29%20or%20both%20%2866.7%25%29.%20Aspects%20of%20HPV%20vaccination%20were%20reported%20in%207%20%2877.8%25%29%20of%20the%209%20countries.%20All%20countries%20%28100%25%29%20planned%20to%20develop%20or%20review%20Information%2C%20Education%20and%20Communication%20%28IEC%29%20materials%20for%20CC%20prevention%20including%20condom%20use%20and%20tobacco%20control.%20Age%20at%20screening%20commencement%20and%20screening%20intervals%20for%20WLHIV%20varied%20across%20countries.%20The%20most%20common%20recommended%20screening%20and%20treatment%20methods%20were%20visual%20inspection%20with%20acetic%20acid%20%28VIA%29%20%2888.9%25%29%2C%20Pap%20smear%20%2877.8%25%29%3B%20cryotherapy%20%28100%25%29%20and%20loop%20electrosurgical%20procedure%20%28LEEP%29%20%2888.9%25%29%20respectively.%20Global%20indicators%20disaggregated%20by%20HIV%20status%20for%20monitoring%20CC%20programs%20were%20rarely%20reported.%20CC%20prevention%20and%20care%20policies%20included%20service%20costs%20at%20various%20stages%20in%20three%20countries%20%2833.3%25%29.%20CONCLUSION%3A%20Considerable%20progress%20has%20been%20made%20in%20policy%20development%20for%20CC%20prevention%20and%20control%20in%20sub%20Saharan%20Africa.%20However%2C%20in%20countries%20with%20a%20high%20HIV%20burden%2C%20there%20is%20need%20to%20tailor%20these%20policies%20to%20respond%20to%20the%20specific%20needs%20of%20WLHIV.%20Countries%20may%20consider%20updating%20policies%20using%20the%20recent%20WHO%20guidelines%20for%20CC%20prevention%2C%20while%20adapting%20them%20to%20context%20realities.%22%2C%22date%22%3A%22Aug%2010%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12889-022-13827-0%22%2C%22ISSN%22%3A%221471-2458%20%28Electronic%29%201471-2458%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A38%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22VZAULTB8%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Christ%20et%20al.%22%2C%22parsedDate%22%3A%222022-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChrist%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3Evan%20Dijk%2C%20J.%20H.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENyandoro%2C%20T.%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EReichmuth%2C%20M.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKunzekwenyika%2C%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Availability%20and%20experiences%20of%20differentiated%20antiretroviral%20therapy%20delivery%20at%20HIV%20care%20facilities%20in%20rural%20Zimbabwe%3A%20a%20mixed-method%20study.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%288%29%2C%20S.%20e25944.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25944%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25944%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Availability%20and%20experiences%20of%20differentiated%20antiretroviral%20therapy%20delivery%20at%20HIV%20care%20facilities%20in%20rural%20Zimbabwe%3A%20a%20mixed-method%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Christ%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20H.%22%2C%22lastName%22%3A%22van%20Dijk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20Y.%22%2C%22lastName%22%3A%22Nyandoro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Reichmuth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kunzekwenyika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Chammartin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Wringe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%20in%20Southern%20Africa%22%2C%22lastName%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Zimbabwe%20adopted%20differentiated%20HIV%20care%20policies%20in%202015%20to%20promote%20client-centred%20care%20and%20relieve%20strain%20on%20health%20facilities.%20We%20examined%20the%20availability%2C%20experiences%20and%20perceptions%20of%20differentiated%20antiretroviral%20therapy%20%28ART%29%20delivery%20in%20rural%20Zimbabwe%20following%20the%20policy%20adoption.%20METHODS%3A%20We%20undertook%20a%20cross-sectional%20mixed%20methods%20study%20in%20all%20the%2026%20facilities%20providing%20HIV%20care%20in%20a%20rural%20district%20in%20Zimbabwe.%20We%20collected%20quantitative%20data%20about%20ART%20delivery%20and%20visit%20durations%20from%2031%20healthcare%20providers%20and%20a%20purposive%20stratified%20sample%20of%20378%20clients%20obtaining%20ART%20either%20through%20routine%20care%20or%20differentiated%20ART%20delivery%20models.%20We%20performed%2026%20semi-structured%20interviews%20among%20healthcare%20providers%20and%20seven%20focus%20group%20discussions%20%28FGDs%29%20among%20clients%20to%20elicit%20their%20perceptions%20and%20experiences%20of%20ART%20delivery.%20Data%20were%20collected%20in%202019%2C%20with%20one%20follow-up%20FGD%20in%202021.%20We%20analysed%20the%20transcripts%20thematically%2C%20with%20inductive%20coding%2C%20to%20identify%20emerging%20themes.%20RESULTS%3A%20Twenty%20facilities%20%2877%25%29%20offered%20at%20least%20one%20differentiated%20ART%20delivery%20models%2C%20including%20community%20ART%20refill%20groups%20%28CARGs%3B%2013%20facilities%2C%2050%25%29%2C%20fast-track%20refill%20%288%2C%2031%25%29%2C%20family%20refill%20%286%2C%2023%25%29%20or%20club%20refill%20%281%2C%204%25%29.%20Thirteen%20facilities%20%2850%25%29%20offered%20only%20one%20model.%20The%20median%20visit%20duration%20was%2028%20minutes%20%28interquartile%20range%20%5BIQR%5D%3A%2016-62%29.%20Participants%20in%20fast-track%20had%20the%20shortest%20visit%20durations%20%2818%20minutes%2C%20IQR%3A%2011-24%29.%20Confidentiality%20and%20disclosure%20of%20HIV%20status%2C%20travelling%20long%20distances%2C%20travel%20costs%20and%20waiting%20times%20were%20the%20main%20issues%20influencing%20clients%27%20views%20on%20differentiated%20ART%20delivery.%20Fast-track%20refill%20was%20perceived%20as%20the%20preferred%20model%20of%20clients%20for%20its%20limited%20involuntary%20disclosure%20and%20efficiency.%20In%20contrast%2C%20group-%20and%20community-based%20refill%20models%20reduced%20travel%20costs%20but%20were%20felt%20to%20be%20associated%20with%20involuntary%20disclosure%20of%20HIV%20status%2C%20which%20could%20discourage%20clients.%20Healthcare%20providers%20also%20experienced%20an%20additional%20workload%20when%20offering%20facility-based%20group%20models%2C%20such%20as%20CARGs.%20CONCLUSIONS%3A%20Differentiated%20ART%20delivery%20models%20were%20widely%20available%20in%20this%20rural%20setting%2C%20but%20most%20facilities%20did%20not%20offer%20a%20choice%20of%20models%20to%20address%20clients%27%20diverse%20preferences.%20A%20minority%20offered%20fast-track%20refills%2C%20although%20this%20model%20was%20often%20mentioned%20as%20desirable.%20Confidentiality%2C%20travel%20expenses%20and%20client%20waiting%20times%20are%20key%20elements%20to%20consider%20when%20planning%20and%20rolling%20out%20differentiated%20HIV%20care.%22%2C%22date%22%3A%22Aug%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25944%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A43%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22998APCFS%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Freeman%20et%20al.%22%2C%22parsedDate%22%3A%222022-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFreeman%2C%20E.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMcCann%2C%20N.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESemeere%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EReddy%2C%20K.%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELaker-Oketta%2C%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Evaluation%20of%20four%20chemotherapy%20regimens%20for%20treatment%20of%20advanced%20AIDS-associated%20Kaposi%20sarcoma%20in%20Kenya%3A%20a%20cost-effectiveness%20analysis.%20%3Ci%3ELancet%20Glob%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E10%3C%5C%2Fi%3E%20%288%29%2C%20S.%20e1179%26%23x2013%3Be1188.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2214-109X%2822%2900242-X%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2214-109X%2822%2900242-X%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20four%20chemotherapy%20regimens%20for%20treatment%20of%20advanced%20AIDS-associated%20Kaposi%20sarcoma%20in%20Kenya%3A%20a%20cost-effectiveness%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20E.%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20C.%22%2C%22lastName%22%3A%22McCann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20P.%22%2C%22lastName%22%3A%22Reddy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Laker-Oketta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20P.%22%2C%22lastName%22%3A%22Pei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20E.%22%2C%22lastName%22%3A%22Hajny%20Fernandez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kiprono%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Busakhala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20N.%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20V.%22%2C%22lastName%22%3A%22Bassett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22Freedberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20P.%22%2C%22lastName%22%3A%22Hyle%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20most%20effective%20treatment%20for%20advanced%20AIDS-associated%20Kaposi%20sarcoma%20is%20paclitaxel%20or%20pegylated%20liposomal%20doxorubicin%20%28PLD%29%3B%20neither%20is%20routinely%20used%20in%20sub-Saharan%20Africa%20due%20to%20limited%20availability%20and%20high%20cost.%20We%20examined%20the%20clinical%20impact%2C%20costs%2C%20and%20cost-effectiveness%20of%20paclitaxel%20or%20PLD%20in%20Kenya%2C%20compared%20with%20etoposide%20or%20bleomycin-vincristine.%20METHODS%3A%20In%20this%20study%2C%20we%20use%20the%20Cost-Effectiveness%20of%20Preventing%20AIDS%20Complications%20%28CEPAC%29-International%20Model%20to%20project%20clinical%20outcomes%20and%20costs%20among%20people%20living%20with%20HIV%20and%20advanced%20Kaposi%20sarcoma%20on%20antiretroviral%20therapy.%20We%20compared%20four%20different%20treatment%20strategies%3A%20etoposide%2C%20bleomycin-vincristine%2C%20paclitaxel%2C%20or%20PLD.%20We%20derived%20cohort%20characteristics%20and%20costs%20from%20the%20Kenyan%20Academic%20Model%20for%20Providing%20Access%20to%20Healthcare%20network%2C%20and%20adverse%20events%2C%20efficacy%2C%20and%20mortality%20from%20clinical%20trials.%20We%20projected%20model%20outcomes%20over%20a%20lifetime%20and%20included%20life%20expectancy%2C%20per-person%20lifetime%20costs%2C%20and%20incremental%20cost-effectiveness%20ratios%20%28ICERs%29.%20We%20conducted%20budget%20impact%20analysis%20for%205-year%20total%20costs%20and%20did%20deterministic%20and%20probabilistic%20sensitivity%20analyses%20to%20evaluate%20the%20effect%20of%20uncertainty%20in%20input%20parameters.%20FINDINGS%3A%20We%20found%20that%20paclitaxel%20would%20be%20more%20effective%20than%20bleomycin-vincristine%20and%20would%20increase%20life%20expectancy%20by%204.2%20years%20per%20person.%20PLD%20would%20further%20increase%20life%20expectancy%20by%200.6%20years%20per%20person.%20Paclitaxel%20would%20be%20the%20most%20cost-effective%20strategy%20%28ICER%20US%24380%20per%20year-of-life-saved%20compared%20with%20bleomycin-vincristine%29%20and%20would%20remain%20cost-effective%20across%20a%20range%20of%20scenarios.%20PLD%20would%20be%20cost-effective%20compared%20with%20paclitaxel%20if%20its%20price%20were%20reduced%20to%20%24100%20per%20cycle%20%28base%20case%20%24180%20per%20cycle%29.%20Implementing%20paclitaxel%20instead%20of%20bleomycin-vincristine%20would%20save%20approximately%206400%20life-years%20and%20would%20increase%20the%20overall%205-year%20Kenyan%20health-care%20costs%20by%20%243.7%20million%3B%20increased%20costs%20would%20be%20primarily%20related%20to%20ongoing%20HIV%20care%20given%20improved%20survival.%20INTERPRETATION%3A%20Paclitaxel%20would%20substantially%20increase%20life%20expectancy%20and%20be%20cost-effective%20compared%20with%20bleomycin-vincristine%20for%20advanced%20AIDS-associated%20Kaposi%20sarcoma%20in%20Kenya%20and%20should%20be%20the%20standard%20of%20care.%20PLD%20would%20further%20improve%20survival%20and%20be%20cost-effective%20with%20a%2044%25%20price%20reduction.%20FUNDING%3A%20US%20National%20Institutes%20of%20Health%20and%20Massachusetts%20General%20Hospital.%20TRANSLATION%3A%20For%20the%20Swahili%20translation%20of%20the%20abstract%20see%20Supplementary%20Materials%20section.%22%2C%22date%22%3A%22Aug%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS2214-109X%2822%2900242-X%22%2C%22ISSN%22%3A%222214-109X%20%28Electronic%29%202214-109X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A44%3A58Z%22%7D%7D%2C%7B%22key%22%3A%22M7JZWQTU%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Teeraananchai%20et%20al.%22%2C%22parsedDate%22%3A%222022-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETeeraananchai%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELaw%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBoettiger%2C%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMata%2C%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGupte%2C%20N.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Virological%20failure%20and%20treatment%20switch%20after%20ART%20initiation%20among%20people%20living%20with%20HIV%20with%20and%20without%20routine%20viral%20load%20monitoring%20in%20Asia.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%288%29%2C%20S.%20e25989.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25989%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25989%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Virological%20failure%20and%20treatment%20switch%20after%20ART%20initiation%20among%20people%20living%20with%20HIV%20with%20and%20without%20routine%20viral%20load%20monitoring%20in%20Asia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Teeraananchai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Law%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Boettiger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Mata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Gupte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20L.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20N.%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Chaiwarith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20S.%22%2C%22lastName%22%3A%22Ly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20J.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kiertiburanakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khusuwan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Yunihastuti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Pujari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Azwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20K.%20A.%22%2C%22lastName%22%3A%22Somia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Tanuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ditangco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Y.%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20T.%22%2C%22lastName%22%3A%22Ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Gani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22Treat%20Asia%20HIV%20Observational%20Database%20of%20IeDEA%20Asia-Pacific%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Viral%20load%20%28VL%29%20testing%20is%20still%20challenging%20to%20monitor%20treatment%20responses%20of%20antiretroviral%20therapy%20%28ART%29%20for%20HIV%20treatment%20programme%20in%20Asia.%20We%20assessed%20the%20association%20between%20routine%20VL%20testing%20and%20virological%20failure%20%28VF%29%20and%20determine%20factors%20associated%20with%20switching%20to%20second-line%20regimen.%20METHODS%3A%20Among%2021%20sites%20from%20the%20TREAT%20Asia%20HIV%20Observational%20Database%20%28TAHOD%29%2C%20people%20living%20with%20HIV%20%28PLHIV%29%20aged%20%3E%5C%2F%3D18%20years%20initiating%20ART%20from%202003%20to%202021%20were%20included.%20We%20calculated%20the%20average%20number%20of%20VL%20tests%20per%20patient%20per%20year%20between%20the%20date%20of%20ART%20initiation%20and%20the%20most%20recent%20visit.%20If%20the%20median%20average%20number%20of%20VL%20tests%20was%20%3E%5C%2F%3D%200.80%20per%20patient%20per%20year%2C%20the%20site%20was%20classified%20as%20a%20routine%20VL%20site.%20A%20site%20with%20a%20median%20%3C%200.80%20was%20classified%20into%20the%20non-routine%20VL%20sites.%20VF%20was%20defined%20as%20VL%20%3E%5C%2F%3D1000%20copies%5C%2Fml%20during%20first-line%20therapy.%20Factors%20associated%20with%20VF%20were%20analysed%20using%20generalized%20estimating%20equations%20with%20Poisson%20distribution.%20RESULTS%3A%20Of%206277%20PLHIV%20starting%20ART%20after%202003%2C%203030%20%2848%25%29%20were%20from%2011%20routine%20VL%20testing%20sites%20and%203247%20%2852%25%29%20were%20from%2010%20non-routine%20VL%20testing%20sites.%20The%20median%20follow-up%20was%209%20years%20%28IQR%205-13%29.%20The%20median%20age%20was%2035%20%2830-42%29%20years%3B%2068%25%20were%20male%20and%205729%20%2891%25%29%20started%20non-nucleoside%20reverse-transcriptase%20inhibitor-based%20regimen.%20The%20median%20pre-ART%20CD4%20count%20in%20PLHIV%20from%20routine%20VL%20sites%20was%20lower%20compared%20to%20non-routine%20VL%20sites%20%28144%20vs.%20156%20cells%5C%2Fmm%283%29%20%2C%20p%20%3C0.001%29.%20Overall%2C%201021%20subsequent%20VF%20at%20a%20rate%20of%202.15%20%2895%25%20CI%202.02-2.29%29%20per%20100%20person-years%20%28PY%29.%20VF%20was%20more%20frequent%20at%20non-routine%20VL%20sites%20%28adjusted%20incidence%20rate%20ratio%202.85%20%5B95%25%20CI%202.27-3.59%5D%29%20compared%20to%20routine%20VL%20sites.%20Other%20factors%20associated%20with%20an%20increased%20rate%20of%20VF%20were%20age%20%3C50%20years%20and%20CD4%20count%20%3C350%20cells%5C%2Fmm%283%29%20.%20A%20total%20of%20817%20%2813%25%29%20patients%20switched%20to%20second-line%20regimen%20at%20a%20rate%20of%201.44%20%2895%25%20CI%201.35-1.54%29%20per%20100%20PY.%20PLHIV%20at%20routine%20VL%20monitoring%20sites%20were%20at%20higher%20risk%20of%20switching%20than%20those%20at%20non-routine%20VL%20sites%20%28adjusted%20sub-hazard%20ratio%201.78%2095%25%20CI%20%5B1.17-2.71%5D%29.%20CONCLUSIONS%3A%20PLHIV%20from%20non-routine%20VL%20sites%20had%20a%20higher%20incidence%20of%20persistent%20VF%20and%20a%20low%20switching%20regimen%20rate%2C%20reflecting%20possible%20under-utilized%20VL%20testing.%22%2C%22date%22%3A%22Aug%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25989%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A33%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22U2PE9QVY%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chihota%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChihota%2C%20B.%20V.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERiebensahm%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMuula%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESinkala%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChilengi%2C%20R.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Liver%20steatosis%20and%20metabolic%20dysfunction-associated%20fatty%20liver%20disease%20among%20HIV-positive%20and%20negative%20adults%20in%20urban%20Zambia.%20%3Ci%3EBMJ%20Open%20Gastroenterol%3C%5C%2Fi%3E%2C%20%3Ci%3E9%3C%5C%2Fi%3E%20%281%29%2C%20S.%20e000945.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgast-2022-000945%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgast-2022-000945%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Liver%20steatosis%20and%20metabolic%20dysfunction-associated%20fatty%20liver%20disease%20among%20HIV-positive%20and%20negative%20adults%20in%20urban%20Zambia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20V.%22%2C%22lastName%22%3A%22Chihota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Riebensahm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Muula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Sinkala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Chilengi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Mulenga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bosomprah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Vinikoor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bolton-Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Rauch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Berzigotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20southern%20Africa%22%2C%22lastName%22%3A%22Ie%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20The%20growing%20importance%20of%20non-communicable%20diseases%20%28NCDs%29%20and%20high%20HIV%20prevalence%20in%20urban%20African%20settings%20may%20increase%20the%20burden%20of%20metabolic%20dysfunction-associated%20fatty%20liver%20disease%20%28MAFLD%29.%20We%20assessed%20liver%20steatosis%20among%20HIV-positive%20and%20negative%20adults%20in%20urban%20Zambia.%20METHODS%3A%20Adults%2030%20years%20and%20older%20who%20were%20newly%20diagnosed%20with%20HIV%2C%20or%20tested%20HIV-negative%20at%20two%20primary%20care%20clinics%20in%20Lusaka%2C%20Zambia%2C%20were%20assessed%20for%20liver%20steatosis.%20Cardiometabolic%20data%20were%20collected%20through%20comprehensive%20clinical%20and%20laboratory%20assessments.%20Transient%20elastography%20was%20performed%20to%20measure%20controlled-attenuation%20parameter%20%28%3E%5C%2F%3D248%20dB%5C%2Fm%29.%20We%20used%20multivariable%20logistic%20regression%20models%20to%20determine%20the%20factors%20associated%20with%20the%20presence%20of%20steatosis.%20RESULTS%3A%20We%20enrolled%20381%20patients%2C%20including%20154%20%2840%25%29%20antiretroviral%20therapy-naive%20people%20living%20with%20HIV%20%28PLWH%29%20with%20a%20median%20CD4%2B%20count%20of%20247%20cells%5C%2Fmm%283%29%20and%20a%20mean%20body%20mass%20index%20%28BMI%29%20of%2023.8%20kg%5C%2Fm%282%29.%20Liver%20steatosis%20was%20observed%20in%2010%25%20of%20participants%20overall%20and%20was%20more%20common%20among%20HIV-negative%20adults%20than%20in%20PLWH%20%2815%25%20vs%203%25%29.%20The%20proportion%20of%20patients%20with%20steatosis%20was%2025%25%20among%20obese%20%28BMI%20%3E%5C%2F%3D30%20kg%5C%2Fm%282%29%29%20participants%2C%2012%25%20among%20those%20overweight%20%28BMI%2025-29.9%20kg%5C%2Fm%282%29%29%2C%20and%207%25%20among%20those%20with%20a%20BMI%20%3C25%20kg%5C%2Fm%282%29.%20Among%20patients%20with%20a%20fasting%20glucose%20%3E%5C%2F%3D7%20mmol%5C%2FL%20or%20confirmed%20diabetes%2C%2057%25%20had%20liver%20steatosis.%20In%20multivariable%20analyses%2C%20HIV%20status%20%28adjusted%20odds%20ratio%20%28aOR%29%200.18%2C%2095%25%20CI%200.06%20to%200.53%29%2C%20confirmed%20diabetes%20or%20elevated%20fasting%20glucose%20%28aOR%203.92%2C%2095%25%20CI%201.57%20to%209.78%29%20and%20elevated%20blood%20pressure%20%28aOR%202.95%2C%2095%25%20CI%201.34%20to%206.48%29%20were%20associated%20with%20steatosis.%20The%20association%20between%20BMI%3E25%20kg%5C%2Fm%282%29%20and%20liver%20steatosis%20was%20attenuated%20after%20adjustment%20for%20potential%20confounders%20%28aOR%201.96%2C%2095%25%20CI%200.88-4.40%29.%20Overall%2C%2021%20%289%25%29%20participants%20without%20HIV%20and%204%20%283%25%29%20with%20HIV%20met%20the%20criteria%20for%20MAFLD.%20Among%20individuals%20with%20liver%20steatosis%2C%2065%25%20%2895%25%20CI%2049%25%20to%2080%25%29%20fulfilled%20criteria%20of%20MAFLD%2C%20whereas%2015%20%2839%25%29%20of%20them%20had%20elevated%20transaminases%20and%203%20%288%25%29%20F2-F4%20fibrosis.%20CONCLUSIONS%3A%20The%20prevalence%20of%20liver%20steatosis%20in%20this%20urban%20cohort%20of%20HIV-positive%20and%20negative%20adults%20in%20Zambia%20was%20low%2C%20despite%20a%20large%20proportion%20of%20patients%20with%20high%20BMI%20and%20central%20obesity.%20Our%20study%20is%20among%20the%20first%20to%20report%20data%20on%20MAFLD%20among%20adults%20in%20Africa%2C%20demonstrating%20that%20metabolic%20risk%20factors%20are%20key%20drivers%20of%20liver%20steatosis%20and%20supporting%20the%20adoption%20of%20the%20criteria%20for%20MAFLD%20in%20African%20populations.%22%2C%22date%22%3A%22Jul%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjgast-2022-000945%22%2C%22ISSN%22%3A%222054-4774%20%28Print%29%202054-4774%20%28Electronic%29%202054-4774%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A36%3A29Z%22%7D%7D%2C%7B%22key%22%3A%228N68RLVP%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Romo%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A10%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERomo%2C%20M.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrazier%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMahambou-Nsonde%2C%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDe%20Waal%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESekaggya-Wiltshire%2C%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Real-world%20use%20and%20outcomes%20of%20dolutegravir-containing%20antiretroviral%20therapy%20in%20HIV%20and%20tuberculosis%20co-infection%3A%20a%20site%20survey%20and%20cohort%20study%20in%20sub-Saharan%20Africa.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%287%29%2C%20S.%20e25961.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25961%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25961%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Real-world%20use%20and%20outcomes%20of%20dolutegravir-containing%20antiretroviral%20therapy%20in%20HIV%20and%20tuberculosis%20co-infection%3A%20a%20site%20survey%20and%20cohort%20study%20in%20sub-Saharan%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Romo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Mahambou-Nsonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22De%20Waal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Sekaggya-Wiltshire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20R.%22%2C%22lastName%22%3A%22Muyindike%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kunzekwenyika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Muhairwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Lelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dzudie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Rafael%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20C.%22%2C%22lastName%22%3A%22Ezechi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20S.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%22%2C%22lastName%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Dolutegravir%20is%20being%20scaled%20up%20globally%20as%20part%20of%20antiretroviral%20therapy%20%28ART%29%2C%20but%20for%20people%20with%20HIV%20and%20tuberculosis%20co-infection%2C%20its%20use%20is%20complicated%20by%20a%20drug-drug%20interaction%20with%20rifampicin%20requiring%20an%20additional%20daily%20dose%20of%20dolutegravir.%20This%20represents%20a%20disadvantage%20over%20efavirenz%2C%20which%20does%20not%20have%20a%20major%20drug-drug%20interaction%20with%20rifampicin.%20We%20sought%20to%20describe%20HIV%20clinic%20practices%20for%20prescribing%20concomitant%20dolutegravir%20and%20rifampicin%2C%20and%20characterize%20virologic%20outcomes%20among%20patients%20with%20tuberculosis%20co-infection%20receiving%20dolutegravir%20or%20efavirenz.%20METHODS%3A%20Within%20the%20four%20sub-Saharan%20Africa%20regions%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20consortium%2C%20we%20conducted%20a%20site%20survey%20%282021%29%20and%20a%20cohort%20study%20%282015-2021%29.%20The%20cohort%20study%20used%20routine%20clinical%20data%20and%20included%20patients%20newly%20initiating%20or%20already%20receiving%20dolutegravir%20or%20efavirenz%20at%20the%20time%20of%20tuberculosis%20diagnosis.%20Patients%20were%20followed%20from%20tuberculosis%20diagnosis%20until%20viral%20suppression%20%28%3C1000%20copies%5C%2Fml%29%2C%20a%20competing%20event%20%28switching%20ART%20regimen%3B%20loss%20to%20program%5C%2Fdeath%29%20or%20administrative%20censoring%20at%2012%20months.%20RESULTS%3A%20In%20the%20survey%2C%2086%20of%2090%20%2896%25%29%20HIV%20clinics%20in%2018%20countries%20reported%20prescribing%20dolutegravir%20to%20patients%20who%20were%20receiving%20rifampicin%20as%20part%20of%20tuberculosis%20treatment%2C%20with%2077%20%2890%25%29%20reporting%20that%20they%20use%20twice-daily%20dosing%20of%20dolutegravir%2C%20of%20which%2074%20%2896%25%29%20reported%20having%2050%20mg%20tablets%20available%20to%20accommodate%20twice-daily%20dosing.%20The%20cohort%20study%20included%203563%20patients%20in%2011%20countries%2C%20with%2067%25%20newly%20or%20recently%20initiating%20ART.%20Among%20patients%20receiving%20dolutegravir%20%28n%20%3D%20465%29%2C%20the%20cumulative%20incidence%20of%20viral%20suppression%20was%2058.9%25%20%2895%25%20confidence%20interval%20%5BCI%5D%3A%2054.3-63.3%25%29%2C%20switching%20ART%20regimen%20was%204.1%25%20%2895%25%20CI%3A%202.6-6.2%25%29%20and%20loss%20to%20program%5C%2Fdeath%20was%2023.4%25%20%2895%25%20CI%3A%2019.7-27.4%25%29.%20Patients%20receiving%20dolutegravir%20had%20improved%20viral%20suppression%20compared%20with%20patients%20receiving%20efavirenz%20who%20had%20a%20tuberculosis%20diagnosis%20before%20site%20dolutegravir%20availability%20%28adjusted%20subdistribution%20hazard%20ratio%20%5BaSHR%5D%3A%201.47%2C%2095%25%20CI%3A%201.28-1.68%29%20and%20after%20site%20dolutegravir%20availability%20%28aSHR%201.28%2C%2095%25%20CI%3A%201.08-1.51%29.%20CONCLUSIONS%3A%20At%20a%20programmatic%20level%2C%20dolutegravir%20was%20being%20widely%20prescribed%20in%20sub-Saharan%20Africa%20for%20people%20with%20HIV%20and%20tuberculosis%20co-infection%20with%20a%20dose%20adjustment%20for%20the%20drug-drug%20interaction%20with%20rifampicin.%20Despite%20this%20more%20complex%20regimen%2C%20our%20cohort%20study%20revealed%20that%20dolutegravir%20did%20not%20negatively%20impact%20viral%20suppression.%22%2C%22date%22%3A%22Jul%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25961%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%22ZBJI578D%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A25%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22K25THJJP%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Baidya%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBaidya%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESangle%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMarbaniang%2C%20I.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKulkarni%2C%20V.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDeshpande%2C%20P.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Clinical%20and%20Immunological%20Markers%20of%20Pulmonary%20Impairment%20Among%20People%20With%20HIV%20in%20India.%20%3Ci%3EOpen%20Forum%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E9%3C%5C%2Fi%3E%20%287%29%2C%20S.%20ofac233.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac233%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac233%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20and%20Immunological%20Markers%20of%20Pulmonary%20Impairment%20Among%20People%20With%20HIV%20in%20India%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Baidya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Sangle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Marbaniang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Kulkarni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Deshpande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Nimkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Chavan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Salvi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lokhande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Kadam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Mave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20N.%22%2C%22lastName%22%3A%22Gupte%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Despite%20antiretroviral%20therapy%2C%20chronic%20lung%20diseases%20remain%20an%20important%20source%20of%20morbidity%20and%20mortality%20in%20people%20with%20HIV%20%28PWH%29.%20We%20sought%20to%20identify%20clinical%20and%20immunological%20markers%20of%20pulmonary%20impairment%20among%20PWH%20in%20India.%20METHODS%3A%20Two%20hundred%20ten%20adult%20PWH%20receiving%20antiretroviral%20therapy%20%28ART%29%20were%20prospectively%20evaluated%20for%203%20years.%20Plasma%20concentrations%20of%20interleukin%20%28IL%29-6%2C%20IL-10%2C%20tumor%20necrosis%20factor%20alpha%2C%20D-dimer%2C%20C-reactive%20protein%2C%20soluble%20%28s%29CD14%2C%20and%20sCD163%20were%20measured%20at%20enrollment.%20We%20used%20multivariable%20linear%20and%20logistic%20regression%20to%20measure%20the%20association%20of%20baseline%20and%20time-varying%20clinical%20and%20immunological%20variables%20with%20spirometry-defined%20chronic%20obstructive%20pulmonary%20disease%20%28COPD%29%2C%20restrictive%20spirometry%20pattern%20%28RSP%29%2C%20preserved%20ratio%20impaired%20spirometry%20%28PRISm%29%2C%20forced%20expiratory%20volume%20in%201%20second%20%28FEV1%29%2C%20and%20forced%20vital%20capacity%20%28FVC%29%20during%20the%20third%20year%20of%20follow-up.%20RESULTS%3A%20After%20adjusting%20confounders%2C%20females%20were%207%20times%20more%20likely%20to%20have%20RSP%20%2895%25%20CI%2C%202.81%20to%2017.62%3B%20P%20%3C%20.001%29%20and%2022%20times%20more%20likely%20to%20have%20PRISm%20%2895%25%20CI%2C%207.42%20to%2069.92%3B%20P%20%3C%20.001%29%20compared%20with%20men.%20Higher%20IL-6%20concentrations%20were%20associated%20with%20lower%20FEV1%20z-scores%20%28beta%2C%20-0.14%20per%20log-higher%3B%2095%25%20CI%2C%20-0.29%20to%200.008%3B%20P%20%3D%20.06%29%20and%20higher%20odds%20of%20COPD%20%28adjusted%20odds%20ratio%20%5BaOR%5D%2C%202.66%20per%20log-higher%3B%2095%25%20CI%2C%201.16%20to%206.09%3B%20P%20%3D%20.02%29.%20Higher%20D-dimer%20concentrations%20were%20associated%20with%20lower%20FVC%20z-scores%20%28beta%2C%20-0.40%20per%20log-higher%3B%2095%25%20CI%2C%20-0.78%20to%20-0.01%3B%20P%20%3D%20.04%29.%20Conversely%2C%20higher%20IL-10%20concentrations%20were%20associated%20with%20lower%20odds%20of%20PRISm%20%28aOR%2C%200.76%20per%20log-higher%3B%2095%25%20CI%2C%200.59%20to%200.99%3B%20P%20%3D%20.04%29.%20CONCLUSIONS%3A%20Female%20sex%2C%20higher%20concentrations%20of%20IL-6%20and%20D-dimer%2C%20and%20lower%20concentrations%20of%20IL-10%20were%20associated%20with%20pulmonary%20impairment%20in%20adult%20PWH%20receiving%20ART%20in%20India.%22%2C%22date%22%3A%22Jul%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofac233%22%2C%22ISSN%22%3A%222328-8957%20%28Print%29%202328-8957%20%28Electronic%29%202328-8957%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A39%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22JKGXEYY8%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kalk%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-29%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKalk%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHeekes%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESlogrove%2C%20A.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPhelanyane%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavies%2C%20M.%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Cohort%20profile%3A%20the%20Western%20Cape%20Pregnancy%20Exposure%20Registry%20%28WCPER%29.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E12%3C%5C%2Fi%3E%20%286%29%2C%20S.%20e060205.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2021-060205%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2021-060205%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cohort%20profile%3A%20the%20Western%20Cape%20Pregnancy%20Exposure%20Registry%20%28WCPER%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Kalk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Slogrove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Phelanyane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Myer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kroon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Petro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Fieggen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Rhoda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Gebhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Osman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Mehta%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20The%20Western%20Cape%20Pregnancy%20Exposure%20Registry%20%28PER%29%20was%20established%20at%20two%20public%20sector%20healthcare%20sentinel%20sites%20in%20the%20Western%20Cape%20province%2C%20South%20Africa%2C%20to%20provide%20ongoing%20surveillance%20of%20drug%20exposures%20in%20pregnancy%20and%20associations%20with%20pregnancy%20outcomes.%20PARTICIPANTS%3A%20Established%20in%202016%2C%20all%20women%20attending%20their%20first%20antenatal%20visit%20at%20primary%20care%20obstetric%20facilities%20were%20enrolled%20and%20followed%20to%20pregnancy%20outcome%20regardless%20of%20the%20site%20%28ie%2C%20primary%2C%20secondary%2C%20tertiary%20facility%29.%20Routine%20operational%20obstetric%20and%20medical%20data%20are%20digitised%20from%20the%20clinical%20stationery%20at%20the%20healthcare%20facilities.%20Data%20collection%20has%20been%20integrated%20into%20existing%20services%20and%20information%20platforms%20and%20supports%20routine%20operations.%20The%20PER%20is%20situated%20within%20the%20Provincial%20Health%20Data%20Centre%2C%20an%20information%20exchange%20that%20harmonises%20and%20consolidates%20all%20health-related%20electronic%20data%20in%20the%20province.%20Data%20are%20contributed%20via%20linkage%20across%20a%20unique%20identifier.%20This%20relationship%20limits%20the%20missing%20data%20in%20the%20PER%2C%20allows%20validation%20and%20avoids%20misclassification%20in%20the%20population-level%20data%20set.%20FINDINGS%20TO%20DATE%3A%20Approximately%205000%20and%203500%20pregnant%20women%20enter%20the%20data%20set%20annually%20at%20the%20urban%20and%20rural%20sites%2C%20respectively.%20As%20of%20August%202021%2C%20%3E30%20000%20pregnancies%20have%20been%20recorded%20and%20outcomes%20have%20been%20determined%20for%2093%25.%20Analysis%20of%20key%20obstetric%20and%20neonatal%20health%20indicators%20derived%20from%20the%20PER%20are%20consistent%20with%20the%20aggregate%20data%20in%20the%20District%20Health%20Information%20System.%20FUTURE%20PLANS%3A%20This%20represents%20significant%20infrastructure%2C%20able%20to%20address%20clinical%20and%20epidemiological%20concerns%20in%20a%20low%5C%2Fmiddle-income%20setting.%22%2C%22date%22%3A%22Jun%2029%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2021-060205%22%2C%22ISSN%22%3A%222044-6055%20%28Electronic%29%202044-6055%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A39%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22IBITJURF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lewis%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-06%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELewis%2C%20J.%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrazier%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKatz%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENash%2C%20D.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDuda%2C%20S.%20N.%3C%5C%2Fspan%3E%20%282022%29.%20A%20Method%20for%20Generating%20Dashboard%20Aggregations%20in%20an%20International%20HIV%20Consortium.%20%3Ci%3EStud%20Health%20Technol%20Inform%3C%5C%2Fi%3E%2C%20%3Ci%3E290%3C%5C%2Fi%3E%2C%20S.%201048%26%23x2013%3B1049.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3233%5C%2FSHTI220261%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3233%5C%2FSHTI220261%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20Method%20for%20Generating%20Dashboard%20Aggregations%20in%20an%20International%20HIV%20Consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20T.%22%2C%22lastName%22%3A%22Lewis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Katz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%5D%2C%22abstractNote%22%3A%22Online%20dashboards%20are%20valuable%20tools%20for%20gaining%20insights%20about%20population%20health%20metrics%20of%20interest%20and%20for%20disseminating%20data%20collected%20through%20research%20networks.%20The%20process%20of%20aggregating%20data%20from%20separate%20databases%20for%20use%20in%20online%20dashboards%2C%20while%20also%20ensuring%20data%20quality%2C%20is%20complex.%20We%20describe%20a%20method%20for%20integrating%20HIV%20dashboard%20aggregation%20scripts%20into%20an%20existing%20web-based%20data%20quality%20checking%20application%20and%20leveraging%20REDCap%20to%20store%20aggregated%20metrics.%22%2C%22date%22%3A%22Jun%206%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3233%5C%2FSHTI220261%22%2C%22ISSN%22%3A%221879-8365%20%28Electronic%29%200926-9630%20%28Print%29%200926-9630%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A12%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22ALEFZH9L%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22van%20der%20Hoven%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-03%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3Evan%20der%20Hoven%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAllen%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECois%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3Ede%20Waal%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMaartens%2C%20G.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Determining%20antenatal%20medicine%20exposures%20in%20South%20African%20women%3A%20a%20comparison%20of%20three%20methods%20of%20ascertainment.%20%3Ci%3EBMC%20Pregnancy%20Childbirth%3C%5C%2Fi%3E%2C%20%3Ci%3E22%3C%5C%2Fi%3E%20%281%29%2C%20S.%20466.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12884-022-04765-1%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12884-022-04765-1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Determining%20antenatal%20medicine%20exposures%20in%20South%20African%20women%3A%20a%20comparison%20of%20three%20methods%20of%20ascertainment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22van%20der%20Hoven%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Allen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Cois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22de%20Waal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Maartens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Myer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Malaba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Madlala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nyemba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Phelanyane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Kalk%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20In%20the%20absence%20of%20clinical%20trials%2C%20data%20on%20the%20safety%20of%20medicine%20exposures%20in%20pregnancy%20are%20dependent%20on%20observational%20studies%20conducted%20after%20the%20agent%20has%20been%20licensed%20for%20use.%20This%20requires%20an%20accurate%20history%20of%20antenatal%20medicine%20use%20to%20determine%20potential%20risks.%20Medication%20use%20is%20commonly%20determined%20by%20self-report%2C%20clinician%20records%2C%20and%20electronic%20pharmacy%20data%3B%20different%20data%20sources%20may%20be%20more%20informative%20for%20different%20types%20of%20medication%20and%20resources%20may%20differ%20by%20setting.%20We%20compared%20three%20methods%20to%20determine%20antenatal%20medicine%20use%20%28self-report%2C%20clinician%20records%20and%20electronic%20pharmacy%20dispensing%20records%20%5BEDR%5D%29%20in%20women%20attending%20antenatal%20care%20at%20a%20primary%20care%20facility%20in%20Cape%20Town%2C%20South%20Africa%20in%20a%20setting%20with%20high%20HIV%20prevalence.%20METHODS%3A%20Structured%2C%20interview-administered%20questionnaires%20recorded%20self-reported%20medicine%20use.%20Data%20were%20collected%20from%20clinician%20records%20and%20EDR%20on%20the%20same%20participants.%20We%20determined%20agreement%20between%20these%20data%20sources%20using%20Cohen%27s%20kappa%20and%2C%20lacking%20a%20gold%20standard%2C%20used%20Latent%20Class%20Analysis%20to%20estimate%20sensitivity%2C%20specificity%20and%20positive%20predictive%20value%20%28PPV%29%20for%20each%20data%20source.%20RESULTS%3A%20Between%2055%25%20and%2089%25%20of%20967%20women%20had%20any%20medicine%20use%20documented%20depending%20on%20the%20data%20source%20%28median%20number%20of%20medicines%5C%2Fparticipant%20%3D%205%20%5BIQR%203-6%5D%29.%20Agreement%20between%20the%20datasets%20was%20poor%20regardless%20of%20class%20except%20for%20antiretroviral%20therapy%20%28ART%3B%20kappa%200.6-0.71%29.%20Overall%2C%20agreement%20was%20better%20between%20the%20EDR%20and%20self-report%20than%20with%20either%20dataset%20and%20the%20clinician%20records.%20Sensitivity%20and%20PPV%20were%20higher%20for%20self-report%20and%20the%20EDR%20and%20were%20similar%20for%20the%20two.%20Self-report%20was%20the%20best%20source%20for%20over-the-counter%2C%20traditional%20and%20complementary%20medicines%3B%20clinician%20records%20for%20vaccines%20and%20supplements%3B%20and%20EDR%20for%20chronic%20medicines.%20CONCLUSIONS%3A%20Medicine%20use%20in%20pregnancy%20was%20common%20and%20no%20single%20data%20source%20included%20all%20the%20medicines%20used.%20ART%20was%20the%20most%20consistently%20reported%20across%20all%20three%20datasets%20but%20otherwise%20agreement%20between%20them%20was%20poor%20and%20dependent%20on%20class.%20Using%20a%20single%20data%20collection%20method%20will%20under-estimate%20medicine%20use%20in%20pregnancy%20and%20the%20choice%20of%20data%20source%20should%20be%20guided%20by%20the%20class%20of%20the%20agents%20being%20investigated.%22%2C%22date%22%3A%22Jun%203%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12884-022-04765-1%22%2C%22ISSN%22%3A%221471-2393%20%28Electronic%29%201471-2393%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A43%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22HUVVKC7Y%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Li%20et%20al.%22%2C%22parsedDate%22%3A%222022-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELi%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBuchanan%2C%20A.%20L.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECole%2C%20S.%20R.%3C%5C%2Fspan%3E%20%282022%29.%20Generalizing%20trial%20evidence%20to%20target%20populations%20in%20non-nested%20designs%3A%20Applications%20to%20AIDS%20clinical%20trials.%20%3Ci%3EJ%20R%20Stat%20Soc%20Ser%20C%20Appl%20Stat%3C%5C%2Fi%3E%2C%20%3Ci%3E71%3C%5C%2Fi%3E%20%283%29%2C%20S.%20669%26%23x2013%3B697.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Frssc.12550%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Frssc.12550%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Generalizing%20trial%20evidence%20to%20target%20populations%20in%20non-nested%20designs%3A%20Applications%20to%20AIDS%20clinical%20trials%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Buchanan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20R.%22%2C%22lastName%22%3A%22Cole%22%7D%5D%2C%22abstractNote%22%3A%22Comparative%20effectiveness%20evidence%20from%20randomized%20trials%20may%20not%20be%20directly%20generalizable%20to%20a%20target%20population%20of%20substantive%20interest%20when%2C%20as%20in%20most%20cases%2C%20trial%20participants%20are%20not%20randomly%20sampled%20from%20the%20target%20population.%20Motivated%20by%20the%20need%20to%20generalize%20evidence%20from%20two%20trials%20conducted%20in%20the%20AIDS%20Clinical%20Trials%20Group%20%28ACTG%29%2C%20we%20consider%20weighting%2C%20regression%20and%20doubly%20robust%20estimators%20to%20estimate%20the%20causal%20effects%20of%20HIV%20interventions%20in%20a%20specified%20population%20of%20people%20living%20with%20HIV%20in%20the%20USA.%20We%20focus%20on%20a%20non-nested%20trial%20design%20and%20discuss%20strategies%20for%20both%20point%20and%20variance%20estimation%20of%20the%20target%20population%20average%20treatment%20effect.%20Specifically%20in%20the%20generalizability%20context%2C%20we%20demonstrate%20both%20analytically%20and%20empirically%20that%20estimating%20the%20known%20propensity%20score%20in%20trials%20does%20not%20increase%20the%20variance%20for%20each%20of%20the%20weighting%2C%20regression%20and%20doubly%20robust%20estimators.%20We%20apply%20these%20methods%20to%20generalize%20the%20average%20treatment%20effects%20from%20two%20ACTG%20trials%20to%20specified%20target%20populations%20and%20operationalize%20key%20practical%20considerations.%20Finally%2C%20we%20report%20on%20a%20simulation%20study%20that%20investigates%20the%20finite-sample%20operating%20characteristics%20of%20the%20generalizability%20estimators%20and%20their%20sandwich%20variance%20estimators.%22%2C%22date%22%3A%22Jun%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Frssc.12550%22%2C%22ISSN%22%3A%220035-9254%20%28Print%29%201467-9876%20%28Electronic%29%200035-9254%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A45%3A34Z%22%7D%7D%2C%7B%22key%22%3A%228NTDZHC5%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hussey%20et%20al.%22%2C%22parsedDate%22%3A%222022-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHussey%2C%20H.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavies%2C%20M.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHeekes%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWilliamson%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EValley-Omar%2C%20Z.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Assessing%20the%20clinical%20severity%20of%20the%20Omicron%20variant%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%2C%20using%20the%20diagnostic%20PCR%20proxy%20marker%20of%20RdRp%20target%20delay%20to%20distinguish%20between%20Omicron%20and%20Delta%20infections%20-%20a%20survival%20analysis.%20%3Ci%3EInt%20J%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E118%3C%5C%2Fi%3E%2C%20S.%20150%26%23x2013%3B154.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2022.02.051%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2022.02.051%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessing%20the%20clinical%20severity%20of%20the%20Omicron%20variant%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%2C%20using%20the%20diagnostic%20PCR%20proxy%20marker%20of%20RdRp%20target%20delay%20to%20distinguish%20between%20Omicron%20and%20Delta%20infections%20-%20a%20survival%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Hussey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Williamson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%22%2C%22lastName%22%3A%22Valley-Omar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Hardie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Korsman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Doolabh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Preiser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Maponga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Iranzadeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Wasserman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Boloko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Symons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Raubenheimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Parker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Schrueder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Solomon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Wolter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Jassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lessells%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20Y.%22%2C%22lastName%22%3A%22Hsiao%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20At%20present%2C%20it%20is%20unclear%20whether%20the%20extent%20of%20reduced%20risk%20of%20severe%20disease%20seen%20with%20SARS-Cov-2%20Omicron%20variant%20infection%20is%20caused%20by%20a%20decrease%20in%20variant%20virulence%20or%20by%20higher%20levels%20of%20population%20immunity.%20METHODS%3A%20RdRp%20target%20delay%20%28RTD%29%20in%20the%20Seegene%20Allplex%28TM%29%202019-nCoV%20PCR%20assay%20is%20a%20proxy%20marker%20for%20the%20Delta%20variant.%20The%20absence%20of%20this%20proxy%20marker%20in%20the%20transition%20period%20was%20used%20to%20identify%20suspected%20Omicron%20infections.%20Cox%20regression%20was%20performed%20for%20the%20outcome%20of%20hospital%20admission%20in%20those%20who%20tested%20positive%20for%20SARS-CoV-2%20on%20the%20Seegene%20Allplex%28TM%29%20assay%20from%20November%201%20to%20December%2014%2C%202021%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%2C%20in%20the%20public%20sector.%20Adjustments%20were%20made%20for%20vaccination%20status%20and%20prior%20diagnosis%20of%20infection.%20RESULTS%3A%20A%20total%20of%20150%20cases%20with%20RTD%20and%201486%20cases%20without%20RTD%20were%20included.%20Cases%20without%20RTD%20had%20a%20lower%20hazard%20of%20admission%20%28adjusted%20hazard%20ratio%20%5BaHR%5D%2C%200.56%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%200.34-0.91%29.%20Complete%20vaccination%20was%20protective%20against%20admission%2C%20with%20an%20aHR%20of%200.45%20%2895%25%20CI%2C%200.26-0.77%29.%20CONCLUSION%3A%20Omicron%20has%20resulted%20in%20a%20lower%20risk%20of%20hospital%20admission%20compared%20with%20contemporaneous%20Delta%20infection%2C%20when%20using%20the%20proxy%20marker%20of%20RTD.%20Under-ascertainment%20of%20reinfections%20with%20an%20immune%20escape%20variant%20remains%20a%20challenge%20to%20accurately%20assessing%20variant%20virulence.%22%2C%22date%22%3A%22May%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijid.2022.02.051%22%2C%22ISSN%22%3A%221878-3511%20%28Electronic%29%201201-9712%20%28Print%29%201201-9712%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A16%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22VVXTPCCD%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Crabtree-Ramirez%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECrabtree-Ramirez%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJenkins%2C%20C.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShepherd%2C%20B.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJayathilake%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVeloso%2C%20V.%20G.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Tuberculosis%20treatment%20intermittency%20in%20the%20continuation%20phase%20and%20mortality%20in%20HIV-positive%20persons%20receiving%20antiretroviral%20therapy.%20%3Ci%3EBMC%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E22%3C%5C%2Fi%3E%20%281%29%2C%20S.%20341.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-022-07330-5%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-022-07330-5%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tuberculosis%20treatment%20intermittency%20in%20the%20continuation%20phase%20and%20mortality%20in%20HIV-positive%20persons%20receiving%20antiretroviral%20therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20A.%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Jayathilake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Carriquiry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Koenig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20W.%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22C.%20CASAnet%20Region%20of%20IeDEA%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Some%20tuberculosis%20%28TB%29%20treatment%20guidelines%20recommend%20daily%20TB%20treatment%20in%20both%20the%20intensive%20and%20continuation%20phases%20of%20treatment%20in%20HIV-positive%20persons%20to%20decrease%20the%20risk%20of%20relapse%20and%20acquired%20drug%20resistance.%20However%2C%20guidelines%20vary%20across%20countries%2C%20and%20treatment%20is%20given%207%2C%205%2C%203%2C%20or%202%20days%5C%2Fweek.%20The%20effect%20of%20TB%20treatment%20intermittency%20in%20the%20continuation%20phase%20on%20mortality%20in%20HIV-positive%20persons%20on%20antiretroviral%20therapy%20%28ART%29%2C%20is%20not%20well-described.%20METHODS%3A%20We%20conducted%20an%20observational%20cohort%20study%20among%20HIV-positive%20adults%20treated%20for%20TB%20between%202000%20and%202018%20and%20after%20enrollment%20into%20the%20Caribbean%2C%20Central%2C%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%3B%20Brazil%2C%20Chile%2C%20Haiti%2C%20Honduras%2C%20Mexico%20and%20Peru%29.%20All%20received%20standard%20TB%20therapy%20%282-month%20initiation%20phase%20of%20daily%20isoniazid%2C%20rifampin%20or%20rifabutin%2C%20pyrazinamide%20%2B%5C%2F-%20ethambutol%29%20and%20continuation%20phase%20of%20isoniazid%20and%20rifampin%20or%20rifabutin%2C%20administered%20concomitantly%20with%20ART.%20Known%20timing%20of%20ART%20and%20TB%20treatment%20were%20also%20inclusion%20criteria.%20Kaplan-Meier%20and%20Cox%20proportional%20hazards%20methods%20compared%20time%20to%20death%20between%20groups.%20Missing%20model%20covariates%20were%20imputed%20via%20multiple%20imputation.%20RESULTS%3A%202303%20patients%20met%20inclusion%20criteria%3A%202003%2887%25%29%20received%20TB%20treatment%205-7%20days%5C%2Fweek%20and%20300%2813%25%29%202-3%20days%5C%2Fweek%20in%20the%20continuation%20phase.%20Intermittency%20varied%20by%20site%3A%20100%25%20of%20patients%20from%20Brazil%20and%20Haiti%20received%20continuation%20phase%20treatment%205-7%20days%5C%2Fweek%2C%20followed%20by%20Honduras%20%2891%25%29%2C%20Peru%20%2842%25%29%2C%20Mexico%20%287%25%29%2C%20and%20Chile%20%280%25%29.%20The%20crude%20risk%20of%20death%20was%20lower%20among%20those%20receiving%20treatment%205-7%20vs.%202-3%20days%5C%2Fweek%20%28HR%20%3D%200.68%3B%2095%25%20CI%20%3D%200.51-0.91%3B%20P%20%3D%200.008%29.%20After%20adjusting%20for%20age%2C%20sex%2C%20CD4%2C%20ART%20use%20at%20TB%20diagnosis%2C%20site%20of%20TB%20disease%20%28pulmonary%20vs.%20extrapulmonary%29%2C%20and%20year%20of%20TB%20diagnosis%2C%20mortality%20risk%20was%20lower%2C%20but%20not%20significantly%2C%20among%20those%20treated%205-7%20days%5C%2Fweek%20vs.%202-3%20days%5C%2Fweek%20%28HR%200.75%2C%2095%25CI%200.55-1.01%3B%20P%20%3D%200.06%29.%20After%20also%20stratifying%20by%20study%20site%2C%20there%20was%20no%20longer%20a%20protective%20effect%20%28HR%201.42%2C%2095%25CI%200.83-2.45%3B%20P%20%3D%200.20%29.%20CONCLUSIONS%3A%20TB%20treatment%205-7%20days%5C%2Fweek%20was%20associated%20with%20a%20marginally%20decreased%20risk%20of%20death%20compared%20to%20TB%20treatment%202-3%20days%5C%2Fweek%20in%20the%20continuation%20phase%20in%20multivariable%2C%20unstratified%20analyses.%20However%2C%20little%20variation%20in%20TB%20treatment%20intermittency%20within%20country%20meant%20the%20results%20could%20have%20been%20driven%20by%20other%20differences%20between%20study%20sites.%20Therefore%2C%20randomized%20trials%20are%20needed%2C%20especially%20in%20heterogenous%20regions%20such%20as%20Latin%20America.%22%2C%22date%22%3A%22Apr%205%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12879-022-07330-5%22%2C%22ISSN%22%3A%221471-2334%20%28Electronic%29%201471-2334%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A50%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22GVRPU4UF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Oyungu%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOyungu%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEl%20Kebbi%2C%20O.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVreeman%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENyandiko%2C%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMonahan%2C%20P.%20O.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Predicting%20neurodevelopmental%20risk%20in%20children%20born%20to%20mothers%20living%20with%20HIV%20in%20Kenya%3A%20protocol%20for%20a%20prospective%20cohort%20study%20%28Tabiri%20Study%29.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E12%3C%5C%2Fi%3E%20%284%29%2C%20S.%20e061051.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2022-061051%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2022-061051%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Predicting%20neurodevelopmental%20risk%20in%20children%20born%20to%20mothers%20living%20with%20HIV%20in%20Kenya%3A%20protocol%20for%20a%20prospective%20cohort%20study%20%28Tabiri%20Study%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Oyungu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22El%20Kebbi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Vreeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Nyandiko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20O.%22%2C%22lastName%22%3A%22Monahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Tu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Khaitan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%22%2C%22lastName%22%3A%22Desta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Slogrove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Humphrey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Were%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20C.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20G.%22%2C%22lastName%22%3A%22Carlucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20S.%22%2C%22lastName%22%3A%22McHenry%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20For%20the%20growing%20number%20of%20children%20with%20in%20utero%20and%20postpartum%20exposure%20to%20HIV%20and%5C%2For%20antiretrovirals%2C%20it%20is%20unclear%20which%20exposures%20or%20risk%20factors%20play%20a%20significant%20role%20in%20predicting%20worse%20neurodevelopmental%20outcomes.%20This%20protocol%20describes%20a%20prospective%20longitudinal%20cohort%20study%20of%20infants%20born%20to%20mothers%20living%20with%20HIV%20and%20those%20born%20to%20mothers%20without%20HIV.%20We%20will%20determine%20which%20risk%20factors%20are%20most%20predictive%20of%20child%20neurodevelopment%20at%2024%20months.%20We%20aim%20to%20create%20a%20risk%20assessment%20tool%20to%20help%20predict%20which%20children%20are%20at%20risk%20for%20worse%20neurodevelopment%20outcomes.%20METHODS%20AND%20ANALYSIS%3A%20This%20study%20leverages%20an%20existing%20Kenyan%20cohort%20to%20prospectively%20enrol%20500%20children%20born%20to%20mothers%20living%20with%20HIV%20and%20500%20to%20those%20without%20HIV%20%28n%3D1000%20total%29%20and%20follow%20them%20from%20birth%20to%20age%2024%20months.%20The%20following%20factors%20will%20be%20measured%20every%206%20months%3A%20infectious%20morbidity%20and%20biological%5C%2Fsociodemographic%5C%2Fpsychosocial%20risk%20factors.%20We%20will%20compare%20these%20factors%20between%20the%20two%20groups.%20We%20will%20then%20measure%20and%20compare%20neurodevelopment%20within%20children%20in%20both%20groups%20at%2024%20months%20of%20age%20using%20the%20Child%20Behaviour%20Checklist%20and%20the%20Bayley%20Scales%20of%20Infant%20and%20Toddler%20Development%2C%20third%20edition.%20Finally%2C%20we%20will%20use%20generalised%20linear%20mixed%20modelling%20to%20quantify%20associations%20with%20neurodevelopment%20and%20create%20a%20risk%20assessment%20tool%20for%20children%20%3C%5C%2F%3D24%20months.%20ETHICS%20AND%20DISSEMINATION%3A%20The%20study%20is%20approved%20by%20the%20Moi%20University%27s%20Institutional%20Research%20and%20Ethics%20Committee%20%28IREC%5C%2F2021%5C%2F55%3B%20Approval%20%230003892%29%2C%20Kenya%27s%20National%20Commission%20for%20Science%2C%20Technology%20and%20Innovation%20%28NACOSTI%2C%20Reference%20%23700244%29%20and%20Indiana%20University%27s%20Institutional%20Review%20Board%20%28IRB%20Protocol%20%23110990%29.%20This%20study%20carries%20minimal%20risk%20to%20the%20children%20and%20their%20mothers%2C%20and%20all%20mothers%20will%20provide%20written%20consent%20for%20participation%20in%20the%20study.%20Results%20will%20be%20disseminated%20to%20maternal%20child%20health%20clinics%20within%20Uasin%20Gishu%20County%2C%20Kenya%20and%20via%20papers%20submitted%20to%20peer-reviewed%20journals%20and%20presentation%20at%20international%20conferences.%22%2C%22date%22%3A%22Apr%204%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2022-061051%22%2C%22ISSN%22%3A%222044-6055%20%28Electronic%29%202044-6055%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A24%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22HP3BNVX6%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kim%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKim%2C%20H.%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENance%2C%20R.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELo%20Re%2C%20V.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESilverberg%2C%20M.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFranco%2C%20R.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Development%20and%20Validation%20of%20a%20Model%20for%20Prediction%20of%20End-Stage%20Liver%20Disease%20in%20People%20With%20HIV.%20%3Ci%3EJ%20Acquir%20Immune%20Defic%20Syndr%3C%5C%2Fi%3E%2C%20%3Ci%3E89%3C%5C%2Fi%3E%20%284%29%2C%20S.%20396%26%23x2013%3B404.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002886%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002886%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Development%20and%20Validation%20of%20a%20Model%20for%20Prediction%20of%20End-Stage%20Liver%20Disease%20in%20People%20With%20HIV%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20N.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20M.%22%2C%22lastName%22%3A%22Nance%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Lo%20Re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Franco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20R.%22%2C%22lastName%22%3A%22Cachay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Justice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20M.%22%2C%22lastName%22%3A%22Crane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Delaney%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20M.%22%2C%22lastName%22%3A%22Kitahata%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20End-stage%20liver%20disease%20%28ESLD%29%20is%20a%20leading%20cause%20of%20non-AIDS-related%20death%20among%20people%20with%20HIV%20%28PWH%29.%20Factors%20that%20increase%20the%20progression%20of%20liver%20disease%20include%20comorbidities%20and%20HIV-specific%20factors%2C%20but%20we%20currently%20lack%20a%20tool%20to%20apply%20this%20evidence%20into%20clinical%20practice.%20METHODS%3A%20We%20developed%20and%20validated%20a%20risk%20prediction%20model%20for%20ESLD%20among%20PWH%20who%20received%20care%20in%2012%20cohorts%20of%20the%20North%20American%20AIDS%20Cohort%20Collaboration%20on%20Research%20and%20Design%20between%202000%20and%202016%20and%20had%20fibrosis-4%20index%20%3E%201.45.%20The%20first%20occurrence%20of%20ascites%2C%20variceal%20bleed%2C%20spontaneous%20bacterial%20peritonitis%2C%20or%20hepatic%20encephalopathy%20was%20verified%20by%20standardized%20medical%20record%20review.%20The%20Bayesian%20model%20averaging%20was%20used%20to%20select%20predictors%20among%20biomarkers%20and%20diagnoses%20and%20the%20Harrell%20C%20statistic%20to%20assess%20model%20discrimination.%20RESULTS%3A%20Among%2013%2C787%20PWH%20in%20the%20training%20set%2C%2082%25%20were%20men%20and%2054%25%20were%20Black%20with%20a%20mean%20age%20of%2048%20years.%20Three%20hundred%20ninety%20ESLD%20events%20occurred%20over%20a%20mean%205.4%20years.%20Among%20the%20ESLD%20cases%2C%2052%25%20had%20hepatitis%20C%20virus%2C%2015%25%20hepatitis%20B%20virus%2C%20and%2031%25%20alcohol%20use%20disorder.%20Twelve%20factors%20together%20predicted%20ESLD%20risk%20moderately%20well%20%28C%20statistic%200.79%2C%2095%25%20confidence%20interval%3A%200.76%20to%200.81%29%3A%20age%2C%20sex%2C%20race%5C%2Fethnicity%2C%20chronic%20hepatitis%20B%20or%20C%2C%20and%20routinely%20collected%20laboratory%20values%20reflecting%20hepatic%20impairment%20%28serum%20albumin%2C%20aspartate%20aminotransferase%2C%20total%20bilirubin%2C%20and%20platelets%29%20and%20lipid%20metabolism%20%28triglycerides%2C%20high-density%20lipoprotein%2C%20and%20total%20cholesterol%29.%20Our%20model%20performed%20well%20in%20the%20test%20set%20%28C%20statistic%200.81%2C%2095%25%20confidence%20interval%3A%200.76%20to%200.86%29.%20CONCLUSION%3A%20This%20model%20of%20readily%20accessible%20clinical%20parameters%20predicted%20ESLD%20in%20a%20large%20diverse%20population%20of%20PWH.%22%2C%22date%22%3A%22Apr%201%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000002886%22%2C%22ISSN%22%3A%221944-7884%20%28Electronic%29%201525-4135%20%28Print%29%201525-4135%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A41%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22UGGK9LMX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Staub%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStaub%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPanczak%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMatthes%2C%20K.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFloris%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBerlin%2C%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Historically%20High%20Excess%20Mortality%20During%20the%20COVID-19%20Pandemic%20in%20Switzerland%2C%20Sweden%2C%20and%20Spain.%20%3Ci%3EAnn%20Intern%20Med%3C%5C%2Fi%3E%2C%20%3Ci%3E175%3C%5C%2Fi%3E%20%284%29%2C%20S.%20523%26%23x2013%3B532.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM21-3824%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM21-3824%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Historically%20High%20Excess%20Mortality%20During%20the%20COVID-19%20Pandemic%20in%20Switzerland%2C%20Sweden%2C%20and%20Spain%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Staub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Panczak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20L.%22%2C%22lastName%22%3A%22Matthes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Floris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Berlin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Junker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Weitkunat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20E.%22%2C%22lastName%22%3A%22Mamelund%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Zwahlen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Riou%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Excess%20mortality%20quantifies%20the%20overall%20mortality%20impact%20of%20a%20pandemic.%20Mortality%20data%20have%20been%20accessible%20for%20many%20countries%20in%20recent%20decades%2C%20but%20few%20continuous%20data%20have%20been%20available%20for%20longer%20periods.%20OBJECTIVE%3A%20To%20assess%20the%20historical%20dimension%20of%20the%20COVID-19%20pandemic%20in%202020%20for%203%20countries%20with%20reliable%20death%20count%20data%20over%20an%20uninterrupted%20span%20of%20more%20than%20100%20years.%20DESIGN%3A%20Observational%20study.%20SETTING%3A%20Switzerland%2C%20Sweden%2C%20and%20Spain%2C%20which%20were%20militarily%20neutral%20and%20not%20involved%20in%20combat%20during%20either%20world%20war%20and%20have%20not%20been%20affected%20by%20significant%20changes%20in%20their%20territory%20since%20the%20end%20of%20the%2019th%20century.%20PARTICIPANTS%3A%20Complete%20populations%20of%20these%203%20countries.%20MEASUREMENTS%3A%20Continuous%20series%20of%20recorded%20deaths%20%28from%20all%20causes%29%20by%20month%20from%20the%20earliest%20available%20year%20%281877%20for%20Switzerland%2C%201851%20for%20Sweden%2C%20and%201908%20for%20Spain%29%20were%20jointly%20modeled%20with%20annual%20age%20group-specific%20death%20and%20total%20population%20counts%20using%20negative%20binomial%20and%20multinomial%20models%2C%20which%20accounted%20for%20temporal%20trends%20and%20seasonal%20variability%20of%20prepandemic%20years.%20The%20aim%20was%20to%20estimate%20the%20expected%20number%20of%20deaths%20in%20a%20pandemic%20year%20for%20a%20nonpandemic%20scenario%20and%20the%20difference%20in%20observed%20and%20expected%20deaths%20aggregated%20over%20the%20year.%20RESULTS%3A%20In%202020%2C%20the%20number%20of%20excess%20deaths%20recorded%20per%20100%20000%20persons%20was%20100%20%2895%25%20credible%20interval%20%5BCrI%5D%2C%2060%20to%20135%29%20for%20Switzerland%2C%2075%20%28CrI%2C%2040%20to%20105%29%20for%20Sweden%2C%20and%20155%20%28CrI%2C%20110%20to%20195%29%20for%20Spain.%20In%201918%2C%20excess%20mortality%20was%206%20to%207%20times%20higher.%20In%20all%203%20countries%2C%20the%20peaks%20of%20monthly%20excess%20mortality%20in%202020%20were%20greater%20than%20most%20monthly%20excess%20mortality%20since%201918%2C%20including%20many%20peaks%20due%20to%20seasonal%20influenza%20and%20heat%20waves%20during%20that%20period.%20LIMITATION%3A%20Historical%20vital%20statistics%20might%20be%20affected%20by%20minor%20completeness%20issues%20before%20the%20beginning%20of%20the%2020th%20century.%20CONCLUSION%3A%20In%202020%2C%20the%20COVID-19%20pandemic%20led%20to%20the%20second-largest%20infection-related%20mortality%20disaster%20in%20Switzerland%2C%20Sweden%2C%20and%20Spain%20since%20the%20beginning%20of%20the%2020th%20century.%20PRIMARY%20FUNDING%20SOURCE%3A%20Foundation%20for%20Research%20in%20Science%20and%20the%20Humanities%20at%20the%20University%20of%20Zurich%2C%20Swiss%20National%20Science%20Foundation%2C%20and%20National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases.%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.7326%5C%2FM21-3824%22%2C%22ISSN%22%3A%221539-3704%20%28Electronic%29%200003-4819%20%28Print%29%200003-4819%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A46%3A29Z%22%7D%7D%2C%7B%22key%22%3A%223L3WMKHX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Walker%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWalker%2C%20T.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMiotto%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKoser%2C%20C.%20U.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFowler%2C%20P.%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKnaggs%2C%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20The%202021%20WHO%20catalogue%20of%20Mycobacterium%20tuberculosis%20complex%20mutations%20associated%20with%20drug%20resistance%3A%20A%20genotypic%20analysis.%20%3Ci%3ELancet%20Microbe%3C%5C%2Fi%3E%2C%20%3Ci%3E3%3C%5C%2Fi%3E%20%284%29%2C%20S.%20e265%26%23x2013%3Be273.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2666-5247%2821%2900301-3%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2666-5247%2821%2900301-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%202021%20WHO%20catalogue%20of%20Mycobacterium%20tuberculosis%20complex%20mutations%20associated%20with%20drug%20resistance%3A%20A%20genotypic%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20M.%22%2C%22lastName%22%3A%22Walker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Miotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20U.%22%2C%22lastName%22%3A%22Koser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20W.%22%2C%22lastName%22%3A%22Fowler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Knaggs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%22%2C%22lastName%22%3A%22Iqbal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Hunt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Chindelevitch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20M.%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Comas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Posey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20V.%22%2C%22lastName%22%3A%22Omar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20E.%22%2C%22lastName%22%3A%22Peto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Suresh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Uplekar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20E.%22%2C%22lastName%22%3A%22Colman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20M.%22%2C%22lastName%22%3A%22Nathanson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Zignol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20S.%22%2C%22lastName%22%3A%22Walker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22C.%20RyPTIC%20Consortium%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22Seq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Consortium%22%2C%22lastName%22%3A%22Treat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20W.%22%2C%22lastName%22%3A%22Crook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Ismail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20C.%22%2C%22lastName%22%3A%22Rodwell%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Molecular%20diagnostics%20are%20considered%20the%20most%20promising%20route%20to%20achieving%20rapid%2C%20universal%20drug%20susceptibility%20testing%20for%20Mycobacterium%20tuberculosiscomplex%20%28MTBC%29.%20We%20aimed%20to%20generate%20a%20WHO%20endorsed%20catalogue%20of%20mutations%20to%20serve%20as%20a%20global%20standard%20for%20interpreting%20molecular%20information%20for%20drug%20resistance%20prediction.%20METHODS%3A%20A%20candidate%20gene%20approach%20was%20used%20to%20identify%20mutations%20as%20associated%20with%20resistance%2C%20or%20consistent%20with%20susceptibility%2C%20for%2013%20WHO%20endorsed%20anti-tuberculosis%20drugs.%2038%2C215%20MTBC%20isolates%20with%20paired%20whole-genome%20sequencing%20and%20phenotypic%20drug%20susceptibility%20testing%20data%20were%20amassed%20from%2045%20countries.%20For%20each%20mutation%2C%20a%20contingency%20table%20of%20binary%20phenotypes%20and%20presence%20or%20absence%20of%20the%20mutation%20computed%20positive%20predictive%20value%2C%20and%20Fisher%27s%20exact%20tests%20generated%20odds%20ratios%20and%20Benjamini-Hochberg%20corrected%20p-values.%20Mutations%20were%20graded%20as%20Associated%20with%20Resistance%20if%20present%20in%20at%20least%205%20isolates%2C%20if%20the%20odds%20ratio%20was%20%3E1%20with%20a%20statistically%20significant%20corrected%20p-value%2C%20and%20if%20the%20lower%20bound%20of%20the%2095%25%20confidence%20interval%20on%20the%20positive%20predictive%20value%20for%20phenotypic%20resistance%20was%20%3E25%25.%20A%20series%20of%20expert%20rules%20were%20applied%20for%20final%20confidence%20grading%20of%20each%20mutation.%20FINDINGS%3A%2015%2C667%20associations%20were%20computed%20for%2013%2C211%20unique%20mutations%20linked%20to%20one%20or%20more%20drugs.%201%2C149%5C%2F15%2C667%20%287.3%25%29%20mutations%20were%20classified%20as%20associated%20with%20phenotypic%20resistance%20and%20107%5C%2F15%2C667%20%280.7%25%29%20were%20deemed%20consistent%20with%20susceptibility.%20For%20rifampicin%2C%20isoniazid%2C%20ethambutol%2C%20fluoroquinolones%2C%20and%20streptomycin%2C%20the%20mutations%27%20pooled%20sensitivity%20was%20%3E80%25.%20Specificity%20was%20over%2095%25%20for%20all%20drugs%20except%20ethionamide%20%2891.4%25%29%2C%20moxifloxacin%20%2891.6%25%29%20and%20ethambutol%20%2893.3%25%29.%20Only%20two%20resistance%20mutations%20were%20classified%20for%20bedaquiline%2C%20delamanid%2C%20clofazimine%2C%20and%20linezolid%20as%20prevalence%20of%20phenotypic%20resistance%20was%20low%20for%20these%20drugs.%20INTERPRETATION%3A%20This%20first%20WHO%20endorsed%20catalogue%20of%20molecular%20targets%20for%20MTBC%20drug%20susceptibility%20testing%20provides%20a%20global%20standard%20for%20resistance%20interpretation.%20Its%20existence%20should%20encourage%20the%20implementation%20of%20molecular%20diagnostics%20by%20National%20Tuberculosis%20Programmes.%20FUNDING%3A%20UNITAID%2C%20Wellcome%2C%20MRC%2C%20BMGF.%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS2666-5247%2821%2900301-3%22%2C%22ISSN%22%3A%222666-5247%20%28Electronic%29%202666-5247%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22D9WC3N3V%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A29%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22LWYD2N35%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Coelho%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A6%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECoelho%2C%20L.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJenkins%2C%20C.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShepherd%2C%20B.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPape%2C%20J.%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMejia%20Cordero%2C%20F.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Weight%20gain%20post-ART%20in%20HIV%2B%20Latinos%5C%2Fas%20differs%20in%20the%20USA%2C%20Haiti%2C%20and%20Latin%20America.%20%3Ci%3ELancet%20Reg%20Health%20Am%3C%5C%2Fi%3E%2C%20%3Ci%3E8%3C%5C%2Fi%3E%2C%20S.%20100173.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2021.100173%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2021.100173%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Weight%20gain%20post-ART%20in%20HIV%2B%20Latinos%5C%2Fas%20differs%20in%20the%20USA%2C%20Haiti%2C%20and%20Latin%20America%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20E.%22%2C%22lastName%22%3A%22Coelho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20A.%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20W.%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Mejia%20Cordero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Crabtree%20Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20R.%22%2C%22lastName%22%3A%22Koethe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20C.%22%2C%22lastName%22%3A%22Marconi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20C.%22%2C%22lastName%22%3A%22Tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Willig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Colasanti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20M.%22%2C%22lastName%22%3A%22Crane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mayor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20An%20obesity%20epidemic%20has%20been%20documented%20among%20adult%20Latinos%5C%2Fas%20in%20Latin%20America%20and%20the%20United%20States%20%28US%29%3B%20however%2C%20little%20is%20known%20about%20obesity%20among%20Latinos%5C%2Fas%20with%20HIV%20%28PWH%29.%20Moreover%2C%20Latinos%5C%2Fas%20PWH%20in%20the%20US%20may%20have%20different%20weight%20trajectories%20than%20those%20in%20Latin%20America%20due%20to%20the%20cultural%20and%20environmental%20contexts.%20We%20assessed%20weight%20and%20body%20mass%20index%20%28BMI%29%20trajectories%20among%20PWH%20initiating%20antiretroviral%20therapy%20%28ART%29%20across%205%20countries%20in%20Latin%20America%20and%20the%20Caribbean%20and%20the%20US.%20METHODS%3A%20ART-nayve%20PWH%20%3E%5C%2F%3D18%20years%20old%2C%20enrolled%20in%20Brazil%2C%20Honduras%2C%20Mexico%2C%20Peru%2C%20and%20Haiti%20%28sites%20within%20CCA-SAnet%29%20and%20the%20US%20%28NA-ACCORD%29%20starting%20ART%20between%202000%20and%202017%2C%20with%20at%20least%20one%20weight%20measured%20after%20ART%20initiation%20were%20included.%20Participants%20were%20classified%20according%20to%20site%5C%2Fethnicity%20as%3A%20Latinos%5C%2Fas%20in%20US%2C%20non-Latinos%5C%2Fas%20in%20US%2C%20Haitians%2C%20and%20Latinos%5C%2Fas%20in%20Latin%20America.%20Generalized%20least%20squares%20models%20were%20used%20to%20assess%20trends%20in%20weight%20and%20BMI.%20Models%20estimating%20probabilities%20of%20becoming%20overweight%5C%2Fobese%20%28BMI%20%3E%5C%2F%3D25%20kg%5C%2Fm%282%29%29%20and%20of%20becoming%20obese%20%28BMI%20%3E%5C%2F%3D30%20kg%5C%2Fm%282%29%29%20post%20ART%20initiation%20for%20males%20and%20females%20were%20fit%20using%20generalized%20estimating%20equations%20with%20a%20logit%20link%20and%20an%20independence%20working%20correlation%20structure.%20FINDINGS%3A%20Among%2059%2C207%20PWH%2C%209%25%20were%20Latinos%5C%2Fas%20from%20Latin%20America%2C%209%25%20Latinos%5C%2Fas%20from%20the%20US%2C%2068%25%20non-Latinos%5C%2Fas%20from%20the%20US%20and%2014%25%20were%20Haitian.%20At%20ART%20initiation%2C%2029%25%20were%20overweight%20and%2014%25%20were%20obese.%20Post-ART%20weight%20and%20BMI%20increases%20were%20steeper%20for%20Latinos%5C%2Fas%20in%20Latin%20America%20compared%20with%20other%20sites%5C%2Fethnicities%3B%20however%2C%20BMI%20at%203-years%20post%20ART%20remained%20lower%20compared%20to%20Latinos%5C%2Fas%20and%20non-Latinos%5C%2Fas%20in%20the%20US.%20Among%20females%2C%20at%203-years%20post%20ART%20initiation%20the%20greatest%20adjusted%20probability%20of%20obesity%20was%20found%20among%20non-Latinas%20in%20the%20US%20%2815.2%25%29%20and%20lowest%20among%20Latinas%20in%20Latin%20America%20%288.6%25%29.%20Among%20males%2C%20while%20starting%20with%20a%20lower%20BMI%2C%20Latinos%20in%20Latin%20America%20had%20the%20greatest%20adjusted%20probability%20of%20becoming%20overweight%20or%20obese%203-years%20post-ART%20initiation.%20INTERPRETATION%3A%20In%20the%20Americas%2C%20PWH%20gain%20substantial%20weight%20after%20ART%20initiation.%20Despite%20environmental%20and%20cultural%20differences%2C%20PWH%20in%20Latin%20America%2C%20Haiti%20and%20Latinos%20and%20non-Latinos%20in%20the%20US%20share%20similar%20BMI%20trajectories%20on%20ART%20and%20high%20probabilities%20of%20becoming%20overweight%20and%20obese%20over%20time.%20Multicohort%20studies%20are%20needed%20to%20better%20understand%20the%20burden%20of%20other%20metabolic%20syndrome%20components%20in%20PWH%20across%20different%20countries.%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lana.2021.100173%22%2C%22ISSN%22%3A%222667-193X%20%28Electronic%29%202667-193X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22D9WC3N3V%22%2C%22F2Y6PLUL%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A23%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22PX7FKVW8%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Caro-Vega%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECaro-Vega%2C%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERebeiro%2C%20P.%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShepherd%2C%20B.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBelaunzaran-Zamudio%2C%20P.%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECrabtree-Ramirez%2C%20B.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Clinical%20effects%20of%20durability%20of%20immunosuppression%20in%20virologically%20suppressed%20ART-initiating%20persons%20with%20HIV%20in%20Latin%20America.%20A%20retrospective%20cohort%20study.%20%3Ci%3ELancet%20Reg%20Health%20Am%3C%5C%2Fi%3E%2C%20%3Ci%3E8%3C%5C%2Fi%3E%2C%20S.%20100175.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2021.100175%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2021.100175%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20effects%20of%20durability%20of%20immunosuppression%20in%20virologically%20suppressed%20ART-initiating%20persons%20with%20HIV%20in%20Latin%20America.%20A%20retrospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Belaunzaran-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Padget%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20G.%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Clinical%20outcomes%20are%20rarely%20studied%20in%20virologically%20suppressed%20people%20living%20with%20HIV%20%28PWH%29%20and%20incomplete%20CD4%20recovery.%20To%20explore%20whether%20time%20living%20with%20severe%20immunosuppression%20predict%20clinical%20outcomes%20better%20than%20baseline%20or%20time%20updated%20CD4%2C%20we%20estimated%20the%20association%20between%20cumulative%20percentage%20of%20time%20with%20CD4%20%3C200%20cells%5C%2FmuL%20during%20viral%20suppression%20%28VS%29%20%28%25t%28CD4%3C200%29%29%2C%20and%20mortality%20and%20comorbidities%20during%202000-2019.%20METHODS%3A%20In%20a%20retrospective%20cohort%20analysis%2C%20we%20followed%20PWH%20initiating%20ART%20in%20Latin%20America%20from%20first%20VS%20%28HIV-RNA%3C200%20copies%5C%2FmuL%29%20to%20death%2C%20virological%20failure%20or%20loss%20to%20follow-up.%20We%20fit%20Cox%20models%20to%20estimate%20risk%20of%20death%20and%5C%2For%20AIDS-defining%20and%20serious%20non-AIDS-defining%20events%20%28ADE%20and%20SNADE%20-cancer%2C%20cardiovascular%2C%20liver%2C%20and%20renal%20diseases%29%20by%20%25t%28CD4%3C200%29%20%28continuous%20variable%29.%20We%20predicted%20survival%20probabilities%20for%20each%20event%20and%20calculated%20risks%20of%20hypothetical%20cases%20of%20different%20%25t%28CD4%3C200%29.%20FINDINGS%3A%20In%208%2C369%20patients%20with%2034.9%20months%20of%20follow-up%20%28median%2C%20IQR%3A%2016.7%2C%2069.1%29%2C%204%2C274%20%2851%25%29%20started%20ART%20with%20CD4%3C200%20cells%5C%2FmuL.%20Median%20%25t%28CD4%3C200%29%20was%200%25%20%28IQR%3A%200%2C%2015%25%29.%20We%20identified%20195%20%282.3%25%29%20deaths%20and%20584%20%287.2%25%29%20patients%20with%20ADE%5C%2FSNADE.%20For%20an%20increased%20%25t%28CD4%3C200%29%20of%2015%25%20%28e.g.%2C%2015%25%20vs.%200%25%29%2C%20the%20adjusted%20relative%20hazard%20%28aHR%29%20of%20death%20was%201.27%20%2895%25%20confidence%20interval%20%5BCI%5D%3A%201.19%20-%201.35%29%2C%20of%20ADE%5C%2FSNADE%20was%201.13%20%2895%25CI%3A%201.09%20-%201.17%29%2C%20of%20SNADE%20was%200.96%20%2895%25CI%3A%200.89%20-%201.02%29%20and%20of%20death%5C%2FADE%5C%2FSNADE%20was%201.11%20%2895%25CI%3A%201.07%20-%201.14%29.%20Estimates%20were%20similar%20after%20adjusting%20for%20time%20updated%20CD4%20count.%20INTERPRETATION%3A%20In%20virologically%20suppressed%20PWH%2C%20increased%20time%20living%20with%20severe%20immunosuppression%20had%20an%20increased%20risk%20of%20death%20and%20ADE%5C%2FSNADE%20in%20this%20Latin%20American%20cohort%2C%20independently%20of%20time%20updated%20CD4%20count.%20FUNDING%3A%20This%20work%20was%20supported%20by%20the%20NIH-funded%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%2C%20U01AI069923%29%2C%20a%20member%20cohort%20of%20the%20International%20Epidemiologic%20Databases%20to%20Evaluate%20AIDS%20%28leDEA%29.%20This%20award%20is%20funded%20by%20the%20following%20institutes%3A%20Eunice%20Kennedy%20Shriver%20National%20Institute%20Of%20Child%20Health%20%26%20Human%20Development%20%28NICHD%29%2C%20National%20Cancer%20Institute%20%28NCI%29%2C%20National%20Institute%20Of%20Allergy%20And%20Infectious%20Diseases%20%28NIAID%29%2C%20National%20Institute%20Of%20Mental%20Health%20%28NIMH%29%2C%20the%20National%20Heart%2C%20Lung%2C%20and%20Blood%20Institute%20%28NHLBI%29%2C%20the%20National%20Institute%20on%20Alcohol%20Abuse%20and%20Alcoholism%20%28NIAAA%29%2C%20the%20National%20Institute%20of%20Diabetes%20and%20Digestive%20and%20Kidney%20Diseases%20%28NIDDK%29%2C%20and%20the%20Fogarty%20International%20Center%20%28FIC%29.%20Specific%20funding%20was%20provided%20from%20the%20Fogarty%20International%20Center%20%28FIC%29%20for%20lead%20author%2C%20Yanink%20Caro-Vega%2C%20for%20the%20Fogarty-IeDEA%20Mentorship%20Program%20%28FIMP%29.%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lana.2021.100175%22%2C%22ISSN%22%3A%222667-193X%20%28Electronic%29%202667-193X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A39%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22V86ICMTD%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Antimycobacterial%20Susceptibility%20Testing%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A16%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAntimycobacterial%20Susceptibility%20Testing%2C%20Group%3C%5C%2Fspan%3E%20%282022%29.%20Updating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment.%20%3Ci%3EEur%20Respir%20J%3C%5C%2Fi%3E%2C%20%3Ci%3E59%3C%5C%2Fi%3E%20%284%29%2C%20S.%202200166.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Updating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Group%22%2C%22lastName%22%3A%22Antimycobacterial%20Susceptibility%20Testing%22%7D%5D%2C%22abstractNote%22%3A%22Inappropriately%20high%20breakpoints%20have%20resulted%20in%20systematic%20false-susceptible%20AST%20results%20to%20anti-TB%20drugs.%20MIC%2C%20PK%5C%2FPD%20and%20clinical%20outcome%20data%20should%20be%20combined%20when%20setting%20breakpoints%20to%20minimise%20the%20emergence%20and%20spread%20of%20antimicrobial%20resistance.%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3i43wb6%5CnApproximately%2085%20000%20deaths%20globally%20in%202019%20were%20due%20to%20drug-resistant%20tuberculosis%20%28TB%29%2C%20which%20corresponds%20to%207%25%20of%20global%20deaths%20attributable%20to%20bacterial%20antimicrobial%20resistance%20%5B1%5D.%20Yet%20concerns%20have%20been%20mounting%20that%20drug-resistant%20TB%20was%20being%20underestimated%20because%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-TB%20agents%20had%20not%20kept%20up%20with%20those%20used%20for%20other%20major%20bacterial%20pathogens%20%5B2-9%5D.%20Here%2C%20we%20outline%20the%20recent%2C%20evidence-based%20initiatives%20spearheaded%20by%20the%20World%20Health%20Organization%20%28WHO%29%20and%20others%20to%20update%20breakpoints%20%28traditionally%20referred%20to%20as%20critical%20concentrations%20%28CCs%29%29%20that%20are%20used%20for%20phenotypic%20antimicrobial%20susceptibility%20testing%20%28AST%29%2C%20also%20called%20drug%20susceptibility%20testing%20in%20the%20TB%20literature.%5Cneng%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00166-2022%22%2C%22ISSN%22%3A%221399-3003%20%28Electronic%29%200903-1936%20%28Print%29%200903-1936%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A32%3A48Z%22%7D%7D%2C%7B%22key%22%3A%227LE2GH88%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Justice%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A16%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJustice%2C%20A.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGoetz%2C%20M.%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStewart%2C%20C.%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHogan%2C%20B.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHumes%2C%20E.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Delayed%20presentation%20of%20HIV%20among%20older%20individuals%3A%20a%20growing%20problem.%20%3Ci%3ELancet%20HIV%3C%5C%2Fi%3E%2C%20%3Ci%3E9%3C%5C%2Fi%3E%20%284%29%2C%20S.%20e269%26%23x2013%3Be280.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2822%2900003-0%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2822%2900003-0%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Delayed%20presentation%20of%20HIV%20among%20older%20individuals%3A%20a%20growing%20problem%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Justice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20B.%22%2C%22lastName%22%3A%22Goetz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20N.%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20C.%22%2C%22lastName%22%3A%22Hogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Humes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Malateste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Shamu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Rajasuriar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%5D%2C%22abstractNote%22%3A%22Late%20presentation%20for%20care%20is%20a%20major%20impediment%20to%20the%20prevention%20and%20effective%20treatment%20of%20HIV%20infection.%20Older%20individuals%20are%20at%20increased%20risk%20of%20late%20presentation%2C%20represent%20a%20growing%20proportion%20of%20people%20with%20late%20presentation%2C%20and%20might%20require%20interventions%20tailored%20to%20their%20age%20group.%20We%20provide%20a%20summary%20of%20the%20literature%20published%20globally%20between%202016-21%20%28reporting%20data%20from%201984-2018%29%20and%20quantify%20the%20association%20of%20age%20with%20delayed%20presentation.%20Using%20the%20most%20common%20definitions%20of%20late%20presentation%20and%20older%20age%20from%20these%20earlier%20studies%2C%20we%20update%20this%20work%20with%20data%20from%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%2C%20focusing%20on%20data%20from%202000-19%2C%20encompassing%20four%20continents.%20Finally%2C%20we%20consider%20how%20late%20presentation%20among%20older%20individuals%20might%20be%20more%20effectively%20addressed%20as%20electronic%20medical%20records%20become%20widely%20adopted.%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS2352-3018%2822%2900003-0%22%2C%22ISSN%22%3A%222352-3018%20%28Electronic%29%202405-4704%20%28Print%29%202352-3018%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A18%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22PWU69TDX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Enane%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-30%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEnane%2C%20L.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EApondi%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELiepmann%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EToromo%2C%20J.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOmollo%2C%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20%26%23x201C%3BWe%20are%20not%20going%20anywhere%26%23x201D%3B%3A%20a%20qualitative%20study%20of%20Kenyan%20healthcare%20worker%20perspectives%20on%20adolescent%20HIV%20care%20engagement%20during%20the%20COVID-19%20pandemic.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E12%3C%5C%2Fi%3E%20%283%29%2C%20S.%20e055948.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2021-055948%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2021-055948%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%27We%20are%20not%20going%20anywhere%27%3A%20a%20qualitative%20study%20of%20Kenyan%20healthcare%20worker%20perspectives%20on%20adolescent%20HIV%20care%20engagement%20during%20the%20COVID-19%20pandemic%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Apondi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Liepmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Toromo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Omollo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bakari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Scanlon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20C.%22%2C%22lastName%22%3A%22Vreeman%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Adolescents%20living%20with%20HIV%20%28ALHIV%29%20may%20be%20vulnerable%20to%20widescale%20impacts%20of%20the%20COVID-19%20pandemic%20and%20to%20health%20system%20responses%20which%20impact%20HIV%20care.%20We%20assessed%20healthcare%20worker%20%28HCW%29%20perspectives%20on%20impacts%20of%20the%20COVID-19%20pandemic%20on%20adolescent%20HIV%20care%20delivery%20and%20engagement%20in%20western%20Kenya.%20METHODS%3A%20We%20performed%20in-depth%20qualitative%20interviews%20with%20HCW%20at%2010%20clinical%20sites%20in%20the%20Academic%20Model%20Providing%20Access%20to%20Healthcare%20in%20Kenya%2C%20from%20January%20to%20March%2C%202021.%20Semistructured%20interviews%20ascertained%20pandemic-related%20impacts%20on%20adolescent%20HIV%20care%20delivery%20and%20retention.%20RESULTS%3A%20Interviews%20were%20conducted%20with%2022%20HCWs%20from%2010%20clinics.%20HCWs%20observed%20adolescent%20financial%20hardships%2C%20unmet%20basic%20needs%20and%20school%20dropouts%20during%20the%20pandemic%2C%20with%20some%20adolescents%20relocating%20to%20rural%20homes%2C%20to%20partners%20or%20to%20the%20street.%20Marked%20increases%20in%20adolescent%20pregnancies%20and%20pregnancy%20complications%20were%20described%2C%20as%20well%20as%20barriers%20to%20family%20planning%20and%20antenatal%20care.%20Transportation%20challenges%20and%20restrictions%20limited%20access%20to%20care%20and%20prompted%20provision%20of%20multi-month%20refills%2C%20refills%20at%20local%20dispensaries%20or%20transfer%20to%20local%20facilities.%20Adolescent-friendly%20services%20were%20compromised%2C%20resulting%20in%20care%20challenges%20and%20disengagement%20from%20care.%20Clinic%20capacities%20to%20respond%20to%20adolescent%20needs%20were%20limited%20by%20funding%20cuts%20to%20multidisciplinary%20staff%20and%20resources.%20HCW%20and%20youth%20peer%20mentors%20%28YPMs%29%20demonstrated%20resilience%2C%20by%20adapting%20services%2C%20taking%20on%20expanded%20roles%20and%20leveraging%20available%20resources%20to%20support%20adolescent%20retention%20and%20access%20to%20care.%20CONCLUSIONS%3A%20ALHIV%20are%20uniquely%20vulnerable%2C%20and%20adolescent-friendly%20services%20are%20essential%20to%20their%20treatment.%20The%20combined%20effects%20of%20the%20pandemic%2C%20health%20system%20changes%20and%20funding%20cuts%20compromised%20adolescent-friendly%20care%20and%20limited%20capacity%20to%20respond%20to%20adolescent%20needs.%20There%20is%20a%20need%20to%20reinforce%20adolescent-friendly%20services%20within%20programmes%20and%20funding%20structures.%20Support%20for%20expanded%20YPM%20roles%20may%20facilitate%20dedicated%2C%20scalable%20and%20effective%20adolescent-friendly%20services%2C%20which%20are%20resilient%20and%20sustainable%20in%20times%20of%20crisis.%22%2C%22date%22%3A%22Mar%2030%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2021-055948%22%2C%22ISSN%22%3A%222044-6055%20%28Electronic%29%202044-6055%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A33%3A54Z%22%7D%7D%2C%7B%22key%22%3A%225WY5NKVK%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Koh%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKoh%2C%20M.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMerrill%2C%20M.%20H.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKoh%2C%20M.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStuver%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAlonso%2C%20C.%20D.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Comparative%20outcomes%20for%20mature%20T-cell%20and%20NK%5C%2FT-cell%20lymphomas%20in%20people%20with%20and%20without%20HIV%20and%20to%20AIDS-defining%20lymphomas.%20%3Ci%3EBlood%20Adv%3C%5C%2Fi%3E%2C%20%3Ci%3E6%3C%5C%2Fi%3E%20%285%29%2C%20S.%201420%26%23x2013%3B1431.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2021006208%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2021006208%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparative%20outcomes%20for%20mature%20T-cell%20and%20NK%5C%2FT-cell%20lymphomas%20in%20people%20with%20and%20without%20HIV%20and%20to%20AIDS-defining%20lymphomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Koh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20H.%22%2C%22lastName%22%3A%22Merrill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Koh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Stuver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Alonso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20M.%22%2C%22lastName%22%3A%22Foss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Mayor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Epeldegui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cachay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20E.%22%2C%22lastName%22%3A%22Thorne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20E.%22%2C%22lastName%22%3A%22Nijhawan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22McGinnis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20S.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20S.%22%2C%22lastName%22%3A%22Rabkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Napravnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Shen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Jain%22%7D%5D%2C%22abstractNote%22%3A%22There%20are%20no%20studies%20comparing%20the%20prognosis%20for%20mature%20T-cell%20lymphoma%20%28TCL%29%20in%20people%20with%20HIV%20%28PWH%29%20to%20people%20without%20HIV%20%28PWoH%29%20and%20to%20AIDS-defining%20B-cell%20lymphomas%20%28A-BCLs%29%20in%20the%20modern%20antiretroviral%20therapy%20era.%20North%20American%20AIDS%20Cohort%20Collaboration%20on%20Research%20and%20Design%20and%20Comprehensive%20Oncology%20Measures%20for%20Peripheral%20T-cell%20Lymphoma%20Treatment%20are%20cohorts%20that%20enroll%20patients%20diagnosed%20with%20HIV%20and%20TCL%2C%20respectively.%20In%20our%20study%2C%2052%2C%2064%2C%20101%2C%20500%2C%20and%20246%20PWH%20with%20histologic%20confirmation%20of%20TCL%2C%20primary%20central%20nervous%20system%20lymphoma%2C%20Burkitt%27s%20lymphoma%2C%20diffuse%20large%20B-cell%20lymphoma%20%28DLBCL%29%2C%20and%20Hodgkin%27s%20lymphoma%20%28HL%29%2C%20respectively%2C%20and%20450%20TCLs%20without%20HIV%20were%20eligible%20for%20analysis.%20At%20the%20time%20of%20TCL%20diagnosis%2C%20anaplastic%20large-cell%20lymphoma%20%28ALCL%29%20was%20the%20most%20common%20TCL%20subtype%20within%20PWH.%20Although%20PWH%20with%20TCL%20diagnosed%20between%201996%20and%202009%20experienced%20a%20low%205-year%20survival%20probability%20at%200.23%20%2895%25%20confidence%20interval%20%5BCI%5D%3A%200.13%2C%200.41%29%2C%20we%20observed%20a%20marked%20improvement%20in%20their%20survival%20when%20diagnosed%20between%202010%20and%202016%20%280.69%3B%2095%25%20CI%3A%200.48%2C%201%3B%20P%20%3D%20.04%29%20in%20contrast%20to%20TCLs%20among%20PWoH%20%280.45%3B%2095%25%20CI%3A%200.41%2C%200.51%3B%20P%20%3D%20.53%29.%20Similarly%2C%20PWH%20with%20ALCLs%20diagnosed%20between%201996%20and%202009%20were%20associated%20with%20a%20conspicuously%20inferior%205-year%20survival%20probability%20%280.17%3B%2095%25%20CI%3A%200.07%2C%200.42%29%20and%20consistently%20lagged%20behind%20A-BCL%20subtypes%20such%20as%20Burkitt%27s%20%280.43%3B%2095%25%20CI%3A0.33%2C%200.57%3B%20P%20%3D%20.09%29%20and%20DLBCL%20%280.17%3B%2095%25%20CI%3A%200.06%2C%200.46%3B%20P%20%3D%20.11%29%20and%20behind%20HL%20%280.57%3B%2095%25%20CI%3A%200.50%2C%200.65%3B%20P%20%3C%20.0001%29.%20Despite%20a%20small%20number%2C%20those%20diagnosed%20between%202010%20and%202016%20experienced%20a%20remarkable%20improvement%20in%20survival%20%280.67%3B%2095%25%20CI%3A%200.3%2C%201%29%20in%20comparison%20with%20PWoH%20%280.76%3B%2095%25%20CI%3A%200.66%2C%200.87%3B%20P%20%3D%20.58%29.%20Thus%2C%20our%20analysis%20confirms%20improved%20overall%20survival%20for%20aggressive%20B-%20and%20T-cell%20malignancies%20among%20PWH%20in%20the%20last%20decade.%22%2C%22date%22%3A%22Mar%208%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fbloodadvances.2021006208%22%2C%22ISSN%22%3A%222473-9537%20%28Electronic%29%202473-9529%20%28Print%29%202473-9529%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A39%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22JSS8DS84%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Collaborative%20Initiative%20for%20Paediatric%20et%20al.%22%2C%22parsedDate%22%3A%222022-03%22%2C%22numChildren%22%3A14%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECollaborative%20Initiative%20for%20Paediatric%2C%20H.%20I.%20V.%20Education%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EResearch%20Global%20Cohort%2C%20Collaboration%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJesson%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECrichton%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EQuartagno%2C%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Growth%20and%20CD4%20patterns%20of%20adolescents%20living%20with%20perinatally%20acquired%20HIV%20worldwide%2C%20a%20CIPHER%20cohort%20collaboration%20analysis.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%283%29%2C%20S.%20e25871.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25871%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25871%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Growth%20and%20CD4%20patterns%20of%20adolescents%20living%20with%20perinatally%20acquired%20HIV%20worldwide%2C%20a%20CIPHER%20cohort%20collaboration%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20I.%20V.%20Education%22%2C%22lastName%22%3A%22Collaborative%20Initiative%20for%20Paediatric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Collaboration%22%2C%22lastName%22%3A%22Research%20Global%20Cohort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Jesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Crichton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Quartagno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20J.%22%2C%22lastName%22%3A%22Abrams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Chokephaibulkit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Le%20Coeur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20H.%22%2C%22lastName%22%3A%22Ake-Assi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Paul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Vreeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ben-Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Van%20Dyke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Judd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Mofenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Vicari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Seage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20G.%22%2C%22lastName%22%3A%22Bekker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Essajee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Gibb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Penazzato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20J.%22%2C%22lastName%22%3A%22Collins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Slogrove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Powis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Matshaba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Thahane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Nyasulu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Lukhele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Mwita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kekitiinwa-Rukyalekere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Wanless%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Goetghebuer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Thorne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Warszawski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Galli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%20C.%22%2C%22lastName%22%3A%22van%20Rossum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Giaquinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Marczynska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Marques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Prata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Ene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Okhonskaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Navarro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Frick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Naver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kahlert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Volokha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Chappell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20W.%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Marcelin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Succi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kariminia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Edmonds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Lelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lyamuya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20A.%22%2C%22lastName%22%3A%22Ogalo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20A.%22%2C%22lastName%22%3A%22Odhiambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bolton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Muhairwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Tweya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Sylla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22D%27Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Renner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Abzug%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Oleske%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Purswani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Teasdale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Nuwagaba-Biribonwoha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Goodall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Leroy%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Adolescents%20living%20with%20HIV%20are%20subject%20to%20multiple%20co-morbidities%2C%20including%20growth%20retardation%20and%20immunodeficiency.%20We%20describe%20growth%20and%20CD4%20evolution%20during%20adolescence%20using%20data%20from%20the%20Collaborative%20Initiative%20for%20Paediatric%20HIV%20Education%20and%20Research%20%28CIPHER%29%20global%20project.%20METHODS%3A%20Data%20were%20collected%20between%201994%20and%202015%20from%2011%20CIPHER%20networks%20worldwide.%20Adolescents%20with%20perinatally%20acquired%20HIV%20infection%20%28APH%29%20who%20initiated%20antiretroviral%20therapy%20%28ART%29%20before%20age%2010%20years%2C%20with%20at%20least%20one%20height%20or%20CD4%20count%20measurement%20while%20aged%2010-17%20years%2C%20were%20included.%20Growth%20was%20measured%20using%20height-for-age%20Z-scores%20%28HAZ%2C%20stunting%20if%20%3C-2%20SD%2C%20WHO%20growth%20charts%29.%20Linear%20mixed-effects%20models%20were%20used%20to%20study%20the%20evolution%20of%20each%20outcome%20between%20ages%2010%20and%2017.%20For%20growth%2C%20sex-specific%20models%20with%20fractional%20polynomials%20were%20used%20to%20model%20non-linear%20relationships%20for%20age%20at%20ART%20initiation%2C%20HAZ%20at%20age%2010%20and%20time%2C%20defined%20as%20current%20age%20from%2010%20to%2017%20years%20of%20age.%20RESULTS%3A%20A%20total%20of%2020%2C939%20and%2019%2C557%20APH%20were%20included%20for%20the%20growth%20and%20CD4%20analyses%2C%20respectively.%20Half%20were%20females%2C%20two-thirds%20lived%20in%20East%20and%20Southern%20Africa%2C%20and%20median%20age%20at%20ART%20initiation%20ranged%20from%20%3C3%20years%20in%20North%20America%20and%20Europe%20to%20%3E7%20years%20in%20sub-Saharan%20African%20regions.%20At%20age%2010%2C%20stunting%20ranged%20from%206%25%20in%20North%20America%20and%20Europe%20to%2039%25%20in%20the%20Asia-Pacific%3B%2019%25%20overall%20had%20CD4%20counts%20%3C500%20cells%5C%2Fmm%283%29%20.%20Across%20adolescence%2C%20higher%20HAZ%20was%20observed%20in%20females%20and%20among%20those%20in%20high-income%20countries.%20APH%20with%20stunting%20at%20age%2010%20and%20those%20with%20late%20ART%20initiation%20%28after%20age%205%29%20had%20the%20largest%20HAZ%20gains%20during%20adolescence%2C%20but%20these%20gains%20were%20insufficient%20to%20catch-up%20with%20non-stunted%2C%20early%20ART-treated%20adolescents.%20From%20age%2010%20to%2016%20years%2C%20mean%20CD4%20counts%20declined%20from%20768%20to%20607%20cells%5C%2Fmm%283%29%20.%20This%20decline%20was%20observed%20across%20all%20regions%2C%20in%20males%20and%20females.%20CONCLUSIONS%3A%20Growth%20patterns%20during%20adolescence%20differed%20substantially%20by%20sex%20and%20region%2C%20while%20CD4%20patterns%20were%20similar%2C%20with%20an%20observed%20CD4%20decline%20that%20needs%20further%20investigation.%20Early%20diagnosis%20and%20timely%20initiation%20of%20treatment%20in%20early%20childhood%20to%20prevent%20growth%20retardation%20and%20immunodeficiency%20are%20critical%20to%20improving%20APH%20growth%20and%20CD4%20outcomes%20by%20the%20time%20they%20reach%20adulthood.%22%2C%22date%22%3A%22Mar%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25871%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A20%3A13Z%22%7D%7D%2C%7B%22key%22%3A%222Z5WU79P%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Shaikh%20et%20al.%22%2C%22parsedDate%22%3A%222022-02-01%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShaikh%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBhondoekhan%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHaberlen%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENakanishi%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERoy%2C%20S.%20K.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Coronary%20artery%20plaque%20progression%20and%20cardiovascular%20risk%20scores%20in%20men%20with%20and%20without%20HIV-infection.%20%3Ci%3EAIDS%3C%5C%2Fi%3E%2C%20%3Ci%3E36%3C%5C%2Fi%3E%20%282%29%2C%20S.%20215%26%23x2013%3B224.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003093%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003093%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Coronary%20artery%20plaque%20progression%20and%20cardiovascular%20risk%20scores%20in%20men%20with%20and%20without%20HIV-infection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Shaikh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Bhondoekhan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Haberlen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Nakanishi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20K.%22%2C%22lastName%22%3A%22Roy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20M.%22%2C%22lastName%22%3A%22Alla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20T.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Osawa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Rahmani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Nezarat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Sheidaee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Jayawardena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Hathiramani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20J.%22%2C%22lastName%22%3A%22Palella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Witt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Ahmad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Kingsley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20S.%22%2C%22lastName%22%3A%22Post%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Budoff%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20The%20aim%20of%20this%20study%20was%20to%20assess%20the%20association%20of%20cardiovascular%20disease%20%28CVD%29%20risk%20scores%20and%20coronary%20artery%20plaque%20%28CAP%29%20progression%20in%20HIV-infected%20participants.%20METHODS%3A%20We%20studied%20men%20with%20and%20without%20HIV-infection%20enrolled%20in%20the%20Multicenter%20AIDS%20Cohort%20Study%20%28MACS%29%20CVD%20study.%20CAP%20at%20baseline%20and%20follow-up%20was%20assessed%20with%20cardiac%20computed%20tomography%20angiography%20%28CCTA%29.%20We%20examined%20the%20association%20between%20baseline%20risk%20scores%20including%20pooled%20cohort%20equation%20%28PCE%29%2C%20Framingham%20risk%20score%20%28FRS%29%2C%20and%20Data%20collect%20of%20Adverse%20effects%20of%20anti-HIV%20drugs%20equation%20%28D%3AA%3AD%29%20and%20CAP%20progression.%20RESULTS%3A%20We%20studied%20495%20men%20%28211%20HIV-uninfected%2C%20284%20HIV-infected%29.%20The%20adjusted%20odds%20ratio%20%28aOR%29%20of%20total%20plaque%20volume%20%28TPV%29%20and%20noncalcified%20plaque%20volume%20%28NCPV%29%20progression%20in%20the%20highest%20relative%20to%20lowest%20tertile%20was%209.4%20%5B95%25%20confidence%20interval%20%2895%25%20CI%29%202.4-12.1%2C%20P%20%3C%200.001%29%5D%20and%207.7%20%2895%25%20CI%203.1-19.1%2C%20P%20%3C%200.001%29%20times%20greater%2C%20respectively%2C%20among%20HIV-uninfected%20men%20in%20the%20PCE%20atherosclerotic%20cardiovascular%20disease%20%28ASCVD%29%20high%20vs.%20low-risk%20category.%20Among%20HIV-infected%20men%2C%20the%20association%20for%20TPV%20and%20NCPV%20progression%20for%20the%20same%20PCE%20risk%20categories%2C%20odds%20ratio%20%28OR%29%202.8%20%2895%25%20CI%201.4-5.8%2C%20P%20%3C%200.01%29%20and%20OR%202.4%20%2895%25%20CI%201.2-4.8%2C%20P%20%3C%200.05%29%2C%20respectively%20%28P%20values%20for%20interaction%20by%20HIV%20%3D%200.02%20and%200.08%2C%20respectively%29.%20Similar%20results%20were%20seen%20for%20the%20FRS%20risk%20scores.%20Among%20HIV-uninfected%20men%2C%20PCE%20high%20risk%20category%20identified%20the%20highest%20proportion%20of%20men%20with%20plaque%20progression%20in%20the%20highest%20tertile%2C%20although%20in%20HIV-infected%20men%2C%20high-risk%20category%20by%20D%3AA%3AD%20identified%20the%20greatest%20percentage%20of%20men%20with%20plaque%20progression%20albeit%20with%20lower%20specificity%20than%20FRS%20and%20PCE.%20CONCLUSION%3A%20PCE%20and%20FRS%20categories%20predict%20CAP%20progression%20better%20in%20HIV-uninfected%20than%20in%20HIV-infected%20men.%20Improved%20CVD%20risk%20scores%20are%20needed%20to%20identify%20high-risk%20HIV-infected%20men%20for%20more%20aggressive%20CVD%20risk%20prevention%20strategies.%22%2C%22date%22%3A%22Feb%201%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003093%22%2C%22ISSN%22%3A%221473-5571%20%28Electronic%29%200269-9370%20%28Print%29%200269-9370%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A40%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22VPFNA8BB%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Myers%20et%20al.%22%2C%22parsedDate%22%3A%222022-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMyers%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EApondi%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EToromo%2C%20J.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOmollo%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBakari%2C%20S.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20%26%23x201C%3BWho%20am%20I%20going%20to%20stay%20with%3F%20Who%20will%20accept%20me%3F%26%23x201D%3B%3A%20family-level%20domains%20influencing%20HIV%20care%20engagement%20among%20disengaged%20adolescents%20in%20Kenya.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%282%29%2C%20S.%20e25890.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25890%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25890%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5C%22Who%20am%20I%20going%20to%20stay%20with%3F%20Who%20will%20accept%20me%3F%5C%22%3A%20family-level%20domains%20influencing%20HIV%20care%20engagement%20among%20disengaged%20adolescents%20in%20Kenya%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Myers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Apondi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Toromo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Omollo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bakari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Aluoch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Sang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Njoroge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%22%2C%22lastName%22%3A%22Morris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Kantor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Braitstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20M.%22%2C%22lastName%22%3A%22Nyandiko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Elul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20C.%22%2C%22lastName%22%3A%22Vreeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Adolescents%20living%20with%20HIV%20%28ALHIV%2C%20ages%2010-19%29%20have%20developmentally%20specific%20needs%20in%20care%2C%20and%20have%20lower%20retention%20compared%20to%20other%20age%20groups.%20Family-level%20contexts%20may%20be%20critical%20to%20adolescent%20HIV%20outcomes%2C%20but%20have%20often%20been%20overlooked.%20We%20investigated%20family-level%20factors%20underlying%20disengagement%20and%20supporting%20re-engagement%20among%20adolescents%20disengaged%20from%20HIV%20care.%20METHODS%3A%20Semi-structured%20interviews%20were%20performed%20with%2042%20disengaged%20ALHIV%2C%2032%20of%20their%20caregivers%20and%2028%20healthcare%20workers%20%28HCW%29%20in%20the%20Academic%20Model%20Providing%20Access%20to%20Healthcare%20%28AMPATH%29%20program%20in%20western%20Kenya%2C%20from%202018%20to%202020.%20Disengaged%20ALHIV%20had%20%3E%5C%2F%3D1%20visit%20within%20the%2018%20months%20prior%20to%20data%20collection%20at%20one%20of%20two%20sites%20and%20nonattendance%20%3E%5C%2F%3D60%20days%20following%20their%20last%20scheduled%20appointment.%20HCW%20were%20recruited%20from%2010%20clinics.%20Transcripts%20were%20analysed%20through%20thematic%20analysis.%20A%20conceptual%20model%20for%20family-level%20domains%20influencing%20adolescent%20HIV%20care%20engagement%20was%20developed%20from%20these%20themes.%20RESULTS%3A%20Family-level%20factors%20emerged%20as%20central%20to%20disengagement.%20ALHIV-particularly%20those%20orphaned%20by%20the%20loss%20of%20one%20or%20both%20parents-experienced%20challenges%20when%20new%20caregivers%20or%20unstable%20living%20situations%20limited%20support%20for%20HIV%20care.%20These%20challenges%20were%20compounded%20by%20anticipated%20stigma%3B%20resultant%20non-disclosure%20of%20HIV%20status%20to%20household%20members%3B%20enacted%20stigma%20in%20the%20household%2C%20with%20overwhelming%20effects%20on%20adolescents%3B%20or%20experiences%20of%20multiple%20forms%20of%20trauma%2C%20which%20undermined%20HIV%20care%20engagement.%20Some%20caregivers%20lacked%20finances%20or%20social%20support%20to%20facilitate%20care.%20Others%20did%20not%20feel%20equipped%20to%20support%20adolescent%20engagement%20or%20adherence.%20Regarding%20facilitators%20to%20re-engagement%2C%20participants%20described%20roles%20for%20household%20disclosure%3B%20and%20solidarity%20from%20caregivers%2C%20especially%20those%20also%20living%20with%20HIV.%20Family-level%20domains%20influencing%20HIV%20care%20engagement%20were%20conceptualized%20as%20follows%3A%20%281%29%20adolescent%20living%20situation%20and%20contexts%3B%20%282%29%20household%20material%20resources%20or%20poverty%3B%20%283%29%20caregiver%20capacities%20and%20skills%20to%20support%20adolescent%20HIV%20care%3B%20and%20%284%29%20HIV%20stigma%20or%20solidarity%20at%20the%20household%20level.%20CONCLUSIONS%3A%20Family-level%20factors%20are%20integral%20to%20retention%20in%20care%20for%20ALHIV.%20The%20conceptual%20model%20developed%20in%20this%20study%20for%20family-level%20influences%20on%20care%20engagement%20may%20inform%20holistic%20approaches%20to%20promote%20healthy%20outcomes%20for%20ALHIV.%20Developmentally%20appropriate%20interventions%20targeting%20household%20relationships%2C%20disclosure%2C%20HIV%20stigma%20reduction%2C%20HIV%20care%20skills%20and%20resources%2C%20and%20economic%20empowerment%20may%20promote%20adolescent%20engagement%20in%20HIV%20care.%22%2C%22date%22%3A%22Feb%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25890%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A23%3A20Z%22%7D%7D%2C%7B%22key%22%3A%222W7XGEKC%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zotova%20et%20al.%22%2C%22parsedDate%22%3A%222022-02%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZotova%2C%20N.%3C%5C%2Fspan%3E%3